{"status": "ok", "message-type": "work-list", "message-version": "1.0.0", "message": {"facets": {}, "total-results": 2461, "items": [{"indexed": {"date-parts": [[2019, 12, 2]], "date-time": "2019-12-02T06:39:31Z", "timestamp": 1575268771807}, "reference-count": 286, "publisher": "Springer Science and Business Media LLC", "issue": "9", "license": [{"URL": "http://www.springer.com/tdm", "start": {"date-parts": [[2013, 8, 30]], "date-time": "2013-08-30T00:00:00Z", "timestamp": 1377820800000}, "delay-in-days": 0, "content-version": "tdm"}], "content-domain": {"domain": [], "crossmark-restriction": false}, "short-container-title": ["Nat Rev Drug Discov"], "published-print": {"date-parts": [[2013, 9]]}, "DOI": "10.1038/nrd4075", "type": "journal-article", "created": {"date-parts": [[2013, 8, 30]], "date-time": "2013-08-30T05:58:33Z", "timestamp": 1377842313000}, "page": "667-687", "source": "Crossref", "is-referenced-by-count": 184, "title": ["50 years of hurdles and hope in anxiolytic drug discovery"], "prefix": "10.1038", "volume": "12", "author": [{"given": "Guy", "family": "Griebel", "sequence": "first", "affiliation": []}, {"given": "Andrew", "family": "Holmes", "sequence": "additional", "affiliation": []}], "member": "297", "published-online": {"date-parts": [[2013, 8, 30]]}, "reference": [{"issue": "Suppl. 2", "key": "BFnrd4075_CR1", "first-page": "10", "volume": "68", "author": "RC Kessler", "year": "2007", "unstructured": "Kessler, R. C. The global burden of anxiety and mood disorders: putting the European Study of the Epidemiology of Mental Disorders (ESEMeD) findings into perspective. J. Clin. Psychiatry 68 (Suppl. 2), 10\u201319 (2007).", "journal-title": "J. Clin. Psychiatry"}, {"key": "BFnrd4075_CR2", "doi-asserted-by": "publisher", "first-page": "655", "DOI": "10.1016/j.euroneuro.2011.07.018", "volume": "21", "author": "HU Wittchen", "year": "2011", "unstructured": "Wittchen, H. U. et al. The size and burden of mental disorders and other disorders of the brain in Europe 2010. Eur. Neuropsychopharmacol. 21, 655\u2013679 (2011). This is a major landmark study that sheds new light on the state of Europe's mental and neurological health.", "journal-title": "Eur. Neuropsychopharmacol."}, {"key": "BFnrd4075_CR3", "doi-asserted-by": "publisher", "first-page": "90", "DOI": "10.1001/archgenpsychiatry.2010.180", "volume": "68", "author": "RC Kessler", "year": "2011", "unstructured": "Kessler, R. C. et al. Development of lifetime comorbidity in the World Health Organization world mental health surveys. Arch. Gen. Psychiatry 68, 90\u2013100 (2011).", "journal-title": "Arch. Gen. Psychiatry"}, {"key": "BFnrd4075_CR4", "first-page": "5", "volume": "6", "author": "RC Kessler", "year": "2009", "unstructured": "Kessler, R. C. et al. The WHO World Mental Health (WMH) Surveys. Psychiatrie 6, 5\u20139 (2009).", "journal-title": "Psychiatrie"}, {"key": "BFnrd4075_CR5", "doi-asserted-by": "publisher", "first-page": "368", "DOI": "10.1192/bjp.bp.107.039107", "volume": "192", "author": "J Ormel", "year": "2008", "unstructured": "Ormel, J. et al. Disability and treatment of specific mental and physical disorders across the world. Br. J. Psychiatry 192, 368\u2013375 (2008).", "journal-title": "Br. J. Psychiatry"}, {"key": "BFnrd4075_CR6", "doi-asserted-by": "publisher", "first-page": "672", "DOI": "10.1176/appi.ajp.2011.11020219", "volume": "168", "author": "DJ Kupfer", "year": "2011", "unstructured": "Kupfer, D. J. & Regier, D. A. Neuroscience, clinical evidence, and the future of psychiatric classification in DSM-5. Am. J. Psychiatry 168, 672\u2013674 (2011).", "journal-title": "Am. J. Psychiatry"}, {"key": "BFnrd4075_CR7", "doi-asserted-by": "publisher", "first-page": "92", "DOI": "10.1192/bjp.bp.109.073429", "volume": "196", "author": "N Craddock", "year": "2010", "unstructured": "Craddock, N. & Owen, M. J. The Kraepelinian dichotomy \u2014 going, going... but still not gone. Br. J. Psychiatry 196, 92\u201395 (2010).", "journal-title": "Br. J. Psychiatry"}, {"key": "BFnrd4075_CR8", "doi-asserted-by": "publisher", "first-page": "1425", "DOI": "10.1007/s00115-011-3349-9", "volume": "82", "author": "S Leucht", "year": "2011", "unstructured": "Leucht, S., Heres, S. & Davis, J. M. Considerations about the efficacy of psychopharmacological drugs. Nervenartz 82, 1425\u20131430 (2011).", "journal-title": "Nervenartz"}, {"key": "BFnrd4075_CR9", "doi-asserted-by": "publisher", "first-page": "509", "DOI": "10.1176/appi.ajp.2010.09101452", "volume": "167", "author": "A Caspi", "year": "2010", "unstructured": "Caspi, A., Hariri, A. R., Holmes, A., Uher, R. & Moffitt, T. E. Genetic sensitivity to the environment: the case of the serotonin transporter gene and its implications for studying complex diseases and traits. Am. J. Psychiatry 167, 509\u2013527 (2010).", "journal-title": "Am. J. Psychiatry"}, {"key": "BFnrd4075_CR10", "doi-asserted-by": "publisher", "first-page": "119", "DOI": "10.1177/0269881112443746", "volume": "27", "author": "DR Owen", "year": "2013", "unstructured": "Owen, D. R., Rupprecht, R. & Nutt, D. J. Stratified medicine in psychiatry: a worrying example or new opportunity in the treatment of anxiety? J. Psychopharmacol. 27, 119\u2013122 (2013).", "journal-title": "J. Psychopharmacol."}, {"key": "BFnrd4075_CR11", "doi-asserted-by": "publisher", "first-page": "360", "DOI": "10.2174/156802612799078748", "volume": "12", "author": "C Nothdurfter", "year": "2012", "unstructured": "Nothdurfter, C., Rupprecht, R. & Rammes, G. Recent developments in potential anxiolytic agents targeting GABAA/BzR complex or the translocator protein (18kDa) (TSPO). Curr. Top. Med. Chem. 12, 360\u2013370 (2012).", "journal-title": "Curr. Top. Med. Chem."}, {"key": "BFnrd4075_CR12", "doi-asserted-by": "publisher", "first-page": "9", "DOI": "10.1186/2045-5380-1-9", "volume": "1", "author": "C Belzung", "year": "2011", "unstructured": "Belzung, C. & Lemoine, M. Criteria of validity for animal models of psychiatric disorders: focus on anxiety disorders and depression. Biol. Mood Anxiety Disord. 1, 9\u201314 (2011). This paper refines the concepts of criteria of the validity of anxiety models based on recent developments.", "journal-title": "Biol. Mood Anxiety Disord."}, {"key": "BFnrd4075_CR13", "unstructured": "Haller, J., Aliczki, M. & Gyimesine, P. K. Classical and novel approaches to the preclinical testing of anxiolytics: a critical evaluation. Neurosci. Biobehav. Rev. \n                    http://dx.doi.org/10.1016/j.neubiorev.2012.09.001\n                    \n                   (2012).", "DOI": "10.1016/j.neubiorev.2012.09.001", "doi-asserted-by": "publisher"}, {"key": "BFnrd4075_CR14", "doi-asserted-by": "publisher", "first-page": "775", "DOI": "10.1038/nrd1825", "volume": "4", "author": "JF Cryan", "year": "2005", "unstructured": "Cryan, J. F. & Holmes, A. The ascent of mouse: advances in modelling human depression and anxiety. Nature Rev. Drug Discov. 4, 775\u2013790 (2005).", "journal-title": "Nature Rev. Drug Discov."}, {"key": "BFnrd4075_CR15", "doi-asserted-by": "publisher", "first-page": "240", "DOI": "10.1001/archpsyc.1969.01740200112015", "volume": "21", "author": "WT McKinney Jr", "year": "1969", "unstructured": "McKinney, W. T. Jr & Bunney, W. E. Jr. Animal model of depression. I. Review of evidence: implications for research. Arch. Gen. Psychiatry 21, 240\u2013248 (1969).", "journal-title": "Arch. Gen. Psychiatry"}, {"key": "BFnrd4075_CR16", "doi-asserted-by": "publisher", "first-page": "385", "DOI": "10.1037/h0071444", "volume": "18", "author": "CS Hall", "year": "1934", "unstructured": "Hall, C. S. Emotional behavior in the rat. I: defecation and urination as measures of individual differences in emotionality. J. Comp. Psychol. 18, 385\u2013403 (1934).", "journal-title": "J. Comp. Psychol."}, {"key": "BFnrd4075_CR17", "doi-asserted-by": "publisher", "first-page": "1", "DOI": "10.1007/BF00504983", "volume": "327", "author": "SL Handley", "year": "1984", "unstructured": "Handley, S. L. & Mithani, S. Effects of \u03b1-adrenoceptor agonists and antagonists in a maze-exploration model of 'fear'-motivated behaviour. Naunyn Schmiedeberg Arch. Pharmacol. 327, 1\u20135 (1984).", "journal-title": "Naunyn Schmiedeberg Arch. Pharmacol."}, {"key": "BFnrd4075_CR18", "doi-asserted-by": "publisher", "first-page": "695", "DOI": "10.1016/0091-3057(81)90007-1", "volume": "15", "author": "JN Crawley", "year": "1981", "unstructured": "Crawley, J. N. Neuropharmacologic specificity of a simple animal model for the behavioral actions of benzodiazepines. Pharmacol. Biochem. Behav. 15, 695\u2013699 (1981).", "journal-title": "Pharmacol. Biochem. Behav."}, {"key": "BFnrd4075_CR19", "first-page": "180", "volume": "92", "author": "RG Lister", "year": "1987", "unstructured": "Lister, R. G. The use of a plus-maze to measure anxiety in the mouse. Psychopharmacology 92, 180\u2013185 (1987).", "journal-title": "Psychopharmacology"}, {"key": "BFnrd4075_CR20", "doi-asserted-by": "publisher", "first-page": "1", "DOI": "10.1007/BF00403989", "volume": "21", "author": "JR Vogel", "year": "1971", "unstructured": "Vogel, J. R., Beer, B. & Clody, D. E. A simple and reliable conflict procedure for testing anti-anxiety agents. Psychopharmacologia 21, 1\u20137 (1971).", "journal-title": "Psychopharmacologia"}, {"key": "BFnrd4075_CR21", "doi-asserted-by": "publisher", "first-page": "374", "DOI": "10.1007/BF00408322", "volume": "3", "author": "I Geller", "year": "1962", "unstructured": "Geller, I., Kulak, J. T. & Seifter, J. The effects of chlordiazepoxide and chlorpromazine on a punishment discrimination. Psychopharmacologia 3, 374\u2013385 (1962).", "journal-title": "Psychopharmacologia"}, {"key": "BFnrd4075_CR22", "author": "G Griebel", "first-page": "97", "year": "2011", "unstructured": "Griebel, G. & Beesk\u00e9, S. in Mood and Anxiety Related Phenotypes in Mice (ed. Gould, T. D.) 97\u2013106 (Springer, 2011).", "volume-title": "Mood and Anxiety Related Phenotypes in Mice", "DOI": "10.1007/978-1-61779-313-4_6", "doi-asserted-by": "publisher"}, {"key": "BFnrd4075_CR23", "doi-asserted-by": "publisher", "first-page": "97", "DOI": "10.1016/S0014-2999(03)01276-7", "volume": "463", "author": "DC Blanchard", "year": "2003", "unstructured": "Blanchard, D. C., Griebel, G. & Blanchard, R. J. The Mouse Defense Test Battery: pharmacological and behavioral assays for anxiety and panic. Eur. J. Pharmacol. 463, 97\u2013116 (2003).", "journal-title": "Eur. J. Pharmacol."}, {"key": "BFnrd4075_CR24", "doi-asserted-by": "publisher", "first-page": "289", "DOI": "10.1590/S0100-879X1997000300002", "volume": "30", "author": "RJ Rodgers", "year": "1997", "unstructured": "Rodgers, R. J., Cao, B. J., Dalvi, A. & Holmes, A. Animal models of anxiety: an ethological perspective. Braz. J. Med. Biol. Res. 30, 289\u2013304 (1997).", "journal-title": "Braz. J. Med. Biol. Res."}, {"key": "BFnrd4075_CR25", "doi-asserted-by": "publisher", "first-page": "617", "DOI": "10.1016/j.neuropharm.2011.06.012", "volume": "62", "author": "T Steckler", "year": "2012", "unstructured": "Steckler, T. & Risbrough, V. Pharmacological treatment of PTSD \u2014 established and new approaches. Neuropharmacology 62, 617\u2013627 (2012).", "journal-title": "Neuropharmacology"}, {"key": "BFnrd4075_CR26", "doi-asserted-by": "publisher", "first-page": "5357", "DOI": "10.1523/JNEUROSCI.5017-09.2010", "volume": "30", "author": "K Mozhui", "year": "2010", "unstructured": "Mozhui, K. et al. Strain differences in stress responsivity are associated with divergent amygdala gene expression and glutamate-mediated neuronal excitability. J. Neurosci. 30, 5357\u20135367 (2010).", "journal-title": "J. Neurosci."}, {"key": "BFnrd4075_CR27", "doi-asserted-by": "publisher", "first-page": "400", "DOI": "10.1016/S0028-3908(01)00072-7", "volume": "41", "author": "C Belzung", "year": "2001", "unstructured": "Belzung, C., El Hage, W., Moindrot, N. & Griebel, G. Behavioral and neurochemical changes following predatory stress in mice. Neuropharmacology 41, 400\u2013408 (2001).", "journal-title": "Neuropharmacology"}, {"key": "BFnrd4075_CR28", "doi-asserted-by": "publisher", "first-page": "e5346", "DOI": "10.1371/journal.pone.0005346", "volume": "4", "author": "P Muigg", "year": "2009", "unstructured": "Muigg, P. et al. Differential stress-induced neuronal activation patterns in mouse lines selectively bred for high, normal or low anxiety. PLoS ONE 4, e5346 (2009).", "journal-title": "PLoS ONE"}, {"key": "BFnrd4075_CR29", "doi-asserted-by": "publisher", "first-page": "23", "DOI": "10.1016/j.tins.2012.11.003", "volume": "36", "author": "A Holmes", "year": "2013", "unstructured": "Holmes, A. & Singewald, N. Individual differences in recovery from traumatic fear. Trends Neurosci. 36, 23\u201331 (2013).", "journal-title": "Trends Neurosci."}, {"key": "BFnrd4075_CR30", "doi-asserted-by": "publisher", "first-page": "1293", "DOI": "10.1016/j.neubiorev.2008.03.006", "volume": "32", "author": "A Holmes", "year": "2008", "unstructured": "Holmes, A. Genetic variation in cortico-amygdala serotonin function and risk for stress-related disease. Neurosci. Biobehav. Rev. 32, 1293\u20131314 (2008).", "journal-title": "Neurosci. Biobehav. Rev."}, {"key": "BFnrd4075_CR31", "doi-asserted-by": "publisher", "first-page": "18087", "DOI": "10.1523/JNEUROSCI.2531-12.2012", "volume": "32", "author": "AJ Holmes", "year": "2012", "unstructured": "Holmes, A. J. et al. Individual differences in amygdala-medial prefrontal anatomy link negative affect, impaired social functioning, and polygenic depression risk. J. Neurosci. 32, 18087\u201318100 (2012).", "journal-title": "J. Neurosci."}, {"key": "BFnrd4075_CR32", "doi-asserted-by": "publisher", "first-page": "399", "DOI": "10.1016/j.conb.2013.01.011", "volume": "23", "author": "ZR Donaldson", "year": "2013", "unstructured": "Donaldson, Z. R., Nautiyal, K. M., Ahmari, S. E. & Hen, R. Genetic approaches for understanding the role of serotonin receptors in mood and behavior. Curr. Opin. Neurobiol. 23, 399\u2013406 (2013).", "journal-title": "Curr. Opin. Neurobiol."}, {"key": "BFnrd4075_CR33", "doi-asserted-by": "publisher", "first-page": "261", "DOI": "10.1016/S0149-7634(01)00012-4", "volume": "25", "author": "A Holmes", "year": "2001", "unstructured": "Holmes, A. Targeted gene mutation approaches to the study of anxiety-like behavior in mice. Neurosci. Biobehav. Rev. 25, 261\u2013273 (2001).", "journal-title": "Neurosci. Biobehav. Rev."}, {"key": "BFnrd4075_CR34", "doi-asserted-by": "publisher", "first-page": "251", "DOI": "10.1038/nrn3171", "volume": "13", "author": "KM Tye", "year": "2012", "unstructured": "Tye, K. M. & Deisseroth, K. Optogenetic investigation of neural circuits underlying brain disease in animal models. Nature Rev. Neurosci. 13, 251\u2013266 (2012).", "journal-title": "Nature Rev. Neurosci."}, {"key": "BFnrd4075_CR35", "doi-asserted-by": "publisher", "first-page": "358", "DOI": "10.1038/nature09820", "volume": "471", "author": "KM Tye", "year": "2011", "unstructured": "Tye, K. M. et al. Amygdala circuitry mediating reversible and bidirectional control of anxiety. Nature 471, 358\u2013362 (2011).", "journal-title": "Nature"}, {"key": "BFnrd4075_CR36", "doi-asserted-by": "publisher", "first-page": "12692", "DOI": "10.1073/pnas.1002418107", "volume": "107", "author": "JP Johansen", "year": "2010", "unstructured": "Johansen, J. P. et al. Optical activation of lateral amygdala pyramidal cells instructs associative fear learning. Proc. Natl Acad. Sci. USA 107, 12692\u201312697 (2010).", "journal-title": "Proc. Natl Acad. Sci. USA"}, {"key": "BFnrd4075_CR37", "doi-asserted-by": "publisher", "first-page": "633", "DOI": "10.1111/j.1601-183X.2012.00786.x", "volume": "11", "author": "PM Fisher", "year": "2012", "unstructured": "Fisher, P. M. & Hariri, A. R. Linking variability in brain chemistry and circuit function through multimodal human neuroimaging. Genes Brain Behav. 11, 633\u2013642 (2012).", "journal-title": "Genes Brain Behav."}, {"key": "BFnrd4075_CR38", "doi-asserted-by": "publisher", "first-page": "2", "DOI": "10.1016/j.tips.2009.10.003", "volume": "31", "author": "A Holmes", "year": "2010", "unstructured": "Holmes, A. & Quirk, G. J. Pharmacological facilitation of fear extinction and the search for adjunct treatments for anxiety disorders \u2014 the case of yohimbine. Trends Pharmacol. Sci. 31, 2\u20137 (2010).", "journal-title": "Trends Pharmacol. Sci."}, {"key": "BFnrd4075_CR39", "doi-asserted-by": "publisher", "first-page": "120", "DOI": "10.1038/sj.mp.4001939", "volume": "12", "author": "KM Myers", "year": "2007", "unstructured": "Myers, K. M. & Davis, M. Mechanisms of fear extinction. Mol. Psychiatry 12, 120\u2013150 (2007).", "journal-title": "Mol. Psychiatry"}, {"key": "BFnrd4075_CR40", "doi-asserted-by": "publisher", "first-page": "510", "DOI": "10.1101/lm.78204", "volume": "11", "author": "R Richardson", "year": "2004", "unstructured": "Richardson, R., Ledgerwood, L. & Cranney, J. Facilitation of fear extinction by d-cycloserine: theoretical and clinical implications. Learn. Mem. 11, 510\u2013516 (2004).", "journal-title": "Learn. Mem."}, {"key": "BFnrd4075_CR41", "author": "DS Baldwin", "first-page": "395", "year": "2008", "unstructured": "Baldwin, D. S. & Garner, M. in Handbook of Anxiety and Fear (eds Blanchard, R. J., Blanchard, D. C., Griebel, G. & Nutt, D.) 395\u2013411 (Elsevier, 2008).", "volume-title": "Handbook of Anxiety and Fear", "DOI": "10.1016/S1569-7339(07)00018-5", "doi-asserted-by": "publisher"}, {"key": "BFnrd4075_CR42", "doi-asserted-by": "publisher", "first-page": "453", "DOI": "10.1007/7854_2009_2", "volume": "2", "author": "DS Baldwin", "year": "2010", "unstructured": "Baldwin, D. S., Ajel, K. I. & Garner, M. Pharmacological treatment of generalized anxiety disorder. Curr. Top. Behav. Neurosci. 2, 453\u2013467 (2010).", "journal-title": "Curr. Top. Behav. Neurosci."}, {"key": "BFnrd4075_CR43", "doi-asserted-by": "publisher", "first-page": "248", "DOI": "10.1002/msj.20041", "volume": "75", "author": "EJ Hoffman", "year": "2008", "unstructured": "Hoffman, E. J. & Mathew, S. J. Anxiety disorders: a comprehensive review of pharmacotherapies. Mt. Sinai J. Med. 75, 248\u2013262 (2008). This article reviews the evidence from randomized, placebo-controlled trials and meta-analyses of pharmacological treatments of the main anxiety disorders.", "journal-title": "Mt. Sinai J. Med."}, {"key": "BFnrd4075_CR44", "doi-asserted-by": "publisher", "first-page": "685", "DOI": "10.1038/nrd3502", "volume": "10", "author": "U Rudolph", "year": "2011", "unstructured": "Rudolph, U. & Knoflach, F. Beyond classical benzodiazepines: novel therapeutic potential of GABAA receptor subtypes. Nature Rev. Drug Discov. 10, 685\u2013697 (2011).", "journal-title": "Nature Rev. Drug Discov."}, {"key": "BFnrd4075_CR45", "doi-asserted-by": "publisher", "first-page": "565", "DOI": "10.1046/j.1365-2125.1996.38514.x", "volume": "41", "author": "AL VanSteveninck", "year": "1996", "unstructured": "VanSteveninck, A. L. et al. Pharmacokinetic and pharmacodynamic interactions of bretazenil and diazepam with alcohol. Br. J. Clin. Pharmacol. 41, 565\u2013573 (1996).", "journal-title": "Br. J. Clin. Pharmacol."}, {"key": "BFnrd4075_CR46", "doi-asserted-by": "publisher", "first-page": "115", "DOI": "10.1007/BF02246085", "volume": "122", "author": "J Guldner", "year": "1995", "unstructured": "Guldner, J. et al. Bretazenil modulates sleep EEG and nocturnal hormone secretion in normal men. Psychopharmacology 122, 115\u2013121 (1995).", "journal-title": "Psychopharmacology"}, {"key": "BFnrd4075_CR47", "doi-asserted-by": "publisher", "first-page": "625", "DOI": "10.1177/0269881108092595", "volume": "23", "author": "SL de Haas", "year": "2008", "unstructured": "de Haas, S. L. et al. The pharmacokinetic and pharmacodynamic effects of SL65.1498, a GABA-A \u03b12,3 selective agonist, in comparison with lorazepam in healthy volunteers. J. Psychopharmacol. 23, 625\u2013632 (2008).", "journal-title": "J. Psychopharmacol."}, {"key": "BFnrd4075_CR48", "author": "LM Surhone", "year": "2010", "unstructured": "Surhone, L. M., Timpledon, M. T. & Marseken, S. F. Ocinaplon (VDM Publishing House, 2010).", "volume-title": "Ocinaplon"}, {"key": "BFnrd4075_CR49", "doi-asserted-by": "publisher", "first-page": "374", "DOI": "10.1177/0269881106072343", "volume": "21", "author": "SL de Haas", "year": "2007", "unstructured": "de Haas, S. L. et al. Pharmacodynamic and pharmacokinetic effects of TPA023, a GABAA \u03b12,3 subtype-selective agonist, compared to lorazepam and placebo in healthy volunteers. J. Psychopharmacol. 21, 374\u2013383 (2007).", "journal-title": "J. Psychopharmacol."}, {"key": "BFnrd4075_CR50", "doi-asserted-by": "publisher", "first-page": "490", "DOI": "10.1126/science.1175055", "volume": "325", "author": "R Rupprecht", "year": "2009", "unstructured": "Rupprecht, R. et al. Translocator protein (18 kD) as target for anxiolytics without benzodiazepine-like side effects. Science 325, 490\u2013493 (2009).", "journal-title": "Science"}, {"key": "BFnrd4075_CR51", "doi-asserted-by": "publisher", "first-page": "257", "DOI": "10.1002/syn.20884", "volume": "65", "author": "DR Owen", "year": "2011", "unstructured": "Owen, D. R. et al. Variation in binding affinity of the novel anxiolytic XBD173 for the 18 kDa translocator protein in human brain. Synapse 65, 257\u2013259 (2011).", "journal-title": "Synapse"}, {"key": "BFnrd4075_CR52", "doi-asserted-by": "publisher", "first-page": "319", "DOI": "10.1016/0163-7258(95)98597-J", "volume": "65", "author": "G Griebel", "year": "1995", "unstructured": "Griebel, G. 5-hydroxytryptamine-interacting drugs in animal models of anxiety disorders: more than 30 years of research. Pharmacol. Ther. 65, 319\u2013395 (1995).", "journal-title": "Pharmacol. Ther."}, {"key": "BFnrd4075_CR53", "doi-asserted-by": "publisher", "first-page": "1527", "DOI": "10.1126/science.274.5292.1527", "volume": "274", "author": "KP Lesch", "year": "1996", "unstructured": "Lesch, K. P. et al. Association of anxiety-related traits with a polymorphism in the serotonin transporter gene regulatory region. Science 274, 1527\u20131531 (1996).", "journal-title": "Science"}, {"key": "BFnrd4075_CR54", "doi-asserted-by": "publisher", "first-page": "182", "DOI": "10.1016/j.tics.2006.02.011", "volume": "10", "author": "AR Hariri", "year": "2006", "unstructured": "Hariri, A. R. & Holmes, A. Genetics of emotional regulation: the role of the serotonin transporter in neural function. Trends Cogn. Sci. 10, 182\u2013191 (2006).", "journal-title": "Trends Cogn. Sci."}, {"key": "BFnrd4075_CR55", "doi-asserted-by": "publisher", "first-page": "141", "DOI": "10.1016/S0166-4328(01)00291-1", "volume": "125", "author": "C Belzung", "year": "2001", "unstructured": "Belzung, C. & Griebel, G. Measuring normal and pathological anxiety-like behaviour in mice: a review. Behav. Brain Res. 125, 141\u2013149 (2001).", "journal-title": "Behav. Brain Res."}, {"key": "BFnrd4075_CR56", "doi-asserted-by": "publisher", "first-page": "161", "DOI": "10.1007/7854_2009_31", "volume": "2", "author": "LH Jacobson", "year": "2010", "unstructured": "Jacobson, L. H. & Cryan, J. F. Genetic approaches to modeling anxiety in animals. Curr. Top. Behav. Neurosci. 2, 161\u2013201 (2010). This is a comprehensive review on models of anxiety involving targeted manipulation of candidate genes.", "journal-title": "Curr. Top. Behav. Neurosci."}, {"key": "BFnrd4075_CR57", "doi-asserted-by": "publisher", "first-page": "1184", "DOI": "10.1176/ajp.136.9.1184", "volume": "136", "author": "HL Goldberg", "year": "1979", "unstructured": "Goldberg, H. L. & Finnerty, R. J. The comparative efficacy of buspirone and diazepam in the treatment of anxiety. Am. J. Psychiatry 136, 1184\u20131187 (1979).", "journal-title": "Am. J. Psychiatry"}, {"key": "BFnrd4075_CR58", "first-page": "81", "volume": "43", "author": "K Rickels", "year": "1982", "unstructured": "Rickels, K. et al. Buspirone and diazepam in anxiety: a controlled study. J. Clin. Psychiatry 43, 81\u201386 (1982).", "journal-title": "J. Clin. Psychiatry"}, {"key": "BFnrd4075_CR59", "doi-asserted-by": "publisher", "first-page": "627", "DOI": "10.1016/j.biopsych.2009.03.012", "volume": "66", "author": "E Akimova", "year": "2009", "unstructured": "Akimova, E., Lanzenberger, R. & Kasper, S. The serotonin-1A receptor in anxiety disorders. Biol. Psychiatry 66, 627\u2013635 (2009).", "journal-title": "Biol. Psychiatry"}, {"key": "BFnrd4075_CR60", "doi-asserted-by": "publisher", "first-page": "10094", "DOI": "10.1523/JNEUROSCI.1960-09.2009", "volume": "29", "author": "NM Goodfellow", "year": "2009", "unstructured": "Goodfellow, N. M., Benekareddy, M., Vaidya, V. A. & Lambe, E. K. Layer II/III of the prefrontal cortex: Inhibition by the serotonin 5-HT1A receptor in development and stress. J. Neurosci. 29, 10094\u201310103 (2009).", "journal-title": "J. Neurosci."}, {"key": "BFnrd4075_CR61", "doi-asserted-by": "publisher", "first-page": "2433", "DOI": "10.1523/JNEUROSCI.5880-09.2010", "volume": "30", "author": "J Zhang", "year": "2010", "unstructured": "Zhang, J. et al. Neuronal nitric oxide synthase alteration accounts for the role of 5-HT1A receptor in modulating anxiety-related behaviors. J. Neurosci. 30, 2433\u20132441 (2010).", "journal-title": "J. Neurosci."}, {"key": "BFnrd4075_CR62", "first-page": "CD006115", "volume": "2006", "author": "CA Chessick", "year": "2006", "unstructured": "Chessick, C. A. et al. Azapirones for generalized anxiety disorder. Cochrane Database Syst. Rev. 2006, CD006115 (2006).", "journal-title": "Cochrane Database Syst. Rev."}, {"key": "BFnrd4075_CR63", "doi-asserted-by": "publisher", "first-page": "41", "DOI": "10.1016/0002-9343(86)90331-1", "volume": "80", "author": "RE Gammans", "year": "1986", "unstructured": "Gammans, R. E., Mayol, R. F. & LaBudde, J. A. Metabolism and disposition of buspirone. Am. J. Med. 80, 41\u201351 (1986).", "journal-title": "Am. J. Med."}, {"key": "BFnrd4075_CR64", "author": "DJ Nutt", "year": "2003", "unstructured": "Nutt, D. J. & Ballenger, J. C. Anxiety Disorders (Blackwell Science, 2003).", "volume-title": "Anxiety Disorders"}, {"key": "BFnrd4075_CR65", "doi-asserted-by": "publisher", "first-page": "812", "DOI": "10.1016/S0006-3223(98)00210-8", "volume": "44", "author": "JM Kent", "year": "1998", "unstructured": "Kent, J. M., Coplan, J. D. & Gorman, J. M. Clinical utility of the selective serotonin reuptake inhibitors in the spectrum of anxiety. Biol. Psychiatry 44, 812\u2013824 (1998).", "journal-title": "Biol. Psychiatry"}, {"key": "BFnrd4075_CR66", "doi-asserted-by": "publisher", "first-page": "49", "DOI": "10.1017/S1092852900009901", "volume": "10", "author": "DJ Nutt", "year": "2005", "unstructured": "Nutt, D. J. Overview of diagnosis and drug treatments of anxiety disorders. CNS Spectr. 10, 49\u201356 (2005).", "journal-title": "CNS Spectr."}, {"key": "BFnrd4075_CR67", "doi-asserted-by": "publisher", "first-page": "1064", "DOI": "10.1111/j.1476-5381.1995.tb15919.x", "volume": "115", "author": "SE Gartside", "year": "1995", "unstructured": "Gartside, S. E., Umbers, V., Hajos, M. & Sharp, T. Interaction between a selective 5-HT1A receptor antagonist and an SSRI in vivo: effects on 5-HT cell firing and extracellular 5-HT. Br. J. Pharmacol. 115, 1064\u20131070 (1995).", "journal-title": "Br. J. Pharmacol."}, {"key": "BFnrd4075_CR68", "doi-asserted-by": "publisher", "first-page": "85", "DOI": "10.1016/S0278-5846(02)00338-X", "volume": "27", "author": "M Vaswani", "year": "2003", "unstructured": "Vaswani, M., Linda, F. K. & Ramesh, S. Role of selective serotonin reuptake inhibitors in psychiatric disorders: a comprehensive review. Prog. Neuropsychopharmacol. Biol. Psychiatry 27, 85\u2013102 (2003).", "journal-title": "Prog. Neuropsychopharmacol. Biol. Psychiatry"}, {"key": "BFnrd4075_CR69", "doi-asserted-by": "publisher", "first-page": "1670", "DOI": "10.1126/science.284.5420.1670", "volume": "284", "author": "JC Crabbe", "year": "1999", "unstructured": "Crabbe, J. C., Wahlsten, D. & Dudek, B. C. Genetics of mouse behavior: interactions with laboratory environment. Science 284, 1670\u20131672 (1999). This study demonstrates that almost undetectable environmental differences may have large behavioural consequences when using anxiety tests.", "journal-title": "Science"}, {"key": "BFnrd4075_CR70", "doi-asserted-by": "publisher", "first-page": "129", "DOI": "10.1016/1056-8719(93)90063-K", "volume": "29", "author": "SL Handley", "year": "1993", "unstructured": "Handley, S. L. & McBlane, J. W. An assessment of the elevated X-maze for studying anxiety and anxiety-modulating drugs. J. Pharmacol. Toxicol. Methods 29, 129\u2013138 (1993).", "journal-title": "J. Pharmacol. Toxicol. Methods"}, {"key": "BFnrd4075_CR71", "first-page": "420", "volume": "254", "author": "DJ Sanger", "year": "1990", "unstructured": "Sanger, D. J. Effects of buspirone and related compounds on suppressed operant responding in rats. J. Pharmacol. Exp. Ther. 254, 420\u2013426 (1990).", "journal-title": "J. Pharmacol. Exp. Ther."}, {"key": "BFnrd4075_CR72", "doi-asserted-by": "publisher", "first-page": "829", "DOI": "10.1016/j.neubiorev.2005.03.021", "volume": "29", "author": "SF Maier", "year": "2005", "unstructured": "Maier, S. F. & Watkins, L. R. Stressor controllability and learned helplessness: the roles of the dorsal raphe nucleus, serotonin, and corticotropin-releasing factor. Neurosci. Biobehav. Rev. 29, 829\u2013841 (2005).", "journal-title": "Neurosci. Biobehav. Rev."}, {"key": "BFnrd4075_CR73", "doi-asserted-by": "publisher", "first-page": "561", "DOI": "10.1097/JCP.0b013e318184ff5b", "volume": "28", "author": "DJ Stein", "year": "2008", "unstructured": "Stein, D. J., Ahokas, A. A., & de Bodinat, C. Efficacy of agomelatine in generalized anxiety disorder: a randomized, double-blind, placebo-controlled study. J. Clin. Psychopharmacol. 28, 561\u2013566 (2008).", "journal-title": "J. Clin. Psychopharmacol."}, {"key": "BFnrd4075_CR74", "doi-asserted-by": "publisher", "first-page": "135", "DOI": "10.2174/187152706776359682", "volume": "5", "author": "C Belzung", "year": "2006", "unstructured": "Belzung, C., Yalcin, I., Griebel, G., Surget, A. & Leman, S. Neuropeptides in psychiatric diseases: an overview with a particular focus on depression and anxiety disorders. CNS Neurol. Disord. Drug Targets 5, 135\u2013145 (2006).", "journal-title": "CNS Neurol. Disord. Drug Targets"}, {"key": "BFnrd4075_CR75", "doi-asserted-by": "publisher", "first-page": "580", "DOI": "10.1016/j.tips.2003.09.011", "volume": "24", "author": "A Holmes", "year": "2003", "unstructured": "Holmes, A., Heilig, M., Rupniak, N. M., Steckler, T. & Griebel, G. Neuropeptide systems as novel therapeutic targets for depression and anxiety disorders. Trends Pharmacol. Sci. 24, 580\u2013588 (2003).", "journal-title": "Trends Pharmacol. Sci."}, {"key": "BFnrd4075_CR76", "doi-asserted-by": "publisher", "first-page": "98", "DOI": "10.1016/j.neuron.2012.09.014", "volume": "76", "author": "AN van den Pol", "year": "2012", "unstructured": "van den Pol, A. N. Neuropeptide transmission in brain circuits. Neuron 76, 98\u2013115 (2012).", "journal-title": "Neuron"}, {"key": "BFnrd4075_CR77", "doi-asserted-by": "publisher", "first-page": "415", "DOI": "10.1007/7854_2009_14", "volume": "2", "author": "T Steckler", "year": "2010", "unstructured": "Steckler, T. Developing small molecule nonpeptidergic drugs for the treatment of anxiety disorders: is the challenge still ahead? Curr. Top. Behav. Neurosci. 2, 415\u2013428 (2010).", "journal-title": "Curr. Top. Behav. Neurosci."}, {"key": "BFnrd4075_CR78", "doi-asserted-by": "publisher", "first-page": "1", "DOI": "10.1016/S0163-7258(98)00041-2", "volume": "82", "author": "G Griebel", "year": "1999", "unstructured": "Griebel, G. Is there a future for neuropeptide receptor ligands in the treatment of anxiety disorders? Pharmacol. Ther. 82, 1\u201361 (1999).", "journal-title": "Pharmacol. Ther."}, {"key": "BFnrd4075_CR79", "doi-asserted-by": "publisher", "first-page": "604", "DOI": "10.1038/257604a0", "volume": "257", "author": "JJ Van der Haegen", "year": "1975", "unstructured": "Van der Haegen, J. J., Signeau, J. C. & Gepts, W. New peptide in the vertebrate CNS reacting with antigastrin antibodies. Nature 257, 604\u2013605 (1975).", "journal-title": "Nature"}, {"key": "BFnrd4075_CR80", "doi-asserted-by": "publisher", "first-page": "175", "DOI": "10.1016/0006-8993(86)91413-7", "volume": "362", "author": "TH Moran", "year": "1986", "unstructured": "Moran, T. H., Robinson, P. H., Goldrich, M. S. & McHugh, P. R. Two brain cholecystokinin receptors: implications for behavioral actions. Brain Res. 362, 175\u2013179 (1986).", "journal-title": "Brain Res."}, {"key": "BFnrd4075_CR81", "doi-asserted-by": "publisher", "first-page": "462", "DOI": "10.1038/nrd3702", "volume": "11", "author": "G Griebel", "year": "2012", "unstructured": "Griebel, G. & Holsboer, F. Neuropeptide receptor ligands as drugs for psychiatric diseases: the end of the beginning? Nature Rev. Drug Discov. 11, 462\u2013478 (2012).", "journal-title": "Nature Rev. Drug Discov."}, {"key": "BFnrd4075_CR82", "doi-asserted-by": "publisher", "first-page": "1394", "DOI": "10.1126/science.6267699", "volume": "213", "author": "WW Vale", "year": "1981", "unstructured": "Vale, W. W., Spiess, J., Rivier, C. & Rivier, J. Characterization of a 41 residue ovine hypothalamic peptide that stimulates the secretion of corticotropin and \u03b2-endorphin. Science 213, 1394\u20131397 (1981).", "journal-title": "Science"}, {"key": "BFnrd4075_CR83", "doi-asserted-by": "publisher", "first-page": "6340", "DOI": "10.1523/JNEUROSCI.15-10-06340.1995", "volume": "15", "author": "DT Chalmers", "year": "1995", "unstructured": "Chalmers, D. T., Lovenberg, T. W. & De Souza, E. B. Localization of novel corticotropin-releasing factor receptor (CRF2) mRNA expression to specific subcortical nuclei in rat brain: comparison with CRF1 receptor mRNA expression. J. Neurosci. 15, 6340\u20136350 (1995).", "journal-title": "J. Neurosci."}, {"key": "BFnrd4075_CR84", "author": "M Turiault", "first-page": "1301", "year": "2010", "unstructured": "Turiault, M., Cohen, C. & Griebel, G. in Encyclopedia of Psychopharmacology (ed. Stolerman, I. P.) 1301\u20131303 (Springer-Verlag, 2010).", "volume-title": "Encyclopedia of Psychopharmacology", "DOI": "10.1007/978-3-540-68706-1_210", "doi-asserted-by": "publisher"}, {"key": "BFnrd4075_CR85", "first-page": "551", "volume": "46", "author": "D Regoli", "year": "1994", "unstructured": "Regoli, D., Boudon, A. & Fauchere, J. L. Receptors and antagonists for substance P and related peptides. Pharmacol. Rev. 46, 551\u2013599 (1994).", "journal-title": "Pharmacol. Rev."}, {"key": "BFnrd4075_CR86", "doi-asserted-by": "publisher", "first-page": "116", "DOI": "10.1016/j.pharmthera.2011.09.007", "volume": "133", "author": "G Griebel", "year": "2012", "unstructured": "Griebel, G. & Beeske, S. Is there still a future for neurokinin 3 receptor antagonists as potential drugs for the treatment of psychiatric diseases? Pharmacol. Ther. 133, 116\u2013123 (2012).", "journal-title": "Pharmacol. Ther."}, {"key": "BFnrd4075_CR87", "doi-asserted-by": "publisher", "first-page": "429", "DOI": "10.1002/emmm.201000100", "volume": "2", "author": "SP Brothers", "year": "2010", "unstructured": "Brothers, S. P. & Wahlestedt, C. Therapeutic potential of neuropeptide Y (NPY) receptor ligands. EMBO Mol. Med. 2, 429\u2013439 (2010).", "journal-title": "EMBO Mol. Med."}, {"key": "BFnrd4075_CR88", "doi-asserted-by": "publisher", "first-page": "1", "DOI": "10.1007/400_2007_057", "volume": "46", "author": "O Civelli", "year": "2008", "unstructured": "Civelli, O. The orphanin FQ/nociceptin (OFQ/N) system. Results Probl. Cell Differ. 46, 1\u201325 (2008).", "journal-title": "Results Probl. Cell Differ."}, {"key": "BFnrd4075_CR89", "doi-asserted-by": "publisher", "first-page": "177", "DOI": "10.1016/j.pharmthera.2007.05.009", "volume": "115", "author": "R Lang", "year": "2007", "unstructured": "Lang, R., Gundlach, A. L. & Kofler, B. The galanin peptide family: receptor pharmacology, pleiotropic biological actions, and implications in health and disease. Pharmacol. Ther. 115, 177\u2013207 (2007).", "journal-title": "Pharmacol. Ther."}, {"key": "BFnrd4075_CR90", "doi-asserted-by": "publisher", "first-page": "801", "DOI": "10.2165/00023210-200620100-00002", "volume": "20", "author": "T Shimazaki", "year": "2006", "unstructured": "Shimazaki, T., Yoshimizu, T. & Chaki, S. Melanin-concentrating hormone MCH1 receptor antagonists: a potential new approach to the treatment of depression and anxiety disorders. CNS Drugs 20, 801\u2013811 (2006).", "journal-title": "CNS Drugs"}, {"key": "BFnrd4075_CR91", "doi-asserted-by": "publisher", "first-page": "e19286", "DOI": "10.1371/journal.pone.0019286", "volume": "6", "author": "S Chung", "year": "2011", "unstructured": "Chung, S. et al. The melanin-concentrating hormone (MCH) system modulates behaviors associated with psychiatric disorders. PLoS ONE 6, e19286 (2011).", "journal-title": "PLoS ONE"}, {"key": "BFnrd4075_CR92", "doi-asserted-by": "publisher", "first-page": "487", "DOI": "10.1016/j.neuron.2004.08.005", "volume": "43", "author": "YL Xu", "year": "2004", "unstructured": "Xu, Y. L. et al. Neuropeptide S: a neuropeptide promoting arousal and anxiolytic-like effects. Neuron 43, 487\u2013497 (2004).", "journal-title": "Neuron"}, {"key": "BFnrd4075_CR93", "doi-asserted-by": "publisher", "first-page": "646", "DOI": "10.1038/mp.2012.101", "volume": "18", "author": "R Sah", "year": "2013", "unstructured": "Sah, R. & Geracioti, T. D. Neuropeptide Y and posttraumatic stress disorder. Mol. Psychiatry 18, 646\u2013655 (2013).", "journal-title": "Mol. Psychiatry"}, {"key": "BFnrd4075_CR94", "doi-asserted-by": "publisher", "first-page": "669", "DOI": "10.2165/11533230-000000000-00000", "volume": "24", "author": "JH Krystal", "year": "2010", "unstructured": "Krystal, J. H. et al. Potential psychiatric applications of metabotropic glutamate receptor agonists and antagonists. CNS Drugs 24, 669\u2013693 (2010).", "journal-title": "CNS Drugs"}, {"key": "BFnrd4075_CR95", "doi-asserted-by": "publisher", "first-page": "1603", "DOI": "10.1038/sj.npp.1301531", "volume": "33", "author": "E Dunayevich", "year": "2008", "unstructured": "Dunayevich, E. et al. Efficacy and tolerability of an mGlu2/3 agonist in the treatment of generalized anxiety disorder. Neuropsychopharmacology 33, 1603\u20131610 (2008).", "journal-title": "Neuropsychopharmacology"}, {"key": "BFnrd4075_CR96", "doi-asserted-by": "publisher", "first-page": "291", "DOI": "10.1097/00004850-200511000-00001", "volume": "20", "author": "V Bergink", "year": "2005", "unstructured": "Bergink, V. & Westenberg, H. G. Metabotropic glutamate II receptor agonists in panic disorder: a double blind clinical trial with LY354740. Int. Clin. Psychopharmacol. 20, 291\u2013293 (2005).", "journal-title": "Int. Clin. Psychopharmacol."}, {"key": "BFnrd4075_CR97", "doi-asserted-by": "publisher", "first-page": "426", "DOI": "10.1038/nrd2462", "volume": "7", "author": "G Sanacora", "year": "2008", "unstructured": "Sanacora, G., Zarate, C. A., Krystal, J. H. & Manji, H. K. Targeting the glutamatergic system to develop novel, improved therapeutics for mood disorders. Nature Rev. Drug Discov. 7, 426\u2013437 (2008).", "journal-title": "Nature Rev. Drug Discov."}, {"key": "BFnrd4075_CR98", "doi-asserted-by": "publisher", "first-page": "1136", "DOI": "10.1001/archpsyc.61.11.1136", "volume": "61", "author": "KJ Ressler", "year": "2004", "unstructured": "Ressler, K. J. et al. Cognitive enhancers as adjuncts to psychotherapy: use of d-cycloserine in phobic individuals to facilitate extinction of fear. Arch. Gen. Psychiatry 61, 1136\u20131144 (2004).", "journal-title": "Arch. Gen. Psychiatry"}, {"key": "BFnrd4075_CR99", "doi-asserted-by": "publisher", "first-page": "1118", "DOI": "10.1016/j.biopsych.2008.01.012", "volume": "63", "author": "MM Norberg", "year": "2008", "unstructured": "Norberg, M. M., Krystal, J. H. & Tolin, D. F. A meta-analysis of d-cycloserine and the facilitation of fear extinction and exposure therapy. Biol. Psychiatry 63, 1118\u20131126 (2008).", "journal-title": "Biol. Psychiatry"}, {"key": "BFnrd4075_CR100", "doi-asserted-by": "publisher", "first-page": "1932", "DOI": "10.1073/pnas.87.5.1932", "volume": "87", "author": "M Herkenham", "year": "1990", "unstructured": "Herkenham, M. et al. Cannabinoid receptor localization in brain. Proc. Natl Acad. Sci. USA 87, 1932\u20131936 (1990).", "journal-title": "Proc. Natl Acad. Sci. USA"}, {"key": "BFnrd4075_CR101", "doi-asserted-by": "publisher", "first-page": "813", "DOI": "10.1038/mp.2012.72", "volume": "18", "author": "O Gunduz-Cinar", "year": "2013", "unstructured": "Gunduz-Cinar, O. et al. Convergent translational evidence of a role for anandamide in amygdala-mediated fear extinction, threat processing and stress-reactivity. Mol. Psychiatry 18, 813\u2013823 (2013).", "journal-title": "Mol. Psychiatry"}, {"key": "BFnrd4075_CR102", "unstructured": "Neumeister, A. et al. Elevated brain cannabinoid CB1 receptor availability in post-traumatic stress disorder: a positron emission tomography study. Mol. Psychiatry \n                    http://dx.doi.org/10.1038/mp.2013.61\n                    \n                   (2013).", "DOI": "10.1038/mp.2013.61", "doi-asserted-by": "publisher"}, {"key": "BFnrd4075_CR103", "doi-asserted-by": "publisher", "first-page": "261", "DOI": "10.1016/j.biopsych.2004.10.032", "volume": "57", "author": "G Griebel", "year": "2005", "unstructured": "Griebel, G., Stemmelin, J. & Scatton, B. Effects of the cannabinoid CB1 receptor antagonist rimonabant in models of emotional reactivity in rodents. Biol. Psychiatry 57, 261\u2013267 (2005).", "journal-title": "Biol. Psychiatry"}, {"key": "BFnrd4075_CR104", "doi-asserted-by": "publisher", "first-page": "685", "DOI": "10.1111/j.1601-183X.2009.00512.x", "volume": "8", "author": "W Jacob", "year": "2009", "unstructured": "Jacob, W. et al. Endocannabinoids render exploratory behaviour largely independent of the test aversiveness: role of glutamatergic transmission. Genes Brain Behav. 8, 685\u2013698 (2009).", "journal-title": "Genes Brain Behav."}, {"key": "BFnrd4075_CR105", "doi-asserted-by": "publisher", "first-page": "299", "DOI": "10.1097/01.fbp.0000135704.56422.40", "volume": "15", "author": "J Haller", "year": "2004", "unstructured": "Haller, J., Varga, B., Ledent, C. & Freund, T. F. CB1 cannabinoid receptors mediate anxiolytic effects: convergent genetic and pharmacological evidence with CB1-specific agents. Behav. Pharmacol. 15, 299\u2013304 (2004).", "journal-title": "Behav. Pharmacol."}, {"key": "BFnrd4075_CR106", "doi-asserted-by": "publisher", "first-page": "429", "DOI": "10.1007/7854_2009_16", "volume": "2", "author": "FA Moreira", "year": "2010", "unstructured": "Moreira, F. A. & Wotjak, C. T. Cannabinoids and anxiety. Curr. Top. Behav. Neurosci. 2, 429\u2013450 (2010).", "journal-title": "Curr. Top. Behav. Neurosci."}, {"key": "BFnrd4075_CR107", "doi-asserted-by": "publisher", "first-page": "7109", "DOI": "10.1523/JNEUROSCI.1054-12.2012", "volume": "32", "author": "M Metna-Laurent", "year": "2012", "unstructured": "Metna-Laurent, M. et al. Bimodal control of fear-coping strategies by CB1 cannabinoid receptors. J. Neurosci. 32, 7109\u20137118 (2012).", "journal-title": "J. Neurosci."}, {"key": "BFnrd4075_CR108", "doi-asserted-by": "publisher", "first-page": "517", "DOI": "10.1016/S0140-6736(10)60935-X", "volume": "376", "author": "EJ Topol", "year": "2010", "unstructured": "Topol, E. J. et al. Rimonabant for prevention of cardiovascular events (CRESCENDO): a randomised, multicentre, placebo-controlled trial. Lancet 376, 517\u2013523 (2010).", "journal-title": "Lancet"}, {"key": "BFnrd4075_CR109", "unstructured": "Hill, M. N. et al. Disruption of fatty acid amide hydrolase activity prevents the effects of chronic stress on anxiety and amygdalar microstructure. Mol. Psychiatry \n                    http://dx.doi.org/10.1038/mp.2012.90\n                    \n                   (2012).", "DOI": "10.1038/mp.2012.90", "doi-asserted-by": "publisher"}, {"key": "BFnrd4075_CR110", "author": "M Bortolato", "first-page": "303", "year": "2008", "unstructured": "Bortolato, M. & Piomelli, D. in Handbook of Anxiety and Fear (eds Blanchard, R. J., Blanchard, D. C., Griebel, G. & Nutt, D.) 303\u2013324 (Elsevier, 2008).", "volume-title": "Handbook of Anxiety and Fear", "DOI": "10.1016/S1569-7339(07)00014-8", "doi-asserted-by": "publisher"}, {"key": "BFnrd4075_CR111", "doi-asserted-by": "publisher", "first-page": "18", "DOI": "10.1016/j.pharmthera.2012.12.002", "volume": "138", "author": "V Micale", "year": "2013", "unstructured": "Micale, V. et al. Endocannabinoid system and mood disorders: priming a target for new therapies. Pharmacol. Ther. 138, 18\u201337 (2013).", "journal-title": "Pharmacol. Ther."}, {"key": "BFnrd4075_CR112", "doi-asserted-by": "publisher", "first-page": "27", "DOI": "10.1038/475027a", "volume": "475", "author": "PY Collins", "year": "2011", "unstructured": "Collins, P. Y. et al. Grand challenges in global mental health. Nature 475, 27\u201330 (2011).", "journal-title": "Nature"}, {"key": "BFnrd4075_CR113", "doi-asserted-by": "publisher", "first-page": "477", "DOI": "10.1097/00008877-199711000-00003", "volume": "8", "author": "RJ Rodgers", "year": "1997", "unstructured": "Rodgers, R. J. Animal models of 'anxiety': where next? Behav. Pharmacol. 8, 477\u2013496 (1997).", "journal-title": "Behav. Pharmacol."}, {"key": "BFnrd4075_CR114", "doi-asserted-by": "publisher", "first-page": "1059", "DOI": "10.1038/80553", "volume": "3", "author": "F Crestani", "year": "2000", "unstructured": "Crestani, F., Martin, J. R., Mohler, H. & Rudolph, U. Resolving differences in GABAA receptor mutant mouse studies. Nature Neurosci. 3, 1059 (2000).", "journal-title": "Nature Neurosci."}, {"key": "BFnrd4075_CR115", "doi-asserted-by": "publisher", "first-page": "381", "DOI": "10.1001/archgenpsychiatry.2011.1603", "volume": "69", "author": "RC Kessler", "year": "2012", "unstructured": "Kessler, R. C. et al. Severity of 12-month DSM-IV disorders in the National Comorbidity Survey Replication Adolescent Supplement. Arch. Gen. Psychiatry 69, 381\u2013389 (2012).", "journal-title": "Arch. Gen. Psychiatry"}, {"key": "BFnrd4075_CR116", "doi-asserted-by": "publisher", "first-page": "79", "DOI": "10.1177/026988119500900201", "volume": "9", "author": "DC Blanchard", "year": "1995", "unstructured": "Blanchard, D. C., Griebel, G. & Blanchard, R. J. Gender bias in the preclinical psychopharmacology of anxiety: male models for (predominantly) female disorders. J. Psychopharmacol. 9, 79\u201382 (1995).", "journal-title": "J. Psychopharmacol."}, {"key": "BFnrd4075_CR117", "doi-asserted-by": "publisher", "first-page": "219", "DOI": "10.1016/S0149-7634(01)00010-0", "volume": "25", "author": "P Palanza", "year": "2001", "unstructured": "Palanza, P. Animal models of anxiety and depression: how are females different? Neurosci. Biobehav. Rev. 25, 219\u2013233 (2001).", "journal-title": "Neurosci. Biobehav. Rev."}, {"key": "BFnrd4075_CR118", "doi-asserted-by": "publisher", "first-page": "143", "DOI": "10.2165/00003088-200948030-00001", "volume": "48", "author": "OP Soldin", "year": "2009", "unstructured": "Soldin, O. P. & Mattison, D. R. Sex differences in pharmacokinetics and pharmacodynamics. Clin. Pharmacokinet. 48, 143\u2013157 (2009).", "journal-title": "Clin. Pharmacokinet."}, {"key": "BFnrd4075_CR119", "doi-asserted-by": "publisher", "first-page": "682", "DOI": "10.1038/nchembio.118", "volume": "4", "author": "AL Hopkins", "year": "2008", "unstructured": "Hopkins, A. L. Network pharmacology: the next paradigm in drug discovery. Nature Chem. Biol. 4, 682\u2013690 (2008).", "journal-title": "Nature Chem. Biol."}, {"key": "BFnrd4075_CR120", "doi-asserted-by": "publisher", "first-page": "27", "DOI": "10.1016/j.tips.2004.11.007", "volume": "26", "author": "MB Youdim", "year": "2005", "unstructured": "Youdim, M. B. & Buccafusco, J. J. Multi-functional drugs for various CNS targets in the treatment of neurodegenerative disorders. Trends Pharmacol. Sci. 26, 27\u201335 (2005).", "journal-title": "Trends Pharmacol. Sci."}, {"key": "BFnrd4075_CR121", "doi-asserted-by": "publisher", "first-page": "215", "DOI": "10.1038/nature11691", "volume": "492", "author": "J Besnard", "year": "2012", "unstructured": "Besnard, J. et al. Automated design of ligands to polypharmacological profiles. Nature 492, 215\u2013220 (2012).", "journal-title": "Nature"}, {"key": "BFnrd4075_CR122", "doi-asserted-by": "publisher", "first-page": "23", "DOI": "10.1016/j.drudis.2011.08.002", "volume": "17", "author": "G Bottegoni", "year": "2012", "unstructured": "Bottegoni, G., Favia, A. D., Recanatini, M. & Cavalli, A. The role of fragment-based and computational methods in polypharmacology. Drug Discov. Today 17, 23\u201334 (2012).", "journal-title": "Drug Discov. Today"}, {"key": "BFnrd4075_CR123", "doi-asserted-by": "publisher", "first-page": "9", "DOI": "10.1016/j.neuron.2011.06.004", "volume": "71", "author": "O Yizhar", "year": "2011", "unstructured": "Yizhar, O., Fenno, L. E., Davidson, T. J., Mogri, M. & Deisseroth, K. Optogenetics in neural systems. Neuron 71, 9\u201334 (2011).", "journal-title": "Neuron"}, {"key": "BFnrd4075_CR124", "doi-asserted-by": "publisher", "first-page": "16082", "DOI": "10.1523/JNEUROSCI.1731-10.2010", "volume": "30", "author": "HE Covington", "year": "2010", "unstructured": "Covington, H. E. et al. Antidepressant effect of optogenetic stimulation of the medial prefrontal cortex. J. Neurosci. 30, 16082\u201316090 (2010).", "journal-title": "J. Neurosci."}, {"key": "BFnrd4075_CR125", "unstructured": "American Psychiatric Association Taskforce on DSM-IV. Diagnostic and Statistical Manual of Mental Disorders: DSM-IV-TR (American Psychiatric Association, 2000)."}, {"key": "BFnrd4075_CR126", "author": "DJ Nutt", "first-page": "365", "year": "2008", "unstructured": "Nutt, D. J., Garcia de Miguel, B. & Davies, S. J. C. in Handbook of Anxiety and Fear (eds Blanchard, R. J., Blanchard, D. C., Griebel, G. & Nutt, D. J.) 365\u2013393 (Academic Press, 2008).", "volume-title": "Handbook of Anxiety and Fear", "DOI": "10.1016/S1569-7339(07)00017-3", "doi-asserted-by": "publisher"}, {"key": "BFnrd4075_CR127", "doi-asserted-by": "publisher", "first-page": "2457", "DOI": "10.1517/14656566.2011.618496", "volume": "12", "author": "JA Reinhold", "year": "2011", "unstructured": "Reinhold, J. A., Mandos, L. A., Rickels, K. & Lohoff, F. W. Pharmacological treatment of generalized anxiety disorder. Expert. Opin. Pharmacother. 12, 2457\u20132467 (2011).", "journal-title": "Expert. Opin. Pharmacother."}, {"key": "BFnrd4075_CR128", "doi-asserted-by": "publisher", "first-page": "593", "DOI": "10.1001/archpsyc.62.6.593", "volume": "62", "author": "RC Kessler", "year": "2005", "unstructured": "Kessler, R. C. et al. Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication. Arch. Gen. Psychiatry 62, 593\u2013602 (2005).", "journal-title": "Arch. Gen. Psychiatry"}, {"key": "BFnrd4075_CR129", "doi-asserted-by": "publisher", "first-page": "617", "DOI": "10.1001/archpsyc.62.6.617", "volume": "62", "author": "RC Kessler", "year": "2005", "unstructured": "Kessler, R. C., Chiu, W. T., Demler, O., Merikangas, K. R. & Walters, E. E. Prevalence, severity, and comorbidity of 12-month DSM-IV disorders in the National Comorbidity Survey Replication. Arch. Gen. Psychiatry 62, 617\u2013627 (2005).", "journal-title": "Arch. Gen. Psychiatry"}, {"key": "BFnrd4075_CR130", "doi-asserted-by": "publisher", "first-page": "703", "DOI": "10.1682/JRRD.2011.09.0183", "volume": "49", "author": "M Jeffreys", "year": "2012", "unstructured": "Jeffreys, M., Capehart, B. & Friedman, M. J. Pharmacotherapy for posttraumatic stress disorder: review with clinical applications. J. Rehabil. Res. Dev. 49, 703\u2013715 (2012).", "journal-title": "J. Rehabil. Res. Dev."}, {"key": "BFnrd4075_CR131", "doi-asserted-by": "publisher", "first-page": "469", "DOI": "10.1007/7854_2009_35", "volume": "2", "author": "M Stein", "year": "2010", "unstructured": "Stein, M., Steckler, T., Lightfoot, J. D., Hay, E. & Goddard, A. W. Pharmacologic treatment of panic disorder. Curr. Top. Behav. Neurosci. 2, 469\u2013485 (2010).", "journal-title": "Curr. Top. Behav. Neurosci."}, {"key": "BFnrd4075_CR132", "doi-asserted-by": "publisher", "first-page": "8", "DOI": "10.1001/archpsyc.1994.03950010008002", "volume": "51", "author": "RC Kessler", "year": "1994", "unstructured": "Kessler, R. C. et al. Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States: results from the National Comorbidity Survey. Arch. Gen. Psychiatry 51, 8\u201319 (1994).", "journal-title": "Arch. Gen. Psychiatry"}, {"key": "BFnrd4075_CR133", "doi-asserted-by": "publisher", "first-page": "487", "DOI": "10.1007/7854_2009_1", "volume": "2", "author": "KA Ganasen", "year": "2010", "unstructured": "Ganasen, K. A. & Stein, D. J. Pharmacotherapy of social anxiety disorder. Curr. Top. Behav. Neurosci. 2, 487\u2013503 (2010).", "journal-title": "Curr. Top. Behav. Neurosci."}, {"key": "BFnrd4075_CR134", "doi-asserted-by": "publisher", "first-page": "585", "DOI": "10.2165/11587860-000000000-00000", "volume": "25", "author": "A Abudy", "year": "2011", "unstructured": "Abudy, A., Juven-Wetzler, A. & Zohar, J. Pharmacological management of treatment-resistant obsessive-compulsive disorder. CNS Drugs 25, 585\u2013596 (2011).", "journal-title": "CNS Drugs"}, {"key": "BFnrd4075_CR135", "doi-asserted-by": "publisher", "first-page": "357", "DOI": "10.1016/S0893-133X(02)00312-3", "volume": "27", "author": "GB Varty", "year": "2002", "unstructured": "Varty, G. B., Morgan, C. A., Cohen-Williams, M. E., Coffin, V. L. & Carey, G. J. The gerbil elevated plus-maze I: behavioral characterization and pharmacological validation. Neuropsychopharmacology 27, 357\u2013370 (2002).", "journal-title": "Neuropsychopharmacology"}, {"key": "BFnrd4075_CR136", "doi-asserted-by": "publisher", "first-page": "56", "DOI": "10.1007/BF02244871", "volume": "116", "author": "JK Shepherd", "year": "1994", "unstructured": "Shepherd, J. K., Grewal, S. S., Fletcher, A., Bill, D. J. & Dourish, C. T. Behavioural and pharmacological characterisation of the elevated \u201czero-maze\u201d as an animal model of anxiety. Psychopharmacology 116, 56\u201364 (1994).", "journal-title": "Psychopharmacology"}, {"key": "BFnrd4075_CR137", "doi-asserted-by": "publisher", "first-page": "490", "DOI": "10.1007/BF02244657", "volume": "110", "author": "A Rex", "year": "1993", "unstructured": "Rex, A., Marsden, C. A. & Fink, H. Effect of diazepam on cortical 5-HT release and behaviour in the guinea-pig on exposure to the elevated plus maze. Psychopharmacology 110, 490\u2013496 (1993).", "journal-title": "Psychopharmacology"}, {"key": "BFnrd4075_CR138", "doi-asserted-by": "publisher", "first-page": "119", "DOI": "10.1016/S0376-6357(89)80010-5", "volume": "8", "author": "R Misslin", "year": "1989", "unstructured": "Misslin, R., Belzung, C. & Vogel, E. Behavioural validation of a light/dark choice procedure for testing anti-anxiety agents. Behav. Process. 8, 119\u2013132 (1989).", "journal-title": "Behav. Process."}, {"key": "BFnrd4075_CR139", "doi-asserted-by": "publisher", "first-page": "127", "DOI": "10.1007/BF00496051", "volume": "64", "author": "L de Angelis", "year": "1979", "unstructured": "de Angelis, L. & File, S. E. Acute and chronic effects of three benzodiazepines in the social interaction anxiety test in mice. Psychopharmacology 64, 127\u2013129 (1979).", "journal-title": "Psychopharmacology"}, {"key": "BFnrd4075_CR140", "doi-asserted-by": "publisher", "first-page": "219", "DOI": "10.1016/0165-0270(80)90012-6", "volume": "2", "author": "SE File", "year": "1980", "unstructured": "File, S. E. The use of social interaction as a method for detecting anxiolytic activity of chlordiazepoxide-like drugs. J. Neurosci. Methods 2, 219\u2013238 (1980).", "journal-title": "J. Neurosci. Methods"}, {"key": "BFnrd4075_CR141", "doi-asserted-by": "publisher", "first-page": "415", "DOI": "10.1007/BF02244298", "volume": "103", "author": "MH Thiebot", "year": "1991", "unstructured": "Thiebot, M. H., Dangoumau, L., Richard, G. & Puech, A. J. Safety signal withdrawal: a behavioural paradigm sensitive to both \u201canxiolytic\u201d and \u201canxiogenic\u201d drugs under identical experimental conditions. Psychopharmacology 103, 415\u2013424 (1991).", "journal-title": "Psychopharmacology"}, {"key": "BFnrd4075_CR142", "doi-asserted-by": "publisher", "first-page": "402", "DOI": "10.1016/0165-6147(91)90616-Z", "volume": "12", "author": "JT Winslow", "year": "1991", "unstructured": "Winslow, J. T. & Insel, T. R. The infant rat separation paradigm: a novel test for novel anxiolytics. Trends Pharmacol. Sci. 12, 402\u2013404 (1991).", "journal-title": "Trends Pharmacol. Sci."}, {"key": "BFnrd4075_CR143", "doi-asserted-by": "publisher", "first-page": "407", "DOI": "10.1016/j.ejphar.2008.02.097", "volume": "585", "author": "CH Vinkers", "year": "2008", "unstructured": "Vinkers, C. H. et al. Translational aspects of pharmacological research into anxiety disorders: the stress-induced hyperthermia (SIH) paradigm. Eur. J. Pharmacol. 585, 407\u2013425 (2008).", "journal-title": "Eur. J. Pharmacol."}, {"key": "BFnrd4075_CR144", "doi-asserted-by": "publisher", "first-page": "145", "DOI": "10.1016/0014-2999(68)90170-2", "volume": "4", "author": "JR Boissier", "year": "1968", "unstructured": "Boissier, J. R., Simon, P. & Aron, C. A new method for the rapid screening of minor tranquillisers in mice. Eur. J. Pharmacol. 4, 145\u2013151 (1968).", "journal-title": "Eur. J. Pharmacol."}, {"key": "BFnrd4075_CR145", "doi-asserted-by": "publisher", "first-page": "63", "DOI": "10.1016/0091-3057(91)90590-X", "volume": "38", "author": "K Njung'e", "year": "1991", "unstructured": "Njung'e, K. & Handley, S. L. Evaluation of marble-burying behavior as a model of anxiety. Pharmacol. Biochem. Behav. 38, 63\u201367 (1991).", "journal-title": "Pharmacol. Biochem. Behav."}, {"key": "BFnrd4075_CR146", "doi-asserted-by": "publisher", "first-page": "619", "DOI": "10.1016/0091-3057(81)90219-7", "volume": "15", "author": "D Treit", "year": "1981", "unstructured": "Treit, D., Pinel, J. P. & Fibiger, H. C. Conditioned defensive burying: a new paradigm for the study of anxiolytic agents. Pharmacol. Biochem. Behav. 15, 619\u2013626 (1981).", "journal-title": "Pharmacol. Biochem. Behav."}, {"key": "BFnrd4075_CR147", "doi-asserted-by": "publisher", "first-page": "814", "DOI": "10.1037/0735-7044.100.6.814", "volume": "100", "author": "M Davis", "year": "1986", "unstructured": "Davis, M. Pharmacological and anatomical analysis of fear conditioning using the fear-potentiated startle paradigm. Behav. Neurosci. 100, 814\u2013824 (1986).", "journal-title": "Behav. Neurosci."}, {"key": "BFnrd4075_CR148", "doi-asserted-by": "publisher", "first-page": "160", "DOI": "10.1016/S0163-1047(80)91041-9", "volume": "30", "author": "MA Geyer", "year": "1980", "unstructured": "Geyer, M. A., Petersen, L. R. & Rose, G. J. Effects of serotonergic lesions on investigatory responding by rats in a holeboard. Behav. Neural. Biol. 30, 160\u2013177 (1980).", "journal-title": "Behav. Neural. Biol."}, {"key": "BFnrd4075_CR149", "doi-asserted-by": "publisher", "first-page": "298", "DOI": "10.1007/BF00181937", "volume": "95", "author": "SR Bodnoff", "year": "1988", "unstructured": "Bodnoff, S. R., Suranyi Cadotte, B., Aitken, D. H., Quirion, R. & Meaney, M. J. The effects of chronic antidepressant treatment in an animal model of anxiety. Psychopharmacology 95, 298\u2013302 (1988).", "journal-title": "Psychopharmacology"}, {"key": "BFnrd4075_CR150", "doi-asserted-by": "publisher", "first-page": "549", "DOI": "10.1016/0091-3057(94)90067-1", "volume": "49", "author": "MB Viana", "year": "1994", "unstructured": "Viana, M. B., Tomaz, C. & Graeff, F. G. The elevated T-maze: a new animal model of anxiety and memory. Pharmacol. Biochem. Behav. 49, 549\u2013554 (1994).", "journal-title": "Pharmacol. Biochem. Behav."}, {"key": "BFnrd4075_CR151", "doi-asserted-by": "publisher", "first-page": "513", "DOI": "10.1016/j.biopsych.2009.06.015", "volume": "67", "author": "J Espana", "year": "2010", "unstructured": "Espana, J. et al. Intraneuronal \u03b2-amyloid accumulation in the amygdala enhances fear and anxiety in Alzheimer's disease transgenic mice. Biol. Psychiatry 67, 513\u2013521 (2010).", "journal-title": "Biol. Psychiatry"}, {"key": "BFnrd4075_CR152", "doi-asserted-by": "publisher", "first-page": "6008", "DOI": "10.1523/JNEUROSCI.5836-10.2011", "volume": "31", "author": "JW Richardson-Jones", "year": "2011", "unstructured": "Richardson-Jones, J. W. et al. Serotonin-1A autoreceptors are necessary and sufficient for the normal formation of circuits underlying innate anxiety. J. Neurosci. 31, 6008\u20136018 (2011).", "journal-title": "J. Neurosci."}, {"key": "BFnrd4075_CR153", "doi-asserted-by": "publisher", "first-page": "7592", "DOI": "10.1073/pnas.0914805107", "volume": "107", "author": "G Gleason", "year": "2010", "unstructured": "Gleason, G. et al. The serotonin1A receptor gene as a genetic and prenatal maternal environmental factor in anxiety. Proc. Natl Acad. Sci. USA 107, 7592\u20137597 (2010).", "journal-title": "Proc. Natl Acad. Sci. USA"}, {"key": "BFnrd4075_CR154", "doi-asserted-by": "publisher", "first-page": "896", "DOI": "10.1038/nn1919", "volume": "10", "author": "T Tsetsenis", "year": "2007", "unstructured": "Tsetsenis, T., Ma, X. H., Lo, I. L., Beck, S. G. & Gross, C. Suppression of conditioning to ambiguous cues by pharmacogenetic inhibition of the dentate gyrus. Nature Neurosci. 10, 896\u2013902 (2007).", "journal-title": "Nature Neurosci."}, {"key": "BFnrd4075_CR155", "doi-asserted-by": "publisher", "first-page": "101", "DOI": "10.1038/sj.npp.1300774", "volume": "31", "author": "KC Klemenhagen", "year": "2005", "unstructured": "Klemenhagen, K. C., Gordon, J. A., David, D. J., Hen, R. & Gross, C. T. Increased fear response to contextual cues in mice lacking the 5-HT1A receptor. Neuropsychopharmacology 31, 101\u2013111 (2005).", "journal-title": "Neuropsychopharmacology"}, {"key": "BFnrd4075_CR156", "doi-asserted-by": "publisher", "first-page": "10868", "DOI": "10.1523/JNEUROSCI.3223-04.2004", "volume": "24", "author": "Q Li", "year": "2004", "unstructured": "Li, Q. et al. Medial hypothalamic 5-hydroxytryptamine (5-HT)1A receptors regulate neuroendocrine responses to stress and exploratory locomotor activity: application of recombinant adenovirus containing 5-HT1A sequences. J. Neurosci. 24, 10868\u201310877 (2004).", "journal-title": "J. Neurosci."}, {"key": "BFnrd4075_CR157", "doi-asserted-by": "publisher", "first-page": "6343", "DOI": "10.1523/JNEUROSCI.0563-04.2004", "volume": "24", "author": "SJ Bailey", "year": "2004", "unstructured": "Bailey, S. J. & Toth, M. Variability in the benzodiazepine response of serotonin 5-HT1A receptor null mice displaying anxiety-like phenotype: evidence for genetic modifiers in the 5-HT-mediated regulation of GABAA receptors. J. Neurosci. 24, 6343\u20136351 (2004).", "journal-title": "J. Neurosci."}, {"key": "BFnrd4075_CR158", "doi-asserted-by": "publisher", "first-page": "380", "DOI": "10.1016/S0893-133X(02)00317-2", "volume": "27", "author": "T Pattij", "year": "2002", "unstructured": "Pattij, T. et al. Autonomic changes associated with enhanced anxiety in 5-HT1A receptor knockout mice. Neuropsychopharmacology 27, 380\u2013390 (2002).", "journal-title": "Neuropsychopharmacology"}, {"key": "BFnrd4075_CR159", "doi-asserted-by": "publisher", "first-page": "396", "DOI": "10.1038/416396a", "volume": "416", "author": "C Gross", "year": "2002", "unstructured": "Gross, C. et al. Serotonin1A receptor acts during development to establish normal anxiety-like behaviour in the adult. Nature 416, 396\u2013400 (2002).", "journal-title": "Nature"}, {"key": "BFnrd4075_CR160", "doi-asserted-by": "publisher", "first-page": "2758", "DOI": "10.1523/JNEUROSCI.20-08-02758.2000", "volume": "20", "author": "E Sibille", "year": "2000", "unstructured": "Sibille, E., Pavlides, C., Benke, D. & Toth, M. Genetic inactivation of the serotonin1A receptor in mice results in downregulation of major GABAA receptor \u03b1 subunits, reduction of GABAA receptor binding, and benzodiazepine-resistant anxiety. J. Neurosci. 20, 2758\u20132765 (2000).", "journal-title": "J. Neurosci."}, {"key": "BFnrd4075_CR161", "doi-asserted-by": "publisher", "first-page": "14476", "DOI": "10.1073/pnas.95.24.14476", "volume": "95", "author": "S Ramboz", "year": "1998", "unstructured": "Ramboz, S. et al. Serotonin receptor 1A knockout: an animal model of anxiety-related disorder. Proc. Natl Acad. Sci. USA 95, 14476\u201314481 (1998).", "journal-title": "Proc. Natl Acad. Sci. USA"}, {"key": "BFnrd4075_CR162", "doi-asserted-by": "publisher", "first-page": "10734", "DOI": "10.1073/pnas.95.18.10734", "volume": "95", "author": "CL Parks", "year": "1998", "unstructured": "Parks, C. L., Robinson, P. S., Sibille, E., Shenk, T. & Toth, M. Increased anxiety of mice lacking the serotonin1A receptor. Proc. Natl Acad. Sci. USA 95, 10734\u201310739 (1998).", "journal-title": "Proc. Natl Acad. Sci. USA"}, {"key": "BFnrd4075_CR163", "doi-asserted-by": "publisher", "first-page": "15049", "DOI": "10.1073/pnas.95.25.15049", "volume": "95", "author": "LK Heisler", "year": "1998", "unstructured": "Heisler, L. K. et al. Elevated anxiety and antidepressant-like responses in serotonin 5-HT1A receptor mutant mice. Proc. Natl Acad. Sci. USA 95, 15049\u201315054 (1998).", "journal-title": "Proc. Natl Acad. Sci. USA"}, {"key": "BFnrd4075_CR164", "doi-asserted-by": "publisher", "first-page": "478", "DOI": "10.1016/j.neuropharm.2011.02.009", "volume": "61", "author": "JP Guilloux", "year": "2011", "unstructured": "Guilloux, J. P. et al. Characterization of 5-HT1A/1B\u2212/\u2212 mice: an animal model sensitive to anxiolytic treatments. Neuropharmacology 61, 478\u2013488 (2011).", "journal-title": "Neuropharmacology"}, {"key": "BFnrd4075_CR165", "doi-asserted-by": "publisher", "first-page": "468", "DOI": "10.1016/j.neuropharm.2010.06.009", "volume": "59", "author": "C Mombereau", "year": "2010", "unstructured": "Mombereau, C., Kawahara, Y., Gundersen, B. B., Nishikura, K. & Blendy, J. A. Functional relevance of serotonin 2C receptor mRNA editing in antidepressant- and anxiety-like behaviors. Neuropharmacology 59, 468\u2013473 (2010).", "journal-title": "Neuropharmacology"}, {"key": "BFnrd4075_CR166", "doi-asserted-by": "publisher", "first-page": "545", "DOI": "10.1016/j.physbeh.2004.01.018", "volume": "81", "author": "S Bhatnagar", "year": "2004", "unstructured": "Bhatnagar, S. et al. Changes in anxiety-related behaviors and hypothalamic\u2013pituitary\u2013adrenal activity in mice lacking the 5-HT-3A receptor. Physiol. Behav. 81, 545\u2013555 (2004).", "journal-title": "Physiol. Behav."}, {"key": "BFnrd4075_CR167", "doi-asserted-by": "publisher", "first-page": "527", "DOI": "10.1016/j.bbr.2004.01.018", "volume": "153", "author": "S Bhatnagar", "year": "2004", "unstructured": "Bhatnagar, S., Nowak, N., Babich, L. & Bok, L. Deletion of the 5-HT3 receptor differentially affects behavior of males and females in the Porsolt forced swim and defensive withdrawal tests. Behav. Brain Res. 153, 527\u2013535 (2004).", "journal-title": "Behav. Brain Res."}, {"key": "BFnrd4075_CR168", "doi-asserted-by": "publisher", "first-page": "e22600", "DOI": "10.1371/journal.pone.0022600", "volume": "6", "author": "V Narayanan", "year": "2011", "unstructured": "Narayanan, V. et al. Social defeat: impact on fear extinction and amygdala-prefrontal cortical theta synchrony in 5-HTT deficient mice. PLoS ONE 6, e22600 (2011).", "journal-title": "PLoS ONE"}, {"key": "BFnrd4075_CR169", "doi-asserted-by": "publisher", "first-page": "108", "DOI": "10.1016/j.euroneuro.2010.08.005", "volume": "21", "author": "SJ Line", "year": "2011", "unstructured": "Line, S. J. et al. Opposing alterations in anxiety and species-typical behaviours in serotonin transporter overexpressor and knockout mice. Eur. Neuropsychopharmacol. 21, 108\u2013116 (2011).", "journal-title": "Eur. Neuropsychopharmacol."}, {"key": "BFnrd4075_CR170", "doi-asserted-by": "publisher", "first-page": "26", "DOI": "10.3389/neuro.08.026.2009", "volume": "3", "author": "RS Heiming", "year": "2009", "unstructured": "Heiming, R. S. et al. Living in a dangerous world: the shaping of behavioral profile by early environment and 5-HTT genotype. Front. Behav. Neurosci. 3, 26 (2009).", "journal-title": "Front. Behav. Neurosci."}, {"key": "BFnrd4075_CR171", "doi-asserted-by": "publisher", "first-page": "684", "DOI": "10.1523/JNEUROSCI.4595-06.2007", "volume": "27", "author": "CL Wellman", "year": "2007", "unstructured": "Wellman, C. L. et al. Impaired stress-coping and fear extinction and abnormal corticolimbic morphology in serotonin transporter knock-out mice. J. Neurosci. 27, 684\u2013691 (2007).", "journal-title": "J. Neurosci."}, {"key": "BFnrd4075_CR172", "doi-asserted-by": "publisher", "first-page": "214", "DOI": "10.1007/s10519-006-9129-9", "volume": "37", "author": "JC Carroll", "year": "2007", "unstructured": "Carroll, J. C. et al. Effects of mild early life stress on abnormal emotion-related behaviors in 5-HTT knockout mice. Behav. Genet. 37, 214\u2013222 (2007).", "journal-title": "Behav. Genet."}, {"key": "BFnrd4075_CR173", "doi-asserted-by": "publisher", "first-page": "879", "DOI": "10.1126/science.1101678", "volume": "306", "author": "MS Ansorge", "year": "2004", "unstructured": "Ansorge, M. S., Zhou, M., Lira, A., Hen, R. & Gingrich, J. A. Early-life blockade of the 5-HT transporter alters emotional behavior in adult mice. Science 306, 879\u2013881 (2004).", "journal-title": "Science"}, {"key": "BFnrd4075_CR174", "doi-asserted-by": "publisher", "first-page": "960", "DOI": "10.1016/S0006-3223(03)00696-6", "volume": "54", "author": "A Lira", "year": "2003", "unstructured": "Lira, A. et al. Altered depression-related behaviors and functional changes in the dorsal raphe nucleus of serotonin transporter-deficient mice. Biol. Psychiatry 54, 960\u2013971 (2003).", "journal-title": "Biol. Psychiatry"}, {"key": "BFnrd4075_CR175", "doi-asserted-by": "publisher", "first-page": "2077", "DOI": "10.1038/sj.npp.1300266", "volume": "28", "author": "A Holmes", "year": "2003", "unstructured": "Holmes, A., Yang, R. J., Lesch, K. P., Crawley, J. N. & Murphy, D. L. Mice lacking the serotonin transporter exhibit 5-HT1A receptor-mediated abnormalities in tests for anxiety-like behavior. Neuropsychopharmacology 28, 2077\u20132088 (2003).", "journal-title": "Neuropsychopharmacology"}, {"key": "BFnrd4075_CR176", "doi-asserted-by": "publisher", "first-page": "6", "DOI": "10.1186/1756-6606-2-6", "volume": "2", "author": "S Hasegawa", "year": "2009", "unstructured": "Hasegawa, S. et al. Transgenic up-regulation of \u03b1-CaMKII in forebrain leads to increased anxiety-like behaviors and aggression. Mol. Brain 2, 6 (2009).", "journal-title": "Mol. Brain"}, {"key": "BFnrd4075_CR177", "doi-asserted-by": "publisher", "first-page": "674", "DOI": "10.1038/41771", "volume": "388", "author": "C Ledent", "year": "1997", "unstructured": "Ledent, C. et al. Aggressiveness, hypoalgesia and high blood pressure in mice lacking the adenosine A2a receptor. Nature 388, 674\u2013678 (1997).", "journal-title": "Nature"}, {"key": "BFnrd4075_CR178", "doi-asserted-by": "publisher", "first-page": "289", "DOI": "10.1016/S0306-4522(02)00185-9", "volume": "113", "author": "J L\u00e4hdesmaki", "year": "2002", "unstructured": "L\u00e4hdesmaki, J. et al. Behavioral and neurochemical characterization of \u03b12a-adrenergic receptor knockout mice. Neuroscience 113, 289\u2013299 (2002).", "journal-title": "Neuroscience"}, {"key": "BFnrd4075_CR179", "doi-asserted-by": "publisher", "first-page": "4875", "DOI": "10.1523/JNEUROSCI.21-13-04875.2001", "volume": "21", "author": "NL Schramm", "year": "2001", "unstructured": "Schramm, N. L., McDonald, M. P. & Limbird, L. E. The \u03b12a-adrenergic receptor plays a protective role in mouse behavioral models of depression and anxiety. J. Neurosci. 21, 4875\u20134882 (2001).", "journal-title": "J. Neurosci."}, {"key": "BFnrd4075_CR180", "doi-asserted-by": "publisher", "first-page": "150", "DOI": "10.1016/S0006-8993(99)01098-7", "volume": "821", "author": "S Okuyama", "year": "1999", "unstructured": "Okuyama, S. et al. Anxiety-like behavior in mice lacking the angiotensin II type-2 receptor. Brain Res. 821, 150\u2013159 (1999).", "journal-title": "Brain Res."}, {"key": "BFnrd4075_CR181", "doi-asserted-by": "publisher", "first-page": "748", "DOI": "10.1038/377748a0", "volume": "377", "author": "T Ichiki", "year": "1995", "unstructured": "Ichiki, T. et al. Effects on blood pressure and exploratory behaviour of mice lacking angiotensin II type-2 receptor. Nature 377, 748\u2013750 (1995).", "journal-title": "Nature"}, {"key": "BFnrd4075_CR182", "doi-asserted-by": "publisher", "first-page": "91236", "DOI": "10.1155/2007/91236", "volume": "2007", "author": "J Raber", "year": "2007", "unstructured": "Raber, J. Role of apolipoprotein E in anxiety. Neural Plast. 2007, 91236 (2007).", "journal-title": "Neural Plast."}, {"key": "BFnrd4075_CR183", "doi-asserted-by": "publisher", "first-page": "1885", "DOI": "10.1038/npp.2012.36", "volume": "37", "author": "S Dubreucq", "year": "2012", "unstructured": "Dubreucq, S. et al. Genetic dissection of the role of cannabinoid type-1 receptors in the emotional consequences of repeated social stress in mice. Neuropsychopharmacology 37, 1885\u20131900 (2012).", "journal-title": "Neuropsychopharmacology"}, {"key": "BFnrd4075_CR184", "doi-asserted-by": "publisher", "first-page": "203", "DOI": "10.1111/j.1601-183X.2008.00463.x", "volume": "8", "author": "K Kamprath", "year": "2009", "unstructured": "Kamprath, K. et al. Endocannabinoids mediate acute fear adaptation via glutamatergic neurons independently of corticotropin-releasing hormone signaling. Genes Brain Behav. 8, 203\u2013211 (2009).", "journal-title": "Genes Brain Behav."}, {"key": "BFnrd4075_CR185", "doi-asserted-by": "publisher", "first-page": "369", "DOI": "10.1016/j.euroneuro.2010.02.003", "volume": "20", "author": "SA Bura", "year": "2010", "unstructured": "Bura, S. A., Burokas, A., Martin-Garcia, E. & Maldonado, R. Effects of chronic nicotine on food intake and anxiety-like behaviour in CB1 knockout mice. Eur. Neuropsychopharmacol. 20, 369\u2013378 (2010).", "journal-title": "Eur. Neuropsychopharmacol."}, {"key": "BFnrd4075_CR186", "doi-asserted-by": "publisher", "first-page": "1030", "DOI": "10.1016/j.biopsych.2007.09.003", "volume": "63", "author": "C Tourino", "year": "2008", "unstructured": "Tourino, C., Ledent, C., Maldonado, R. & Valverde, O. CB1 cannabinoid receptor modulates 3,4-methylenedioxymethamphetamine acute responses and reinforcement. Biol. Psychiatry 63, 1030\u20131038 (2008).", "journal-title": "Biol. Psychiatry"}, {"key": "BFnrd4075_CR187", "doi-asserted-by": "publisher", "first-page": "6677", "DOI": "10.1523/JNEUROSCI.0153-06.2006", "volume": "26", "author": "K Kamprath", "year": "2006", "unstructured": "Kamprath, K. et al. Cannabinoid CB1 receptor mediates fear extinction via habituation-like processes. J. Neurosci. 26, 6677\u20136686 (2006).", "journal-title": "J. Neurosci."}, {"key": "BFnrd4075_CR188", "doi-asserted-by": "publisher", "first-page": "1906", "DOI": "10.1111/j.1460-9568.2004.03293.x", "volume": "19", "author": "J Haller", "year": "2004", "unstructured": "Haller, J., Varga, B., Ledent, C., Barna, I. & Freund, T. F. Context-dependent effects of CB1 cannabinoid gene disruption on anxiety-like and social behaviour in mice. Eur. J. Neurosci. 19, 1906\u20131912 (2004).", "journal-title": "Eur. J. Neurosci."}, {"key": "BFnrd4075_CR189", "doi-asserted-by": "publisher", "first-page": "530", "DOI": "10.1038/nature00839", "volume": "418", "author": "G Marsicano", "year": "2002", "unstructured": "Marsicano, G. et al. The endogenous cannabinoid system controls extinction of aversive memories. Nature 418, 530\u2013534 (2002).", "journal-title": "Nature"}, {"key": "BFnrd4075_CR190", "doi-asserted-by": "publisher", "first-page": "1395", "DOI": "10.1046/j.1460-9568.2002.02192.x", "volume": "16", "author": "J Haller", "year": "2002", "unstructured": "Haller, J., Bakos, N., Szirmay, M., Ledent, C. & Freund, T. F. The effects of genetic and pharmacological blockade of the CB1 cannabinoid receptor on anxiety. Eur. J. Neurosci. 16, 1395\u20131398 (2002).", "journal-title": "Eur. J. Neurosci."}, {"key": "BFnrd4075_CR191", "doi-asserted-by": "publisher", "first-page": "1178", "DOI": "10.1046/j.1460-9568.2002.01957.x", "volume": "15", "author": "M Maccarrone", "year": "2002", "unstructured": "Maccarrone, M. et al. Age-related changes of anandamide metabolism in CB1 cannabinoid receptor knockout mice: correlation with behaviour. Eur. J. Neurosci. 15, 1178\u20131186 (2002).", "journal-title": "Eur. J. Neurosci."}, {"key": "BFnrd4075_CR192", "doi-asserted-by": "publisher", "first-page": "379", "DOI": "10.1007/s00213-001-0946-5", "volume": "159", "author": "M Martin", "year": "2002", "unstructured": "Martin, M., Ledent, C., Parmentier, M., Maldonado, R. & Valverde, O. Involvement of CB1 cannabinoid receptors in emotional behaviour. Psychopharmacology 159, 379\u2013387 (2002).", "journal-title": "Psychopharmacology"}, {"key": "BFnrd4075_CR193", "doi-asserted-by": "publisher", "first-page": "9991", "DOI": "10.1073/pnas.95.17.9991", "volume": "95", "author": "JA Gogos", "year": "1998", "unstructured": "Gogos, J. A. et al. Catechol-O-methyltransferase-deficient mice exhibit sexually dimorphic changes in catecholamine levels and behavior. Proc. Natl Acad. Sci. USA 95, 9991\u20139996 (1998).", "journal-title": "Proc. Natl Acad. Sci. USA"}, {"key": "BFnrd4075_CR194", "doi-asserted-by": "publisher", "first-page": "789", "DOI": "10.1016/S0361-9230(00)00407-X", "volume": "53", "author": "Y Yamamoto", "year": "2000", "unstructured": "Yamamoto, Y. et al. Increased anxiety behavior in OLETF rats without cholecystokinin-A receptor. Brain Res. Bull. 53, 789\u2013792 (2000).", "journal-title": "Brain Res. Bull."}, {"key": "BFnrd4075_CR195", "doi-asserted-by": "publisher", "first-page": "61", "DOI": "10.1016/0304-3940(96)12881-0", "volume": "214", "author": "S Kobayashi", "year": "1996", "unstructured": "Kobayashi, S., Ohta, M., Miyasaka, K. & Funakoshi, A. Decrease in exploratory behavior in naturally occurring cholecystokinin (CCK)A receptor gene knockout rats. Neurosci. Lett. 214, 61\u201364 (1996).", "journal-title": "Neurosci. Lett."}, {"key": "BFnrd4075_CR196", "doi-asserted-by": "publisher", "first-page": "108", "DOI": "10.1016/j.bbr.2008.04.027", "volume": "193", "author": "U Abramov", "year": "2008", "unstructured": "Abramov, U. et al. Different housing conditions alter the behavioural phenotype of CCK2 receptor-deficient mice. Behav. Brain Res. 193, 108\u2013116 (2008).", "journal-title": "Behav. Brain Res."}, {"key": "BFnrd4075_CR197", "doi-asserted-by": "publisher", "first-page": "115", "DOI": "10.1016/S0304-3940(02)01176-X", "volume": "335", "author": "K Miyasaka", "year": "2002", "unstructured": "Miyasaka, K. et al. Anxiety-related behaviors in cholecystokinin-A, B, and AB receptor gene knockout mice in the plus-maze. Neurosci. Lett. 335, 115\u2013118 (2002).", "journal-title": "Neurosci. Lett."}, {"issue": "Suppl. 2", "key": "BFnrd4075_CR198", "first-page": "69", "volume": "10", "author": "E Vasar", "year": "2000", "unstructured": "Vasar, E. et al. CCKB receptor knockout mice: gender related behavioural differences. Eur. Neuropsychopharmacol. 10 (Suppl. 2), 69 (2000).", "journal-title": "Eur. Neuropsychopharmacol."}, {"key": "BFnrd4075_CR199", "doi-asserted-by": "publisher", "first-page": "3881", "DOI": "10.1073/pnas.0505407103", "volume": "103", "author": "Q Chen", "year": "2006", "unstructured": "Chen, Q., Nakajima, A., Meacham, C. & Tang, Y. P. Elevated cholecystokininergic tone constitutes an important molecular/neuronal mechanism for the expression of anxiety in the mouse. Proc. Natl Acad. Sci. USA 103, 3881\u20133886 (2006).", "journal-title": "Proc. Natl Acad. Sci. USA"}, {"key": "BFnrd4075_CR200", "doi-asserted-by": "publisher", "first-page": "2571", "DOI": "10.1523/JNEUROSCI.4470-09.2010", "volume": "30", "author": "BJ Kolber", "year": "2010", "unstructured": "Kolber, B. J. et al. Transient early-life forebrain corticotropin-releasing hormone elevation causes long-lasting anxiogenic and despair-like changes in mice. J. Neurosci. 30, 2571\u20132581 (2010).", "journal-title": "J. Neurosci."}, {"key": "BFnrd4075_CR201", "doi-asserted-by": "publisher", "first-page": "2007", "DOI": "10.1046/j.1460-9568.2002.02040.x", "volume": "15", "author": "MM van Gaalen", "year": "2002", "unstructured": "van Gaalen, M. M., Stenzel-Poore, M. P., Holsboer, F. & Steckler, T. Effects of transgenic overproduction of CRH on anxiety-like behaviour. Eur. J. Neurosci. 15, 2007\u20132015 (2002).", "journal-title": "Eur. J. Neurosci."}, {"key": "BFnrd4075_CR202", "doi-asserted-by": "publisher", "first-page": "215", "DOI": "10.1016/S0306-4530(97)00030-9", "volume": "22", "author": "SC Heinrichs", "year": "1997", "unstructured": "Heinrichs, S. C. et al. Anti-sexual and anxiogenic behavioral consequences of corticotropin-releasing factor overexpression are centrally mediated. Psychoneuroendocrinology 22, 215\u2013224 (1997).", "journal-title": "Psychoneuroendocrinology"}, {"key": "BFnrd4075_CR203", "doi-asserted-by": "publisher", "first-page": "36", "DOI": "10.1111/j.1749-6632.1996.tb15110.x", "volume": "780", "author": "MP Stenzel-Poore", "year": "1996", "unstructured": "Stenzel-Poore, M. P., Duncan, J. E., Rittenberg, M. B., Bakke, A. C. & Heinrichs, S. C. CRH overproduction in transgenic mice: behavioral and immune system modulation. Ann. NY Acad. Sci. 780, 36\u201348 (1996).", "journal-title": "Ann. NY Acad. Sci."}, {"key": "BFnrd4075_CR204", "doi-asserted-by": "publisher", "first-page": "2579", "DOI": "10.1523/JNEUROSCI.14-05-02579.1994", "volume": "14", "author": "MP Stenzel-Poore", "year": "1994", "unstructured": "Stenzel-Poore, M. P., Heinrichs, S. C., Rivest, S., Koob, G. F. & Vale, W. W. Overproduction of corticotropin-releasing factor in transgenic mice: a genetic model of anxiogenic behavior. J. Neurosci. 14, 2579\u20132584 (1994).", "journal-title": "J. Neurosci."}, {"key": "BFnrd4075_CR205", "first-page": "505", "volume": "24", "author": "TM Ramesh", "year": "1998", "unstructured": "Ramesh, T. M., Karolyi, I. J., Nakajima, M., Camper, S. A. & Seasholtz, A. F. Altered physiological and behavioral responses in CRH-binding protein deficient mice. Abstr. Soc. Neurosci. 24, 505 (1998).", "journal-title": "Abstr. Soc. Neurosci."}, {"key": "BFnrd4075_CR206", "doi-asserted-by": "publisher", "first-page": "11595", "DOI": "10.1073/pnas.96.20.11595", "volume": "96", "author": "IJ Karolyi", "year": "1999", "unstructured": "Karolyi, I. J. et al. Altered anxiety and weight gain in corticotropin-releasing hormone-binding protein-deficient mice. Proc. Natl Acad. Sci. USA 96, 11595\u201311600 (1999).", "journal-title": "Proc. Natl Acad. Sci. USA"}, {"key": "BFnrd4075_CR207", "doi-asserted-by": "publisher", "first-page": "1903", "DOI": "10.1126/science.1202107", "volume": "333", "author": "D Refojo", "year": "2011", "unstructured": "Refojo, D. et al. Glutamatergic and dopaminergic neurons mediate anxiogenic and anxiolytic effects of CRHR1. Science 333, 1903\u20131907 (2011).", "journal-title": "Science"}, {"key": "BFnrd4075_CR208", "doi-asserted-by": "publisher", "first-page": "415", "DOI": "10.1038/74271", "volume": "24", "author": "T Kishimoto", "year": "2000", "unstructured": "Kishimoto, T. et al. Deletion of Crhr2 reveals an anxiolytic role for corticotropin-releasing hormone receptor-2. Nature Genet. 24, 415\u2013419 (2000).", "journal-title": "Nature Genet."}, {"key": "BFnrd4075_CR209", "doi-asserted-by": "publisher", "first-page": "403", "DOI": "10.1038/74255", "volume": "24", "author": "SC Coste", "year": "2000", "unstructured": "Coste, S. C. et al. Abnormal adaptations to stress and impaired cardiovascular function in mice lacking corticotropin-releasing hormone receptor-2. Nature Genet. 24, 403\u2013409 (2000).", "journal-title": "Nature Genet."}, {"key": "BFnrd4075_CR210", "doi-asserted-by": "publisher", "first-page": "410", "DOI": "10.1038/74263", "volume": "24", "author": "TL Bale", "year": "2000", "unstructured": "Bale, T. L. et al. Mice deficient for corticotropin-releasing hormone receptor-2 display anxiety-like behaviour and are hypersensitive to stress. Nature Genet. 24, 410\u2013414 (2000).", "journal-title": "Nature Genet."}, {"key": "BFnrd4075_CR211", "doi-asserted-by": "publisher", "first-page": "167", "DOI": "10.1016/j.bbr.2006.07.022", "volume": "174", "author": "F Umehara", "year": "2006", "unstructured": "Umehara, F. et al. Elevated anxiety-like and depressive behavior in Desert hedgehog knockout male mice. Behav. Brain Res. 174, 167\u2013173 (2006).", "journal-title": "Behav. Brain Res."}, {"key": "BFnrd4075_CR212", "doi-asserted-by": "publisher", "first-page": "9550", "DOI": "10.1523/JNEUROSCI.19-21-09550.1999", "volume": "19", "author": "SC Dulawa", "year": "1999", "unstructured": "Dulawa, S. C., Grandy, D. K., Low, M. J., Paulus, M. P. & Geyer, M. A. Dopamine D4 receptor-knock-out mice exhibit reduced exploration of novel stimuli. J. Neurosci. 19, 9550\u20139556 (1999).", "journal-title": "J. Neurosci."}, {"key": "BFnrd4075_CR213", "doi-asserted-by": "publisher", "first-page": "1476", "DOI": "10.1073/pnas.94.4.1476", "volume": "94", "author": "S Ogawa", "year": "1997", "unstructured": "Ogawa, S., Lubahn, D. B., Korach, K. S. & Pfaff, D. W. Behavioral effects of estrogen receptor gene disruption in male mice. Proc. Natl Acad. Sci. USA 94, 1476\u20131481 (1997).", "journal-title": "Proc. Natl Acad. Sci. USA"}, {"key": "BFnrd4075_CR214", "doi-asserted-by": "publisher", "first-page": "420", "DOI": "10.1111/j.1601-183X.2005.00123.x", "volume": "4", "author": "CM Spencer", "year": "2005", "unstructured": "Spencer, C. M., Alekseyenko, O., Serysheva, E., Yuva-Paylor, L. A. & Paylor, R. Altered anxiety-related and social behaviors in the Fmr1 knockout mouse model of fragile X syndrome. Genes Brain Behav. 4, 420\u2013430 (2005).", "journal-title": "Genes Brain Behav."}, {"key": "BFnrd4075_CR215", "doi-asserted-by": "publisher", "first-page": "179", "DOI": "10.1016/0169-328X(94)90201-1", "volume": "27", "author": "T Miyakawa", "year": "1994", "unstructured": "Miyakawa, T., Yagi, T., Watanabe, S. & Niki, H. Increased fearfulness of Fyn tyrosine kinase deficient mice. Brain Res. Mol. Brain Res. 27, 179\u2013182 (1994).", "journal-title": "Brain Res. Mol. Brain Res."}, {"key": "BFnrd4075_CR216", "doi-asserted-by": "publisher", "first-page": "61", "DOI": "10.1124/mol.104.009936", "volume": "68", "author": "JM Sonner", "year": "2005", "unstructured": "Sonner, J. M. et al. \u03b11 subunit-containing GABA type A receptors in forebrain contribute to the effect of inhaled anesthetics on conditioned fear. Mol. Pharmacol. 68, 61\u201368 (2005).", "journal-title": "Mol. Pharmacol."}, {"key": "BFnrd4075_CR217", "doi-asserted-by": "publisher", "first-page": "1", "DOI": "10.1016/j.pbb.2008.01.015", "volume": "90", "author": "CI Dixon", "year": "2008", "unstructured": "Dixon, C. I., Rosahl, T. W. & Stephens, D. N. Targeted deletion of the GABRA2 gene encoding \u03b12-subunits of GABAA receptors facilitates performance of a conditioned emotional response, and abolishes anxiolytic effects of benzodiazepines and barbiturates. Pharmacol. Biochem. Behav. 90, 1\u20138 (2008).", "journal-title": "Pharmacol. Biochem. Behav."}, {"key": "BFnrd4075_CR218", "doi-asserted-by": "publisher", "first-page": "191", "DOI": "10.1016/j.brainres.2006.10.050", "volume": "1129", "author": "E Hashemi", "year": "2007", "unstructured": "Hashemi, E., Sahbaie, P., Davies, M. F., Clark, J. D. & Delorey, T. M. Gabrb3 gene deficient mice exhibit increased risk assessment behavior, hypotonia and expansion of the plexus of locus coeruleus dendrites. Brain Res. 1129, 191\u2013199 (2007).", "journal-title": "Brain Res."}, {"key": "BFnrd4075_CR219", "doi-asserted-by": "publisher", "first-page": "99", "DOI": "10.1016/j.eplepsyres.2005.07.005", "volume": "66", "author": "P Liljelund", "year": "2005", "unstructured": "Liljelund, P., Ferguson, C., Homanics, G. & Olsen, R. W. Long-term effects of diazepam treatment of epileptic GABAA receptor \u03b23 subunit knockout mouse in early life. Epilepsy Res. 66, 99\u2013115 (2005).", "journal-title": "Epilepsy Res."}, {"key": "BFnrd4075_CR220", "doi-asserted-by": "publisher", "first-page": "3845", "DOI": "10.1523/JNEUROSCI.3609-06.2007", "volume": "27", "author": "JC Earnheart", "year": "2007", "unstructured": "Earnheart, J. C. et al. GABAergic control of adult hippocampal neurogenesis in relation to behavior indicative of trait anxiety and depression states. J. Neurosci. 27, 3845\u20133854 (2007).", "journal-title": "J. Neurosci."}, {"key": "BFnrd4075_CR221", "doi-asserted-by": "publisher", "first-page": "253", "DOI": "10.1016/S0028-3908(98)00177-4", "volume": "38", "author": "GE Homanics", "year": "1999", "unstructured": "Homanics, G. E. et al. Normal electrophysiological and behavioral responses to ethanol in mice lacking the long splice variant of the \u03b32 subunit of the \u03b3-aminobutyrate type A receptor. Neuropharmacology 38, 253\u2013265 (1999).", "journal-title": "Neuropharmacology"}, {"key": "BFnrd4075_CR222", "doi-asserted-by": "publisher", "first-page": "833", "DOI": "10.1038/12207", "volume": "2", "author": "F Crestani", "year": "1999", "unstructured": "Crestani, F. et al. Decreased GABAA-receptor clustering results in enhanced anxiety and a bias for threat cues. Nature Neurosci. 2, 833\u2013839 (1999).", "journal-title": "Nature Neurosci."}, {"key": "BFnrd4075_CR223", "doi-asserted-by": "publisher", "first-page": "30", "DOI": "10.1186/1471-2202-6-30", "volume": "6", "author": "D Chandra", "year": "2005", "unstructured": "Chandra, D., Korpi, E. R., Miralles, C. P., De Blas, A. L. & Homanics, G. E. GABAA receptor \u03b32 subunit knockdown mice have enhanced anxiety-like behavior but unaltered hypnotic response to benzodiazepines. BMC Neurosci. 6, 30 (2005).", "journal-title": "BMC Neurosci."}, {"key": "BFnrd4075_CR224", "doi-asserted-by": "publisher", "first-page": "307", "DOI": "10.1097/00001756-200502280-00021", "volume": "16", "author": "C Mombereau", "year": "2005", "unstructured": "Mombereau, C. et al. Altered anxiety and depression-related behaviour in mice lacking GABAB(2) receptor subunits. Neuroreport 16, 307\u2013310 (2005).", "journal-title": "Neuroreport"}, {"key": "BFnrd4075_CR225", "doi-asserted-by": "publisher", "first-page": "119", "DOI": "10.1016/j.ejphar.2004.06.036", "volume": "497", "author": "C Mombereau", "year": "2004", "unstructured": "Mombereau, C., Kaupmann, K., van der Putten, H. & Cryan, J. F. Altered response to benzodiazepine anxiolytics in mice lacking GABAB(1) receptors. Eur. J. Pharmacol. 497, 119\u2013120 (2004).", "journal-title": "Eur. J. Pharmacol."}, {"key": "BFnrd4075_CR226", "doi-asserted-by": "publisher", "first-page": "1050", "DOI": "10.1038/sj.npp.1300413", "volume": "29", "author": "C Mombereau", "year": "2004", "unstructured": "Mombereau, C. et al. Genetic and pharmacological evidence of a role for GABAB receptors in the modulation of anxiety- and antidepressant-like behavior. Neuropsychopharmacology 29, 1050\u20131062 (2004).", "journal-title": "Neuropsychopharmacology"}, {"key": "BFnrd4075_CR227", "doi-asserted-by": "publisher", "first-page": "15713", "DOI": "10.1523/JNEUROSCI.2620-09.2009", "volume": "29", "author": "S Sangha", "year": "2009", "unstructured": "Sangha, S. et al. Deficiency of the 65 kDa isoform of glutamic acid decarboxylase impairs extinction of cued but not contextual fear memory. J. Neurosci. 29, 15713\u201315720 (2009).", "journal-title": "J. Neurosci."}, {"key": "BFnrd4075_CR228", "doi-asserted-by": "publisher", "first-page": "163", "DOI": "10.1101/lm.705408", "volume": "15", "author": "JR Bergado-Acosta", "year": "2008", "unstructured": "Bergado-Acosta, J. R. et al. Critical role of the 65-kDa isoform of glutamic acid decarboxylase in consolidation and generalization of Pavlovian fear memory. Learn. Mem. 15, 163\u2013171 (2008).", "journal-title": "Learn. Mem."}, {"key": "BFnrd4075_CR229", "doi-asserted-by": "publisher", "first-page": "65", "DOI": "10.1034/j.1601-183X.2003.00008.x", "volume": "2", "author": "O Stork", "year": "2003", "unstructured": "Stork, O., Yamanaka, H., Stork, S., Kume, N. & Obata, K. Altered conditioned fear behavior in glutamate decarboxylase 65 null mutant mice. Genes Brain Behav. 2, 65\u201370 (2003).", "journal-title": "Genes Brain Behav."}, {"key": "BFnrd4075_CR230", "doi-asserted-by": "publisher", "first-page": "45", "DOI": "10.1016/S0006-8993(00)02206-X", "volume": "865", "author": "O Stork", "year": "2000", "unstructured": "Stork, O. et al. Postnatal development of a GABA deficit and disturbance of neural functions in mice lacking GAD65. Brain Res. 865, 45\u201358 (2000).", "journal-title": "Brain Res."}, {"key": "BFnrd4075_CR231", "doi-asserted-by": "publisher", "first-page": "1698", "DOI": "10.1073/pnas.96.4.1698", "volume": "96", "author": "SF Kash", "year": "1999", "unstructured": "Kash, S. F., Tecott, L. H., Hodge, C. & Baekkeskov, S. Increased anxiety and altered responses to anxiolytics in mice deficient in the 65-kDa isoform of glutamic acid decarboxylase. Proc. Natl Acad. Sci. USA 96, 1698\u20131703 (1999).", "journal-title": "Proc. Natl Acad. Sci. USA"}, {"key": "BFnrd4075_CR232", "doi-asserted-by": "publisher", "first-page": "3234", "DOI": "10.1523/JNEUROSCI.3364-04.2005", "volume": "25", "author": "CS Chiu", "year": "2005", "unstructured": "Chiu, C. S. et al. GABA transporter deficiency causes tremor, ataxia, nervousness, and increased GABA-induced tonic conductance in cerebellum. J. Neurosci. 25, 3234\u20133245 (2005).", "journal-title": "J. Neurosci."}, {"key": "BFnrd4075_CR233", "doi-asserted-by": "publisher", "first-page": "1031", "DOI": "10.1038/sj.npp.1300164", "volume": "28", "author": "A Holmes", "year": "2003", "unstructured": "Holmes, A. et al. Galanin GAL-R1 receptor null mutant mice display increased anxiety-like behavior specific to the elevated plus-maze. Neuropsychopharmacology 28, 1031\u20131044 (2003).", "journal-title": "Neuropsychopharmacology"}, {"key": "BFnrd4075_CR234", "doi-asserted-by": "publisher", "first-page": "11851", "DOI": "10.1073/pnas.0402208101", "volume": "101", "author": "Q Wei", "year": "2004", "unstructured": "Wei, Q. et al. Glucocorticoid receptor overexpression in forebrain: a mouse model of increased emotional lability. Proc. Natl Acad. Sci. USA 101, 11851\u201311856 (2004).", "journal-title": "Proc. Natl Acad. Sci. USA"}, {"key": "BFnrd4075_CR235", "doi-asserted-by": "publisher", "first-page": "351", "DOI": "10.1016/j.neubiorev.2009.08.002", "volume": "34", "author": "V Labrie", "year": "2009", "unstructured": "Labrie, V. & Roder, J. C. The involvement of the NMDA receptor d-serine/glycine site in the pathophysiology and treatment of schizophrenia. Neurosci. Biobehav. Rev. 34, 351\u2013372 (2009).", "journal-title": "Neurosci. Biobehav. Rev."}, {"key": "BFnrd4075_CR236", "doi-asserted-by": "publisher", "first-page": "37", "DOI": "10.1186/1756-6606-3-37", "volume": "3", "author": "M Delawary", "year": "2010", "unstructured": "Delawary, M. et al. NMDAR2B tyrosine phosphorylation regulates anxiety-like behavior and CRF expression in the amygdala. Mol. Brain 3, 37 (2010).", "journal-title": "Mol. Brain"}, {"key": "BFnrd4075_CR237", "doi-asserted-by": "publisher", "first-page": "21", "DOI": "10.1016/j.bbr.2011.12.037", "volume": "229", "author": "MJ Davis", "year": "2012", "unstructured": "Davis, M. J., Haley, T., Duvoisin, R. M. & Raber, J. Measures of anxiety, sensorimotor function, and memory in male and female mGluR4\u2212/\u2212 mice. Behav. Brain Res. 229, 21\u201328 (2012).", "journal-title": "Behav. Brain Res."}, {"key": "BFnrd4075_CR238", "doi-asserted-by": "publisher", "first-page": "e167", "DOI": "10.1371/journal.pone.0000167", "volume": "2", "author": "LJ Wu", "year": "2007", "unstructured": "Wu, L. J. et al. Increased anxiety-like behavior and enhanced synaptic efficacy in the amygdala of GluR5 knockout mice. PLoS ONE 2, e167 (2007).", "journal-title": "PLoS ONE"}, {"key": "BFnrd4075_CR239", "doi-asserted-by": "publisher", "first-page": "251", "DOI": "10.1016/S0028-3908(02)00079-5", "volume": "43", "author": "AM Linden", "year": "2002", "unstructured": "Linden, A. M. et al. Increased anxiety-related behavior in mice deficient for metabotropic glutamate 8 (mGlu8) receptor. Neuropharmacology 43, 251\u2013259 (2002).", "journal-title": "Neuropharmacology"}, {"key": "BFnrd4075_CR240", "doi-asserted-by": "publisher", "first-page": "50", "DOI": "10.1016/j.bbr.2011.02.049", "volume": "221", "author": "RM Duvoisin", "year": "2011", "unstructured": "Duvoisin, R. M., Villasana, L., Davis, M. J., Winder, D. G. & Raber, J. Opposing roles of mGluR8 in measures of anxiety involving non-social and social challenges. Behav. Brain Res. 221, 50\u201354 (2011).", "journal-title": "Behav. Brain Res."}, {"key": "BFnrd4075_CR241", "doi-asserted-by": "publisher", "first-page": "215", "DOI": "10.1016/j.brainres.2007.03.028", "volume": "1152", "author": "MJ Robbins", "year": "2007", "unstructured": "Robbins, M. J. et al. Evaluation of the mGlu8 receptor as a putative therapeutic target in schizophrenia. Brain Res. 1152, 215\u2013227 (2007).", "journal-title": "Brain Res."}, {"key": "BFnrd4075_CR242", "doi-asserted-by": "publisher", "first-page": "297", "DOI": "10.1016/j.drugalcdep.2007.04.001", "volume": "90", "author": "DR Sparta", "year": "2007", "unstructured": "Sparta, D. R., Fee, J. R., Knapp, D. J., Breese, G. R. & Thiele, T. E. Elevated anxiety-like behavior following ethanol exposure in mutant mice lacking neuropeptide Y (NPY). Drug Alcohol Depend. 90, 297\u2013300 (2007).", "journal-title": "Drug Alcohol Depend."}, {"key": "BFnrd4075_CR243", "doi-asserted-by": "publisher", "first-page": "425", "DOI": "10.1111/j.1460-9568.2005.04210.x", "volume": "22", "author": "RM Duvoisin", "year": "2005", "unstructured": "Duvoisin, R. M. et al. Increased measures of anxiety and weight gain in mice lacking the group III metabotropic glutamate receptor mGluR8. Eur. J. Neurosci. 22, 425\u2013436 (2005).", "journal-title": "Eur. J. Neurosci."}, {"key": "BFnrd4075_CR244", "doi-asserted-by": "publisher", "first-page": "92", "DOI": "10.1016/j.bbr.2005.10.016", "volume": "168", "author": "SF Acevedo", "year": "2006", "unstructured": "Acevedo, S. F., Pfankuch, T., Ohtsu, H. & Raber, J. Anxiety and cognition in female histidine decarboxylase knockout (Hdc\u2212/\u2212) mice. Behav. Brain Res. 168, 92\u201399 (2006).", "journal-title": "Behav. Brain Res."}, {"key": "BFnrd4075_CR245", "doi-asserted-by": "publisher", "first-page": "308", "DOI": "10.1006/brbi.1998.0546", "volume": "12", "author": "Y Kustova", "year": "1998", "unstructured": "Kustova, Y., Sei, Y., Morse, H. C. Jr. & Basile, A. S. The influence of a targeted deletion of the IFN\u03b3 gene on emotional behaviors. Brain Behav. Immun. 12, 308\u2013324 (1998).", "journal-title": "Brain Behav. Immun."}, {"key": "BFnrd4075_CR246", "doi-asserted-by": "publisher", "first-page": "160", "DOI": "10.1016/S0165-5728(98)00199-4", "volume": "92", "author": "A Armario", "year": "1998", "unstructured": "Armario, A., Hernandez, J., Bluethmann, H. & Hidalgo, J. IL-6 deficiency leads to increased emotionality in mice: evidence in transgenic mice carrying a null mutation for IL-6. J. Neuroimmunol. 92, 160\u2013169 (1998).", "journal-title": "J. Neuroimmunol."}, {"key": "BFnrd4075_CR247", "doi-asserted-by": "publisher", "first-page": "11867", "DOI": "10.1074/jbc.273.19.11867", "volume": "273", "author": "T Walther", "year": "1998", "unstructured": "Walther, T. et al. Sustained long term potentiation and anxiety in mice lacking the Mas protooncogene. J. Biol. Chem. 273, 11867\u201311873 (1998).", "journal-title": "J. Biol. Chem."}, {"key": "BFnrd4075_CR248", "doi-asserted-by": "publisher", "first-page": "811", "DOI": "10.1046/j.1365-2443.1998.00231.x", "volume": "3", "author": "E Nakamura", "year": "1998", "unstructured": "Nakamura, E. et al. Disruption of the midkine gene (Mdk) resulted in altered expression of a calcium binding protein in the hippocampus of infant mice and their abnormal behaviour. Genes Cells 3, 811\u2013822 (1998).", "journal-title": "Genes Cells"}, {"key": "BFnrd4075_CR249", "doi-asserted-by": "publisher", "first-page": "343", "DOI": "10.1002/(SICI)1097-4695(19990905)40:3<343::AID-NEU6>3.0.CO;2-S", "volume": "40", "author": "O Stork", "year": "1999", "unstructured": "Stork, O. et al. Anxiety and increased 5-HT1A receptor response in NCAM null mutant mice. J. Neurobiol. 40, 343\u2013355 (1999).", "journal-title": "J. Neurobiol."}, {"key": "BFnrd4075_CR250", "doi-asserted-by": "publisher", "first-page": "6431", "DOI": "10.1523/JNEUROSCI.20-17-06431.2000", "volume": "20", "author": "SA Ross", "year": "2000", "unstructured": "Ross, S. A. et al. Phenotypic characterization of an \u03b14 neuronal nicotinic acetylcholine receptor subunit knock-out mouse. J. Neurosci. 20, 6431\u20136441 (2000).", "journal-title": "J. Neurosci."}, {"key": "BFnrd4075_CR251", "doi-asserted-by": "publisher", "first-page": "111", "DOI": "10.1016/S0166-4328(03)00066-4", "volume": "144", "author": "AM Ouagazzal", "year": "2003", "unstructured": "Ouagazzal, A. M., Moreau, J. L., Pauly-Evers, M. & Jenck, Z. F. Impact of environmental housing conditions on the emotional responses of mice deficient for nociceptin/orphanin FQ peptide precursor gene. Behav. Brain Res. 144, 111\u2013117 (2003).", "journal-title": "Behav. Brain Res."}, {"key": "BFnrd4075_CR252", "doi-asserted-by": "publisher", "first-page": "6694", "DOI": "10.1523/JNEUROSCI.20-17-06694.2000", "volume": "20", "author": "C Frisch", "year": "2000", "unstructured": "Frisch, C. et al. Superior water maze performance and increase in fear-related behavior in the endothelial nitric oxide synthase-deficient mouse together with monoamine changes in cerebellum and ventral striatum. J. Neurosci. 20, 6694\u20136700 (2000).", "journal-title": "J. Neurosci."}, {"key": "BFnrd4075_CR253", "doi-asserted-by": "publisher", "first-page": "10444", "DOI": "10.1073/pnas.96.18.10444", "volume": "96", "author": "A K\u00f6ster", "year": "1999", "unstructured": "K\u00f6ster, A. et al. Targeted disruption of the orphanin FQ/nociceptin gene increases stress susceptibility and impairs stress adaptation in mice. Proc. Natl Acad. Sci. USA 96, 10444\u201310449 (1999).", "journal-title": "Proc. Natl Acad. Sci. USA"}, {"key": "BFnrd4075_CR254", "doi-asserted-by": "publisher", "first-page": "1229", "DOI": "10.1016/j.peptides.2007.04.012", "volume": "28", "author": "EC Gavioli", "year": "2007", "unstructured": "Gavioli, E. C. et al. Altered anxiety-related behavior in nociceptin/orphanin FQ receptor gene knockout mice. Peptides 28, 1229\u20131239 (2007).", "journal-title": "Peptides"}, {"key": "BFnrd4075_CR255", "doi-asserted-by": "publisher", "first-page": "1302", "DOI": "10.1111/j.1476-5381.2011.01326.x", "volume": "163", "author": "E Painsipp", "year": "2011", "unstructured": "Painsipp, E., Herzog, H., Sperk, G. & Holzer, P. Sex-dependent control of murine emotional-affective behaviour in health and colitis by peptide YY and neuropeptide Y. Br. J. Pharmacol. 163, 1302\u20131314 (2011).", "journal-title": "Br. J. Pharmacol."}, {"key": "BFnrd4075_CR256", "doi-asserted-by": "publisher", "first-page": "79", "DOI": "10.1016/S0006-8993(00)02285-X", "volume": "868", "author": "AW Bannon", "year": "2000", "unstructured": "Bannon, A. W. et al. Behavioral characterization of neuropeptide Y knockout mice. Brain Res. 868, 79\u201387 (2000).", "journal-title": "Brain Res."}, {"key": "BFnrd4075_CR257", "first-page": "163", "volume": "53", "author": "RD Palmiter", "year": "1998", "unstructured": "Palmiter, R. D., Erickson, J. C., Hollopeter, G., Baraban, S. C. & Schwartz, M. W. Life without neuropeptide Y. Recent Prog. Horm. Res. 53, 163\u2013199 (1998).", "journal-title": "Recent Prog. Horm. Res."}, {"key": "BFnrd4075_CR258", "first-page": "171", "volume": "110", "author": "A Inui", "year": "1998", "unstructured": "Inui, A. et al. Anxiety-like behavior in transgenic mice with brain expression of neuropeptide Y. Proc. Assoc. Am. Physicians 110, 171\u2013182 (1998).", "journal-title": "Proc. Assoc. Am. Physicians"}, {"key": "BFnrd4075_CR259", "doi-asserted-by": "publisher", "first-page": "87", "DOI": "10.1016/j.bbr.2005.08.019", "volume": "167", "author": "T Karl", "year": "2006", "unstructured": "Karl, T., Burne, T. H. & Herzog, H. Effect of Y1 receptor deficiency on motor activity, exploration, and anxiety. Behav. Brain Res. 167, 87\u201393 (2006).", "journal-title": "Behav. Brain Res."}, {"key": "BFnrd4075_CR260", "doi-asserted-by": "publisher", "first-page": "535", "DOI": "10.1038/383535a0", "volume": "383", "author": "M Konig", "year": "1996", "unstructured": "Konig, M. et al. Pain responses, anxiety and aggression in mice deficient in pre-proenkephalin. Nature 383, 535\u2013538 (1996).", "journal-title": "Nature"}, {"key": "BFnrd4075_CR261", "doi-asserted-by": "publisher", "first-page": "6068", "DOI": "10.1523/JNEUROSCI.19-14-06068.1999", "volume": "19", "author": "T Osada", "year": "1999", "unstructured": "Osada, T. et al. Increased anxiety and impaired pain response in puromycin-sensitive aminopeptidase gene-deficient mice obtained by a mouse gene-trap method. J. Neurosci. 19, 6068\u20136078 (1999).", "journal-title": "J. Neurosci."}, {"key": "BFnrd4075_CR262", "doi-asserted-by": "publisher", "first-page": "1403", "DOI": "10.1210/me.2008-0034", "volume": "22", "author": "L Zhao", "year": "2008", "unstructured": "Zhao, L. et al. Central nervous system-specific knockout of steroidogenic factor 1 results in increased anxiety-like behavior. Mol. Endocrinol. 22, 1403\u20131415 (2008).", "journal-title": "Mol. Endocrinol."}, {"key": "BFnrd4075_CR263", "doi-asserted-by": "publisher", "first-page": "1853", "DOI": "10.1093/hmg/9.12.1853", "volume": "9", "author": "R Chrast", "year": "2000", "unstructured": "Chrast, R. et al. Mice trisomic for a bacterial artificial chromosome with the single-minded 2 gene (Sim2) show phenotypes similar to some of those present in the partial trisomy 16 mouse models of Down syndrome. Hum. Mol. Genet. 9, 1853\u20131864 (2000).", "journal-title": "Hum. Mol. Genet."}, {"key": "BFnrd4075_CR264", "doi-asserted-by": "publisher", "first-page": "1601", "DOI": "10.1038/npp.2008.217", "volume": "34", "author": "Y Sun", "year": "2009", "unstructured": "Sun, Y., Zupan, B., Raaka, B. M., Toth, M. & Gershengorn, M. C. TRH-receptor-type-2-deficient mice are euthyroid and exhibit increased depression and reduced anxiety phenotypes. Neuropsychopharmacology 34, 1601\u20131608 (2009).", "journal-title": "Neuropsychopharmacology"}, {"key": "BFnrd4075_CR265", "doi-asserted-by": "publisher", "first-page": "319", "DOI": "10.1016/j.bbrc.2009.05.054", "volume": "385", "author": "K Sekiyama", "year": "2009", "unstructured": "Sekiyama, K. et al. Abnormalities in aggression and anxiety in transgenic mice overexpressing activin E. Biochem. Biophys. Res. Commun. 385, 319\u2013323 (2009).", "journal-title": "Biochem. Biophys. Res. Commun."}, {"key": "BFnrd4075_CR266", "doi-asserted-by": "publisher", "first-page": "403", "DOI": "10.1016/j.nbd.2006.07.015", "volume": "24", "author": "M Dierssen", "year": "2006", "unstructured": "Dierssen, M. et al. Transgenic mice overexpressing the full-length neurotrophin receptor TrkC exhibit increased catecholaminergic neuron density in specific brain areas and increased anxiety-like behavior and panic reaction. Neurobiol. Dis. 24, 403\u2013418 (2006).", "journal-title": "Neurobiol. Dis."}, {"key": "BFnrd4075_CR267", "doi-asserted-by": "publisher", "first-page": "571", "DOI": "10.1016/S0031-9384(97)00514-3", "volume": "63", "author": "M Fiore", "year": "1998", "unstructured": "Fiore, M. et al. Exploratory and displacement behavior in transgenic mice expressing high levels of brain TNF-\u03b1. Physiol. Behav. 63, 571\u2013576 (1998).", "journal-title": "Physiol. Behav."}, {"key": "BFnrd4075_CR268", "doi-asserted-by": "publisher", "first-page": "357", "DOI": "10.1007/s10519-010-9398-1", "volume": "41", "author": "D Ehninger", "year": "2011", "unstructured": "Ehninger, D. & Silva, A. J. Increased levels of anxiety-related behaviors in a Tsc2 dominant negative transgenic mouse model of tuberous sclerosis. Behav. Genet. 41, 357\u2013363 (2011).", "journal-title": "Behav. Genet."}, {"key": "BFnrd4075_CR269", "doi-asserted-by": "publisher", "first-page": "503", "DOI": "10.1016/j.neuron.2005.06.031", "volume": "47", "author": "IF Bielsky", "year": "2005", "unstructured": "Bielsky, I. F., Hu, S. B., Ren, X., Terwilliger, E. F. & Young, L. J. The V1a vasopressin receptor is necessary and sufficient for normal social recognition: a gene replacement study. Neuron 47, 503\u2013513 (2005).", "journal-title": "Neuron"}, {"key": "BFnrd4075_CR270", "doi-asserted-by": "publisher", "first-page": "609", "DOI": "10.1016/0361-9230(82)90087-9", "volume": "8", "author": "JN Crawley", "year": "1982", "unstructured": "Crawley, J. N. & Davis, L. G. Baseline exploratory activity predicts anxiolytic responsiveness to diazepam in five mouse strains. Brain Res. Bull. 8, 609\u2013612 (1982).", "journal-title": "Brain Res. Bull."}, {"key": "BFnrd4075_CR271", "doi-asserted-by": "publisher", "first-page": "107", "DOI": "10.1007/s002130050327", "volume": "132", "author": "JN Crawley", "year": "1997", "unstructured": "Crawley, J. N. et al. Behavioral phenotypes of inbred mouse strains: implications and recommendations for molecular studies. Psychopharmacology 132, 107\u2013124 (1997).", "journal-title": "Psychopharmacology"}, {"key": "BFnrd4075_CR272", "doi-asserted-by": "publisher", "first-page": "637", "DOI": "10.1097/00008877-199312000-00009", "volume": "4", "author": "G Griebel", "year": "1993", "unstructured": "Griebel, G., Belzung, C., Misslin, R. & Vogel, E. The free-exploratory paradigm: an effective method for measuring neophobic behaviour in mice and testing potential neophobia-reducing drugs. Behav. Pharmacol. 4, 637\u2013644 (1993).", "journal-title": "Behav. Pharmacol."}, {"key": "BFnrd4075_CR273", "doi-asserted-by": "publisher", "first-page": "446", "DOI": "10.1016/j.bbr.2010.08.039", "volume": "216", "author": "RL Pobbe", "year": "2011", "unstructured": "Pobbe, R. L. et al. General and social anxiety in the BTBR T+ tf/J mouse strain. Behav. Brain Res. 216, 446\u2013451 (2011).", "journal-title": "Behav. Brain Res."}, {"key": "BFnrd4075_CR274", "doi-asserted-by": "publisher", "first-page": "551", "DOI": "10.1016/S0031-9384(00)00374-7", "volume": "71", "author": "S Kantor", "year": "2000", "unstructured": "Kantor, S., Anheuer, Z. E. & Bagdy, G. High social anxiety and low aggression in Fawn-Hooded rats. Physiol. Behav. 71, 551\u2013557 (2000).", "journal-title": "Physiol. Behav."}, {"key": "BFnrd4075_CR275", "doi-asserted-by": "publisher", "first-page": "4375", "DOI": "10.1523/JNEUROSCI.0115-05.2005", "volume": "25", "author": "SA Kromer", "year": "2005", "unstructured": "Kromer, S. A. et al. Identification of glyoxalase-I as a protein marker in a mouse model of extremes in trait anxiety. J. Neurosci. 25, 4375\u20134384 (2005).", "journal-title": "J. Neurosci."}, {"key": "BFnrd4075_CR276", "doi-asserted-by": "publisher", "first-page": "227", "DOI": "10.1016/S0166-4328(02)00135-3", "volume": "136", "author": "N Salome", "year": "2002", "unstructured": "Salome, N. et al. Reliability of high and low anxiety-related behaviour: influence of laboratory environment and multifactorial analysis. Behav. Brain Res. 136, 227\u2013237 (2002).", "journal-title": "Behav. Brain Res."}, {"key": "BFnrd4075_CR277", "doi-asserted-by": "publisher", "first-page": "89", "DOI": "10.1016/j.neubiorev.2006.07.003", "volume": "31", "author": "R Landgraf", "year": "2007", "unstructured": "Landgraf, R. et al. Candidate genes of anxiety-related behavior in HAB/LAB rats and mice: focus on vasopressin and glyoxalase-I. Neurosci. Biobehav. Rev. 31, 89\u2013102 (2007).", "journal-title": "Neurosci. Biobehav. Rev."}, {"key": "BFnrd4075_CR278", "doi-asserted-by": "publisher", "first-page": "287", "DOI": "10.1007/BF02244595", "volume": "100", "author": "RL Commissaris", "year": "1990", "unstructured": "Commissaris, R. L., Harrington, G. M. & Altman, H. J. Benzodiazepine anti-conflict effects in Maudsley reactive (MR/Har) and non-reactive (MNRA/Har) rats. Psychopharmacology 100, 287\u2013292 (1990).", "journal-title": "Psychopharmacology"}, {"key": "BFnrd4075_CR279", "doi-asserted-by": "publisher", "first-page": "801", "DOI": "10.1016/0091-3057(89)90037-3", "volume": "32", "author": "RL Commissaris", "year": "1989", "unstructured": "Commissaris, R. L., McCloskey, T. C., Harrington, G. M. & Altman, H. J. MR/Har and MNRA/Har Maudsley rat strains: differential response to chlordiazepoxide in a conflict task. Pharmacol. Biochem. Behav. 32, 801\u2013805 (1989).", "journal-title": "Pharmacol. Biochem. Behav."}, {"key": "BFnrd4075_CR280", "doi-asserted-by": "publisher", "first-page": "277", "DOI": "10.1023/A:1020206120248", "volume": "32", "author": "DA Blizard", "year": "2002", "unstructured": "Blizard, D. A. & Adams, N. The Maudsley reactive and nonreactive strains: a new perspective. Behav. Genet. 32, 277\u2013299 (2002).", "journal-title": "Behav. Genet."}, {"key": "BFnrd4075_CR281", "doi-asserted-by": "publisher", "first-page": "92", "DOI": "10.1016/j.bbr.2009.03.024", "volume": "202", "author": "R Lopez-Aumatell", "year": "2009", "unstructured": "Lopez-Aumatell, R. et al. Unlearned anxiety predicts learned fear: a comparison among heterogeneous rats and the Roman rat strains. Behav. Brain Res. 202, 92\u2013101 (2009).", "journal-title": "Behav. Brain Res."}, {"key": "BFnrd4075_CR282", "doi-asserted-by": "publisher", "first-page": "1206", "DOI": "10.1046/j.1460-9568.2002.01945.x", "volume": "15", "author": "DM Yilmazer-Hanke", "year": "2002", "unstructured": "Yilmazer-Hanke, D. M., Faber-Zuschratter, H., Linke, R. & Schwegler, H. Contribution of amygdala neurons containing peptides and calcium-binding proteins to fear-potentiated startle and exploration-related anxiety in inbred Roman high- and low-avoidance rats. Eur. J. Neurosci. 15, 1206\u20131218 (2002).", "journal-title": "Eur. J. Neurosci."}, {"key": "BFnrd4075_CR283", "doi-asserted-by": "publisher", "first-page": "169", "DOI": "10.1046/j.1365-2826.1997.t01-1-00571.x", "volume": "9", "author": "T Steimer", "year": "1997", "unstructured": "Steimer, T., Driscoll, P. & Schulz, P. E. Brain metabolism of progesterone, coping behaviour and emotional reactivity in male rats from two psychogenetically selected lines. J. Neuroendocrinol. 9, 169\u2013175 (1997).", "journal-title": "J. Neuroendocrinol."}, {"key": "BFnrd4075_CR284", "doi-asserted-by": "publisher", "first-page": "162", "DOI": "10.1016/j.bbr.2009.05.036", "volume": "204", "author": "JD McAuley", "year": "2009", "unstructured": "McAuley, J. D. et al. Wistar-Kyoto rats as an animal model of anxiety vulnerability: support for a hypervigilance hypothesis. Behav. Brain Res. 204, 162\u2013168 (2009).", "journal-title": "Behav. Brain Res."}, {"key": "BFnrd4075_CR285", "first-page": "1583", "volume": "25", "author": "WP Par\u00e9", "year": "1999", "unstructured": "Par\u00e9, W. P., Kluczynski, S. M. & Tejani-Butt, S. M. Strain differences in the open field test and the Porsolt forced swim test following antidepressant treatment. Abstr. Soc. Neurosci. 25, 1583 (1999).", "journal-title": "Abstr. Soc. Neurosci."}, {"key": "BFnrd4075_CR286", "doi-asserted-by": "publisher", "first-page": "105", "DOI": "10.1038/npp.2009.109", "volume": "35", "author": "M Davis", "year": "2010", "unstructured": "Davis, M., Walker, D. L., Miles, L. & Grillon, C. Phasic versus sustained fear in rats and humans: role of the extended amygdala in fear versus anxiety. Neuropsychopharmacology 35, 105\u2013135 (2010).", "journal-title": "Neuropsychopharmacology"}], "container-title": ["Nature Reviews Drug Discovery"], "language": "en", "link": [{"URL": "http://www.nature.com/articles/nrd4075.pdf", "content-type": "application/pdf", "content-version": "vor", "intended-application": "text-mining"}, {"URL": "http://www.nature.com/articles/nrd4075", "content-type": "text/html", "content-version": "vor", "intended-application": "text-mining"}, {"URL": "http://www.nature.com/articles/nrd4075.pdf", "content-type": "application/pdf", "content-version": "vor", "intended-application": "similarity-checking"}], "deposited": {"date-parts": [[2019, 10, 1]], "date-time": "2019-10-01T07:26:45Z", "timestamp": 1569914805000}, "score": 73.54706, "issued": {"date-parts": [[2013, 8, 30]]}, "references-count": 286, "journal-issue": {"published-print": {"date-parts": [[2013, 9]]}, "issue": "9"}, "alternative-id": ["BFnrd4075"], "URL": "http://dx.doi.org/10.1038/nrd4075", "relation": {"cites": []}, "ISSN": ["1474-1776", "1474-1784"], "issn-type": [{"value": "1474-1776", "type": "print"}, {"value": "1474-1784", "type": "electronic"}], "subject": ["Pharmacology", "Drug Discovery", "General Medicine"]}, {"indexed": {"date-parts": [[2019, 11, 23]], "date-time": "2019-11-23T02:42:57Z", "timestamp": 1574476977541}, "reference-count": 179, "publisher": "Springer Science and Business Media LLC", "issue": "6", "license": [{"URL": "http://www.springer.com/tdm", "start": {"date-parts": [[2012, 5, 18]], "date-time": "2012-05-18T00:00:00Z", "timestamp": 1337299200000}, "delay-in-days": 0, "content-version": "tdm"}], "content-domain": {"domain": [], "crossmark-restriction": false}, "short-container-title": ["Nat Rev Drug Discov"], "published-print": {"date-parts": [[2012, 6]]}, "DOI": "10.1038/nrd3702", "type": "journal-article", "created": {"date-parts": [[2012, 5, 18]], "date-time": "2012-05-18T10:02:32Z", "timestamp": 1337335352000}, "page": "462-478", "source": "Crossref", "is-referenced-by-count": 114, "title": ["Neuropeptide receptor ligands as drugs for psychiatric diseases: the end of the beginning?"], "prefix": "10.1038", "volume": "11", "author": [{"given": "Guy", "family": "Griebel", "sequence": "first", "affiliation": []}, {"given": "Florian", "family": "Holsboer", "sequence": "additional", "affiliation": []}], "member": "297", "published-online": {"date-parts": [[2012, 5, 18]]}, "reference": [{"key": "BFnrd3702_CR1", "doi-asserted-by": "publisher", "first-page": "1640", "DOI": "10.1126/science.281.5383.1640", "volume": "281", "author": "MS Kramer", "year": "1998", "unstructured": "Kramer, M. S. et al. Distinct mechanism for antidepressant activity by blockade of central substance P receptors. Science 281, 1640\u20131645 (1998).", "journal-title": "Science"}, {"key": "BFnrd3702_CR2", "doi-asserted-by": "publisher", "first-page": "135", "DOI": "10.2174/187152706776359682", "volume": "5", "author": "C Belzung", "year": "2006", "unstructured": "Belzung, C., Yalcin, I., Griebel, G., Surget, A. & Leman, S. Neuropeptides in psychiatric diseases: an overview with a particular focus on depression and anxiety disorders. CNS Neurol. Disord. Drug Targets 5, 135\u2013145 (2006).", "journal-title": "CNS Neurol. Disord. Drug Targets"}, {"key": "BFnrd3702_CR3", "doi-asserted-by": "publisher", "first-page": "1", "DOI": "10.1016/S0163-7258(98)00041-2", "volume": "82", "author": "G Griebel", "year": "1999", "unstructured": "Griebel, G. Is there a future for neuropeptide receptor ligands in the treatment of anxiety disorders? Pharmacol. Ther. 82, 1\u201361 (1999).", "journal-title": "Pharmacol. Ther."}, {"key": "BFnrd3702_CR4", "doi-asserted-by": "publisher", "first-page": "415", "DOI": "10.1007/7854_2009_14", "volume": "2", "author": "T Steckler", "year": "2010", "unstructured": "Steckler, T. Developing small molecule nonpeptidergic drugs for the treatment of anxiety disorders: is the challenge still ahead? Curr. Top. Behav. Neurosci. 2, 415\u2013428 (2010).", "journal-title": "Curr. Top. Behav. Neurosci."}, {"key": "BFnrd3702_CR5", "doi-asserted-by": "publisher", "first-page": "559", "DOI": "10.1002/med.10042", "volume": "23", "author": "R Herranz", "year": "2003", "unstructured": "Herranz, R. Cholecystokinin antagonists: pharmacological and therapeutic potential. Med. Res. Rev. 23, 559\u2013605 (2003).", "journal-title": "Med. Res. Rev."}, {"key": "BFnrd3702_CR6", "author": "M Turiault", "first-page": "1301", "year": "2010", "unstructured": "Turiault, M., Cohen, C. & Griebel, G. in Encyclopedia of Psychopharmacology (ed. Stolerman, I. P.) 1301\u20131303 (Springer-Verlag 2010).", "volume-title": "Encyclopedia of Psychopharmacology", "DOI": "10.1007/978-3-540-68706-1_210", "doi-asserted-by": "publisher"}, {"key": "BFnrd3702_CR7", "first-page": "551", "volume": "46", "author": "D Regoli", "year": "1994", "unstructured": "Regoli, D., Boudon, A. & Fauchere, J. L. Receptors and antagonists for substance P and related peptides. Pharmacol. Rev. 46, 551\u2013599 (1994).", "journal-title": "Pharmacol. Rev."}, {"key": "BFnrd3702_CR8", "doi-asserted-by": "publisher", "first-page": "335", "DOI": "10.1002/cne.20664", "volume": "490", "author": "M Rigby", "year": "2005", "unstructured": "Rigby, M., O'Donnell, R. & Rupniak, N. M. Species differences in tachykinin receptor distribution: further evidence that the substance P (NK1) receptor predominates in human brain. J. Comp. Neurol. 490, 335\u2013353 (2005).", "journal-title": "J. Comp. Neurol."}, {"key": "BFnrd3702_CR9", "doi-asserted-by": "publisher", "first-page": "339", "DOI": "10.1016/j.peptides.2004.02.011", "volume": "25", "author": "JC Beaujouan", "year": "2004", "unstructured": "Beaujouan, J. C., Torrens, Y., Saffroy, M., Kemel, M. L. & Glowinski, J. A 25 year adventure in the field of tachykinins. Peptides 25, 339\u2013357 (2004).", "journal-title": "Peptides"}, {"key": "BFnrd3702_CR10", "doi-asserted-by": "publisher", "first-page": "371", "DOI": "10.1016/S0893-133X(02)00313-5", "volume": "27", "author": "GB Varty", "year": "2002", "unstructured": "Varty, G. B. et al. The gerbil elevated plus-maze II: anxiolytic-like effects of selective neurokinin NK1 receptor antagonists. Neuropsychopharmacology 27, 371\u2013379 (2002).", "journal-title": "Neuropsychopharmacology"}, {"key": "BFnrd3702_CR11", "doi-asserted-by": "publisher", "first-page": "357", "DOI": "10.1016/S0893-133X(02)00312-3", "volume": "27", "author": "GB Varty", "year": "2002", "unstructured": "Varty, G. B., Morgan, C. A., Cohen-Williams, M. E., Coffin, V. L. & Carey, G. J. The gerbil elevated plus-maze I: behavioral characterization and pharmacological validation. Neuropsychopharmacology 27, 357\u2013370 (2002).", "journal-title": "Neuropsychopharmacology"}, {"key": "BFnrd3702_CR12", "doi-asserted-by": "publisher", "first-page": "481", "DOI": "10.1016/S0143-4179(98)90075-0", "volume": "32", "author": "N Marco", "year": "1998", "unstructured": "Marco, N. et al. Activation of dopaminergic and cholinergic neurotransmission by tachykinin NK3 receptor stimulation: an in vivo microdialysis approach in guinea pig. Neuropeptides 32, 481\u2013488 (1998).", "journal-title": "Neuropeptides"}, {"key": "BFnrd3702_CR13", "doi-asserted-by": "publisher", "first-page": "435", "DOI": "10.1126/science.1703323", "volume": "251", "author": "RM Snider", "year": "1991", "unstructured": "Snider, R. M. et al. A potent nonpeptide antagonist of the substance P (NK1) receptor. Science 251, 435\u2013437 (1991).", "journal-title": "Science"}, {"key": "BFnrd3702_CR14", "doi-asserted-by": "publisher", "first-page": "275", "DOI": "10.2165/00023210-200519040-00001", "volume": "19", "author": "I Herpfer", "year": "2005", "unstructured": "Herpfer, I. & Lieb, K. Substance P receptor antagonists in psychiatry: rationale for development and therapeutic potential. CNS Drugs 19, 275\u2013293 (2005).", "journal-title": "CNS Drugs"}, {"key": "BFnrd3702_CR15", "doi-asserted-by": "publisher", "first-page": "251", "DOI": "10.1007/s00726-006-0335-9", "volume": "31", "author": "K Ebner", "year": "2006", "unstructured": "Ebner, K. & Singewald, N. The role of substance P in stress and anxiety responses. Amino Acids 31, 251\u2013272 (2006).", "journal-title": "Amino Acids"}, {"key": "BFnrd3702_CR16", "doi-asserted-by": "publisher", "first-page": "1383", "DOI": "10.1016/j.peptides.2005.03.032", "volume": "26", "author": "G Gobbi", "year": "2005", "unstructured": "Gobbi, G. & Blier, P. Effect of neurokinin-1 receptor antagonists on serotoninergic, noradrenergic and hippocampal neurons: comparison with antidepressant drugs. Peptides 26, 1383\u20131393 (2005).", "journal-title": "Peptides"}, {"key": "BFnrd3702_CR17", "doi-asserted-by": "publisher", "first-page": "385", "DOI": "10.1038/sj.npp.1300260", "volume": "29", "author": "MS Kramer", "year": "2004", "unstructured": "Kramer, M. S. et al. Demonstration of the efficacy and safety of a novel substance P (NK1) receptor antagonist in major depression. Neuropsychopharmacology 29, 385\u2013392 (2004).", "journal-title": "Neuropsychopharmacology"}, {"key": "BFnrd3702_CR18", "author": "P Chappell", "year": "2002", "unstructured": "Chappell, P. Effect of CP-122,721, a selective NK-1 receptor antagonist, in patients with MDD. In: Proceedings of the 42nd Annual Meeting of the New Clinical Drug Evaluation Unit (Boca Raton, Florida, 2002).", "volume-title": "Proceedings of the 42nd Annual Meeting of the New Clinical Drug Evaluation Unit"}, {"key": "BFnrd3702_CR19", "doi-asserted-by": "publisher", "first-page": "727", "DOI": "10.1097/JCP.0b013e31823608ca", "volume": "31", "author": "E Ratti", "year": "2011", "unstructured": "Ratti, E. et al. Results from 2 randomized, double-blind, placebo-controlled studies of the novel NK1 receptor antagonist casopitant in patients with major depressive disorder. J. Clin. Psychopharmacol. 31, 727\u2013733 (2011).", "journal-title": "J. Clin. Psychopharmacol."}, {"key": "BFnrd3702_CR20", "doi-asserted-by": "publisher", "first-page": "216", "DOI": "10.1016/j.biopsych.2005.07.013", "volume": "59", "author": "M Keller", "year": "2006", "unstructured": "Keller, M. et al. Lack of efficacy of the substance P (neurokinin1 receptor) antagonist aprepitant in the treatment of major depressive disorder. Biol. Psychiatry 59, 216\u2013223 (2006).", "journal-title": "Biol. Psychiatry"}, {"key": "BFnrd3702_CR21", "doi-asserted-by": "publisher", "first-page": "622", "DOI": "10.1016/j.jpsychires.2007.07.003", "volume": "42", "author": "KS Liu", "year": "2008", "unstructured": "Liu, K. S. et al. Is bigger better for depression trials? J. Psychiatr. Res. 42, 622\u2013630 (2008).", "journal-title": "J. Psychiatr. Res."}, {"key": "BFnrd3702_CR22", "doi-asserted-by": "publisher", "first-page": "727", "DOI": "10.1097/JCP.0b013e31823608ca", "volume": "31", "author": "E Ratti", "year": "2011", "unstructured": "Ratti, E. et al. Results from 2 randomized, double-blind, placebo-controlled studies of the novel NK1 receptor antagonist casopitant in patients with major depressive disorder. J. Clin. Psychopharmacol. 31, 727\u2013733 (2011).", "journal-title": "J. Clin. Psychopharmacol."}, {"key": "BFnrd3702_CR23", "author": "M Liebowitz", "year": "2007", "unstructured": "Liebowitz, M., Sheehan, D., Melia, L. A. & Siffert, J. Safety and efficacy of AV608 in subjects with social anxiety disorder. In: Proceedings of the 47th Annual Meeting of the New Clinical Drug Evaluation Unit (Boca Raton, Florida, 2007).", "volume-title": "Proceedings of the 47th Annual Meeting of the New Clinical Drug Evaluation Unit"}, {"key": "BFnrd3702_CR24", "doi-asserted-by": "publisher", "first-page": "80", "DOI": "10.1016/j.euroneuro.2009.10.005", "volume": "20", "author": "J Tauscher", "year": "2010", "unstructured": "Tauscher, J. et al. Development of the 2nd generation neurokinin-1 receptor antagonist LY686017 for social anxiety disorder. Eur. Neuropsychopharmacol. 20, 80\u201387 (2010).", "journal-title": "Eur. Neuropsychopharmacol."}, {"key": "BFnrd3702_CR25", "doi-asserted-by": "publisher", "first-page": "221", "DOI": "10.1016/j.euroneuro.2010.11.012", "volume": "21", "author": "SJ Mathew", "year": "2011", "unstructured": "Mathew, S. J. et al. A selective neurokinin-1 receptor antagonist in chronic PTSD: a randomized, double-blind, placebo-controlled, proof-of-concept trial. Eur. Neuropsychopharmacol. 21, 221\u2013229 (2011).", "journal-title": "Eur. Neuropsychopharmacol."}, {"key": "BFnrd3702_CR26", "doi-asserted-by": "publisher", "first-page": "485", "DOI": "10.1016/S0165-6147(99)01396-6", "volume": "20", "author": "NM Rupniak", "year": "1999", "unstructured": "Rupniak, N. M. & Kramer, M. S. Discovery of the antidepressant and anti-emetic efficacy of substance P receptor (NK1) antagonists. Trends Pharmacol. Sci. 20, 485\u2013490 (1999).", "journal-title": "Trends Pharmacol. Sci."}, {"key": "BFnrd3702_CR27", "doi-asserted-by": "publisher", "first-page": "1647", "DOI": "10.2174/138161209788168074", "volume": "15", "author": "K Ebner", "year": "2009", "unstructured": "Ebner, K., Sartori, S. B. & Singewald, N. Tachykinin receptors as therapeutic targets in stress-related disorders. Curr. Pharm. Des. 15, 1647\u20131674 (2009).", "journal-title": "Curr. Pharm. Des."}, {"key": "BFnrd3702_CR28", "doi-asserted-by": "publisher", "first-page": "239", "DOI": "10.1007/s00213-010-2133-z", "volume": "215", "author": "A Pringle", "year": "2011", "unstructured": "Pringle, A. et al. Short-term NK1 receptor antagonism and emotional processing in healthy volunteers. Psychopharmacology (Berl.) 215, 239\u2013246 (2011).", "journal-title": "Psychopharmacology (Berl.)"}, {"key": "BFnrd3702_CR29", "doi-asserted-by": "publisher", "first-page": "481", "DOI": "10.1177/0269881109103101", "volume": "24", "author": "P Chandra", "year": "2010", "unstructured": "Chandra, P. et al. NK1 receptor antagonism and emotional processing in healthy volunteers. J. Psychopharmacol. 24, 481\u2013487 (2010).", "journal-title": "J. Psychopharmacol."}, {"key": "BFnrd3702_CR30", "doi-asserted-by": "publisher", "first-page": "1261", "DOI": "10.1017/S1461145709990150", "volume": "12", "author": "C McCabe", "year": "2009", "unstructured": "McCabe, C., Cowen, P. J. & Harmer, C. J. NK1 receptor antagonism and the neural processing of emotional information in healthy volunteers. Int. J. Neuropsychopharmacol. 12, 1261\u20131274 (2009).", "journal-title": "Int. J. Neuropsychopharmacol."}, {"key": "BFnrd3702_CR31", "doi-asserted-by": "publisher", "first-page": "PL101", "DOI": "10.1016/0024-3205(92)90352-P", "volume": "50", "author": "X Emonds-Alt", "year": "1992", "unstructured": "Emonds-Alt, X. et al. A potent and selective non-peptide antagonist of the neurokinin A (NK2) receptor. Life Sci. 50, PL101\u2013PL106 (1992).", "journal-title": "Life Sci."}, {"key": "BFnrd3702_CR32", "first-page": "449", "volume": "299", "author": "R Steinberg", "year": "2001", "unstructured": "Steinberg, R. et al. Selective blockade of neurokinin-2 receptors produces antidepressant-like effects associated with reduced corticotropin-releasing factor function. J. Pharmacol. Exp. Ther. 299, 449\u2013458 (2001).", "journal-title": "J. Pharmacol. Exp. Ther."}, {"key": "BFnrd3702_CR33", "doi-asserted-by": "publisher", "first-page": "36", "DOI": "10.1016/j.pbb.2007.10.020", "volume": "89", "author": "C Louis", "year": "2008", "unstructured": "Louis, C. et al. Additional evidence for anxiolytic- and antidepressant-like activities of saredutant (SR48968), an antagonist at the neurokinin-2 receptor in various rodent-models. Pharmacol. Biochem. Behav. 89, 36\u201345 (2008).", "journal-title": "Pharmacol. Biochem. Behav."}, {"key": "BFnrd3702_CR34", "doi-asserted-by": "publisher", "first-page": "206", "DOI": "10.1016/j.pbb.2010.05.006", "volume": "96", "author": "DH Overstreet", "year": "2010", "unstructured": "Overstreet, D. H., Naimoli, V. M. & Griebel, G. Saredutant, an NK2 receptor antagonist, has both antidepressant-like effects and synergizes with desipramine in an animal model of depression. Pharmacol. Biochem. Behav. 96, 206\u2013210 (2010).", "journal-title": "Pharmacol. Biochem. Behav."}, {"key": "BFnrd3702_CR35", "doi-asserted-by": "publisher", "first-page": "241", "DOI": "10.1007/s002130100830", "volume": "158", "author": "G Griebel", "year": "2001", "unstructured": "Griebel, G., Perrault, G. & Soubrie, P. Effects of SR48968, a selective non-peptide NK2 receptor antagonist on emotional processes in rodents. Psychopharmacology 158, 241\u2013251 (2001).", "journal-title": "Psychopharmacology"}, {"key": "BFnrd3702_CR36", "first-page": "L27", "volume": "56", "author": "X Emonds-Alt", "year": "1995", "unstructured": "Emonds-Alt, X. et al. SR 142801, the first potent non-peptide antagonist of the tachykinin NK3 receptor. Life Sci. 56, L27\u2013L32 (1995).", "journal-title": "Life Sci."}, {"key": "BFnrd3702_CR37", "doi-asserted-by": "publisher", "first-page": "344", "DOI": "10.2174/138161210790170067", "volume": "16", "author": "LA Dawson", "year": "2010", "unstructured": "Dawson, L. A. & Smith, P. W. Therapeutic utility of NK3 receptor antagonists for the treatment of schizophrenia. Curr. Pharm. Des. 16, 344\u2013357 (2010).", "journal-title": "Curr. Pharm. Des."}, {"key": "BFnrd3702_CR38", "doi-asserted-by": "publisher", "first-page": "1498", "DOI": "10.1016/j.bmcl.2010.12.135", "volume": "21", "author": "K Juhl", "year": "2011", "unstructured": "Juhl, K. et al. Identification of a new series of non-peptidic NK3 receptor antagonists. Bioorg. Med.Chem. Lett. 21, 1498\u20131501 (2011).", "journal-title": "Bioorg. Med.Chem. Lett."}, {"key": "BFnrd3702_CR39", "first-page": "379", "volume": "13", "author": "KB Simonsen", "year": "2010", "unstructured": "Simonsen, K. B., Juhl, K., Steiniger-Brach, B. & Nielsen, S. M. Novel NK3 receptor antagonists for the treatment of schizophrenia and other CNS indications. Curr. Opin. Drug Discov. Devel. 13, 379\u2013388 (2010).", "journal-title": "Curr. Opin. Drug Discov. Devel."}, {"key": "BFnrd3702_CR40", "doi-asserted-by": "publisher", "first-page": "637", "DOI": "10.1517/13543776.2011.568482", "volume": "21", "author": "P Malherbe", "year": "2011", "unstructured": "Malherbe, P., Ballard, T. M. & Ratni, H. Tachykinin neurokinin 3 receptor antagonists: a patent review (2005\u20132010). Expert. Opin. Ther. Pat. 21, 637\u2013655 (2011).", "journal-title": "Expert. Opin. Ther. Pat."}, {"key": "BFnrd3702_CR41", "doi-asserted-by": "publisher", "first-page": "116", "DOI": "10.1016/j.pharmthera.2011.09.007", "volume": "133", "author": "G Griebel", "year": "2011", "unstructured": "Griebel, G. & Beeske, S. Is there still a future for neurokinin 3 receptor antagonists as potential drugs for the treatment of psychiatric diseases? Pharmacol. Ther. 133, 116\u2013123 (2011).", "journal-title": "Pharmacol. Ther."}, {"key": "BFnrd3702_CR42", "doi-asserted-by": "publisher", "first-page": "967", "DOI": "10.1038/nrd1905", "volume": "4", "author": "W Spooren", "year": "2005", "unstructured": "Spooren, W., Riemer, C. & Meltzer, H. NK3 receptor antagonists: the next generation of antipsychotics? Nature Rev. Drug Discov. 4, 967\u2013975 (2005).", "journal-title": "Nature Rev. Drug Discov."}, {"key": "BFnrd3702_CR43", "doi-asserted-by": "publisher", "first-page": "975", "DOI": "10.1176/appi.ajp.161.6.975", "volume": "161", "author": "HY Meltzer", "year": "2004", "unstructured": "Meltzer, H. Y., Arvanitis, L., Bauer, D. & Rein, W. Placebo-controlled evaluation of four novel compounds for the treatment of schizophrenia and schizoaffective disorder. Am. J. Psychiatry 161, 975\u2013984 (2004).", "journal-title": "Am. J. Psychiatry"}, {"key": "BFnrd3702_CR44", "first-page": "717", "volume": "6", "author": "S Evangelista", "year": "2005", "unstructured": "Evangelista, S. Talnetant GlaxoSmithKline. Curr. Opin. Investig. Drugs 6, 717\u2013721 (2005).", "journal-title": "Curr. Opin. Investig. Drugs"}, {"key": "BFnrd3702_CR45", "doi-asserted-by": "publisher", "first-page": "73", "DOI": "10.1177/0269881108094524", "volume": "24", "author": "M Liem-Moolenaar", "year": "2010", "unstructured": "Liem-Moolenaar, M. et al. Psychomotor and cognitive effects of a single oral dose of talnetant (SB223412) in healthy volunteers compared with placebo or haloperidol. J. Psychopharmacol. 24, 73\u201382 (2010).", "journal-title": "J. Psychopharmacol."}, {"key": "BFnrd3702_CR46", "doi-asserted-by": "publisher", "first-page": "1394", "DOI": "10.1126/science.6267699", "volume": "213", "author": "WW Vale", "year": "1981", "unstructured": "Vale, W. W., Spiess, J., Rivier, C. & Rivier, J. Characterization of a 41 residue ovine hypothalamic peptide that stimulates the secretion of corticotropin and \u03b2-endorphin. Science 213, 1394\u20131397 (1981).", "journal-title": "Science"}, {"key": "BFnrd3702_CR47", "doi-asserted-by": "publisher", "first-page": "21", "DOI": "10.1124/pr.55.1.3", "volume": "55", "author": "RL Hauger", "year": "2003", "unstructured": "Hauger, R. L. et al. International Union of Pharmacology. XXXVI. Current status of the nomenclature for receptors for corticotropin-releasing factor and their ligands. Pharmacol. Rev. 55, 21\u201326 (2003).", "journal-title": "Pharmacol. Rev."}, {"key": "BFnrd3702_CR48", "doi-asserted-by": "publisher", "first-page": "6340", "DOI": "10.1523/JNEUROSCI.15-10-06340.1995", "volume": "15", "author": "DT Chalmers", "year": "1995", "unstructured": "Chalmers, D. T., Lovenberg, T. W. & De Souza, E. B. Localization of novel corticotropin-releasing factor receptor (CRF2) mRNA expression to specific subcortical nuclei in rat brain: comparison with CRF1 receptor mRNA expression. J. Neurosci. 15, 6340\u20136350 (1995).", "journal-title": "J. Neurosci."}, {"key": "BFnrd3702_CR49", "doi-asserted-by": "publisher", "first-page": "145", "DOI": "10.1016/j.ejphar.2004.12.030", "volume": "509", "author": "DR Gehlert", "year": "2005", "unstructured": "Gehlert, D. R. et al. Stress and central urocortin increase anxiety-like behavior in the social interaction test via the CRF1 receptor. Eur. J. Pharmacol. 509, 145\u2013153 (2005).", "journal-title": "Eur. J. Pharmacol."}, {"key": "BFnrd3702_CR50", "doi-asserted-by": "publisher", "first-page": "789", "DOI": "10.1016/0306-4530(95)00011-9", "volume": "20", "author": "EB De Souza", "year": "1995", "unstructured": "De Souza, E. B. Corticotropin-releasing factor receptors: physiology, pharmacology, biochemistry and role in central nervous system and immune disorders. Psychoneuroendocrinology 20, 789\u2013819 (1995).", "journal-title": "Psychoneuroendocrinology"}, {"key": "BFnrd3702_CR51", "doi-asserted-by": "publisher", "first-page": "23", "DOI": "10.1016/S1471-4892(01)00117-5", "volume": "2", "author": "JM Reul", "year": "2002", "unstructured": "Reul, J. M. & Holsboer, F. Corticotropin-releasing factor receptors 1 and 2 in anxiety and depression. Curr. Opin. Pharmacol. 2, 23\u201333 (2002).", "journal-title": "Curr. Opin. Pharmacol."}, {"key": "BFnrd3702_CR52", "first-page": "265", "volume": "1", "author": "DP Behan", "year": "1996", "unstructured": "Behan, D. P. et al. Neurobiology of corticotropin releasing factor (CRF) receptors and CRF-binding protein: implications for the treatment of CNS disorders. Mol. Psychiatr. 1, 265\u2013277 (1996).", "journal-title": "Mol. Psychiatr."}, {"key": "BFnrd3702_CR53", "doi-asserted-by": "publisher", "first-page": "453", "DOI": "10.2174/187152706777950684", "volume": "5", "author": "RL Hauger", "year": "2006", "unstructured": "Hauger, R. L., Risbrough, V., Brauns, O. & Dautzenberg, F. M. Corticotropin releasing factor (CRF) receptor signaling in the central nervous system: new molecular targets. CNS Neurol. Disord. Drug Targets 5, 453\u2013479 (2006).", "journal-title": "CNS Neurol. Disord. Drug Targets"}, {"key": "BFnrd3702_CR54", "doi-asserted-by": "publisher", "first-page": "6183", "DOI": "10.1073/pnas.0502070102", "volume": "102", "author": "D Refojo", "year": "2005", "unstructured": "Refojo, D. et al. Corticotropin-releasing hormone activates ERK1/2 MAPK in specific brain areas. Proc. Natl Acad. Sci. USA 102, 6183\u20136188 (2005).", "journal-title": "Proc. Natl Acad. Sci. USA"}, {"key": "BFnrd3702_CR55", "doi-asserted-by": "publisher", "first-page": "171", "DOI": "10.1016/S0022-3956(00)00016-9", "volume": "34", "author": "AW Zobel", "year": "2000", "unstructured": "Zobel, A. W. et al. Effects of the high-affinity corticotropin-releasing hormone receptor 1 antagonist R121919 in major depression: the first 20 patients treated. J. Psychiatr. Res. 34, 171\u2013181 (2000).", "journal-title": "J. Psychiatr. Res."}, {"key": "BFnrd3702_CR56", "doi-asserted-by": "publisher", "first-page": "1161", "DOI": "10.1038/nn.2647", "volume": "13", "author": "EJ Nestler", "year": "2010", "unstructured": "Nestler, E. J. & Hyman, S. E. Animal models of neuropsychiatric disorders. Nature Neurosci. 13, 1161\u20131169 (2010).", "journal-title": "Nature Neurosci."}, {"key": "BFnrd3702_CR57", "doi-asserted-by": "publisher", "first-page": "245", "DOI": "10.1017/S003329170001429X", "volume": "8", "author": "ES Paykel", "year": "1978", "unstructured": "Paykel, E. S. Contribution of life events to causation of psychiatric illness. Psychol. Med. 8, 245\u2013253 (1978).", "journal-title": "Psychol. Med."}, {"key": "BFnrd3702_CR58", "doi-asserted-by": "publisher", "first-page": "837", "DOI": "10.1176/ajp.156.6.837", "volume": "156", "author": "KS Kendler", "year": "1999", "unstructured": "Kendler, K. S., Karkowski, L. M. & Prescott, C. A. Causal relationship between stressful life events and the onset of major depression. Am. J. Psychiatr. 156, 837\u2013841 (1999).", "journal-title": "Am. J. Psychiatr."}, {"key": "BFnrd3702_CR59", "doi-asserted-by": "publisher", "first-page": "293", "DOI": "10.1146/annurev.clinpsy.1.102803.143938", "volume": "1", "author": "C Hammen", "year": "2005", "unstructured": "Hammen, C. Stress and depression. Annu. Rev. Clin. Psychol. 1, 293\u2013319 (2005).", "journal-title": "Annu. Rev. Clin. Psychol."}, {"key": "BFnrd3702_CR60", "doi-asserted-by": "publisher", "first-page": "154", "DOI": "10.1038/mp.2009.46", "volume": "15", "author": "M Kimura", "year": "2010", "unstructured": "Kimura, M. et al. Conditional corticotropin-releasing hormone overexpression in the mouse forebrain enhances rapid eye movement sleep. Mol. Psychiatry 15, 154\u2013165 (2010).", "journal-title": "Mol. Psychiatry"}, {"key": "BFnrd3702_CR61", "doi-asserted-by": "publisher", "first-page": "989", "DOI": "10.1038/mp.2008.107", "volume": "13", "author": "A Lu", "year": "2008", "unstructured": "Lu, A. et al. Conditional CRH overexpressing mice: an animal model for stress-elicited pathologies and treatments that target the central CRH system. Mol. Psychiatry 13, 989 (2008).", "journal-title": "Mol. Psychiatry"}, {"key": "BFnrd3702_CR62", "doi-asserted-by": "publisher", "first-page": "145", "DOI": "10.1001/archpsyc.1995.03950140063009", "volume": "52", "author": "CJ Lauer", "year": "1995", "unstructured": "Lauer, C. J., Schreiber, W., Holsboer, F. & Krieg, J. C. In quest of identifying vulnerability markers for psychiatric disorders by all-night polysomnography. Arch. Gen. Psychiatry 52, 145\u2013153 (1995).", "journal-title": "Arch. Gen. Psychiatry"}, {"key": "BFnrd3702_CR63", "doi-asserted-by": "publisher", "first-page": "129", "DOI": "10.1016/S0022-3956(03)00076-1", "volume": "38", "author": "K Held", "year": "2004", "unstructured": "Held, K. et al. Treatment with the CRH1-receptor-antagonist R121919 improves sleep-EEG in patients with depression. J. Psychiatr. Res. 38, 129\u2013136 (2004).", "journal-title": "J. Psychiatr. Res."}, {"key": "BFnrd3702_CR64", "doi-asserted-by": "publisher", "first-page": "81", "DOI": "10.1146/annurev.psych.093008.100321", "volume": "61", "author": "F Holsboer", "year": "2010", "unstructured": "Holsboer, F. & Ising, M. Stress hormone regulation: biological role and translation into therapy. Annu. Rev. Psychol. 61, 81\u2013109 (2010).", "journal-title": "Annu. Rev. Psychol."}, {"key": "BFnrd3702_CR65", "doi-asserted-by": "publisher", "first-page": "1196", "DOI": "10.1002/ajmg.b.30750", "volume": "147B", "author": "ME Keck", "year": "2008", "unstructured": "Keck, M. E. et al. Combined effects of exonic polymorphisms in CRHR1 and AVPR1B genes in a case/control study for panic disorder. Am. J. Med. Genet. B Neuropsychiatr. Genet. 147B, 1196\u20131204 (2008).", "journal-title": "Am. J. Med. Genet. B Neuropsychiatr. Genet."}, {"key": "BFnrd3702_CR66", "doi-asserted-by": "publisher", "first-page": "167", "DOI": "10.2174/187152706776359664", "volume": "5", "author": "R Landgraf", "year": "2006", "unstructured": "Landgraf, R. The involvement of the vasopressin system in stress-related disorders. CNS Neurol. Disord. Drug Targets 5, 167\u2013179 (2006).", "journal-title": "CNS Neurol. Disord. Drug Targets"}, {"key": "BFnrd3702_CR67", "doi-asserted-by": "publisher", "first-page": "241", "DOI": "10.1007/s00726-006-0333-y", "volume": "31", "author": "ME Keck", "year": "2006", "unstructured": "Keck, M. E. Corticotropin-releasing factor, vasopressin and receptor systems in depression and anxiety. Amino Acids 31, 241\u2013250 (2006).", "journal-title": "Amino Acids"}, {"key": "BFnrd3702_CR68", "doi-asserted-by": "publisher", "first-page": "1075", "DOI": "10.1038/sj.mp.4001587", "volume": "9", "author": "J Licinio", "year": "2004", "unstructured": "Licinio, J. et al. Association of a corticotropin-releasing hormone receptor 1 haplotype and antidepressant treatment response in Mexican-Americans. Mol. Psychiatry 9, 1075\u20131082 (2004).", "journal-title": "Mol. Psychiatry"}, {"key": "BFnrd3702_CR69", "doi-asserted-by": "publisher", "first-page": "358", "DOI": "10.1016/j.neulet.2006.06.016", "volume": "404", "author": "Z Liu", "year": "2006", "unstructured": "Liu, Z. et al. Association of corticotropin-releasing hormone receptor1 gene SNP and haplotype with major depression. Neurosci. Lett. 404, 358\u2013362 (2006).", "journal-title": "Neurosci. Lett."}, {"key": "BFnrd3702_CR70", "doi-asserted-by": "publisher", "first-page": "369", "DOI": "10.1001/archgenpsychiatry.2010.18", "volume": "67", "author": "EB Binder", "year": "2010", "unstructured": "Binder, E. B. et al. Association of polymorphisms in genes regulating the corticotropin-releasing factor system with antidepressant treatment response. Arch. Gen. Psychiatry 67, 369\u2013379 (2010).", "journal-title": "Arch. Gen. Psychiatry"}, {"key": "BFnrd3702_CR71", "doi-asserted-by": "publisher", "first-page": "1105", "DOI": "10.1038/mp.2009.92", "volume": "14", "author": "C Dong", "year": "2009", "unstructured": "Dong, C., Wong, M. L. & Licinio, J. Sequence variations of ABCB1, SLC6A2, SLC6A3, SLC6A4, CREB1, CRHR1 and NTRK2: association with major depression and antidepressant response in Mexican-Americans. Mol. Psychiatry 14, 1105\u20131118 (2009).", "journal-title": "Mol. Psychiatry"}, {"key": "BFnrd3702_CR72", "doi-asserted-by": "publisher", "first-page": "190", "DOI": "10.1001/archgenpsychiatry.2007.26", "volume": "65", "author": "RG Bradley", "year": "2008", "unstructured": "Bradley, R. G. et al. Influence of child abuse on adult depression: moderation by the corticotropin-releasing hormone receptor gene. Arch. Gen. Psychiatry 65, 190\u2013200 (2008).", "journal-title": "Arch. Gen. Psychiatry"}, {"key": "BFnrd3702_CR73", "doi-asserted-by": "publisher", "first-page": "978", "DOI": "10.1001/archgenpsychiatry.2009.114", "volume": "66", "author": "G Polanczyk", "year": "2009", "unstructured": "Polanczyk, G. et al. Protective effect of CRHR1 gene variants on the development of adult depression following childhood maltreatment: replication and extension. Arch. Gen. Psychiatry 66, 978\u2013985 (2009).", "journal-title": "Arch. Gen. Psychiatry"}, {"key": "BFnrd3702_CR74", "doi-asserted-by": "publisher", "first-page": "1483", "DOI": "10.1002/ajmg.b.31131", "volume": "153B", "author": "HJ Grabe", "year": "2010", "unstructured": "Grabe, H. J. et al. Childhood maltreatment, the corticotropin-releasing hormone receptor gene and adult depression in the general population. Am. J. Med. Genet. B Neuropsychiatr. Genet. 153B, 1483\u20131493 (2010).", "journal-title": "Am. J. Med. Genet. B Neuropsychiatr. Genet."}, {"key": "BFnrd3702_CR75", "doi-asserted-by": "publisher", "first-page": "681", "DOI": "10.1016/j.biopsych.2009.05.012", "volume": "66", "author": "AR Tyrka", "year": "2009", "unstructured": "Tyrka, A. R. et al. Interaction of childhood maltreatment with the corticotropin-releasing hormone receptor gene: effects on hypothalamic\u2013pituitary\u2013adrenal axis reactivity. Biol. Psychiatry 66, 681\u2013685 (2009).", "journal-title": "Biol. Psychiatry"}, {"key": "BFnrd3702_CR76", "doi-asserted-by": "publisher", "first-page": "1559", "DOI": "10.1038/nn.2436", "volume": "12", "author": "C Murgatroyd", "year": "2009", "unstructured": "Murgatroyd, C. et al. Dynamic DNA methylation programs persistent adverse effects of early-life stress. Nature Neurosci. 12, 1559\u20131566 (2009).", "journal-title": "Nature Neurosci."}, {"key": "BFnrd3702_CR77", "doi-asserted-by": "publisher", "first-page": "1351", "DOI": "10.1038/nn.2642", "volume": "13", "author": "E Elliott", "year": "2010", "unstructured": "Elliott, E., Ezra-Nevo, G., Regev, L., Neufeld-Cohen, A. & Chen, A. Resilience to social stress coincides with functional DNA methylation of the Crf gene in adult mice. Nature Neurosci. 13, 1351\u20131353 (2010).", "journal-title": "Nature Neurosci."}, {"key": "BFnrd3702_CR78", "first-page": "1931", "volume": "6", "author": "D Spengler", "year": "1992", "unstructured": "Spengler, D., Rupprecht, R., Van, L. P. & Holsboer, F. Identification and characterization of a 3\u2032,5\u2032-cyclic adenosine monophosphate-responsive element in the human corticotropin-releasing hormone gene promoter. Mol. Endocrinol. 6, 1931\u20131941 (1992).", "journal-title": "Mol. Endocrinol."}, {"key": "BFnrd3702_CR79", "doi-asserted-by": "publisher", "first-page": "236", "DOI": "10.1055/s-0031-1286282", "volume": "44", "author": "G Grunder", "year": "2011", "unstructured": "Grunder, G., Hiemke, C., Paulzen, M., Veselinovic, T. & Vernaleken, I. Therapeutic plasma concentrations of antidepressants and antipsychotics: lessons from PET imaging. Pharmacopsychiatry 44, 236\u2013248 (2011).", "journal-title": "Pharmacopsychiatry"}, {"key": "BFnrd3702_CR80", "doi-asserted-by": "publisher", "first-page": "353", "DOI": "10.1016/j.nucmedbio.2007.01.012", "volume": "34", "author": "GM Sullivan", "year": "2007", "unstructured": "Sullivan, G. M. et al. PET Imaging of CRF1 with [11C]R121920 and [11C]DMP696: is the target of sufficient density? Nucl. Med. Biol. 34, 353\u2013361 (2007).", "journal-title": "Nucl. Med. Biol."}, {"key": "BFnrd3702_CR81", "doi-asserted-by": "publisher", "first-page": "203", "DOI": "10.1016/j.neuron.2007.11.017", "volume": "57", "author": "M Uhr", "year": "2008", "unstructured": "Uhr, M. et al. Polymorphisms in the drug transporter gene ABCB1 predict antidepressant treatment response in depression. Neuron 57, 203\u2013209 (2008).", "journal-title": "Neuron"}, {"key": "BFnrd3702_CR82", "doi-asserted-by": "publisher", "first-page": "1941", "DOI": "10.1038/sj.npp.1301328", "volume": "32", "author": "M Ising", "year": "2007", "unstructured": "Ising, M. et al. High-affinity CRF1 receptor antagonist NBI-34041: preclinical and clinical data suggest safety and efficacy in attenuating elevated stress response. Neuropsychopharmacology 32, 1941\u20131949 (2007).", "journal-title": "Neuropsychopharmacology"}, {"key": "BFnrd3702_CR83", "first-page": "318", "volume": "87", "author": "SM McCann", "year": "1954", "unstructured": "McCann, S. M. & Brobeck, J. R. Evidence for a role of the supraopticohypophyseal system in the regulation of adrenocorticotropin secretion. Proc. Natl Acad. Sci. USA 87, 318\u2013324 (1954).", "journal-title": "Proc. Natl Acad. Sci. USA"}, {"key": "BFnrd3702_CR84", "doi-asserted-by": "publisher", "first-page": "76", "DOI": "10.1006/frne.1993.1004", "volume": "14", "author": "FA Antoni", "year": "1993", "unstructured": "Antoni, F. A. Vasopressinergic control of pituitary adrenocorticotropin secretion comes of age. Front. Neuroendocrinol. 14, 76\u2013122 (1993).", "journal-title": "Front. Neuroendocrinol."}, {"key": "BFnrd3702_CR85", "doi-asserted-by": "publisher", "first-page": "321", "DOI": "10.1006/frne.1994.1013", "volume": "15", "author": "G Aguilera", "year": "1994", "unstructured": "Aguilera, G. Regulation of pituitary ACTH secretion during chronic stress. Front. Neuroendocrinol. 15, 321\u2013350 (1994).", "journal-title": "Front. Neuroendocrinol."}, {"key": "BFnrd3702_CR86", "doi-asserted-by": "publisher", "first-page": "341", "DOI": "10.1016/0149-7634(95)00059-3", "volume": "20", "author": "M Engelmann", "year": "1996", "unstructured": "Engelmann, M., Wotjak, C. T., Neumann, I., Ludwig, M. & Landgraf, R. Behavioral consequences of intracerebral vasopressin and oxytocin: focus on learning and memory. Neurosci. Biobehav. Rev. 20, 341\u2013358 (1996).", "journal-title": "Neurosci. Biobehav. Rev."}, {"key": "BFnrd3702_CR87", "doi-asserted-by": "publisher", "first-page": "237", "DOI": "10.1002/cne.902610206", "volume": "261", "author": "AR Caff\u00e9", "year": "1987", "unstructured": "Caff\u00e9, A. R., van Leeuwen, F. W. & Luiten, P. G. M. Vasopressin cells in the medial amygdala of the rat project to the lateral septum and ventral hippocampus. J. Comp. Neurol. 261, 237\u2013252 (1987).", "journal-title": "J. Comp. Neurol."}, {"key": "BFnrd3702_CR88", "doi-asserted-by": "publisher", "first-page": "307", "DOI": "10.1016/0006-8993(83)90855-7", "volume": "273", "author": "GJ De Vries", "year": "1983", "unstructured": "De Vries, G. J. & Buijs, R. M. The origin of the vasopressinergic and oxytocinergic innervation of the rat brain with special reference to the lateral septum. Brain Res. 273, 307\u2013317 (1983).", "journal-title": "Brain Res."}, {"key": "BFnrd3702_CR89", "doi-asserted-by": "publisher", "first-page": "525", "DOI": "10.1007/BF00211473", "volume": "28", "author": "FW van Leeuwen", "year": "1983", "unstructured": "van Leeuwen, F. W. & Caff\u00e9, A. R. Vasopressin-immunoreactive cell bodies in the bed nucleus of the stria terminalis of the rat. Cell Tissue Res. 28, 525\u2013534 (1983).", "journal-title": "Cell Tissue Res."}, {"key": "BFnrd3702_CR90", "doi-asserted-by": "publisher", "first-page": "6783", "DOI": "10.1073/pnas.92.15.6783", "volume": "92", "author": "SJ Lolait", "year": "1995", "unstructured": "Lolait, S. J. et al. Extrapituitary expression of the rat V1b vasopressin receptor gene. Proc. Natl Acad. Sci. USA 92, 6783\u20136787 (1995).", "journal-title": "Proc. Natl Acad. Sci. USA"}, {"key": "BFnrd3702_CR91", "doi-asserted-by": "publisher", "first-page": "291", "DOI": "10.1046/j.1365-2826.1999.00332.x", "volume": "11", "author": "LJ Young", "year": "1999", "unstructured": "Young, L. J., Toloczko, D. & Insel, T. R. Localization of vasopressin (V1a) receptor binding and mRNA in the rhesus monkey brain. J. Neuroendocrinol. 11, 291\u2013297 (1999).", "journal-title": "J. Neuroendocrinol."}, {"key": "BFnrd3702_CR92", "doi-asserted-by": "publisher", "first-page": "5015", "DOI": "10.1210/endo.139.12.6382", "volume": "139", "author": "C Vaccari", "year": "1998", "unstructured": "Vaccari, C., Lolait, S. J. & Ostrowski, N. L. Comparative distribution of vasopressin V1b and oxytocin receptor messenger ribonucleic acids in brain. Endocrinology 139, 5015\u20135033 (1998).", "journal-title": "Endocrinology"}, {"key": "BFnrd3702_CR93", "doi-asserted-by": "publisher", "first-page": "523", "DOI": "10.1038/356523a0", "volume": "356", "author": "A Morel", "year": "1992", "unstructured": "Morel, A., O'Carroll, A. M., Brownstein, M. J. & Lolait, S. J. Molecular cloning and expression of a rat V1a arginine vasopressin receptor. Nature 356, 523\u2013526 (1992).", "journal-title": "Nature"}, {"key": "BFnrd3702_CR94", "doi-asserted-by": "publisher", "first-page": "113", "DOI": "10.1159/000054409", "volume": "69", "author": "E Tribollet", "year": "1999", "unstructured": "Tribollet, E., Raufaste, D., Maffrand, J. & Serradeil-Le Gal, C. Binding of the non-peptide vasopressin V1a receptor antagonist SR-49059 in the rat brain: an in vitro and in vivo autoradiographic study. Neuroendocrinology 69, 113\u2013120 (1999).", "journal-title": "Neuroendocrinology"}, {"key": "BFnrd3702_CR95", "doi-asserted-by": "publisher", "first-page": "35", "DOI": "10.1038/sj.npp.1300562", "volume": "30", "author": "J Stemmelin", "year": "2005", "unstructured": "Stemmelin, J., Lukovic, L., Salome, N. & Griebel, G. Evidence that the lateral septum is involved in the antidepressant-like effects of the vasopressin V1b receptor antagonist, SSR149415. Neuropsychopharmacology 30, 35\u201342 (2005).", "journal-title": "Neuropsychopharmacology"}, {"key": "BFnrd3702_CR96", "doi-asserted-by": "publisher", "first-page": "23", "DOI": "10.1016/S0167-0115(00)00196-8", "volume": "96", "author": "G Aguilera", "year": "2000", "unstructured": "Aguilera, G. & Rabadan-Diehl, C. Vasopressinergic regulation of the hypothalamic\u2013pituitary\u2013adrenal axis: implications for stress adaptation. Regul. Pept. 96, 23\u201329 (2000).", "journal-title": "Regul. Pept."}, {"key": "BFnrd3702_CR97", "doi-asserted-by": "publisher", "first-page": "161", "DOI": "10.1016/S0893-133X(00)00182-2", "volume": "24", "author": "JL Abelson", "year": "2001", "unstructured": "Abelson, J. L., Le Mell\u00e9do, J. M. & Bichet, D. G. Dose response of arginine vasopressin to the CCK-B agonist pentagastrin. Neuropsychopharmacology 24, 161\u2013169 (2001).", "journal-title": "Neuropsychopharmacology"}, {"key": "BFnrd3702_CR98", "doi-asserted-by": "publisher", "first-page": "137", "DOI": "10.1001/archpsyc.1996.01830020055007", "volume": "53", "author": "JS Purba", "year": "1996", "unstructured": "Purba, J. S., Hoogendijk, W. J. G., Hofman, M. A. & Swaab, D. F. Increased number of vasopressin- and oxytocin-expressing neurons in the paraventricular nucleus of the hypothalamus in depression. Arch. Gen. Psychiatry 53, 137\u2013143 (1996).", "journal-title": "Arch. Gen. Psychiatry"}, {"key": "BFnrd3702_CR99", "doi-asserted-by": "publisher", "first-page": "655", "DOI": "10.1001/archpsyc.58.7.655", "volume": "58", "author": "JN Zhou", "year": "2001", "unstructured": "Zhou, J. N. et al. Alterations in arginine vasopressin neurons in the suprachiasmatic nucleus in depression. Arch. Gen. Psychiatry 58, 655\u2013662 (2001).", "journal-title": "Arch. Gen. Psychiatry"}, {"key": "BFnrd3702_CR100", "doi-asserted-by": "publisher", "first-page": "284", "DOI": "10.1016/S0893-133X(97)00054-7", "volume": "17", "author": "L van Londen", "year": "1997", "unstructured": "van Londen, L. et al. Plasma levels of arginine vasopressin elevated in patients with major depression. Neuropsychopharmacology 17, 284\u2013292 (1997).", "journal-title": "Neuropsychopharmacology"}, {"key": "BFnrd3702_CR101", "doi-asserted-by": "publisher", "first-page": "696", "DOI": "10.1192/bjp.147.6.696", "volume": "147", "author": "A Gjerris", "year": "1985", "unstructured": "Gjerris, A., Hammer, M., Vendsborg, P., Christensen, N. J. & Rafaelsen, O. J. Cerebrospinal fluid vasopressin \u2014 changes in depression. Br. J. Psychiatry 147, 696\u2013701 (1985).", "journal-title": "Br. J. Psychiatry"}, {"key": "BFnrd3702_CR102", "doi-asserted-by": "publisher", "first-page": "9", "DOI": "10.1001/archpsyc.1992.01820010009002", "volume": "49", "author": "M Altemus", "year": "1992", "unstructured": "Altemus, M. et al. Abnormalities in the regulation of vasopressin and corticotropin releasing factor secretion in obsessive-compulsive disorder. Arch. Gen. Psychiatry 49, 9\u201320 (1992).", "journal-title": "Arch. Gen. Psychiatry"}, {"key": "BFnrd3702_CR103", "doi-asserted-by": "publisher", "first-page": "187", "DOI": "10.1210/edrv-17-2-187", "volume": "17", "author": "F Holsboer", "year": "1996", "unstructured": "Holsboer, F. & Barden, N. Antidepressants and hypothalamic\u2013pituitary\u2013adrenocortical regulation. Endocrine Rev. 17, 187\u2013205 (1996).", "journal-title": "Endocrine Rev."}, {"key": "BFnrd3702_CR104", "doi-asserted-by": "publisher", "first-page": "2238", "DOI": "10.1210/jcem.84.6.5723", "volume": "84", "author": "TG Dinan", "year": "1999", "unstructured": "Dinan, T. G. et al. Desmopressin normalizes the blunted adrenocorticotropin response to corticotropin-releasing hormone in melancholic depression: evidence of enhanced vasopressinergic responsivity. J. Clin. Endocrinol. Metab. 84, 2238\u20132240 (1999).", "journal-title": "J. Clin. Endocrinol. Metab."}, {"key": "BFnrd3702_CR105", "doi-asserted-by": "publisher", "first-page": "6370", "DOI": "10.1073/pnas.092012099", "volume": "99", "author": "G Griebel", "year": "2002", "unstructured": "Griebel, G. et al. Anxiolytic- and antidepressant-like effects of the non-peptide vasopressin V1b receptor antagonist, SSR149415, suggest an innovative approach for the treatment of stress-related disorders. Proc. Natl Acad. Sci. USA 99, 6370\u20136375 (2002).", "journal-title": "Proc. Natl Acad. Sci. USA"}, {"key": "BFnrd3702_CR106", "doi-asserted-by": "publisher", "first-page": "355", "DOI": "10.1038/299355a0", "volume": "299", "author": "GE Gillies", "year": "1982", "unstructured": "Gillies, G. E., Linton, E. A. & Lowry, P. J. Corticotropin releasing activity of the new CRF is potentiated several times by vasopressin. Nature 299, 355\u2013357 (1982).", "journal-title": "Nature"}, {"key": "BFnrd3702_CR107", "doi-asserted-by": "publisher", "first-page": "1613", "DOI": "10.1016/0024-3205(85)90480-1", "volume": "37", "author": "U von Bardeleben", "year": "1985", "unstructured": "von Bardeleben, U., Holsboer, F., Stalla, G. K. & Muller, O. A. Combined administration of human corticotropin-releasing factor and lysine vasopressin induces cortisol escape from dexamethasone suppression in healthy subjects. Life Sci. 37, 1613\u20131618 (1985).", "journal-title": "Life Sci."}, {"key": "BFnrd3702_CR108", "doi-asserted-by": "publisher", "first-page": "463", "DOI": "10.1038/nrn1683", "volume": "6", "author": "ER De Kloet", "year": "2005", "unstructured": "De Kloet, E. R., Joels, M. & Holsboer, F. Stress and the brain: from adaptation to disease. Nature Rev. Neurosci. 6, 463\u2013475 (2005).", "journal-title": "Nature Rev. Neurosci."}, {"key": "BFnrd3702_CR109", "doi-asserted-by": "publisher", "first-page": "47", "DOI": "10.1016/j.biopsych.2006.07.039", "volume": "62", "author": "M Ising", "year": "2007", "unstructured": "Ising, M. et al. Combined dexamethasone/corticotropin releasing hormone test predicts treatment response in major depression \u2014 a potential biomarker? Biol. Psychiatry 62, 47\u201354 (2007).", "journal-title": "Biol. Psychiatry"}, {"key": "BFnrd3702_CR110", "doi-asserted-by": "publisher", "first-page": "e7098", "DOI": "10.1371/journal.pone.0007098", "volume": "4", "author": "S Schule", "year": "2009", "unstructured": "Schule, S. et al. Restriction of HIV-1 replication in monocytes is abolished by Vpx of SIVsmmPBj. PLoS ONE 4, e7098 (2009).", "journal-title": "PLoS ONE"}, {"key": "BFnrd3702_CR111", "doi-asserted-by": "publisher", "first-page": "215", "DOI": "10.1016/j.jpsychires.2008.05.002", "volume": "43", "author": "JM Hennings", "year": "2009", "unstructured": "Hennings, J. M. et al. Clinical characteristics and treatment outcome in a representative sample of depressed inpatients \u2014 findings from the Munich Antidepressant Response Signature (MARS) project. J. Psychiatr. Res. 43, 215\u2013229 (2009).", "journal-title": "J. Psychiatr. Res."}, {"key": "BFnrd3702_CR112", "doi-asserted-by": "publisher", "first-page": "556", "DOI": "10.1016/j.jpsychires.2009.11.015", "volume": "44", "author": "G Paslakis", "year": "2010", "unstructured": "Paslakis, G. et al. Venlafaxine and mirtazapine treatment lowers serum concentrations of dehydroepiandrosterone-sulfate in depressed patients remitting during the course of treatment. J. Psychiatr. Res. 44, 556\u2013560 (2010).", "journal-title": "J. Psychiatr. Res."}, {"key": "BFnrd3702_CR113", "doi-asserted-by": "publisher", "first-page": "1122", "DOI": "10.1124/jpet.300.3.1122", "volume": "300", "author": "C Serradeil-Le Gal", "year": "2002", "unstructured": "Serradeil-Le Gal, C. et al. Characterization of (2S,4R)-1-[5-chloro-1-[(2,4-dimethoxyphenyl)sulfonyl]-3-(2-methoxy-phenyl)-2-oxo-2,3-dihydro-1H-indol-3-yl]-4-hydroxy-N,N-dimethyl-2-pyrrolidine carboxamide (SSR149415), a selective and orally active vasopressin V1b receptor antagonist. J. Pharmacol. Exp. Ther. 300, 1122\u20131130 (2002).", "journal-title": "J. Pharmacol. Exp. Ther."}, {"key": "BFnrd3702_CR114", "doi-asserted-by": "publisher", "first-page": "1549", "DOI": "10.2174/1381612053764797", "volume": "11", "author": "G Griebel", "year": "2005", "unstructured": "Griebel, G., Stemmelin, J., Serradeil-Le Gal, C. & Soubri\u00e9, P. Non-peptide vasopressin V1b receptor antagonists as potential drugs for the treatment of stress-related disorders. Curr. Pharm. Des. 11, 1549\u20131559 (2005).", "journal-title": "Curr. Pharm. Des."}, {"key": "BFnrd3702_CR115", "doi-asserted-by": "publisher", "first-page": "98", "DOI": "10.3109/10253890.2010.512376", "volume": "14", "author": "J Roper", "year": "2011", "unstructured": "Roper, J., O'Carroll, A. M., Young, W. & Lolait, S. The vasopressin Avpr1b receptor: molecular and pharmacological studies. Stress 14, 98\u2013115 (2011).", "journal-title": "Stress"}, {"key": "BFnrd3702_CR116", "doi-asserted-by": "publisher", "first-page": "527", "DOI": "10.1016/S0079-6123(08)00440-8", "volume": "170", "author": "M Craighead", "year": "2008", "unstructured": "Craighead, M. et al. Characterization of a novel and selective V1B receptor antagonist. Prog. Brain Res. 170, 527\u2013535 (2008).", "journal-title": "Prog. Brain Res."}, {"key": "BFnrd3702_CR117", "author": "W Wernet", "year": "2008", "unstructured": "Wernet, W. et al. In vitro characterization of the selective vasopressin V1b receptor antagonists ABT-436 and ABT-558. Program No. 560.16. 2008 Neuroscience Meeting Planner (Washington DC; Society for Neuroscience; 2008).", "volume-title": "2008 Neuroscience Meeting Planner"}, {"key": "BFnrd3702_CR118", "first-page": "6854", "volume": "248", "author": "R Carraway", "year": "1973", "unstructured": "Carraway, R. & Leeman, S. E. The isolation of a new hypotensive peptide, neurotensin, from bovine hypothalami. J. Biol. Chem. 248, 6854\u20136861 (1973).", "journal-title": "J. Biol. Chem."}, {"key": "BFnrd3702_CR119", "first-page": "1447", "volume": "109", "author": "S St Pierre", "year": "1980", "unstructured": "St Pierre, S. et al. Neurotensin, a multi-action peptide hormone. Union Med. Can. 109, 1447\u20131455 (1980).", "journal-title": "Union Med. Can."}, {"key": "BFnrd3702_CR120", "doi-asserted-by": "publisher", "first-page": "2385", "DOI": "10.1016/j.peptides.2006.04.024", "volume": "27", "author": "R Caceda", "year": "2006", "unstructured": "Caceda, R., Kinkead, B. & Nemeroff, C. B. Neurotensin: role in psychiatric and neurological diseases. Peptides 27, 2385\u20132404 (2006).", "journal-title": "Peptides"}, {"key": "BFnrd3702_CR121", "doi-asserted-by": "publisher", "first-page": "205", "DOI": "10.2174/187152706776359655", "volume": "5", "author": "B Kinkead", "year": "2006", "unstructured": "Kinkead, B. & Nemeroff, C. B. Novel treatments of schizophrenia: targeting the neurotensin system. CNS Neurol. Disord. Drug Targets 5, 205\u2013218 (2006).", "journal-title": "CNS Neurol. Disord. Drug Targets"}, {"key": "BFnrd3702_CR122", "doi-asserted-by": "publisher", "first-page": "13", "DOI": "10.2165/00023210-200721010-00002", "volume": "21", "author": "M Boules", "year": "2007", "unstructured": "Boules, M., Shaw, A., Fredrickson, P. & Richelson, E. Neurotensin agonists: potential in the treatment of schizophrenia. CNS Drugs 21, 13\u201323 (2007).", "journal-title": "CNS Drugs"}, {"key": "BFnrd3702_CR123", "doi-asserted-by": "publisher", "first-page": "847", "DOI": "10.1016/0896-6273(90)90137-5", "volume": "4", "author": "K Tanaka", "year": "1990", "unstructured": "Tanaka, K., Masu, M. & Nakanishi, S. Structure and functional expression of the cloned rat neurotensin receptor. Neuron 4, 847\u2013854 (1990).", "journal-title": "Neuron"}, {"key": "BFnrd3702_CR124", "doi-asserted-by": "publisher", "first-page": "91", "DOI": "10.1016/0014-5793(96)00397-3", "volume": "386", "author": "P Chalon", "year": "1996", "unstructured": "Chalon, P. et al. Molecular cloning of a levocabastine-sensitive neurotensin binding site. FEBS Lett. 386, 91\u201394 (1996).", "journal-title": "FEBS Lett."}, {"key": "BFnrd3702_CR125", "doi-asserted-by": "publisher", "first-page": "26273", "DOI": "10.1074/jbc.273.41.26273", "volume": "273", "author": "J Mazella", "year": "1998", "unstructured": "Mazella, J. et al. The 100-kDa neurotensin receptor is gp95/sortilin, a non-G-protein-coupled receptor. J. Biol. Chem. 273, 26273\u201326276 (1998).", "journal-title": "J. Biol. Chem."}, {"key": "BFnrd3702_CR126", "doi-asserted-by": "publisher", "first-page": "305", "DOI": "10.1124/jpet.300.1.305", "volume": "300", "author": "DJ Pettibone", "year": "2002", "unstructured": "Pettibone, D. J. et al. The effects of deleting the mouse neurotensin receptor NTR1 on central and peripheral responses to neurotensin. J. Pharmacol. Exp. Ther. 300, 305\u2013313 (2002).", "journal-title": "J. Pharmacol. Exp. Ther."}, {"key": "BFnrd3702_CR127", "doi-asserted-by": "publisher", "first-page": "76", "DOI": "10.1002/(SICI)1096-9861(19960909)373:1<76::AID-CNE7>3.0.CO;2-A", "volume": "373", "author": "H Boudin", "year": "1996", "unstructured": "Boudin, H., Pelaprat, D., Rostene, W. & Beaudet, A. Cellular distribution of neurotensin receptors in rat brain: immunohistochemical study using an antipeptide antibody against the cloned high affinity receptor. J. Comp. Neurol. 373, 76\u201389 (1996).", "journal-title": "J. Comp. Neurol."}, {"key": "BFnrd3702_CR128", "doi-asserted-by": "publisher", "first-page": "134", "DOI": "10.1016/0304-3940(90)90187-E", "volume": "120", "author": "R Elde", "year": "1990", "unstructured": "Elde, R., Schalling, M., Ceccatelli, S., Nakanishi, S. & Hokfelt, T. Localization of neuropeptide receptor mRNA in rat brain: initial observations using probes for neurotensin and substance P receptors. Neurosci. Lett. 120, 134\u2013138 (1990).", "journal-title": "Neurosci. Lett."}, {"key": "BFnrd3702_CR129", "doi-asserted-by": "publisher", "first-page": "1430", "DOI": "10.1016/S0028-3908(00)00060-5", "volume": "39", "author": "A Fassio", "year": "2000", "unstructured": "Fassio, A. et al. Distribution of the neurotensin receptor NTS1 in the rat CNS studied using an amino-terminal directed antibody. Neuropharmacology 39, 1430\u20131442 (2000).", "journal-title": "Neuropharmacology"}, {"key": "BFnrd3702_CR130", "doi-asserted-by": "publisher", "first-page": "475", "DOI": "10.1002/(SICI)1096-9861(19981228)402:4<475::AID-CNE4>3.0.CO;2-9", "volume": "402", "author": "MJ Alexander", "year": "1998", "unstructured": "Alexander, M. J. & Leeman, S. E. Widespread expression in adult rat forebrain of mRNA encoding high-affinity neurotensin receptor. J. Comp. Neurol. 402, 475\u2013500 (1998).", "journal-title": "J. Comp. Neurol."}, {"key": "BFnrd3702_CR131", "doi-asserted-by": "publisher", "first-page": "1", "DOI": "10.1016/S0006-8993(01)02981-X", "volume": "919", "author": "M Boules", "year": "2001", "unstructured": "Boules, M. et al. Neurotensin analog selective for hypothermia over antinociception and exhibiting atypical neuroleptic-like properties. Brain Res. 919, 1\u201311 (2001).", "journal-title": "Brain Res."}, {"key": "BFnrd3702_CR132", "doi-asserted-by": "publisher", "first-page": "1027", "DOI": "10.1016/S0028-3908(99)00011-8", "volume": "38", "author": "BM Tyler", "year": "1999", "unstructured": "Tyler, B. M. et al. In vitro binding and CNS effects of novel neurotensin agonists that cross the blood\u2013brain barrier. Neuropharmacology 38, 1027\u20131034 (1999).", "journal-title": "Neuropharmacology"}, {"key": "BFnrd3702_CR133", "doi-asserted-by": "publisher", "first-page": "107", "DOI": "10.1016/S0014-2999(99)00877-8", "volume": "390", "author": "BM Tyler-McMahon", "year": "2000", "unstructured": "Tyler-McMahon, B. M., Stewart, J. A., Farinas, F., McCormick, D. J. & Richelson, E. Highly potent neurotensin analog that causes hypothermia and antinociception. Eur. J. Pharmacol. 390, 107\u2013111 (2000).", "journal-title": "Eur. J. Pharmacol."}, {"key": "BFnrd3702_CR134", "doi-asserted-by": "publisher", "first-page": "43", "DOI": "10.1248/bpb.16.43", "volume": "16", "author": "R Machida", "year": "1993", "unstructured": "Machida, R., Tokumura, T., Tsuchiya, Y., Sasaki, A. & Abe, K. Pharmacokinetics of novel hexapeptides with neurotensin activity in rats. Biol. Pharm. Bull. 16, 43\u201347 (1993).", "journal-title": "Biol. Pharm. Bull."}, {"key": "BFnrd3702_CR135", "doi-asserted-by": "publisher", "first-page": "3094", "DOI": "10.1248/cpb.38.3094", "volume": "38", "author": "T Tokumura", "year": "1990", "unstructured": "Tokumura, T. et al. Stability of a novel hexapeptide, (Me)Arg-Lys-Pro-Trp-tert-Leu-Leu-OEt, with neurotensin activity, in aqueous solution and in the solid state. Chem. Pharm. Bull. (Tokyo) 38, 3094\u20133098 (1990).", "journal-title": "Chem. Pharm. Bull. (Tokyo)"}, {"key": "BFnrd3702_CR136", "doi-asserted-by": "publisher", "first-page": "1437", "DOI": "10.1097/00001756-200005150-00017", "volume": "11", "author": "JC Michaud", "year": "2000", "unstructured": "Michaud, J. C., Gueudet, C. & Soubrie, P. Effects of neurotensin receptor antagonists on the firing rate of rat ventral pallidum neurons. Neuroreport 11, 1437\u20131441 (2000).", "journal-title": "Neuroreport"}, {"key": "BFnrd3702_CR137", "first-page": "S50", "volume": "30", "author": "E Richelson", "year": "2005", "unstructured": "Richelson, E. NT69L: a neurotensin receptor agonist for treatment of neuropsychiatric diseases. Neuropsychopharmacology 30, S50 (2005).", "journal-title": "Neuropsychopharmacology"}, {"key": "BFnrd3702_CR138", "doi-asserted-by": "publisher", "first-page": "15", "DOI": "10.1038/478015a", "volume": "478", "author": "K Smith", "year": "2011", "unstructured": "Smith, K. Trillion-dollar brain drain. Nature 478, 15 (2011).", "journal-title": "Nature"}, {"key": "BFnrd3702_CR139", "unstructured": "American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision (DSM-IV-TR). (American Psychiatric Association, Washington DC, 2000)."}, {"key": "BFnrd3702_CR140", "doi-asserted-by": "publisher", "first-page": "638", "DOI": "10.1038/nrn2453", "volume": "9", "author": "F Holsboer", "year": "2008", "unstructured": "Holsboer, F. How can we realize the promise of personalized antidepressant medicines? Nature Rev. Neurosci. 9, 638\u2013646 (2008).", "journal-title": "Nature Rev. Neurosci."}, {"key": "BFnrd3702_CR141", "author": "I Kirsch", "year": "2010", "unstructured": "Kirsch, I. The Emperor's New Drugs: Exploring the Antidepressant Myth (Bodley Head, 2010).", "volume-title": "The Emperor's New Drugs: Exploring the Antidepressant Myth"}, {"key": "BFnrd3702_CR142", "doi-asserted-by": "publisher", "first-page": "1425", "DOI": "10.1007/s00115-011-3349-9", "volume": "82", "author": "S Leucht", "year": "2011", "unstructured": "Leucht, S., Heres, S. & Davis, J. M. Considerations about the efficacy of psychopharmacological drugs. Nervenarzt 82, 1425\u20131430 (2011).", "journal-title": "Nervenarzt"}, {"key": "BFnrd3702_CR143", "doi-asserted-by": "publisher", "first-page": "463", "DOI": "10.1016/S1474-4422(03)00482-4", "volume": "2", "author": "T Hokfelt", "year": "2003", "unstructured": "Hokfelt, T., Bartfai, T. & Bloom, F. Neuropeptides: opportunities for drug discovery. Lancet Neurol. 2, 463\u2013472 (2003).", "journal-title": "Lancet Neurol."}, {"key": "BFnrd3702_CR144", "doi-asserted-by": "publisher", "first-page": "515", "DOI": "10.1038/284515a0", "volume": "284", "author": "T Hokfelt", "year": "1980", "unstructured": "Hokfelt, T., Johansson, O., Ljungdahl, A., Lundberg, J. M. & Schultzberg, M. Peptidergic neurones. Nature 284, 515\u2013521 (1980).", "journal-title": "Nature"}, {"key": "BFnrd3702_CR145", "doi-asserted-by": "publisher", "first-page": "1903", "DOI": "10.1126/science.1202107", "volume": "333", "author": "D Refojo", "year": "2011", "unstructured": "Refojo, D. et al. Glutamatergic and dopaminergic neurons mediate anxiogenic and anxiolytic effects of CRHR1. Science 333, 1903\u20131907 (2011).", "journal-title": "Science"}, {"key": "BFnrd3702_CR146", "doi-asserted-by": "publisher", "first-page": "233", "DOI": "10.1093/jpepsy/jsg011", "volume": "28", "author": "TC Edwards", "year": "2003", "unstructured": "Edwards, T. C., Patrick, D. L. & Topolski, T. D. Quality of life of adolescents with perceived disabilities. J. Pediatr. Psychol. 28, 233\u2013241 (2003).", "journal-title": "J. Pediatr. Psychol."}, {"key": "BFnrd3702_CR147", "doi-asserted-by": "publisher", "first-page": "693", "DOI": "10.1016/j.psyneuen.2008.03.008", "volume": "33", "author": "C Heim", "year": "2008", "unstructured": "Heim, C., Newport, D. J., Mletzko, T., Miller, A. H. & Nemeroff, C. B. The link between childhood trauma and depression: insights from HPA axis studies in humans. Psychoneuroendocrinology 33, 693\u2013710 (2008).", "journal-title": "Psychoneuroendocrinology"}, {"key": "BFnrd3702_CR148", "doi-asserted-by": "publisher", "first-page": "1362", "DOI": "10.1001/jama.1997.03540410040028", "volume": "277", "author": "J McCauley", "year": "1997", "unstructured": "McCauley, J. et al. Clinical characteristics of women with a history of childhood abuse: unhealed wounds. JAMA 277, 1362\u20131368 (1997).", "journal-title": "JAMA"}, {"key": "BFnrd3702_CR149", "doi-asserted-by": "publisher", "first-page": "753", "DOI": "10.2105/AJPH.91.5.753", "volume": "91", "author": "BE Molnar", "year": "2001", "unstructured": "Molnar, B. E., Buka, S. L. & Kessler, R. C. Child sexual abuse and subsequent psychopathology: results from the National Comorbidity Survey. Am. J. Public Health 91, 753\u2013760 (2001).", "journal-title": "Am. J. Public Health"}, {"key": "BFnrd3702_CR150", "doi-asserted-by": "publisher", "first-page": "477", "DOI": "10.1016/S0893-133X(00)00159-7", "volume": "23", "author": "F Holsboer", "year": "2000", "unstructured": "Holsboer, F. The corticosteroid receptor hypothesis of depression. Neuropsychopharmacology 23, 477\u2013501 (2000).", "journal-title": "Neuropsychopharmacology"}, {"key": "BFnrd3702_CR151", "doi-asserted-by": "publisher", "first-page": "1085", "DOI": "10.1016/j.pnpbp.2005.03.014", "volume": "29", "author": "M Ising", "year": "2005", "unstructured": "Ising, M. et al. The combined dexamethasone/CRH test as a potential surrogate marker in depression. Prog. Neuropsychopharmacol. Biol. Psychiatry 29, 1085\u20131093 (2005).", "journal-title": "Prog. Neuropsychopharmacol. Biol. Psychiatry"}, {"key": "BFnrd3702_CR152", "doi-asserted-by": "publisher", "first-page": "1554", "DOI": "10.1176/appi.ajp.160.9.1554", "volume": "160", "author": "CL Raison", "year": "2003", "unstructured": "Raison, C. L. & Miller, A. H. When not enough is too much: the role of insufficient glucocorticoid signaling in the pathophysiology of stress-related disorders. Am. J. Psychiatry 160, 1554\u20131565 (2003).", "journal-title": "Am. J. Psychiatry"}, {"key": "BFnrd3702_CR153", "doi-asserted-by": "publisher", "first-page": "76", "DOI": "10.1055/s-2007-1014652", "volume": "21", "author": "CB Nemeroff", "year": "1988", "unstructured": "Nemeroff, C. B. The role of corticotropin-releasing factor in the pathogenesis of major depression. Pharmacopsychiatry 21, 76\u201382 (1988).", "journal-title": "Pharmacopsychiatry"}, {"key": "BFnrd3702_CR154", "doi-asserted-by": "publisher", "first-page": "83", "DOI": "10.1016/j.jad.2007.02.017", "volume": "104", "author": "S Papiol", "year": "2007", "unstructured": "Papiol, S. et al. Genetic variability at HPA axis in major depression and clinical response to antidepressant treatment. J. Affect. Disord. 104, 83\u201390 (2007).", "journal-title": "J. Affect. Disord."}, {"key": "BFnrd3702_CR155", "doi-asserted-by": "publisher", "first-page": "181", "DOI": "10.1016/S0022-3956(98)90056-5", "volume": "33", "author": "F Holsboer", "year": "1999", "unstructured": "Holsboer, F. The rationale for corticotropin-releasing hormone receptor (CRH-R) antagonists to treat depression and anxiety. J. Psychiatr. Res. 33, 181\u2013214 (1999).", "journal-title": "J. Psychiatr. Res."}, {"key": "BFnrd3702_CR156", "doi-asserted-by": "publisher", "first-page": "13123", "DOI": "10.1073/pnas.1003825107", "volume": "107", "author": "Y Chen", "year": "2010", "unstructured": "Chen, Y. et al. Correlated memory defects and hippocampal dendritic spine loss after acute stress involve corticotropin-releasing hormone signaling. Proc. Natl Acad. Sci. USA 107, 13123\u201313128 (2010).", "journal-title": "Proc. Natl Acad. Sci. USA"}, {"key": "BFnrd3702_CR157", "doi-asserted-by": "publisher", "first-page": "1619", "DOI": "10.1073/pnas.93.4.1619", "volume": "93", "author": "JD Coplan", "year": "1996", "unstructured": "Coplan, J. D. et al. Persistent elevations of cerebrospinal fluid concentrations of corticotropin-releasing factor in adult nonhuman primates exposed to early-life stressors: implications for the pathophysiology of mood and anxiety disorders. Proc. Natl Acad. Sci. USA 93, 1619\u20131623 (1996).", "journal-title": "Proc. Natl Acad. Sci. USA"}, {"key": "BFnrd3702_CR158", "doi-asserted-by": "publisher", "first-page": "13625", "DOI": "10.1523/JNEUROSCI.2259-11.2011", "volume": "31", "author": "XD Wang", "year": "2011", "unstructured": "Wang, X. D. et al. Forebrain CRF modulates early-life stress-programmed cognitive deficits. J. Neurosci. 31, 13625\u201313634 (2011).", "journal-title": "J. Neurosci."}, {"key": "BFnrd3702_CR159", "doi-asserted-by": "publisher", "first-page": "8856", "DOI": "10.1073/pnas.151224898", "volume": "98", "author": "KL Brunson", "year": "2001", "unstructured": "Brunson, K. L., Eghbal-Ahmadi, M., Bender, R., Chen, Y. & Baram, T. Z. Long-term, progressive hippocampal cell loss and dysfunction induced by early-life administration of corticotropin-releasing hormone reproduce the effects of early-life stress. Proc. Natl Acad. Sci. USA 98, 8856\u20138861 (2001).", "journal-title": "Proc. Natl Acad. Sci. USA"}, {"key": "BFnrd3702_CR160", "doi-asserted-by": "publisher", "first-page": "13005", "DOI": "10.1523/JNEUROSCI.1784-10.2010", "volume": "30", "author": "AS Ivy", "year": "2010", "unstructured": "Ivy, A. S. et al. Hippocampal dysfunction and cognitive impairments provoked by chronic early-life stress involve excessive activation of CRH receptors. J. Neurosci. 30, 13005\u201313015 (2010).", "journal-title": "J. Neurosci."}, {"key": "BFnrd3702_CR161", "doi-asserted-by": "publisher", "first-page": "1100", "DOI": "10.1038/nn1123", "volume": "6", "author": "MB Muller", "year": "2003", "unstructured": "Muller, M. B. et al. Limbic corticotropin-releasing hormone receptor 1 mediates anxiety-related behavior and hormonal adaptation to stress. Nature Neurosci. 6, 1100\u20131107 (2003).", "journal-title": "Nature Neurosci."}, {"key": "BFnrd3702_CR162", "doi-asserted-by": "publisher", "first-page": "2571", "DOI": "10.1523/JNEUROSCI.4470-09.2010", "volume": "30", "author": "BJ Kolber", "year": "2010", "unstructured": "Kolber, B. J. et al. Transient early-life forebrain corticotropin-releasing hormone elevation causes long-lasting anxiogenic and despair-like changes in mice. J. Neurosci. 30, 2571\u20132581 (2010).", "journal-title": "J. Neurosci."}, {"key": "BFnrd3702_CR163", "doi-asserted-by": "publisher", "first-page": "55", "DOI": "10.1007/s002130050645", "volume": "138", "author": "G Griebel", "year": "1998", "unstructured": "Griebel, G., Perrault, G. & Sanger, D. J. Characterization of the behavioral profile of the non-peptide CRF receptor antagonist CP-154,526 in anxiety models in rodents. Comparison with diazepam and buspirone. Psychopharmacology 138, 55\u201366 (1998).", "journal-title": "Psychopharmacology"}, {"key": "BFnrd3702_CR164", "doi-asserted-by": "publisher", "first-page": "6079", "DOI": "10.1073/pnas.97.11.6079", "volume": "97", "author": "KE Habib", "year": "2000", "unstructured": "Habib, K. E. et al. Oral administration of a corticotropin-releasing hormone receptor antagonist significantly attenuates behavioral, neuroendocrine, and autonomic responses to stress in primates. Proc. Natl Acad. Sci. USA 97, 6079\u20136084 (2000).", "journal-title": "Proc. Natl Acad. Sci. USA"}, {"key": "BFnrd3702_CR165", "doi-asserted-by": "publisher", "first-page": "429", "DOI": "10.1002/emmm.201000100", "volume": "2", "author": "SP Brothers", "year": "2010", "unstructured": "Brothers, S. P. & Wahlestedt, C. Therapeutic potential of neuropeptide Y (NPY) receptor ligands. EMBO Mol. Med. 2, 429\u2013439 (2010).", "journal-title": "EMBO Mol. Med."}, {"key": "BFnrd3702_CR166", "doi-asserted-by": "publisher", "first-page": "1", "DOI": "10.1007/400_2007_057", "volume": "46", "author": "O Civelli", "year": "2008", "unstructured": "Civelli, O. The orphanin FQ/nociceptin (OFQ/N) system. Results Probl. Cell Differ. 46, 1\u201325 (2008).", "journal-title": "Results Probl. Cell Differ."}, {"key": "BFnrd3702_CR167", "doi-asserted-by": "publisher", "first-page": "801", "DOI": "10.2165/00023210-200620100-00002", "volume": "20", "author": "T Shimazaki", "year": "2006", "unstructured": "Shimazaki, T., Yoshimizu, T. & Chaki, S. Melanin-concentrating hormone MCH1 receptor antagonists: a potential new approach to the treatment of depression and anxiety disorders. CNS Drugs 20, 801\u2013811 (2006).", "journal-title": "CNS Drugs"}, {"key": "BFnrd3702_CR168", "doi-asserted-by": "publisher", "first-page": "e19286", "DOI": "10.1371/journal.pone.0019286", "volume": "6", "author": "S Chung", "year": "2011", "unstructured": "Chung, S. et al. The melanin-concentrating hormone (MCH) system modulates behaviors associated with psychiatric disorders. PLoS. ONE 6, e19286 (2011).", "journal-title": "PLoS. ONE"}, {"key": "BFnrd3702_CR169", "doi-asserted-by": "publisher", "first-page": "580", "DOI": "10.1016/j.tips.2003.09.011", "volume": "24", "author": "A Holmes", "year": "2003", "unstructured": "Holmes, A., Heilig, M., Rupniak, N. M., Steckler, T. & Griebel, G. Neuropeptide systems as novel therapeutic targets for depression and anxiety disorders. Trends Pharmacol. Sci. 24, 580\u2013588 (2003).", "journal-title": "Trends Pharmacol. Sci."}, {"key": "BFnrd3702_CR170", "doi-asserted-by": "publisher", "first-page": "177", "DOI": "10.1016/j.pharmthera.2007.05.009", "volume": "115", "author": "R Lang", "year": "2007", "unstructured": "Lang, R., Gundlach, A. L. & Kofler, B. The galanin peptide family: receptor pharmacology, pleiotropic biological actions, and implications in health and disease. Pharmacol. Ther. 115, 177\u2013207 (2007).", "journal-title": "Pharmacol. Ther."}, {"key": "BFnrd3702_CR171", "doi-asserted-by": "publisher", "first-page": "426", "DOI": "10.1016/j.yfrne.2011.07.001", "volume": "32", "author": "N Striepens", "year": "2011", "unstructured": "Striepens, N., Kendrick, K. M., Maier, W. & Hurlemann, R. Prosocial effects of oxytocin and clinical evidence for its therapeutic potential. Front. Neuroendocrinol. 32, 426\u2013450 (2011).", "journal-title": "Front. Neuroendocrinol."}, {"key": "BFnrd3702_CR172", "doi-asserted-by": "publisher", "first-page": "487", "DOI": "10.1016/j.neuron.2004.08.005", "volume": "43", "author": "YL Xu", "year": "2004", "unstructured": "Xu, Y. L. et al. Neuropeptide S: a neuropeptide promoting arousal and anxiolytic-like effects. Neuron 43, 487\u2013497 (2004).", "journal-title": "Neuron"}, {"key": "BFnrd3702_CR173", "doi-asserted-by": "publisher", "first-page": "1323", "DOI": "10.1038/npp.2011.317", "volume": "37", "author": "I Ionescu", "year": "2012", "unstructured": "Ionescu, I. et al. Intranasally administered neuropeptide S (NPS) exerts anxiolytic effects following internalization into NPS receptor-expressing neurons. Neuropsychopharmacology 37, 1323\u20131337 (2012).", "journal-title": "Neuropsychopharmacology"}, {"key": "BFnrd3702_CR174", "doi-asserted-by": "publisher", "first-page": "617", "DOI": "10.1176/appi.ajp.2008.07071199", "volume": "165", "author": "B Binneman", "year": "2008", "unstructured": "Binneman, B. et al. A 6-week randomized, placebo-controlled trial of CP-316,311 (a selective CRH1 antagonist) in the treatment of major depression. Am. J. Psychiatry 165, 617\u2013620 (2008).", "journal-title": "Am. J. Psychiatry"}, {"key": "BFnrd3702_CR175", "doi-asserted-by": "publisher", "first-page": "1431", "DOI": "10.1517/13543780903184591", "volume": "18", "author": "VD Kirchhoff", "year": "2009", "unstructured": "Kirchhoff, V. D., Nguyen, H. T., Soczynska, J. K., Woldeyohannes, H. & McIntyre, R. S. Discontinued psychiatric drugs in 2008. Expert. Opin. Investig. Drugs 18, 1431\u20131443 (2009).", "journal-title": "Expert. Opin. Investig. Drugs"}, {"key": "BFnrd3702_CR176", "doi-asserted-by": "publisher", "first-page": "417", "DOI": "10.1002/da.20695", "volume": "27", "author": "V Coric", "year": "2010", "unstructured": "Coric, V. et al. Multicenter, randomized, double-blind, active comparator and placebo-controlled trial of a corticotropin-releasing factor receptor-1 antagonist in generalized anxiety disorder. Depress. Anxiety 27, 417\u2013425 (2010).", "journal-title": "Depress. Anxiety"}, {"key": "BFnrd3702_CR177", "first-page": "S351", "volume": "36", "author": "G Griebel", "year": "2011", "unstructured": "Griebel, G., Stahl, S. & Arvanitis, L. The V1b receptor antagonist SSR149415 in the treatment of major depressive and generalized anxiety disorders: results from three double-blind, placebo-controlled studies. Neuropsychopharmacology 36, S351 (2011).", "journal-title": "Neuropsychopharmacology"}, {"key": "BFnrd3702_CR178", "doi-asserted-by": "publisher", "first-page": "132", "DOI": "10.1016/j.biopsych.2005.03.029", "volume": "58", "author": "T Furmark", "year": "2005", "unstructured": "Furmark, T. et al. Cerebral blood flow changes after treatment of social phobia with the neurokinin-1 antagonist GR205171, citalopram, or placebo. Biol. Psychiatry 58, 132\u2013142 (2005).", "journal-title": "Biol. Psychiatry"}, {"key": "BFnrd3702_CR179", "doi-asserted-by": "publisher", "first-page": "24", "DOI": "10.1055/s-2005-837768", "volume": "38", "author": "G Kronenberg", "year": "2005", "unstructured": "Kronenberg, G. et al. Randomized, double-blind study of SR142801 (osanetant). A novel neurokinin-3 (NK3) receptor antagonist in panic disorder with pre- and posttreatment cholecystokinin tetrapeptide (CCK-4) challenges. Pharmacopsychiatry 38, 24\u201329 (2005).", "journal-title": "Pharmacopsychiatry"}], "container-title": ["Nature Reviews Drug Discovery"], "language": "en", "link": [{"URL": "http://www.nature.com/articles/nrd3702.pdf", "content-type": "application/pdf", "content-version": "vor", "intended-application": "text-mining"}, {"URL": "http://www.nature.com/articles/nrd3702", "content-type": "text/html", "content-version": "vor", "intended-application": "text-mining"}, {"URL": "http://www.nature.com/articles/nrd3702.pdf", "content-type": "application/pdf", "content-version": "vor", "intended-application": "similarity-checking"}], "deposited": {"date-parts": [[2019, 4, 20]], "date-time": "2019-04-20T06:11:54Z", "timestamp": 1555740714000}, "score": 34.26413, "issued": {"date-parts": [[2012, 5, 18]]}, "references-count": 179, "journal-issue": {"published-print": {"date-parts": [[2012, 6]]}, "issue": "6"}, "alternative-id": ["BFnrd3702"], "URL": "http://dx.doi.org/10.1038/nrd3702", "relation": {"cites": []}, "ISSN": ["1474-1776", "1474-1784"], "issn-type": [{"value": "1474-1776", "type": "print"}, {"value": "1474-1784", "type": "electronic"}]}, {"indexed": {"date-parts": [[2019, 11, 23]], "date-time": "2019-11-23T19:44:45Z", "timestamp": 1574538285103}, "edition-number": "1", "reference-count": 69, "publisher": "Wiley", "isbn-type": [{"value": "9783527333288", "type": "print"}, {"value": "9783527679348", "type": "electronic"}], "license": [{"URL": "http://doi.wiley.com/10.1002/tdm_license_1.1", "start": {"date-parts": [[2014, 6, 18]], "date-time": "2014-06-18T00:00:00Z", "timestamp": 1403049600000}, "delay-in-days": 0, "content-version": "tdm"}, {"URL": "http://doi.wiley.com/10.1002/tdm_license_1.1", "start": {"date-parts": [[2014, 6, 18]], "date-time": "2014-06-18T00:00:00Z", "timestamp": 1403049600000}, "delay-in-days": 0, "content-version": "tdm"}, {"URL": "http://doi.wiley.com/10.1002/tdm_license_1.1", "start": {"date-parts": [[2014, 6, 18]], "date-time": "2014-06-18T00:00:00Z", "timestamp": 1403049600000}, "delay-in-days": 0, "content-version": "tdm"}], "content-domain": {"domain": [], "crossmark-restriction": false}, "published-print": {"date-parts": [[2014, 6, 18]]}, "DOI": "10.1002/9783527679348.ch09", "type": "other", "created": {"date-parts": [[2014, 8, 11]], "date-time": "2014-08-11T16:25:53Z", "timestamp": 1407774353000}, "page": "193-206", "source": "Crossref", "is-referenced-by-count": 0, "title": ["Mood and Anxiety Disorders"], "prefix": "10.1002", "author": [{"given": "Guy", "family": "Griebel", "sequence": "first", "affiliation": []}, {"given": "Sandra", "family": "Beesk\u00e9", "sequence": "additional", "affiliation": []}], "member": "311", "published-online": {"date-parts": [[2014, 8, 11]]}, "reference": [{"issue": "2", "key": "e_1_2_1_2_2", "first-page": "10", "article-title": "The global burden of anxiety and mood disorders: putting the European Study of the Epidemiology of Mental Disorders (ESEMeD) findings into perspective", "volume": "68", "author": "Kessler R.C.", "year": "2007", "journal-title": "Journal of Clinical Psychiatry"}, {"key": "e_1_2_1_3_2", "DOI": "10.1016/j.euroneuro.2011.07.018", "doi-asserted-by": "publisher"}, {"key": "e_1_2_1_4_2", "DOI": "10.1001/archgenpsychiatry.2010.180", "doi-asserted-by": "publisher"}, {"key": "e_1_2_1_5_2", "first-page": "5", "article-title": "The WHO World Mental Health (WMH) surveys", "volume": "6", "author": "Kessler R.C.", "year": "2009", "journal-title": "Psychiatrie (Stuttgart, Germany)"}, {"key": "e_1_2_1_6_2", "DOI": "10.1192/bjp.bp.107.039107", "doi-asserted-by": "publisher"}, {"key": "e_1_2_1_7_2", "DOI": "10.1016/j.neubiorev.2012.09.001", "doi-asserted-by": "publisher"}, {"key": "e_1_2_1_8_2", "DOI": "10.1186/2045-5380-1-9", "doi-asserted-by": "publisher"}, {"key": "e_1_2_1_9_2", "DOI": "10.1038/nrd1825", "doi-asserted-by": "publisher"}, {"key": "e_1_2_1_10_2", "DOI": "10.1038/nrd4075", "doi-asserted-by": "publisher"}, {"key": "e_1_2_1_11_2", "DOI": "10.1001/archpsyc.1969.01740200112015", "doi-asserted-by": "publisher"}, {"key": "e_1_2_1_12_2", "DOI": "10.1037/h0071444", "doi-asserted-by": "publisher"}, {"key": "e_1_2_1_13_2", "DOI": "10.1007/BF00504983", "doi-asserted-by": "publisher"}, {"key": "e_1_2_1_14_2", "DOI": "10.1016/0091-3057(81)90007-1", "doi-asserted-by": "publisher"}, {"key": "e_1_2_1_15_2", "DOI": "10.1007/BF00177912", "doi-asserted-by": "publisher"}, {"key": "e_1_2_1_16_2", "DOI": "10.1177/026988119601000307", "doi-asserted-by": "publisher"}, {"key": "e_1_2_1_17_2", "DOI": "10.1016/S0893-133X(02)00312-3", "doi-asserted-by": "publisher"}, {"key": "e_1_2_1_18_2", "DOI": "10.1007/BF00403989", "doi-asserted-by": "publisher"}, {"key": "e_1_2_1_19_2", "DOI": "10.1007/BF00408322", "doi-asserted-by": "publisher"}, {"key": "e_1_2_1_20_2", "DOI": "10.1007/978-1-61779-313-4_6", "doi-asserted-by": "publisher"}, {"key": "e_1_2_1_21_2", "DOI": "10.1016/S0014-2999(03)01276-7", "doi-asserted-by": "publisher"}, {"key": "e_1_2_1_22_2", "DOI": "10.1590/S0100-879X1997000300002", "doi-asserted-by": "publisher"}, {"key": "e_1_2_1_23_2", "DOI": "10.1016/j.neuropharm.2011.06.012", "doi-asserted-by": "publisher"}, {"key": "e_1_2_1_24_2", "DOI": "10.1523/JNEUROSCI.5017-09.2010", "doi-asserted-by": "publisher"}, {"key": "e_1_2_1_25_2", "DOI": "10.1016/S0028-3908(01)00072-7", "doi-asserted-by": "publisher"}, {"key": "e_1_2_1_26_2", "DOI": "10.1371/journal.pone.0005346", "doi-asserted-by": "publisher"}, {"key": "e_1_2_1_27_2", "DOI": "10.1016/j.tins.2012.11.003", "doi-asserted-by": "publisher"}, {"key": "e_1_2_1_28_2", "DOI": "10.1016/j.neubiorev.2008.03.006", "doi-asserted-by": "publisher"}, {"key": "e_1_2_1_29_2", "DOI": "10.1523/JNEUROSCI.2531-12.2012", "doi-asserted-by": "publisher"}, {"key": "e_1_2_1_30_2", "DOI": "10.1016/j.conb.2013.01.011", "doi-asserted-by": "publisher"}, {"key": "e_1_2_1_31_2", "DOI": "10.1016/j.tips.2009.10.003", "doi-asserted-by": "publisher"}, {"key": "e_1_2_1_32_2", "DOI": "10.1038/sj.mp.4001939", "doi-asserted-by": "publisher"}, {"key": "e_1_2_1_33_2", "DOI": "10.1101/lm.78204", "doi-asserted-by": "publisher"}, {"key": "e_1_2_1_34_2", "DOI": "10.1126/science.1222940", "doi-asserted-by": "publisher"}, {"key": "e_1_2_1_35_2", "DOI": "10.1038/266730a0", "doi-asserted-by": "publisher"}, {"key": "e_1_2_1_36_2", "DOI": "10.1007/BF00428203", "doi-asserted-by": "publisher"}, {"key": "e_1_2_1_37_2", "DOI": "10.1016/S0278-5846(84)80032-9", "doi-asserted-by": "publisher"}, {"key": "e_1_2_1_38_2", "DOI": "10.1176/appi.books.9780890423349", "doi-asserted-by": "publisher"}, {"key": "e_1_2_1_39_2", "DOI": "10.1186/1744-9081-7-9", "doi-asserted-by": "publisher"}, {"key": "e_1_2_1_40_2", "DOI": "10.1007/BF02244188", "doi-asserted-by": "publisher"}, {"key": "e_1_2_1_41_2", "DOI": "10.1016/0924-977X(92)90035-7", "doi-asserted-by": "publisher"}, {"key": "e_1_2_1_42_2", "DOI": "10.1038/nprot.2007.441", "doi-asserted-by": "publisher"}, {"key": "e_1_2_1_43_2", "DOI": "10.1073/pnas.0500587102", "doi-asserted-by": "publisher"}, {"key": "e_1_2_1_44_2", "DOI": "10.1176/ajp.140.8.1027", "doi-asserted-by": "publisher"}, {"key": "e_1_2_1_45_2", "DOI": "10.1371/journal.pone.0019855", "doi-asserted-by": "publisher"}, {"key": "e_1_2_1_46_2", "DOI": "10.1126/science.1120972", "doi-asserted-by": "publisher"}, {"key": "e_1_2_1_47_2", "DOI": "10.1016/S0149-7634(05)80068-5", "doi-asserted-by": "publisher"}, {"key": "e_1_2_1_48_2", "DOI": "10.1016/0166-4328(93)90096-9", "doi-asserted-by": "publisher"}, {"key": "e_1_2_1_49_2", "DOI": "10.1038/nrn3027", "doi-asserted-by": "publisher"}, {"key": "e_1_2_1_50_2", "DOI": "10.1016/0892-0362(96)00027-X", "doi-asserted-by": "publisher"}, {"key": "e_1_2_1_51_2", "DOI": "10.1523/JNEUROSCI.5048-11.2012", "doi-asserted-by": "publisher"}, {"key": "e_1_2_1_52_2", "DOI": "10.1073/pnas.0711496105", "doi-asserted-by": "publisher"}, {"key": "e_1_2_1_53_2", "DOI": "10.1073/pnas.0809449106", "doi-asserted-by": "publisher"}, {"key": "e_1_2_1_54_2", "DOI": "10.1016/j.molmed.2011.09.002", "doi-asserted-by": "publisher"}, {"key": "e_1_2_1_55_2", "DOI": "10.1126/science.1202107", "doi-asserted-by": "publisher"}, {"key": "e_1_2_1_56_2", "DOI": "10.1124/pr.111.005397", "doi-asserted-by": "publisher"}, {"key": "e_1_2_1_57_2", "DOI": "10.1038/sj.mp.4001345", "doi-asserted-by": "publisher"}, {"key": "e_1_2_1_58_2", "DOI": "10.1016/j.psyneuen.2008.03.013", "doi-asserted-by": "publisher"}, {"key": "e_1_2_1_59_2", "DOI": "10.1016/S0091-3057(98)00075-6", "doi-asserted-by": "publisher"}, {"key": "e_1_2_1_60_2", "DOI": "10.1016/S1385-299X(01)00067-8", "doi-asserted-by": "publisher"}, {"key": "e_1_2_1_61_2", "DOI": "10.1007/978-1-60761-303-9_16", "doi-asserted-by": "publisher"}, {"key": "e_1_2_1_62_2", "DOI": "10.1016/j.neubiorev.2007.05.007", "doi-asserted-by": "publisher"}, {"key": "e_1_2_1_63_2", "DOI": "10.1007/BF00426631", "doi-asserted-by": "publisher"}, {"key": "e_1_2_1_64_2", "DOI": "10.1038/mp.2010.3", "doi-asserted-by": "publisher"}, {"key": "e_1_2_1_65_2", "DOI": "10.1073/pnas.0609625104", "doi-asserted-by": "publisher"}, {"key": "e_1_2_1_66_2", "DOI": "10.1038/mp.2008.20", "doi-asserted-by": "publisher"}, {"key": "e_1_2_1_67_2", "DOI": "10.1111/j.1399-5618.2009.00697.x", "doi-asserted-by": "publisher"}, {"key": "e_1_2_1_68_2", "DOI": "10.1523/JNEUROSCI.5216-05.2006", "doi-asserted-by": "publisher"}, {"key": "e_1_2_1_69_2", "DOI": "10.1038/nn.2647", "doi-asserted-by": "publisher"}, {"key": "e_1_2_1_70_2", "DOI": "10.1038/nrd3702", "doi-asserted-by": "publisher"}], "container-title": ["In Vivo Models for Drug Discovery", "Methods and Principles in Medicinal Chemistry"], "link": [{"URL": "https://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1002%2F9783527679348.ch09", "content-type": "application/pdf", "content-version": "vor", "intended-application": "text-mining"}, {"URL": "https://onlinelibrary.wiley.com/doi/pdf/10.1002/9783527679348.ch09", "content-type": "application/pdf", "content-version": "vor", "intended-application": "text-mining"}, {"URL": "https://onlinelibrary.wiley.com/doi/pdf/10.1002/9783527679348.ch09", "content-type": "unspecified", "content-version": "vor", "intended-application": "similarity-checking"}], "deposited": {"date-parts": [[2018, 12, 11]], "date-time": "2018-12-11T11:29:11Z", "timestamp": 1544527751000}, "score": 34.033607, "issued": {"date-parts": [[2014, 6, 18]]}, "ISBN": ["9783527333288", "9783527679348"], "references-count": 69, "alternative-id": ["10.1002/9783527679348.ch09", "10.1002/SERIES6138", "10.1002/9783527679348"], "URL": "http://dx.doi.org/10.1002/9783527679348.ch09", "archive": ["Portico"], "relation": {"cites": []}, "ISSN": ["1865-0562"], "issn-type": [{"value": "1865-0562", "type": "electronic"}]}, {"indexed": {"date-parts": [[2019, 11, 18]], "date-time": "2019-11-18T20:13:54Z", "timestamp": 1574108034004}, "reference-count": 512, "publisher": "Elsevier BV", "issue": "3", "license": [{"URL": "https://www.elsevier.com/tdm/userlicense/1.0/", "start": {"date-parts": [[1995, 1, 1]], "date-time": "1995-01-01T00:00:00Z", "timestamp": 788918400000}, "delay-in-days": 0, "content-version": "tdm"}], "content-domain": {"domain": [], "crossmark-restriction": false}, "short-container-title": ["Pharmacology & Therapeutics"], "published-print": {"date-parts": [[1995, 1]]}, "DOI": "10.1016/0163-7258(95)98597-j", "type": "journal-article", "created": {"date-parts": [[2002, 7, 26]], "date-time": "2002-07-26T02:08:54Z", "timestamp": 1027649334000}, "page": "319-395", "source": "Crossref", "is-referenced-by-count": 306, "title": ["5-Hydroxytryptamine-interacting drugs in animal models of anxiety disorders: More than 30 years of research"], "prefix": "10.1016", "volume": "65", "author": [{"given": "Guy", "family": "Griebel", "sequence": "first", "affiliation": []}], "member": "78", "container-title": ["Pharmacology & Therapeutics"], "language": "en", "link": [{"URL": "https://api.elsevier.com/content/article/PII:016372589598597J?httpAccept=text/xml", "content-type": "text/xml", "content-version": "vor", "intended-application": "text-mining"}, {"URL": "https://api.elsevier.com/content/article/PII:016372589598597J?httpAccept=text/plain", "content-type": "text/plain", "content-version": "vor", "intended-application": "text-mining"}], "deposited": {"date-parts": [[2019, 4, 15]], "date-time": "2019-04-15T00:28:56Z", "timestamp": 1555288136000}, "score": 29.217178, "issued": {"date-parts": [[1995, 1]]}, "references-count": 512, "journal-issue": {"published-print": {"date-parts": [[1995, 1]]}, "issue": "3"}, "alternative-id": ["016372589598597J"], "URL": "http://dx.doi.org/10.1016/0163-7258(95)98597-j", "ISSN": ["0163-7258"], "issn-type": [{"value": "0163-7258", "type": "print"}]}, {"indexed": {"date-parts": [[2019, 11, 21]], "date-time": "2019-11-21T20:48:38Z", "timestamp": 1574369318397}, "reference-count": 0, "publisher": "Bentham Science Publishers Ltd.", "issue": "2", "content-domain": {"domain": [], "crossmark-restriction": false}, "short-container-title": ["CNSNDDT"], "published-print": {"date-parts": [[2006, 4, 1]]}, "DOI": "10.2174/187152706776359637", "type": "journal-article", "created": {"date-parts": [[2008, 5, 13]], "date-time": "2008-05-13T00:53:51Z", "timestamp": 1210640031000}, "page": "133-133", "source": "Crossref", "is-referenced-by-count": 1, "title": ["Editorial [Hot Topic: Neuropeptide Systems as Novel Targets for Psychiatric Disorders (Guest Editor: Guy Griebel) ]"], "prefix": "10.2174", "volume": "5", "author": [{"given": "Guy", "family": "Griebel", "sequence": "first", "affiliation": []}], "member": "965", "container-title": ["CNS & Neurological Disorders - Drug Targets"], "language": "en", "link": [{"URL": "http://eurekaselect.com/article/download/57573", "content-type": "unspecified", "content-version": "vor", "intended-application": "similarity-checking"}], "deposited": {"date-parts": [[2015, 11, 23]], "date-time": "2015-11-23T14:46:31Z", "timestamp": 1448289991000}, "score": 28.726679, "issued": {"date-parts": [[2006, 4, 1]]}, "references-count": 0, "journal-issue": {"published-print": {"date-parts": [[2006, 4, 1]]}, "issue": "2"}, "alternative-id": ["LiveAll1"], "URL": "http://dx.doi.org/10.2174/187152706776359637", "ISSN": ["1871-5273"], "issn-type": [{"value": "1871-5273", "type": "print"}]}, {"indexed": {"date-parts": [[2019, 11, 26]], "date-time": "2019-11-26T11:31:19Z", "timestamp": 1574767879116}, "reference-count": 12, "publisher": "Wiley", "issue": "13", "license": [{"URL": "http://doi.wiley.com/10.1002/tdm_license_1.1", "start": {"date-parts": [[2017, 4, 3]], "date-time": "2017-04-03T00:00:00Z", "timestamp": 1491177600000}, "delay-in-days": 0, "content-version": "tdm"}, {"URL": "http://onlinelibrary.wiley.com/termsAndConditions#vor", "start": {"date-parts": [[2017, 4, 3]], "date-time": "2017-04-03T00:00:00Z", "timestamp": 1491177600000}, "delay-in-days": 0, "content-version": "vor"}], "content-domain": {"domain": [], "crossmark-restriction": false}, "short-container-title": ["British Journal of Pharmacology"], "published-print": {"date-parts": [[2017, 7]]}, "DOI": "10.1111/bph.13775", "type": "journal-article", "created": {"date-parts": [[2017, 4, 5]], "date-time": "2017-04-05T15:10:37Z", "timestamp": 1491405037000}, "page": "2152-2153", "source": "Crossref", "is-referenced-by-count": 0, "title": ["Creativity in large pharmaceutical research organizations: unleash the hungry drug hunter"], "prefix": "10.1111", "volume": "174", "author": [{"given": "Guy", "family": "Griebel", "sequence": "first", "affiliation": [{"name": "Sanofi, Strategy and Business Development; Chilly-Mazarin France"}]}], "member": "311", "published-online": {"date-parts": [[2017, 4, 3]]}, "reference": [{"key": "10.1111/bph.13775-BIB0001|bph13775-cit-0002", "unstructured": "Booth B 2013 Culture as a culprit of the pharma R&D crisis Life Sci VC http://lifescivc.com/2012/04/culture-as-a-culprit-of-the-pharma-rd-crisis"}, {"key": "10.1111/bph.13775-BIB0002|bph13775-cit-0003", "doi-asserted-by": "crossref", "first-page": "2837", "DOI": "10.1172/JCI29999", "article-title": "Drug discovery in jeopardy", "volume": "116", "author": "Cuatrecasas", "year": "2006", "journal-title": "J Clin Investig"}, {"key": "10.1111/bph.13775-BIB0003|bph13775-cit-0004", "doi-asserted-by": "crossref", "first-page": "609", "DOI": "10.1038/nrd2948", "article-title": "Pharmaceutical R&D: the road to positive returns", "volume": "8", "author": "David", "year": "2009", "journal-title": "Nat Rev Drug Discov"}, {"key": "10.1111/bph.13775-BIB0004|bph13775-cit-0005", "doi-asserted-by": "crossref", "first-page": "171", "DOI": "10.1038/nrd3388", "article-title": "Managing the health of early-stage discovery", "volume": "10", "author": "Edwards", "year": "2011", "journal-title": "Nat Rev Drug Discov"}, {"key": "10.1111/bph.13775-BIB0005|bph13775-cit-0006", "doi-asserted-by": "crossref", "first-page": "1043", "DOI": "10.1016/j.cell.2016.05.005", "article-title": "Lessons from a recovering academic", "volume": "165", "author": "Ehlers", "year": "2016", "journal-title": "Cell"}, {"key": "10.1111/bph.13775-BIB0006|bph13775-cit-0007", "doi-asserted-by": "crossref", "first-page": "16569", "DOI": "10.1073/pnas.0507655102", "article-title": "An index to quantify an individual's scientific research output", "volume": "102", "author": "Hirsch", "year": "2005", "journal-title": "Proc Natl Acad Sci"}, {"key": "10.1111/bph.13775-BIB0007|bph13775-cit-0008", "doi-asserted-by": "crossref", "first-page": "73", "DOI": "10.1038/nrd.2017.14", "article-title": "2016 FDA drug appovals", "volume": "16", "author": "Mullard", "year": "2017", "journal-title": "Nat Rev Drug Discov"}, {"key": "10.1111/bph.13775-BIB0008|bph13775-cit-0009", "doi-asserted-by": "crossref", "first-page": "22", "DOI": "10.1016/j.techfore.2012.06.007", "article-title": "Big pharma, little science? A bibliometric perspective on big pharma's R&D decline", "volume": "81", "author": "Rafols", "year": "2014", "journal-title": "Technol Forecast Soc Change"}, {"key": "10.1111/bph.13775-BIB0009|bph13775-cit-0010", "doi-asserted-by": "crossref", "first-page": "901", "DOI": "10.1038/nrd4164", "article-title": "Does size matter in R&D productivity? If not, what does?", "volume": "12", "author": "Ringel", "year": "2013", "journal-title": "Nat Rev Drug Discov"}, {"key": "10.1111/bph.13775-BIB0010|bph13775-cit-0011", "doi-asserted-by": "crossref", "first-page": "507", "DOI": "10.1038/nrd3480", "article-title": "How were new medicines discovered?", "volume": "10", "author": "Swinney", "year": "2011", "journal-title": "Nat Rev Drug Discov"}, {"key": "10.1111/bph.13775-BIB0011|bph13775-cit-0012", "doi-asserted-by": "crossref", "first-page": "441", "DOI": "10.1038/nrd.2016.91", "article-title": "Organizational effectiveness: a key to R&D productivity", "volume": "15", "author": "Tollman", "year": "2016", "journal-title": "Nat Rev Drug Discov"}, {"key": "10.1111/bph.13775-BIB0012|bph13775-cit-0013", "doi-asserted-by": "crossref", "first-page": "945", "DOI": "10.1038/nbt0807-945", "article-title": "Mission possible: managing innovation in drug discovery", "volume": "25", "author": "Zhong", "year": "2007", "journal-title": "Nat Biotechnol"}], "container-title": ["British Journal of Pharmacology"], "language": "en", "link": [{"URL": "https://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1111%2Fbph.13775", "content-type": "application/pdf", "content-version": "vor", "intended-application": "text-mining"}, {"URL": "http://onlinelibrary.wiley.com/wol1/doi/10.1111/bph.13775/fullpdf", "content-type": "unspecified", "content-version": "vor", "intended-application": "similarity-checking"}], "deposited": {"date-parts": [[2017, 11, 15]], "date-time": "2017-11-15T09:02:24Z", "timestamp": 1510736544000}, "score": 28.726679, "subtitle": ["Letter to the Editor"], "issued": {"date-parts": [[2017, 4, 3]]}, "references-count": 12, "journal-issue": {"published-print": {"date-parts": [[2017, 7]]}, "issue": "13"}, "URL": "http://dx.doi.org/10.1111/bph.13775", "archive": ["Portico"], "relation": {"cites": []}, "ISSN": ["0007-1188"], "issn-type": [{"value": "0007-1188", "type": "print"}]}, {"indexed": {"date-parts": [[2019, 11, 20]], "date-time": "2019-11-20T20:29:35Z", "timestamp": 1574281775181}, "reference-count": 46, "publisher": "SAGE Publications", "issue": "4", "license": [{"URL": "http://journals.sagepub.com/page/policies/text-and-data-mining-license", "start": {"date-parts": [[1998, 7, 1]], "date-time": "1998-07-01T00:00:00Z", "timestamp": 899251200000}, "delay-in-days": 0, "content-version": "tdm"}], "content-domain": {"domain": [], "crossmark-restriction": false}, "short-container-title": ["J Psychopharmacol"], "published-print": {"date-parts": [[1998, 7]]}, "DOI": "10.1177/026988119801200405", "type": "journal-article", "created": {"date-parts": [[2007, 3, 18]], "date-time": "2007-03-18T03:45:17Z", "timestamp": 1174189517000}, "page": "356-365", "source": "Crossref", "is-referenced-by-count": 28, "title": ["Limited anxiolytic-like effects of non-benzodiazepine hypnotics in rodents"], "prefix": "10.1177", "volume": "12", "author": [{"given": "Guy", "family": "Griebel", "sequence": "first", "affiliation": [{"name": "CNS Research Department, Synth\u00e9labo Recherche, 31 avenue Paul Vaillant-Couturier; 92220 Bagneux, France"}]}, {"given": "Ghislaine", "family": "Perrault", "sequence": "additional", "affiliation": [{"name": "CNS Research Department, Synth\u00e9labo Recherche, 31 avenue Paul Vaillant-Couturier; 92220 Bagneux, France"}]}, {"given": "David J.", "family": "Sanger", "sequence": "additional", "affiliation": [{"name": "CNS Research Department, Synth\u00e9labo Recherche, 31 avenue Paul Vaillant-Couturier; 92220 Bagneux, France"}]}], "member": "179", "published-online": {"date-parts": [[2016, 7, 2]]}, "reference": [{"key": "atypb1", "author": "Agnoli A.", "volume": "9", "first-page": "277", "year": "1989", "journal-title": "Int J Clin Pharmac Res"}, {"key": "atypb2", "author": "Barrett J.E.", "volume": "236", "first-page": "313", "year": "1986", "journal-title": "J Pharmac Exp Ther"}, {"key": "atypb3", "author": "Bayley P.J.", "volume": "117", "first-page": "171P", "year": "1996", "journal-title": "Br J Pharmac"}, {"key": "atypb4", "DOI": "10.1002/j.1552-4604.1994.tb02002.x", "doi-asserted-by": "publisher"}, {"key": "atypb5", "DOI": "10.1016/0024-3205(79)90449-1", "doi-asserted-by": "publisher"}, {"issue": "2", "key": "atypb6", "first-page": "21", "volume": "5", "author": "Chaudoir P.J.", "year": "1990", "journal-title": "Int Clin Psychopharmac"}, {"key": "atypb7", "author": "Day I.P.", "volume": "18", "first-page": "725", "year": "1992", "journal-title": "Soc Neurosci Abstr"}, {"key": "atypb8", "author": "Depoortere H.", "volume": "237", "first-page": "649", "year": "1986", "journal-title": "J Pharmac Exp Ther"}, {"key": "atypb9", "author": "Dmgemanse J.", "volume": "17", "first-page": "67", "year": "1995", "journal-title": "Pharm Wld Sci"}, {"key": "atypb10", "DOI": "10.1016/0922-4106(93)90043-9", "doi-asserted-by": "publisher"}, {"key": "atypb11", "author": "Freeman H.L.", "volume": "7", "first-page": "289", "year": "1996", "journal-title": "J Drug Dev Clin Pract"}, {"key": "atypb12", "DOI": "10.1016/0028-3908(83)90118-1", "doi-asserted-by": "publisher"}, {"key": "atypb13", "author": "Griebel G.", "volume": "6", "first-page": "732", "year": "1995", "journal-title": "Behav Pharmac"}, {"key": "atypb14", "DOI": "10.1016/S0031-9384(96)00230-2", "doi-asserted-by": "publisher"}, {"key": "atypb15", "DOI": "10.1016/0278-5846(95)00305-3", "doi-asserted-by": "publisher"}, {"key": "atypb16", "DOI": "10.1016/S0028-3908(96)00080-9", "doi-asserted-by": "publisher"}, {"key": "atypb17", "DOI": "10.1007/BF02246664", "doi-asserted-by": "publisher"}, {"key": "atypb18", "author": "Griebel G.", "volume": "7", "first-page": "560", "year": "1996", "journal-title": "Behav Pharmac"}, {"key": "atypb19", "DOI": "10.1016/S0091-3057(96)00402-9", "doi-asserted-by": "publisher"}, {"key": "atypb20", "DOI": "10.1002/(SICI)1098-2337(1997)23:1<19::AID-AB3>3.0.CO;2-O", "doi-asserted-by": "publisher"}, {"issue": "2", "key": "atypb21", "first-page": "109", "volume": "17", "author": "Inanaga K.", "year": "1982", "journal-title": "Int Pharmacopsychiat"}, {"key": "atypb22", "DOI": "10.1016/0028-3908(91)90009-Z", "doi-asserted-by": "publisher"}, {"key": "atypb23", "DOI": "10.1002/hup.470100309", "doi-asserted-by": "publisher"}, {"key": "atypb24", "DOI": "10.1097/00004850-198610000-00001", "doi-asserted-by": "publisher"}, {"key": "atypb25", "DOI": "10.1016/0091-3057(88)90202-X", "doi-asserted-by": "publisher"}, {"key": "atypb26", "author": "Langtry H.D.", "volume": "40", "first-page": "291", "year": "1990", "journal-title": "Drugs", "DOI": "10.2165/00003495-199040020-00008", "doi-asserted-by": "crossref"}, {"key": "atypb27", "DOI": "10.1016/S0376-6357(89)80010-5", "doi-asserted-by": "publisher"}, {"key": "atypb28", "DOI": "10.1007/BF00432111", "doi-asserted-by": "publisher"}, {"key": "atypb29", "DOI": "10.1007/BF00558070", "doi-asserted-by": "publisher"}, {"key": "atypb30", "author": "OhtaT.", "volume": "16", "first-page": "161", "year": "1996", "journal-title": "Jap J Psychopharmac"}, {"key": "atypb31", "DOI": "10.1016/S0011-393X(05)80159-6", "doi-asserted-by": "publisher"}, {"key": "atypb32", "DOI": "10.1016/0165-0270(85)90031-7", "doi-asserted-by": "publisher"}, {"key": "atypb33", "DOI": "10.1016/0014-2999(90)90375-G", "doi-asserted-by": "publisher"}, {"key": "atypb34", "DOI": "10.1016/S0924-9338(97)80015-6", "doi-asserted-by": "publisher"}, {"key": "atypb35", "DOI": "10.1111/j.1471-4159.1990.tb01237.x", "doi-asserted-by": "publisher"}, {"key": "atypb36", "author": "Rodgers R.J.", "year": "1994", "volume-title": "The elevated plus-maze: pharmacology, methodology and ethology"}, {"key": "atypb37", "author": "Sanger D.J.", "volume": "6", "first-page": "116", "year": "1995", "journal-title": "Behav Pharmac"}, {"key": "atypb38", "DOI": "10.1016/0028-3908(88)90007-X", "doi-asserted-by": "publisher"}, {"key": "atypb39", "author": "Sanger D.J.", "volume": "232", "first-page": "831", "year": "1985", "journal-title": "J Pharmac Exp Ther"}, {"key": "atypb40", "DOI": "10.1016/0014-2999(96)00510-9", "doi-asserted-by": "publisher"}, {"key": "atypb41", "author": "Stutzmann J.M.", "volume": "18", "first-page": "393", "year": "1992", "journal-title": "Encephale"}, {"key": "atypb42", "DOI": "10.1093/sleep/10.suppl_1.1", "doi-asserted-by": "publisher"}, {"key": "atypb43", "DOI": "10.1007/BF02245068", "doi-asserted-by": "publisher"}, {"key": "atypb44", "DOI": "10.1007/BF00403989", "doi-asserted-by": "publisher"}, {"key": "atypb45", "DOI": "10.1016/0091-3057(87)90542-9", "doi-asserted-by": "publisher"}, {"key": "atypb46", "author": "Zivkovic B.", "year": "1988", "volume-title": "Comparative pharmacology of zolpidem and other hypnotics and sleep inducers"}], "container-title": ["Journal of Psychopharmacology"], "language": "en", "link": [{"URL": "http://journals.sagepub.com/doi/pdf/10.1177/026988119801200405", "content-type": "application/pdf", "content-version": "vor", "intended-application": "text-mining"}, {"URL": "http://journals.sagepub.com/doi/pdf/10.1177/026988119801200405", "content-type": "unspecified", "content-version": "vor", "intended-application": "similarity-checking"}], "deposited": {"date-parts": [[2018, 1, 12]], "date-time": "2018-01-12T02:16:13Z", "timestamp": 1515723373000}, "score": 27.344656, "issued": {"date-parts": [[1998, 7]]}, "references-count": 46, "journal-issue": {"published-online": {"date-parts": [[2016, 7, 2]]}, "published-print": {"date-parts": [[1998, 7]]}, "issue": "4"}, "alternative-id": ["10.1177/026988119801200405"], "URL": "http://dx.doi.org/10.1177/026988119801200405", "relation": {"cites": []}, "ISSN": ["0269-8811", "1461-7285"], "issn-type": [{"value": "0269-8811", "type": "print"}, {"value": "1461-7285", "type": "electronic"}]}, {"indexed": {"date-parts": [[2019, 11, 22]], "date-time": "2019-11-22T21:01:23Z", "timestamp": 1574456483842}, "reference-count": 48, "publisher": "Wiley", "issue": "1", "license": [{"URL": "http://doi.wiley.com/10.1002/tdm_license_1.1", "start": {"date-parts": [[2015, 9, 1]], "date-time": "2015-09-01T00:00:00Z", "timestamp": 1441065600000}, "delay-in-days": 2246, "content-version": "tdm"}], "content-domain": {"domain": [], "crossmark-restriction": false}, "DOI": "10.1111/j.1465-3362.2009.00092.x", "type": "journal-article", "created": {"date-parts": [[2010, 8, 16]], "date-time": "2010-08-16T11:11:45Z", "timestamp": 1281957105000}, "page": "101-111", "source": "Crossref", "is-referenced-by-count": 9, "title": ["Anxiolytic and hypnotic drug misuse in Thailand: Findings from a national household survey"], "prefix": "10.1111", "volume": "29", "author": [{"given": "SAWITRI", "family": "ASSANANGKORNCHAI", "sequence": "first", "affiliation": []}, {"given": "NISAN", "family": "SAM-ANGSRI", "sequence": "additional", "affiliation": []}, {"given": "SIRINPORN", "family": "RERNGPONGPAN", "sequence": "additional", "affiliation": []}, {"given": "J. GUY", "family": "EDWARDS", "sequence": "additional", "affiliation": []}], "member": "311", "published-online": {"date-parts": [[2009, 7, 8]]}, "reference": [{"issue": "2", "key": "10.1111/j.1465-3362.2009.00092.x-BIB1|cit1", "first-page": "29", "article-title": "Dependence on psychotropic drugs: an overview", "volume": "60", "author": "Edwards", "year": "1984", "journal-title": "Postgrad Med J"}, {"key": "10.1111/j.1465-3362.2009.00092.x-BIB2|cit2", "doi-asserted-by": "crossref", "first-page": "273", "DOI": "10.1016/S0895-4356(97)00238-2", "article-title": "Psychotropic medication consumption patterns in the UK general population", "volume": "51", "author": "Ohayon", "year": "1998", "journal-title": "J Clin Epidemiol"}, {"key": "10.1111/j.1465-3362.2009.00092.x-BIB3|cit3", "doi-asserted-by": "crossref", "first-page": "817", "DOI": "10.4088/JCP.v63n0912", "article-title": "Use of psychotropic medication in the general population of France, Germany, Italy, and the United Kingdom", "volume": "63", "author": "Ohayon", "year": "2002", "journal-title": "J Clin Psychiatry"}, {"key": "10.1111/j.1465-3362.2009.00092.x-BIB4|cit4", "doi-asserted-by": "crossref", "first-page": "309", "DOI": "10.1016/j.jclinepi.2003.05.001", "article-title": "Prescription psychotropic medication use among the U.S. adult population: results from the third National Health and Nutrition Examination Survey, 1988-1994", "volume": "57", "author": "Paulose-Ram", "year": "2004", "journal-title": "J Clin Epidemiol"}, {"key": "10.1111/j.1465-3362.2009.00092.x-BIB5|cit5", "doi-asserted-by": "crossref", "first-page": "1062", "DOI": "10.4088/JCP.v67n0708", "article-title": "Prevalence, correlates, and comorbidity of nonmedical prescription drug use and drug use disorders in the United States: results of the National Epidemiologic Survey on Alcohol and Related Conditions", "volume": "67", "author": "Huang", "year": "2006", "journal-title": "J Clin Psychiatry"}, {"key": "10.1111/j.1465-3362.2009.00092.x-BIB6|cit6", "doi-asserted-by": "crossref", "first-page": "1920", "DOI": "10.1111/j.1360-0443.2007.02015.x", "article-title": "Does early onset of non-medical use of prescription drugs predict subsequent prescription drug abuse and dependence? Results from a national study", "volume": "102", "author": "McCabe", "year": "2007", "journal-title": "Addiction"}, {"key": "10.1111/j.1465-3362.2009.00092.x-BIB7|cit7", "doi-asserted-by": "crossref", "first-page": "1", "DOI": "10.1081/JA-120027764", "article-title": "Gender and other factors associated with the nonmedical use of abusable prescription drugs", "volume": "39", "author": "Simoni-Wastila", "year": "2004", "journal-title": "Subst Use Misuse"}, {"key": "10.1111/j.1465-3362.2009.00092.x-BIB8|cit8", "doi-asserted-by": "crossref", "first-page": "266", "DOI": "10.2105/AJPH.94.2.266", "article-title": "Risk factors associated with problem use of prescription drugs", "volume": "94", "author": "Simoni-Wastila", "year": "2004", "journal-title": "Am J Public Health"}, {"key": "10.1111/j.1465-3362.2009.00092.x-BIB9|cit9", "author": "Perngparn", "year": "2005", "volume-title": "An evaluation of the prevention and control programs for AIDS among patients of the substance treatment centers"}, {"key": "10.1111/j.1465-3362.2009.00092.x-BIB10|cit10", "author": "Assanangkornchai", "first-page": "105", "year": "2000", "volume-title": "Situational review of substance-related problems in Thailand between 2000 and 2004"}, {"key": "10.1111/j.1465-3362.2009.00092.x-BIB11|cit11", "author": "Office of Narcotics Control Board", "year": "2005", "volume-title": "Statistics of the indictments and seizures of psychotropic drugs between 2000 and 2004"}, {"key": "10.1111/j.1465-3362.2009.00092.x-BIB12|cit12", "author": "Administrative Committee on Substance Abuse Research Network", "year": "2002", "volume-title": "Status of substance use 2001: national household survey, estimation of population related with substance abuse"}, {"key": "10.1111/j.1465-3362.2009.00092.x-BIB13|cit13", "author": "Administrative Committee on Substance Abuse Research Network", "year": "2004", "volume-title": "Status of substance use 2003: national household survey, estimation of population related with substance abuse"}, {"key": "10.1111/j.1465-3362.2009.00092.x-BIB14|cit14", "author": "Administrative Committee on Substance Abuse Research Network", "year": "2008", "volume-title": "National Household Survey of Substance use, 2007"}, {"key": "10.1111/j.1465-3362.2009.00092.x-BIB15|cit15", "author": "Johnston", "first-page": "125", "year": "2000", "volume-title": "Guide to drug abuse epidemiology (WHO/MSD/MSB 00.3)"}, {"key": "10.1111/j.1465-3362.2009.00092.x-BIB16|cit16", "first-page": "31", "article-title": "Issues of validity and population coverage in student surveys of drug use", "volume": "57", "author": "Johnston", "year": "1985", "journal-title": "NIDA Res Monogr"}, {"key": "10.1111/j.1465-3362.2009.00092.x-BIB17|cit17", "doi-asserted-by": "crossref", "first-page": "805", "DOI": "10.3109/10826088309033049", "article-title": "Reliability and consistency in self-reports of drug use", "volume": "18", "author": "O'Malley", "year": "1983", "journal-title": "Int J Addict"}, {"key": "10.1111/j.1465-3362.2009.00092.x-BIB18|cit18", "doi-asserted-by": "crossref", "first-page": "225", "DOI": "10.1001/archpediatrics.2007.41", "article-title": "Screening for drug abuse among medical and nonmedical users of prescription drugs in a probability sample of college students", "volume": "162", "author": "McCabe", "year": "2008", "journal-title": "Arch Pediatr Adolesc Med"}, {"key": "10.1111/j.1465-3362.2009.00092.x-BIB19|cit19", "doi-asserted-by": "crossref", "first-page": "713", "DOI": "10.1016/j.addbeh.2007.12.008", "article-title": "Misperceptions of non-medical prescription drug use: a web survey of college students", "volume": "33", "author": "McCabe", "year": "2008", "journal-title": "Addict Behav"}, {"key": "10.1111/j.1465-3362.2009.00092.x-BIB20|cit20", "doi-asserted-by": "crossref", "first-page": "545", "DOI": "10.1016/j.addbeh.2004.08.004", "article-title": "Household survey on drug abuse in Brazil: study involving the 107 major cities of the country-2001", "volume": "30", "author": "Galduroz", "year": "2005", "journal-title": "Addict Behav"}, {"key": "10.1111/j.1465-3362.2009.00092.x-BIB21|cit21", "doi-asserted-by": "crossref", "first-page": "1722", "DOI": "10.1176/appi.ajp.161.9.1722-a", "article-title": "Potential for misuse of sedatives", "volume": "161", "author": "Sareen", "year": "2004", "journal-title": "Am J Psychiatry"}, {"key": "10.1111/j.1465-3362.2009.00092.x-BIB22|cit22", "doi-asserted-by": "crossref", "first-page": "555", "DOI": "10.1046/j.1360-0443.2002.00098.x", "article-title": "Sedative use and misuse in the United States", "volume": "97", "author": "Goodwin", "year": "2002", "journal-title": "Addiction"}, {"key": "10.1111/j.1465-3362.2009.00092.x-BIB23|cit23", "unstructured": "Australian Institute of Health and Welfare 2007 National Drug Strategy Household Survey: first results 2008 http://www.aihw.gov.au/publications/phe/ndshs07-fr/ndshs07-fr-no-questionnaire.pdf"}, {"key": "10.1111/j.1465-3362.2009.00092.x-BIB24|cit24", "doi-asserted-by": "crossref", "first-page": "271", "DOI": "10.2165/00002512-200623040-00001", "article-title": "Use of sleep-promoting medications in nursing home residents: risks versus benefits", "volume": "23", "author": "Conn", "year": "2006", "journal-title": "Drugs Aging"}, {"key": "10.1111/j.1465-3362.2009.00092.x-BIB25|cit25", "doi-asserted-by": "crossref", "first-page": "619", "DOI": "10.1016/j.clinthera.2006.04.011", "article-title": "Drugs and falls in community-dwelling older people: a national veterans study", "volume": "28", "author": "French", "year": "2006", "journal-title": "Clin Ther"}, {"key": "10.1111/j.1465-3362.2009.00092.x-BIB26|cit26", "doi-asserted-by": "crossref", "first-page": "1172", "DOI": "10.1093/gerona/62.10.1172", "article-title": "Medication as a risk factor for falls: critical systematic review", "volume": "62", "author": "Hartikainen", "year": "2007", "journal-title": "J Gerontol A Biol Sci Med Sci"}, {"key": "10.1111/j.1465-3362.2009.00092.x-BIB27|cit27", "doi-asserted-by": "crossref", "first-page": "61", "DOI": "10.2165/00002512-200825010-00007", "article-title": "Benzodiazepines and injurious falls in community dwelling elders", "volume": "25", "author": "Pariente", "year": "2008", "journal-title": "Drugs Aging"}, {"key": "10.1111/j.1465-3362.2009.00092.x-BIB28|cit28", "doi-asserted-by": "crossref", "first-page": "506", "DOI": "10.1177/0269881106059804", "article-title": "Sedation and memory: studies with a histamine H-1 receptor antagonist", "volume": "20", "author": "Turner", "year": "2006", "journal-title": "J Psychopharmacol"}, {"key": "10.1111/j.1465-3362.2009.00092.x-BIB29|cit29", "first-page": "24S", "article-title": "Current situation of substance-related problems in Thailand", "volume": "53", "author": "Assanangkornchai", "year": "2008", "journal-title": "J Psychiatr Assoc Thailand"}, {"key": "10.1111/j.1465-3362.2009.00092.x-BIB30|cit30", "doi-asserted-by": "crossref", "first-page": "2145", "DOI": "10.1080/10826080701205869", "article-title": "The use of mitragynine speciosa (\u2018Krathom\u2019), an addictive plant, in Thailand", "volume": "42", "author": "Assanangkornchai", "year": "2007", "journal-title": "Subst Use Misuse"}, {"key": "10.1111/j.1465-3362.2009.00092.x-BIB31|cit31", "doi-asserted-by": "crossref", "first-page": "222", "DOI": "10.1016/j.drugalcdep.2006.06.010", "article-title": "Nonmedical use of prescription drugs among a longitudinal sample of dependent and problem drinkers", "volume": "86", "author": "Matzger", "year": "2007", "journal-title": "Drug Alcohol Depend"}, {"key": "10.1111/j.1465-3362.2009.00092.x-BIB32|cit32", "author": "Edwards", "first-page": "573", "year": "2004", "volume-title": "Seminars in clinical psychopharmacology"}, {"key": "10.1111/j.1465-3362.2009.00092.x-BIB33|cit33", "author": "Edwards", "first-page": "601", "year": "2004", "volume-title": "Seminars in clinical psychopharmacology"}, {"key": "10.1111/j.1465-3362.2009.00092.x-BIB34|cit34", "doi-asserted-by": "crossref", "first-page": "87", "DOI": "10.1111/j.1360-0443.1986.tb00299.x", "article-title": "Patterns of benzodiazepine abuse and dependence", "volume": "81", "author": "Busto", "year": "1986", "journal-title": "Br J Addiction"}, {"issue": "2", "key": "10.1111/j.1465-3362.2009.00092.x-BIB35|cit35", "first-page": "S27", "article-title": "Benzodiazepine dependence and the problems of withdrawal", "volume": "66", "author": "Edwards", "year": "1990", "journal-title": "Postgrad Med J"}, {"key": "10.1111/j.1465-3362.2009.00092.x-BIB36|cit36", "doi-asserted-by": "crossref", "first-page": "235", "DOI": "10.1159/000468500", "article-title": "Benzodiazepine withdrawal phenomena", "volume": "16", "author": "Hallstrom", "year": "1981", "journal-title": "Int Pharmacopsychiatry"}, {"key": "10.1111/j.1465-3362.2009.00092.x-BIB37|cit37", "doi-asserted-by": "crossref", "first-page": "385", "DOI": "10.2165/00003495-198325040-00003", "article-title": "Benzodiazepine dependence. A review of the evidence", "volume": "25", "author": "Owen", "year": "1983", "journal-title": "Drugs"}, {"key": "10.1111/j.1465-3362.2009.00092.x-BIB38|cit38", "doi-asserted-by": "crossref", "first-page": "643", "DOI": "10.1136/bmj.283.6292.643", "article-title": "Withdrawal from long-term benzodiazepine treatment", "volume": "283", "author": "Petursson", "year": "1981", "journal-title": "Br Med J"}, {"key": "10.1111/j.1465-3362.2009.00092.x-BIB39|cit39", "first-page": "608", "article-title": "Long-term benzodiazepine therapy: benefits and risks", "volume": "20", "author": "Rickels", "year": "1984", "journal-title": "Psychopharmacol Bull"}, {"key": "10.1111/j.1465-3362.2009.00092.x-BIB40|cit40", "doi-asserted-by": "crossref", "first-page": "1041", "DOI": "10.1016/0002-9343(88)90309-9", "article-title": "Benzodiazepine withdrawal: overview and implications for the treatment of anxiety", "volume": "84", "author": "Roy-Byrne", "year": "1988", "journal-title": "Am J Med"}, {"key": "10.1111/j.1465-3362.2009.00092.x-BIB41|cit41", "doi-asserted-by": "crossref", "first-page": "1402", "DOI": "10.1016/S0140-6736(83)92355-3", "article-title": "Gradual withdrawal of diazepam after long-term therapy", "volume": "1", "author": "Tyrer", "year": "1983", "journal-title": "Lancet"}, {"key": "10.1111/j.1465-3362.2009.00092.x-BIB42|cit42", "author": "Office of Food and Drug Administrative Board", "year": "2005", "volume-title": "Supply of psychotropic drugs for use in medical practices between 2000-2004"}, {"key": "10.1111/j.1465-3362.2009.00092.x-BIB43|cit43", "doi-asserted-by": "crossref", "first-page": "1047", "DOI": "10.1016/S0140-6736(07)60464-4", "article-title": "Development of a rational scale to assess the harm of drugs of potential misuse", "volume": "369", "author": "Nutt", "year": "2007", "journal-title": "Lancet"}, {"key": "10.1111/j.1465-3362.2009.00092.x-BIB44|cit44", "unstructured": "Office of Narcotics Control Board Summary of the news on important seizures of drugs 2005 http://www1.oncb.go.th/document/c2-work19-1-04051101.htm"}, {"key": "10.1111/j.1465-3362.2009.00092.x-BIB45|cit45", "unstructured": "United States of America Food and Drug Administration FDA/US Customs import blitz exams reveal potentially dangerous import drug shipments FDA News 2003"}, {"key": "10.1111/j.1465-3362.2009.00092.x-BIB46|cit46", "unstructured": "The National Center on Addiction and Substance Abuse at Columbia University \u2018You've Got Drugs!\u2019 Prescription Drug Pushers on the Internet: 2006 Update CASA White Paper 2006"}, {"key": "10.1111/j.1465-3362.2009.00092.x-BIB47|cit47", "unstructured": "Central Narcotics Bureau S Largest Erimin-5 seizure this year! 2006 http://www.cnb.gov.sg/Newsroom/index.asp?name=TmV3c3Jvb20gLSBPcGVyYXRpb25z&year=MjAwNg&page=NjY4&type=Q3VycmVudA"}, {"key": "10.1111/j.1465-3362.2009.00092.x-BIB48|cit48", "doi-asserted-by": "crossref", "first-page": "117", "DOI": "10.1002/hup.470010210", "article-title": "Two hundred years of dependence on antianxiety drugs", "volume": "1", "author": "Olivieri", "year": "1986", "journal-title": "Hum Psychopharmacol"}], "container-title": ["Drug and Alcohol Review"], "language": "en", "link": [{"URL": "https://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1111%2Fj.1465-3362.2009.00092.x", "content-type": "unspecified", "content-version": "vor", "intended-application": "text-mining"}], "deposited": {"date-parts": [[2019, 3, 3]], "date-time": "2019-03-03T18:09:41Z", "timestamp": 1551636581000}, "score": 25.88068, "subtitle": ["Anxiolytic/hypnotic misuse in Thailand"], "issued": {"date-parts": [[2009, 7, 8]]}, "references-count": 48, "journal-issue": {"issue": "1"}, "URL": "http://dx.doi.org/10.1111/j.1465-3362.2009.00092.x", "relation": {"cites": []}, "ISSN": ["0959-5236"], "issn-type": [{"value": "0959-5236", "type": "print"}]}, {"indexed": {"date-parts": [[2019, 11, 18]], "date-time": "2019-11-18T19:31:11Z", "timestamp": 1574105471495}, "reference-count": 24, "publisher": "Elsevier BV", "issue": "4", "license": [{"URL": "https://www.elsevier.com/tdm/userlicense/1.0/", "start": {"date-parts": [[1999, 4, 1]], "date-time": "1999-04-01T00:00:00Z", "timestamp": 922924800000}, "delay-in-days": 0, "content-version": "tdm"}], "content-domain": {"domain": [], "crossmark-restriction": false}, "short-container-title": ["Pharmacology Biochemistry and Behavior"], "published-print": {"date-parts": [[1999, 4]]}, "DOI": "10.1016/s0091-3057(98)00209-3", "type": "journal-article", "created": {"date-parts": [[2002, 7, 25]], "date-time": "2002-07-25T23:21:23Z", "timestamp": 1027639283000}, "page": "689-694", "source": "Crossref", "is-referenced-by-count": 11, "title": ["Differences in Anxiolytic-Like Profile of Two Novel Nonbenzodiazepine BZ (\u03d6) Receptor Agonists on Defensive Behaviors of Mice"], "prefix": "10.1016", "volume": "62", "author": [{"given": "Guy", "family": "Griebel", "sequence": "first", "affiliation": []}, {"given": "Ghislaine", "family": "Perrault", "sequence": "additional", "affiliation": []}, {"given": "David J", "family": "Sanger", "sequence": "additional", "affiliation": []}], "member": "78", "container-title": ["Pharmacology Biochemistry and Behavior"], "language": "en", "link": [{"URL": "https://api.elsevier.com/content/article/PII:S0091305798002093?httpAccept=text/xml", "content-type": "text/xml", "content-version": "vor", "intended-application": "text-mining"}, {"URL": "https://api.elsevier.com/content/article/PII:S0091305798002093?httpAccept=text/plain", "content-type": "text/plain", "content-version": "vor", "intended-application": "text-mining"}], "deposited": {"date-parts": [[2019, 4, 18]], "date-time": "2019-04-18T05:30:21Z", "timestamp": 1555565421000}, "score": 25.40946, "issued": {"date-parts": [[1999, 4]]}, "references-count": 24, "journal-issue": {"published-print": {"date-parts": [[1999, 4]]}, "issue": "4"}, "alternative-id": ["S0091305798002093"], "URL": "http://dx.doi.org/10.1016/s0091-3057(98)00209-3", "ISSN": ["0091-3057"], "issn-type": [{"value": "0091-3057", "type": "print"}]}, {"indexed": {"date-parts": [[2019, 11, 23]], "date-time": "2019-11-23T08:34:59Z", "timestamp": 1574498099440}, "publisher-location": "Cambridge", "reference-count": 0, "publisher": "Royal Society of Chemistry", "isbn-type": [{"value": "9781849733618", "type": "print"}], "content-domain": {"domain": [], "crossmark-restriction": false}, "published-print": {"date-parts": [[2012]]}, "DOI": "10.1039/9781849734950-00079", "type": "book-chapter", "created": {"date-parts": [[2012, 8, 21]], "date-time": "2012-08-21T14:00:19Z", "timestamp": 1345557619000}, "page": "79-95", "source": "Crossref", "is-referenced-by-count": 0, "title": ["Chapter 5. Progress in Enhancing the Neurotrophic Effects of Natural FKBP Ligands"], "prefix": "10.1039", "author": [{"given": "Guy T.", "family": "Carter*", "sequence": "first", "affiliation": []}], "member": "292", "container-title": ["Drug Discovery", "Drug Discovery from Natural Products"], "deposited": {"date-parts": [[2019, 2, 26]], "date-time": "2019-02-26T11:06:26Z", "timestamp": 1551179186000}, "score": 25.07097, "issued": {"date-parts": [[2012]]}, "ISBN": ["9781849733618"], "references-count": 0, "URL": "http://dx.doi.org/10.1039/9781849734950-00079", "ISSN": ["2041-3211"], "issn-type": [{"value": "2041-3211", "type": "print"}]}, {"indexed": {"date-parts": [[2019, 11, 20]], "date-time": "2019-11-20T09:13:01Z", "timestamp": 1574241181493}, "reference-count": 0, "publisher": "Ovid Technologies (Wolters Kluwer Health)", "issue": "3", "content-domain": {"domain": [], "crossmark-restriction": false}, "short-container-title": ["NeuroReport"], "published-print": {"date-parts": [[1990, 11]]}, "DOI": "10.1097/00001756-199011000-00025", "type": "journal-article", "created": {"date-parts": [[2006, 10, 31]], "date-time": "2006-10-31T11:38:22Z", "timestamp": 1162294702000}, "page": "267", "source": "Crossref", "is-referenced-by-count": 23, "title": ["Anxiolytic and sedative effects of 5-HT1A ligands, 8-OH-DPAT and MDL 73005EF, in mice"], "prefix": "10.1097", "volume": "1", "author": [{"given": "Rene", "family": "Misslin", "sequence": "first", "affiliation": []}, {"given": "Guy", "family": "Griebel", "sequence": "additional", "affiliation": []}, {"given": "Martine", "family": "Saffroy-Spittler", "sequence": "additional", "affiliation": []}, {"given": "Elise", "family": "Vogel", "sequence": "additional", "affiliation": []}], "member": "276", "container-title": ["NeuroReport"], "language": "en", "deposited": {"date-parts": [[2018, 2, 8]], "date-time": "2018-02-08T19:30:02Z", "timestamp": 1518118202000}, "score": 24.729317, "subtitle": [""], "issued": {"date-parts": [[1990, 11]]}, "references-count": 0, "journal-issue": {"issue": "3"}, "URL": "http://dx.doi.org/10.1097/00001756-199011000-00025", "ISSN": ["0959-4965"], "issn-type": [{"value": "0959-4965", "type": "print"}]}, {"indexed": {"date-parts": [[2019, 12, 18]], "date-time": "2019-12-18T18:43:14Z", "timestamp": 1576694594580}, "reference-count": 132, "publisher": "Springer Science and Business Media LLC", "issue": "9", "license": [{"URL": "http://www.springer.com/tdm", "start": {"date-parts": [[2010, 9, 1]], "date-time": "2010-09-01T00:00:00Z", "timestamp": 1283299200000}, "delay-in-days": 0, "content-version": "tdm"}], "content-domain": {"domain": [], "crossmark-restriction": false}, "short-container-title": ["Nat Rev Drug Discov"], "published-print": {"date-parts": [[2010, 9]]}, "DOI": "10.1038/nrd3053", "type": "journal-article", "created": {"date-parts": [[2010, 9, 2]], "date-time": "2010-09-02T03:35:23Z", "timestamp": 1283398523000}, "page": "690-701", "source": "Crossref", "is-referenced-by-count": 275, "title": ["Emerging principles in protease-based drug discovery"], "prefix": "10.1038", "volume": "9", "author": [{"given": "Marcin", "family": "Drag", "sequence": "first", "affiliation": []}, {"given": "Guy S.", "family": "Salvesen", "sequence": "additional", "affiliation": []}], "member": "297", "reference": [{"key": "BFnrd3053_CR1", "doi-asserted-by": "crossref", "first-page": "785", "DOI": "10.1038/nrd2092", "volume": "5", "author": "B Turk", "year": "2006", "unstructured": "Turk, B. Targeting proteases: successes, failures and future prospects. Nature Rev. Drug Discov. 5, 785\u2013799 (2006).", "journal-title": "Nature Rev. Drug Discov."}, {"key": "BFnrd3053_CR2", "doi-asserted-by": "crossref", "first-page": "788", "DOI": "10.1096/fj.03-0093life", "volume": "17", "author": "CG Smith", "year": "2003", "unstructured": "Smith, C. G. & Vane, J. R. The discovery of captopril. FASEB J. 17, 788\u2013789 (2003).", "journal-title": "FASEB J."}, {"key": "BFnrd3053_CR3", "doi-asserted-by": "crossref", "first-page": "955", "DOI": "10.1038/nrd1907", "volume": "4", "author": "C Flexner", "year": "2005", "unstructured": "Flexner, C., Bate, G. & Kirkpatrick, P. Tipranavir. Nature Rev. Drug Discov. 4, 955\u2013956 (2005).", "journal-title": "Nature Rev. Drug Discov."}, {"key": "BFnrd3053_CR4", "doi-asserted-by": "crossref", "first-page": "353", "DOI": "10.1038/nrd2851", "volume": "8", "author": "I Melnikova", "year": "2009", "unstructured": "Melnikova, I. The anticoagulants market. Nature Rev. Drug Discov. 8, 353\u2013354 (2009).", "journal-title": "Nature Rev. Drug Discov."}, {"key": "BFnrd3053_CR5", "doi-asserted-by": "crossref", "first-page": "D320", "DOI": "10.1093/nar/gkm954", "volume": "36", "author": "ND Rawlings", "year": "2008", "unstructured": "Rawlings, N. D., Morton, F. R., Kok, C. Y., Kong, J. & Barrett, A. J. MEROPS: the peptidase database. Nucleic Acids Res. 36, D320\u2013D325 (2008).", "journal-title": "Nucleic Acids Res."}, {"key": "BFnrd3053_CR6", "doi-asserted-by": "crossref", "first-page": "1101", "DOI": "10.1038/nsmb.1668", "volume": "16", "author": "JC Timmer", "year": "2009", "unstructured": "Timmer, J. C. et al. Structural and kinetic determinants of protease substrates. Nature Struct. Mol. Biol. 16, 1101\u20131108 (2009).", "journal-title": "Nature Struct. Mol. Biol."}, {"key": "BFnrd3053_CR7", "doi-asserted-by": "crossref", "first-page": "799", "DOI": "10.1146/annurev.bi.44.070175.004055", "volume": "44", "author": "EW Davie", "year": "1975", "unstructured": "Davie, E. W. & Fujikawa, K. Basic mechanisms in blood coagulation. Annu. Rev. Biochem. 44, 799\u2013829 (1975).", "journal-title": "Annu. Rev. Biochem."}, {"key": "BFnrd3053_CR8", "doi-asserted-by": "crossref", "first-page": "50819", "DOI": "10.1074/jbc.X300009200", "volume": "278", "author": "EW Davie", "year": "2003", "unstructured": "Davie, E. W. A brief historical review of the waterfall/cascade of blood coagulation. J. Biol. Chem. 278, 50819\u201350832 (2003).", "journal-title": "J. Biol. Chem."}, {"key": "BFnrd3053_CR9", "first-page": "1230", "volume": "14", "author": "JC Peden Jr", "year": "1959", "unstructured": "Peden, J. C. Jr & Mc Farland, J. A. Use of the plasma thrombin time to assess the adequacy of in vivo neutralization of heparin: comparative studies following operations employing extracorporeal circulation. Blood 14, 1230\u20131236 (1959).", "journal-title": "Blood"}, {"key": "BFnrd3053_CR10", "doi-asserted-by": "crossref", "first-page": "95", "DOI": "10.1016/S0025-7125(16)32425-7", "volume": "56", "author": "B Bennett", "year": "1972", "unstructured": "Bennett, B. & Ratnoff, O. D. The normal coagulation mechanism. Med. Clin. North Am. 56, 95\u2013104 (1972).", "journal-title": "Med. Clin. North Am."}, {"key": "BFnrd3053_CR11", "doi-asserted-by": "crossref", "first-page": "1623", "DOI": "10.2174/1381612023394124", "volume": "8", "author": "B Turk", "year": "2002", "unstructured": "Turk, B., Turk, D. & Salvesen, G. S. Regulating cysteine protease activity: essential role of protease inhibitors as guardians and regulators. Curr. Pharm. Des 8, 1623\u20131637 (2002).", "journal-title": "Curr. Pharm. Des"}, {"key": "BFnrd3053_CR12", "doi-asserted-by": "crossref", "first-page": "375", "DOI": "10.1080/10409230290771546", "volume": "37", "author": "PE Van den Steen", "year": "2002", "unstructured": "Van den Steen, P. E. et al. Biochemistry and molecular biology of gelatinase B or matrix metalloproteinase-9 (MMP-9). Crit. Rev. Biochem. Mol. Biol. 37, 375\u2013536 (2002).", "journal-title": "Crit. Rev. Biochem. Mol. Biol."}, {"key": "BFnrd3053_CR13", "doi-asserted-by": "crossref", "first-page": "1202", "DOI": "10.1126/science.289.5482.1202", "volume": "289", "author": "GA McQuibban", "year": "2000", "unstructured": "McQuibban, G. A. et al. Inflammation dampened by gelatinase A cleavage of monocyte chemoattractant protein-3. Science 289, 1202\u20131206 (2000).", "journal-title": "Science"}, {"key": "BFnrd3053_CR14", "doi-asserted-by": "crossref", "first-page": "69", "DOI": "10.1007/s10555-006-7890-0", "volume": "25", "author": "CM Overall", "year": "2006", "unstructured": "Overall, C. M. & Dean, R. A. Degradomics: systems biology of the protease web. Pleiotropic roles of MMPs in cancer. Cancer Metastasis Rev. 25, 69\u201375 (2006).", "journal-title": "Cancer Metastasis Rev."}, {"key": "BFnrd3053_CR15", "doi-asserted-by": "crossref", "first-page": "11", "DOI": "10.1083/jcb.200807195", "volume": "185", "author": "F Sabeh", "year": "2009", "unstructured": "Sabeh, F., Shimizu-Hirota, R. & Weiss, S. J. Protease-dependent versus-independent cancer cell invasion programs: three-dimensional amoeboid movement revisited. J. Cell Biol. 185, 11\u201319 (2009).", "journal-title": "J. Cell Biol."}, {"key": "BFnrd3053_CR16", "doi-asserted-by": "crossref", "first-page": "113", "DOI": "10.1080/10409230701340019", "volume": "42", "author": "B Cauwe", "year": "2007", "unstructured": "Cauwe, B., Van den Steen, P. E. & Opdenakker, G. The biochemical, biological, and pathological kaleidoscope of cell surface substrates processed by matrix metalloproteinases. Crit. Rev. Biochem. Mol. Biol. 42, 113\u2013185 (2007).", "journal-title": "Crit. Rev. Biochem. Mol. Biol."}, {"key": "BFnrd3053_CR17", "doi-asserted-by": "crossref", "first-page": "3262", "DOI": "10.1182/blood-2002-12-3791", "volume": "102", "author": "K Wolf", "year": "2003", "unstructured": "Wolf, K., Muller, R., Borgmann, S., Brocker, E. B. & Friedl, P. Amoeboid shape change and contact guidance: T-lymphocyte crawling through fibrillar collagen is independent of matrix remodeling by MMPs and other proteases. Blood 102, 3262\u20133269 (2003).", "journal-title": "Blood"}, {"key": "BFnrd3053_CR18", "doi-asserted-by": "crossref", "first-page": "375", "DOI": "10.1016/S0092-8674(00)00130-6", "volume": "103", "author": "F Uhlmann", "year": "2000", "unstructured": "Uhlmann, F., Wernic, D., Poupart, M. A., Koonin, E. V. & Nasmyth, M. Cleavage of cohesin by the CD clan protease separin triggers anaphase in yeast. Cell 103, 375\u2013386 (2000).", "journal-title": "Cell"}, {"key": "BFnrd3053_CR19", "doi-asserted-by": "crossref", "first-page": "39", "DOI": "10.1016/j.ymeth.2005.07.005", "volume": "38", "author": "C Kraft", "year": "2006", "unstructured": "Kraft, C., Gmachl, M. & Peters, J. M. Methods to measure ubiquitin-dependent proteolysis mediated by the anaphase-promoting complex. Methods 38, 39\u201351 (2006).", "journal-title": "Methods"}, {"key": "BFnrd3053_CR20", "doi-asserted-by": "crossref", "first-page": "363", "DOI": "10.1146/annurev.biochem.78.082307.091526", "volume": "78", "author": "FE Reyes-Turcu", "year": "2009", "unstructured": "Reyes-Turcu, F. E., Ventii, K. H. & Wilkinson, K. D. Regulation and cellular roles of ubiquitin-specific deubiquitinating enzymes. Annu. Rev. Biochem. 78, 363\u2013397 (2009).", "journal-title": "Annu. Rev. Biochem."}, {"key": "BFnrd3053_CR21", "doi-asserted-by": "crossref", "first-page": "54", "DOI": "10.1111/j.1538-7836.2004.01021.x", "volume": "3", "author": "S Krishnaswamy", "year": "2005", "unstructured": "Krishnaswamy, S. Exosite-driven substrate specificity and function in coagulation. J. Thromb. Haemost. 3, 54\u201367 (2005).", "journal-title": "J. Thromb. Haemost."}, {"key": "BFnrd3053_CR22", "doi-asserted-by": "crossref", "first-page": "4", "DOI": "10.1111/j.1538-7836.2008.03220.x", "volume": "7", "author": "DC Rijken", "year": "2009", "unstructured": "Rijken, D. C. & Lijnen, H. R. New insights into the molecular mechanisms of the fibrinolytic system. J. Thromb. Haemost. 7, 4\u201313 (2009).", "journal-title": "J. Thromb. Haemost."}, {"key": "BFnrd3053_CR23", "doi-asserted-by": "crossref", "first-page": "480", "DOI": "10.1038/nrd2308", "volume": "6", "author": "J Hu", "year": "2007", "unstructured": "Hu, J., Van den Steen, P. E., Sang, Q. X. & Opdenakker, G. Matrix metalloproteinase inhibitors as therapy for inflammatory and vascular diseases. Nature Rev. Drug Discov. 6, 480\u2013498 (2007).", "journal-title": "Nature Rev. Drug Discov."}, {"key": "BFnrd3053_CR24", "doi-asserted-by": "crossref", "first-page": "2287", "DOI": "10.1185/03007990903152045", "volume": "25", "author": "R Dusing", "year": "2009", "unstructured": "Dusing, R. & Sellers, F. ACE inhibitors, angiotensin receptor blockers and direct renin inhibitors in combination: a review of their role after the ONTARGET trial. Curr. Med. Res. Opin. 25, 2287\u20132301 (2009).", "journal-title": "Curr. Med. Res. Opin."}, {"key": "BFnrd3053_CR25", "doi-asserted-by": "crossref", "first-page": "e27", "DOI": "10.1017/S1462399408000811", "volume": "10", "author": "HC Maisey", "year": "2008", "unstructured": "Maisey, H. C., Doran, K. S. & Nizet, V. Recent advances in understanding the molecular basis of group B Streptococcus virulence. Expert Rev. Mol. Med. 10, e27 (2008).", "journal-title": "Expert Rev. Mol. Med."}, {"key": "BFnrd3053_CR26", "doi-asserted-by": "crossref", "first-page": "989", "DOI": "10.1515/BC.2004.129", "volume": "385", "author": "T Imamura", "year": "2004", "unstructured": "Imamura, T., Potempa, J. & Travis, J. Activation of the kallikrein\u2013kinin system and release of new kinins through alternative cleavage of kininogens by microbial and human cell proteinases. Biol. Chem. 385, 989\u2013996 (2004).", "journal-title": "Biol. Chem."}, {"key": "BFnrd3053_CR27", "doi-asserted-by": "crossref", "first-page": "304", "DOI": "10.1081/CNV-120030218", "volume": "22", "author": "J Adams", "year": "2004", "unstructured": "Adams, J. & Kauffman, M. Development of the proteasome inhibitor Velcade (Bortezomib). Cancer Invest. 22, 304\u2013311 (2004).", "journal-title": "Cancer Invest."}, {"key": "BFnrd3053_CR28", "doi-asserted-by": "crossref", "first-page": "19", "DOI": "10.1016/S1535-6108(02)00024-7", "volume": "1", "author": "DR Green", "year": "2002", "unstructured": "Green, D. R. & Evan, G. I. A matter of life and death. Cancer Cell 1, 19\u201330 (2002).", "journal-title": "Cancer Cell"}, {"key": "BFnrd3053_CR29", "doi-asserted-by": "crossref", "first-page": "764", "DOI": "10.1038/nrc1949", "volume": "6", "author": "MM Mohamed", "year": "2006", "unstructured": "Mohamed, M. M. & Sloane, B. F. Cysteine cathepsins: multifunctional enzymes in cancer. Nature Rev. Cancer 6, 764\u2013775 (2006).", "journal-title": "Nature Rev. Cancer"}, {"key": "BFnrd3053_CR30", "doi-asserted-by": "crossref", "first-page": "25", "DOI": "10.1016/S1535-6108(03)00332-5", "volume": "5", "author": "AD Schimmer", "year": "2004", "unstructured": "Schimmer, A. D. et al. Small-molecule antagonists of apoptosis suppressor XIAP exhibit broad antitumor activity. Cancer Cell 5, 25\u201335 (2004).", "journal-title": "Cancer Cell"}, {"key": "BFnrd3053_CR31", "doi-asserted-by": "crossref", "first-page": "145", "DOI": "10.1002/jnr.10294", "volume": "69", "author": "CM Troy", "year": "2002", "unstructured": "Troy, C. M. & Salvesen, G. S. Caspases on the brain. J. Neurosci. Res. 69, 145\u2013150 (2002).", "journal-title": "J. Neurosci. Res."}, {"key": "BFnrd3053_CR32", "doi-asserted-by": "crossref", "first-page": "800", "DOI": "10.1038/nrc2228", "volume": "7", "author": "C Lopez-Otin", "year": "2007", "unstructured": "Lopez-Otin, C. & Matrisian, L. M. Emerging roles of proteases in tumour suppression. Nature Rev. Cancer 7, 800\u2013808 (2007).", "journal-title": "Nature Rev. Cancer"}, {"key": "BFnrd3053_CR33", "doi-asserted-by": "crossref", "first-page": "720", "DOI": "10.2174/156800908786733478", "volume": "8", "author": "X Lu", "year": "2008", "unstructured": "Lu, X., Lu, D., Scully, M. & Kakkar, V. ADAM proteins \u2014 therapeutic potential in cancer. Curr. Cancer Drug Targets. 8, 720\u2013732 (2008).", "journal-title": "Curr. Cancer Drug Targets."}, {"key": "BFnrd3053_CR34", "doi-asserted-by": "crossref", "first-page": "22", "DOI": "10.1016/j.tips.2007.10.011", "volume": "29", "author": "C Palermo", "year": "2008", "unstructured": "Palermo, C. & Joyce, J. A. Cysteine cathepsin proteases as pharmacological targets in cancer. Trends Pharmacol. Sci. 29, 22\u201328 (2008).", "journal-title": "Trends Pharmacol. Sci."}, {"key": "BFnrd3053_CR35", "doi-asserted-by": "crossref", "first-page": "1471", "DOI": "10.1016/j.jmb.2006.01.039", "volume": "357", "author": "C Mattos", "year": "2006", "unstructured": "Mattos, C. et al. Multiple solvent crystal structures: probing binding sites, plasticity and hydration. J. Mol. Biol. 357, 1471\u20131482 (2006).", "journal-title": "J. Mol. Biol."}, {"key": "BFnrd3053_CR36", "doi-asserted-by": "crossref", "first-page": "141", "DOI": "10.1021/jm0493156", "volume": "48", "author": "D Kim", "year": "2005", "unstructured": "Kim, D. et al. (2R)-4-oxo-4-[3-(trifluoromethyl)-5,6-dihydro[1,2,4]triazolo[4,3-\u03b1]pyrazin -7(8H)-yl]-1-(2,4,5-trifluorophenyl)butan-2-amine: a potent, orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes. J. Med. Chem. 48, 141\u2013151 (2005).", "journal-title": "J. Med. Chem."}, {"key": "BFnrd3053_CR37", "doi-asserted-by": "crossref", "first-page": "589", "DOI": "10.1021/jm070330v", "volume": "51", "author": "D Kim", "year": "2008", "unstructured": "Kim, D. et al. Discovery of potent and selective dipeptidyl peptidase IV inhibitors derived from \u03b2-aminoamides bearing subsituted triazolopiperazines. J. Med. Chem. 51, 589\u2013602 (2008).", "journal-title": "J. Med. Chem."}, {"key": "BFnrd3053_CR38", "doi-asserted-by": "crossref", "first-page": "525", "DOI": "10.1042/bj20021643", "volume": "371", "author": "B Leiting", "year": "2003", "unstructured": "Leiting, B. et al. Catalytic properties and inhibition of proline-specific dipeptidyl peptidases, II, IV and VII. Biochem. J. 371, 525\u2013532 (2003).", "journal-title": "Biochem. J."}, {"key": "BFnrd3053_CR39", "doi-asserted-by": "crossref", "first-page": "149", "DOI": "10.1016/S1074-5521(97)90258-1", "volume": "4", "author": "TA Rano", "year": "1997", "unstructured": "Rano, T. A. et al. A combinatorial approach for determining protease specificities: application to interleukin-1\u03b2 converting enzyme (ICE). Chem. Biol. 4, 149\u2013155 (1997).", "journal-title": "Chem. Biol."}, {"key": "BFnrd3053_CR40", "doi-asserted-by": "crossref", "first-page": "15521", "DOI": "10.1021/ja0547230", "volume": "127", "author": "WJ Wood", "year": "2005", "unstructured": "Wood, W. J., Patterson, A. W., Tsuruoka, H., Jain, R. K. & Ellman, J. A. Substrate activity screening: a fragment-based method for the rapid identification of nonpeptidic protease inhibitors. J. Am. Chem. Soc. 127, 15521\u201315527 (2005).", "journal-title": "J. Am. Chem. Soc."}, {"key": "BFnrd3053_CR41", "doi-asserted-by": "crossref", "first-page": "555", "DOI": "10.1021/cr9402081", "volume": "96", "author": "LA Thompson", "year": "1996", "unstructured": "Thompson, L. A. & Ellman, J. A. Synthesis and applications of small molecule libraries. Chem. Rev. 96, 555\u2013600 (1996).", "journal-title": "Chem. Rev."}, {"key": "BFnrd3053_CR42", "doi-asserted-by": "crossref", "first-page": "59", "DOI": "10.1007/978-1-60327-003-8_4", "volume": "539", "author": "EL Schneider", "year": "2009", "unstructured": "Schneider, E. L. & Craik, C. S. Positional scanning synthetic combinatorial libraries for substrate profiling. Methods Mol. Biol. 539, 59\u201378 (2009).", "journal-title": "Methods Mol. Biol."}, {"key": "BFnrd3053_CR43", "doi-asserted-by": "crossref", "first-page": "28766", "DOI": "10.1074/jbc.M500588200", "volume": "280", "author": "J Li", "year": "2005", "unstructured": "Li, J. et al. Functional profiling of recombinant NS3 proteases from all four serotypes of dengue virus using tetrapeptide and octapeptide substrate libraries. J. Biol. Chem. 280, 28766\u201328774 (2005).", "journal-title": "J. Biol. Chem."}, {"key": "BFnrd3053_CR44", "doi-asserted-by": "crossref", "first-page": "187", "DOI": "10.1038/72642", "volume": "18", "author": "BJ Backes", "year": "2000", "unstructured": "Backes, B. J., Harris, J. L., Leonetti, F., Craik, C. S. & Ellman, J. A. Synthesis of positional-scanning libraries of fluorogenic peptide substrates to define the extended substrate specificity of plasmin and thrombin. Nature Biotechnol. 18, 187\u2013193 (2000).", "journal-title": "Nature Biotechnol."}, {"key": "BFnrd3053_CR45", "doi-asserted-by": "crossref", "first-page": "7754", "DOI": "10.1073/pnas.140132697", "volume": "97", "author": "JL Harris", "year": "2000", "unstructured": "Harris, J. L. et al. Rapid and general profiling of protease specificity by using combinatorial fluorogenic substrate libraries. Proc. Natl Acad. Sci. USA 97, 7754\u20137759 (2000).", "journal-title": "Proc. Natl Acad. Sci. USA"}, {"key": "BFnrd3053_CR46", "doi-asserted-by": "crossref", "first-page": "367", "DOI": "10.1042/BJ20080779", "volume": "415", "author": "M Drag", "year": "2008", "unstructured": "Drag, M. et al. Positional-scanning fluorigenic substrate libraries reveal unexpected specificity determinants of DUBs (deubiquitinating enzymes). Biochem. J. 415, 367\u2013375 (2008).", "journal-title": "Biochem. J."}, {"key": "BFnrd3053_CR47", "doi-asserted-by": "crossref", "first-page": "938", "DOI": "10.1038/cdd.2008.23", "volume": "15", "author": "SJ Snipas", "year": "2008", "unstructured": "Snipas, S. J., Drag, M., Stennicke, H. R. & Salvesen, G. S. Activation mechanism and substrate specificity of the Drosophila initiator caspase DRONC. Cell Death Differ. 15, 938\u2013945 (2008).", "journal-title": "Cell Death Differ."}, {"key": "BFnrd3053_CR48", "doi-asserted-by": "crossref", "first-page": "12824", "DOI": "10.1074/jbc.M513331200", "volume": "281", "author": "Y Choe", "year": "2006", "unstructured": "Choe, Y. et al. Substrate profiling of cysteine proteases using a combinatorial peptide library identifies functionally unique specificities. J. Biol. Chem. 281, 12824\u201312832 (2006).", "journal-title": "J. Biol. Chem."}, {"key": "BFnrd3053_CR49", "doi-asserted-by": "crossref", "first-page": "6404", "DOI": "10.1021/ja710254m", "volume": "130", "author": "K Brak", "year": "2008", "unstructured": "Brak, K., Doyle, P. S., McKerrow, J. H. & Ellman, J. A. Identification of a new class of nonpeptidic inhibitors of cruzain. J. Am. Chem. Soc. 130, 6404\u20136410 (2008).", "journal-title": "J. Am. Chem. Soc."}, {"key": "BFnrd3053_CR50", "doi-asserted-by": "crossref", "first-page": "2693", "DOI": "10.1021/jm070111+", "volume": "50", "author": "H Inagaki", "year": "2007", "unstructured": "Inagaki, H. et al. Characterization and optimization of selective, nonpeptidic inhibitors of cathepsin S with an unprecedented binding mode. J. Med. Chem. 50, 2693\u20132699 (2007).", "journal-title": "J. Med. Chem."}, {"key": "BFnrd3053_CR51", "doi-asserted-by": "crossref", "first-page": "799", "DOI": "10.1038/nrd2661", "volume": "7", "author": "I Melnikova", "year": "2008", "unstructured": "Melnikova, I. Hepatitis C therapies. Nature Rev. Drug Discov. 7, 799\u2013800 (2008).", "journal-title": "Nature Rev. Drug Discov."}, {"key": "BFnrd3053_CR52", "doi-asserted-by": "crossref", "first-page": "535", "DOI": "10.1016/j.bcp.2005.04.047", "volume": "70", "author": "J Hu", "year": "2005", "unstructured": "Hu, J., Van den Steen, P. E., Dillen, C. & Opdenakker, G. Targeting neutrophil collagenase/matrix metalloproteinase-8 and gelatinase B/matrix metalloproteinase-9 with a peptidomimetic inhibitor protects against endotoxin shock. Biochem. Pharmacol. 70, 535\u2013544 (2005).", "journal-title": "Biochem. Pharmacol."}, {"key": "BFnrd3053_CR53", "doi-asserted-by": "crossref", "first-page": "2116", "DOI": "10.1021/ac048631p", "volume": "77", "author": "J Hu", "year": "2005", "unstructured": "Hu, J., Fiten, P., Van den Steen, P. E., Chaltin, P. & Opdenakker, G. Simulation of evolution-selected propeptide by high-throughput selection of a peptidomimetic inhibitor on a capillary DNA sequencer platform. Anal. Chem. 77, 2116\u20132124 (2005).", "journal-title": "Anal. Chem."}, {"key": "BFnrd3053_CR54", "doi-asserted-by": "crossref", "first-page": "2366", "DOI": "10.1002/elps.200800698", "volume": "30", "author": "H Piccard", "year": "2009", "unstructured": "Piccard, H. et al. \u201cReverse degradomics\u201d, monitoring of proteolytic trimming by multi-CE and confocal detection of fluorescent substrates and reaction products. Electrophoresis 30, 2366\u20132377 (2009).", "journal-title": "Electrophoresis"}, {"key": "BFnrd3053_CR55", "doi-asserted-by": "crossref", "first-page": "661", "DOI": "10.1038/90273", "volume": "19", "author": "BE Turk", "year": "2001", "unstructured": "Turk, B. E., Huang, L. L., Piro, E. T. & Cantley, L. C. Determination of protease cleavage site motifs using mixture-based oriented peptide libraries. Nature Biotechnol. 19, 661\u2013667 (2001).", "journal-title": "Nature Biotechnol."}, {"key": "BFnrd3053_CR56", "doi-asserted-by": "crossref", "first-page": "3863", "DOI": "10.1021/bi052252o", "volume": "45", "author": "BE Turk", "year": "2006", "unstructured": "Turk, B. E. et al. MMP-20 is predominately a tooth-specific enzyme with a deep catalytic pocket that hydrolyzes type V collagen. Biochemistry 45, 3863\u20133874 (2006).", "journal-title": "Biochemistry"}, {"key": "BFnrd3053_CR57", "doi-asserted-by": "crossref", "first-page": "60", "DOI": "10.1038/nsmb708", "volume": "11", "author": "BE Turk", "year": "2004", "unstructured": "Turk, B. E. et al. The structural basis for substrate and inhibitor selectivity of the anthrax lethal factor. Nature Struct. Mol. Biol. 11, 60\u201366 (2004).", "journal-title": "Nature Struct. Mol. Biol."}, {"key": "BFnrd3053_CR58", "doi-asserted-by": "crossref", "first-page": "406", "DOI": "10.1002/anie.200702811", "volume": "47", "author": "A Watzke", "year": "2008", "unstructured": "Watzke, A. et al. Selective activity-based probes for cysteine cathepsins. Angew. Chem. Int. Edn Engl. 47, 406\u2013409 (2008).", "journal-title": "Angew. Chem. Int. Edn Engl."}, {"key": "BFnrd3053_CR59", "doi-asserted-by": "crossref", "first-page": "1113", "DOI": "10.1126/science.8493554", "volume": "260", "author": "DJ Matthews", "year": "1993", "unstructured": "Matthews, D. J. & Wells, J. A. Substrate phage: selection of protease substrates by monovalent phage display. Science 260, 1113\u20131117 (1993).", "journal-title": "Science"}, {"key": "BFnrd3053_CR60", "doi-asserted-by": "crossref", "first-page": "38424", "DOI": "10.1074/jbc.M505933200", "volume": "280", "author": "M Hansen", "year": "2005", "unstructured": "Hansen, M. et al. A urokinase-type plasminogen activator-inhibiting cyclic peptide with an unusual P2 residue and an extended protease binding surface demonstrates new modalities for enzyme inhibition. J. Biol. Chem. 280, 38424\u201338437 (2005).", "journal-title": "J. Biol. Chem."}, {"key": "BFnrd3053_CR61", "doi-asserted-by": "crossref", "first-page": "834", "DOI": "10.1002/cbic.200500427", "volume": "7", "author": "MD Scholle", "year": "2006", "unstructured": "Scholle, M. D. et al. Mapping protease substrates by using a biotinylated phage substrate library. Chembiochem 7, 834\u2013838 (2006).", "journal-title": "Chembiochem"}, {"key": "BFnrd3053_CR62", "doi-asserted-by": "crossref", "first-page": "66", "DOI": "10.1038/sj.cdd.4402059", "volume": "14", "author": "JC Timmer", "year": "2007", "unstructured": "Timmer, J. C. & Salvesen, G. S. Caspase substrates. Cell Death Differ. 14, 66\u201372 (2007).", "journal-title": "Cell Death Differ."}, {"key": "BFnrd3053_CR63", "doi-asserted-by": "crossref", "first-page": "1284", "DOI": "10.1002/pmic.200900418", "volume": "10", "author": "F Impens", "year": "2010", "unstructured": "Impens, F. et al. MS-driven protease substrate degradomics. Proteomics 10, 1284\u20131296 (2010).", "journal-title": "Proteomics"}, {"key": "BFnrd3053_CR64", "doi-asserted-by": "crossref", "first-page": "14548", "DOI": "10.1073/pnas.0604101103", "volume": "103", "author": "X Chen", "year": "2006", "unstructured": "Chen, X. et al. Inhibitors of Plasmodium falciparum methionine aminopeptidase 1b possess antimalarial activity. Proc. Natl Acad. Sci. USA 103, 14548\u201314553 (2006).", "journal-title": "Proc. Natl Acad. Sci. USA"}, {"key": "BFnrd3053_CR65", "doi-asserted-by": "crossref", "first-page": "738", "DOI": "10.1038/nrd2606", "volume": "7", "author": "M Pellecchia", "year": "2008", "unstructured": "Pellecchia, M. et al. Perspectives on NMR in drug discovery: a technique comes of age. Nature Rev. Drug Discov. 7, 738\u2013745 (2008).", "journal-title": "Nature Rev. Drug Discov."}, {"key": "BFnrd3053_CR66", "doi-asserted-by": "crossref", "first-page": "308", "DOI": "10.1038/nbt786", "volume": "21", "author": "DA Erlanson", "year": "2003", "unstructured": "Erlanson, D. A. et al. In situ assembly of enzyme inhibitors using extended tethering. Nature Biotechnol. 21, 308\u2013314 (2003).", "journal-title": "Nature Biotechnol."}, {"key": "BFnrd3053_CR67", "doi-asserted-by": "crossref", "first-page": "988", "DOI": "10.1038/sj.embor.7400795", "volume": "7", "author": "BP Eckelman", "year": "2006", "unstructured": "Eckelman, B. P., Salvesen, G. S. & Scott, F. L. Human inhibitor of apoptosis proteins: why XIAP is the black sheep of the family. EMBO Rep. 7, 988\u2013994 (2006).", "journal-title": "EMBO Rep."}, {"key": "BFnrd3053_CR68", "doi-asserted-by": "crossref", "first-page": "277", "DOI": "10.1126/science.2374926", "volume": "249", "author": "TJ Rydel", "year": "1990", "unstructured": "Rydel, T. J. et al. The structure of a complex of recombinant hirudin and human \u03b1-thrombin. Science 249, 277\u2013280 (1990).", "journal-title": "Science"}, {"key": "BFnrd3053_CR69", "doi-asserted-by": "crossref", "first-page": "1255", "DOI": "10.2174/1568026043388015", "volume": "4", "author": "CK Wada", "year": "2004", "unstructured": "Wada, C. K. The evolution of the matrix metalloproteinase inhibitor drug discovery program at Abbott laboratories. Curr. Top. Med. Chem. 4, 1255\u20131267 (2004).", "journal-title": "Curr. Top. Med. Chem."}, {"key": "BFnrd3053_CR70", "first-page": "7861", "volume": "63", "author": "J Wang", "year": "2003", "unstructured": "Wang, J. et al. Tumor suppression by a rationally designed reversible inhibitor of methionine aminopeptidase-2. Cancer Res. 63, 7861\u20137869 (2003).", "journal-title": "Cancer Res."}, {"key": "BFnrd3053_CR71", "doi-asserted-by": "crossref", "first-page": "9499", "DOI": "10.1073/pnas.0502733102", "volume": "102", "author": "M Forino", "year": "2005", "unstructured": "Forino, M. et al. Efficient synthetic inhibitors of anthrax lethal factor. Proc. Natl Acad. Sci. USA 102, 9499\u20139504 (2005).", "journal-title": "Proc. Natl Acad. Sci. USA"}, {"key": "BFnrd3053_CR72", "doi-asserted-by": "crossref", "first-page": "12461", "DOI": "10.1073/pnas.0404781101", "volume": "101", "author": "JA Hardy", "year": "2004", "unstructured": "Hardy, J. A., Lam, J., Nguyen, J. T., O'Brien, T. & Wells, J. A. Discovery of an allosteric site in the caspases. Proc. Natl Acad. Sci. USA 101, 12461\u201312466 (2004).", "journal-title": "Proc. Natl Acad. Sci. USA"}, {"key": "BFnrd3053_CR73", "doi-asserted-by": "crossref", "first-page": "761", "DOI": "10.1038/sj.clpt.6100167", "volume": "81", "author": "GA Herman", "year": "2007", "unstructured": "Herman, G. A., Stein, P. P., Thornberry, N. A. & Wagner, J. A. Dipeptidyl peptidase-4 inhibitors for the treatment of type 2 diabetes: focus on sitagliptin. Clin. Pharmacol. Ther. 81, 761\u2013767 (2007).", "journal-title": "Clin. Pharmacol. Ther."}, {"key": "BFnrd3053_CR74", "doi-asserted-by": "crossref", "first-page": "639", "DOI": "10.1016/S0968-0896(99)00008-5", "volume": "7", "author": "JH McKerrow", "year": "1999", "unstructured": "McKerrow, J. H., Engel, J. C. & Caffrey, C. R. Cysteine protease inhibitors as chemotherapy for parasitic infections. Bioorg Med. Chem. 7, 639\u2013644 (1999).", "journal-title": "Bioorg Med. Chem."}, {"key": "BFnrd3053_CR75", "doi-asserted-by": "crossref", "first-page": "1293", "DOI": "10.1016/j.str.2006.06.012", "volume": "14", "author": "M Renatus", "year": "2006", "unstructured": "Renatus, M. et al. Structural basis of ubiquitin recognition by the deubiquitinating protease USP2. Structure 14, 1293\u20131302 (2006).", "journal-title": "Structure"}, {"key": "BFnrd3053_CR76", "doi-asserted-by": "crossref", "first-page": "26217", "DOI": "10.1074/jbc.M702444200", "volume": "282", "author": "J Mikolajczyk", "year": "2007", "unstructured": "Mikolajczyk, J. et al. Small ubiquitin-related modifier (SUMO)-specific proteases: profiling the specificities and activities of human SENPs. J. Biol. Chem. 282, 26217\u201326224 (2007).", "journal-title": "J. Biol. Chem."}, {"key": "BFnrd3053_CR77", "doi-asserted-by": "crossref", "first-page": "461", "DOI": "10.1042/BJ20070940", "volume": "409", "author": "M Drag", "year": "2008", "unstructured": "Drag, M., Mikolajczyk, J., Krishnakumar, I. M., Huang, Z. & Salvesen, G. S. Activity profiling of human deSUMOylating enzymes (SENPs) with synthetic substrates suggests an unexpected specificity of two newly characterized members of the family. Biochem. J. 409, 461\u2013469 (2008).", "journal-title": "Biochem. J."}, {"key": "BFnrd3053_CR78", "doi-asserted-by": "crossref", "first-page": "1197", "DOI": "10.1016/j.cell.2006.02.038", "volume": "124", "author": "FE Reyes-Turcu", "year": "2006", "unstructured": "Reyes-Turcu, F. E. et al. The ubiquitin binding domain ZnF UBP recognizes the C-terminal diglycine motif of unanchored ubiquitin. Cell 124, 1197\u20131208 (2006).", "journal-title": "Cell"}, {"key": "BFnrd3053_CR79", "doi-asserted-by": "crossref", "first-page": "11567", "DOI": "10.1021/bi050932l", "volume": "44", "author": "MG Kornacker", "year": "2005", "unstructured": "Kornacker, M. G. et al. An inhibitor binding pocket distinct from the catalytic active site on human \u03b2-APP cleaving enzyme. Biochemistry 44, 11567\u201311573 (2005).", "journal-title": "Biochemistry"}, {"key": "BFnrd3053_CR80", "doi-asserted-by": "crossref", "first-page": "640", "DOI": "10.1038/nchembio.192", "volume": "5", "author": "T Shahian", "year": "2009", "unstructured": "Shahian, T. et al. Inhibition of a viral enzyme by a small-molecule dimer disruptor. Nat. Chem. Biol. 5, 640\u2013646 (2009).", "journal-title": "Nat. Chem. Biol."}, {"key": "BFnrd3053_CR81", "doi-asserted-by": "crossref", "first-page": "625", "DOI": "10.1016/j.str.2007.03.014", "volume": "15", "author": "A Schweizer", "year": "2007", "unstructured": "Schweizer, A. et al. Inhibition of caspase-2 by a designed ankyrin repeat protein: specificity, structure, and inhibition mechanism. Structure 15, 625\u2013636 (2007).", "journal-title": "Structure"}, {"key": "BFnrd3053_CR82", "doi-asserted-by": "crossref", "first-page": "17907", "DOI": "10.1074/jbc.272.29.17907", "volume": "272", "author": "NA Thornberry", "year": "1997", "unstructured": "Thornberry, N. A. et al. A combinatorial approach defines specificities of members of the caspase family and granzyme B. Functional relationships established for key mediators of apoptosis. J. Biol. Chem. 272, 17907\u201317911 (1997).", "journal-title": "J. Biol. Chem."}, {"key": "BFnrd3053_CR83", "doi-asserted-by": "crossref", "first-page": "33293", "DOI": "10.1074/jbc.R100016200", "volume": "276", "author": "GA Silverman", "year": "2001", "unstructured": "Silverman, G. A. et al. The serpins are an expanding superfamily of structurally similar but funtionally diverse proteins: evolution, mechanism of inhibition, novel functions, and a revised nomenclature. J. Biol. Chem. 276, 33293\u201333296 (2001).", "journal-title": "J. Biol. Chem."}, {"key": "BFnrd3053_CR84", "doi-asserted-by": "crossref", "first-page": "229", "DOI": "10.1183/09031936.00159606", "volume": "29", "author": "S Brennan", "year": "2007", "unstructured": "Brennan, S. Revisiting \u03b11-antitrypsin therapy in cystic fibrosis: can it still offer promise? Eur. Respir. J. 29, 229\u2013230 (2007).", "journal-title": "Eur. Respir. J."}, {"key": "BFnrd3053_CR85", "doi-asserted-by": "crossref", "first-page": "1063", "DOI": "10.1038/nbt860", "volume": "21", "author": "AA Stoop", "year": "2003", "unstructured": "Stoop, A. A. & Craik, C. S. Engineering of a macromolecular scaffold to develop specific protease inhibitors. Nature Biotechnol. 21, 1063\u20131068 (2003).", "journal-title": "Nature Biotechnol."}, {"key": "BFnrd3053_CR86", "doi-asserted-by": "crossref", "first-page": "25411", "DOI": "10.1074/jbc.270.43.25411", "volume": "270", "author": "MS Dennis", "year": "1995", "unstructured": "Dennis, M. S., Herzka, A. & Lazarus, R. A. Potent and selective Kunitz domain inhibitors of plasma kallikrein designed by phage display. J. Biol. Chem. 270, 25411\u201325417 (1995).", "journal-title": "J. Biol. Chem."}, {"key": "BFnrd3053_CR87", "doi-asserted-by": "crossref", "first-page": "1077", "DOI": "10.1517/13543784.15.9.1077", "volume": "15", "author": "JH Levy", "year": "2006", "unstructured": "Levy, J. H. & O'Donnell, P. S. The therapeutic potential of a kallikrein inhibitor for treating hereditary angioedema. Expert Opin. Investig. Drugs 15, 1077\u20131090 (2006).", "journal-title": "Expert Opin. Investig. Drugs"}, {"key": "BFnrd3053_CR88", "doi-asserted-by": "crossref", "first-page": "3611", "DOI": "10.1158/0008-5472.CAN-05-2983", "volume": "66", "author": "JA Xuan", "year": "2006", "unstructured": "Xuan, J. A. et al. Antibodies neutralizing hepsin protease activity do not impact cell growth but inhibit invasion of prostate and ovarian tumor cells in culture. Cancer Res. 66, 3611\u20133619 (2006).", "journal-title": "Cancer Res."}, {"key": "BFnrd3053_CR89", "doi-asserted-by": "crossref", "first-page": "892", "DOI": "10.1021/bi026878f", "volume": "42", "author": "J Sun", "year": "2003", "unstructured": "Sun, J., Pons, J. & Craik, C. S. Potent and selective inhibition of membrane-type serine protease 1 by human single-chain antibodies. Biochemistry 42, 892\u2013900 (2003).", "journal-title": "Biochemistry"}, {"key": "BFnrd3053_CR90", "doi-asserted-by": "crossref", "first-page": "1517", "DOI": "10.1158/0008-5472.CAN-08-3255", "volume": "69", "author": "L Devy", "year": "2009", "unstructured": "Devy, L. et al. Selective inhibition of matrix metalloproteinase-14 blocks tumor growth, invasion, and angiogenesis. Cancer Res. 69, 1517\u20131526 (2009).", "journal-title": "Cancer Res."}, {"key": "BFnrd3053_CR91", "doi-asserted-by": "crossref", "first-page": "2275", "DOI": "10.2174/0929867043364568", "volume": "11", "author": "RA Lazarus", "year": "2004", "unstructured": "Lazarus, R. A., Olivero, A. G., Eigenbrot, C. & Kirchhofer, D. Inhibitors of tissue factor. Factor VIIa for anticoagulant therapy. Curr. Med. Chem. 11, 2275\u20132290 (2004).", "journal-title": "Curr. Med. Chem."}, {"key": "BFnrd3053_CR92", "doi-asserted-by": "crossref", "first-page": "527", "DOI": "10.1042/BJ20091645", "volume": "429", "author": "MW Chang", "year": "2010", "unstructured": "Chang, M.W. et al. Identification of broad-based HIV-1 protease inhibitors from combinatorial libraries. Biochem J. 429, 527\u2013532 (2010).", "journal-title": "Biochem J."}, {"key": "BFnrd3053_CR93", "doi-asserted-by": "crossref", "first-page": "621", "DOI": "10.1093/bioinformatics/btp036", "volume": "25", "author": "R Brenke", "year": "2009", "unstructured": "Brenke, R. et al. Fragment-based identification of druggable 'hot spots' of proteins using Fourier domain correlation techniques. Bioinformatics 25, 621\u2013627 (2009).", "journal-title": "Bioinformatics"}, {"key": "BFnrd3053_CR94", "doi-asserted-by": "crossref", "first-page": "622", "DOI": "10.1016/j.drudis.2007.06.008", "volume": "12", "author": "MA Bogoyevitch", "year": "2007", "unstructured": "Bogoyevitch, M. A. & Fairlie, D. P. A new paradigm for protein kinase inhibition: blocking phosphorylation without directly targeting ATP binding. Drug Discov. Today 12, 622\u2013633 (2007).", "journal-title": "Drug Discov. Today"}, {"key": "BFnrd3053_CR95", "doi-asserted-by": "crossref", "first-page": "41", "DOI": "10.1038/nrd2760", "volume": "8", "author": "PJ Conn", "year": "2009", "unstructured": "Conn, P. J., Christopoulos, A. & Lindsley, C. W. Allosteric modulators of GPCRs: a novel approach for the treatment of CNS disorders. Nature Rev. Drug Discov. 8, 41\u201354 (2009).", "journal-title": "Nature Rev. Drug Discov."}, {"key": "BFnrd3053_CR96", "doi-asserted-by": "crossref", "first-page": "474", "DOI": "10.1038/nchembio.98", "volume": "4", "author": "NM Goodey", "year": "2008", "unstructured": "Goodey, N. M. & Benkovic, S. J. Allosteric regulation and catalysis emerge via a common route. Nat. Chem. Biol. 4, 474\u2013482 (2008).", "journal-title": "Nat. Chem. Biol."}, {"key": "BFnrd3053_CR97", "doi-asserted-by": "crossref", "first-page": "1175", "DOI": "10.1038/nm782", "volume": "8", "author": "S Falati", "year": "2002", "unstructured": "Falati, S., Gross, P., Merrill-Skoloff, G., Furie, B. C. & Furie, B. Real-time in vivo imaging of platelets, tissue factor and fibrin during arterial thrombus formation in the mouse. Nature Med. 8, 1175\u20131181 (2002).", "journal-title": "Nature Med."}, {"key": "BFnrd3053_CR98", "doi-asserted-by": "crossref", "first-page": "139", "DOI": "10.1023/B:THRO.0000037670.42776.cd", "volume": "17", "author": "A Girolami", "year": "2004", "unstructured": "Girolami, A., Randi, M. L., Gavasso, S., Lombardi, A. M. & Spiezia, F. The occasional venous thromboses seen in patients with severe (homozygous) FXII deficiency are probably due to associated risk factors: a study of prevalence in 21 patients and review of the literature. J. Thromb. Thrombolysis 17, 139\u2013143 (2004).", "journal-title": "J. Thromb. Thrombolysis"}, {"key": "BFnrd3053_CR99", "doi-asserted-by": "crossref", "first-page": "20514", "DOI": "10.1074/jbc.M000464200", "volume": "275", "author": "FA Baglia", "year": "2000", "unstructured": "Baglia, F. A. & Walsh, P. N. Thrombin-mediated feedback activation of factor XI on the activated platelet surface is preferred over contact activation by factor XIIa or factor XIa. J. Biol. Chem. 275, 20514\u201320519 (2000).", "journal-title": "J. Biol. Chem."}, {"key": "BFnrd3053_CR100", "doi-asserted-by": "crossref", "first-page": "733", "DOI": "10.1586/14779072.5.4.733", "volume": "5", "author": "D Gailani", "year": "2007", "unstructured": "Renn\u00e9, T. & Gailani, D. Role of factor XII in hemostasis and thrombosis: clinical implications. Expert Rev. Cardiovasc. Ther. 5, 733\u2013741 (2007).", "journal-title": "Expert Rev. Cardiovasc. Ther."}, {"key": "BFnrd3053_CR101", "doi-asserted-by": "crossref", "first-page": "387", "DOI": "10.1016/j.biochi.2007.07.023", "volume": "90", "author": "RC Duncan", "year": "2008", "unstructured": "Duncan, R. C., Wijeyewickrema, L. C. & Pike, R. N. The initiating proteases of the complement system: controlling the cleavage. Biochimie 90, 387\u2013395 (2008).", "journal-title": "Biochimie"}, {"key": "BFnrd3053_CR102", "doi-asserted-by": "crossref", "first-page": "201", "DOI": "10.1042/BJ20041142", "volume": "384", "author": "P Fuentes-Prior", "year": "2004", "unstructured": "Fuentes-Prior, P. & Salvesen, G. S. The protein structures that shape caspase activity, specificity, activation and inhibition. Biochem. J. 384, 201\u2013232 (2004).", "journal-title": "Biochem. J."}, {"key": "BFnrd3053_CR103", "doi-asserted-by": "crossref", "first-page": "348", "DOI": "10.1038/ni.1714", "volume": "10", "author": "NS Wilson", "year": "2009", "unstructured": "Wilson, N. S., Dixit, V. & Ashkenazi, A. Death receptor signal transducers: nodes of coordination in immune signaling networks. Nature Immunol. 10, 348\u2013355 (2009).", "journal-title": "Nature Immunol."}, {"key": "BFnrd3053_CR104", "doi-asserted-by": "crossref", "first-page": "405", "DOI": "10.1038/nrm2153", "volume": "5", "author": "SJ Riedl", "year": "2007", "unstructured": "Riedl, S. J. & Salvesen, G. S. The apoptosome: signalling platform of cell death. Nature Rev. Mol. Cell Biol. 5, 405\u2013413 (2007).", "journal-title": "Nature Rev. Mol. Cell Biol."}, {"key": "BFnrd3053_CR105", "doi-asserted-by": "crossref", "first-page": "5055", "DOI": "10.1073/pnas.081026598", "volume": "98", "author": "EK LeMosy", "year": "2001", "unstructured": "LeMosy, E. K., Tan, Y. Q. & Hashimoto, C. Activation of a protease cascade involved in patterning the Drosophila embryo. Proc. Natl Acad. Sci. USA 98, 5055\u20135060 (2001).", "journal-title": "Proc. Natl Acad. Sci. USA"}, {"key": "BFnrd3053_CR106", "doi-asserted-by": "crossref", "first-page": "2387", "DOI": "10.1126/science.1067100", "volume": "295", "author": "LM Coussens", "year": "2002", "unstructured": "Coussens, L. M., Fingleton, B. & Matrisian, L. M. Matrix metalloproteinase inhibitors and cancer: trials and tribulations. Science 295, 2387\u20132392 (2002).", "journal-title": "Science"}, {"key": "BFnrd3053_CR107", "doi-asserted-by": "crossref", "first-page": "941", "DOI": "10.1038/sj.bjc.6603043", "volume": "94", "author": "CM Overall", "year": "2006", "unstructured": "Overall, C. M. & Kleifeld, O. Towards third generation matrix metalloproteinase inhibitors for cancer therapy. Br. J. Cancer 94, 941\u2013946 (2006).", "journal-title": "Br. J. Cancer"}, {"key": "BFnrd3053_CR108", "doi-asserted-by": "crossref", "first-page": "399", "DOI": "10.1038/nrd2550", "volume": "7", "author": "C Jensen", "year": "2008", "unstructured": "Jensen, C., Herold, P. & Brunner, H. R. Aliskiren: the first renin inhibitor for clinical treatment. Nature Rev. Drug Discov. 7, 399\u2013410 (2008).", "journal-title": "Nature Rev. Drug Discov."}, {"key": "BFnrd3053_CR109", "doi-asserted-by": "crossref", "first-page": "555", "DOI": "10.1038/299555a0", "volume": "299", "author": "M Szelke", "year": "1982", "unstructured": "Szelke, M. et al. Potent new inhibitors of human renin. Nature 299, 555\u2013557 (1982).", "journal-title": "Nature"}, {"key": "BFnrd3053_CR110", "first-page": "260", "volume": "43", "author": "JP Clozel", "year": "1993", "unstructured": "Clozel, J. P. & Fischli, W. Discovery of remikiren as the first orally active renin inhibitor. Arzneimittelforschung 43, 260\u2013262 (1993).", "journal-title": "Arzneimittelforschung"}, {"key": "BFnrd3053_CR111", "doi-asserted-by": "crossref", "first-page": "1205", "DOI": "10.2147/VHRM.S3364", "volume": "4", "author": "KK Sureshkumar", "year": "2008", "unstructured": "Sureshkumar, K. K. Renin inhibition with aliskiren in hypertension: focus on aliskiren/hydrochlorothiazide combination therapy. Vasc. Health Risk Manag. 4, 1205\u20131220 (2008).", "journal-title": "Vasc. Health Risk Manag."}, {"key": "BFnrd3053_CR112", "doi-asserted-by": "crossref", "first-page": "557", "DOI": "10.2174/156802607780091028", "volume": "7", "author": "NA Thornberry", "year": "2007", "unstructured": "Thornberry, N. A. & Weber, A. E. Discovery of Januvia (sitagliptin), a selective dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes. Curr. Top. Med. Chem. 7, 557\u2013568 (2007).", "journal-title": "Curr. Top. Med. Chem."}, {"key": "BFnrd3053_CR113", "doi-asserted-by": "crossref", "first-page": "4135", "DOI": "10.1021/jm030628v", "volume": "47", "author": "AE Weber", "year": "2004", "unstructured": "Weber, A. E. Dipeptidyl peptidase IV inhibitors for the treatment of diabetes. J. Med. Chem. 47, 4135\u20134141 (2004).", "journal-title": "J. Med. Chem."}, {"key": "BFnrd3053_CR114", "doi-asserted-by": "crossref", "first-page": "837", "DOI": "10.1016/j.chembiol.2003.08.010", "volume": "10", "author": "Y Liu", "year": "2003", "unstructured": "Liu, Y. et al. Discovery of inhibitors that elucidate the role of UCH-L1 activity in the H1299 lung cancer cell line. Chem. Biol. 10, 837\u2013846 (2003).", "journal-title": "Chem. Biol."}, {"key": "BFnrd3053_CR115", "doi-asserted-by": "crossref", "first-page": "2069", "DOI": "10.1074/jbc.M609251200", "volume": "282", "author": "CM Stack", "year": "2007", "unstructured": "Stack, C. M. et al. Characterization of the Plasmodium falciparum M17 leucyl aminopeptidase. A protease involved in amino acid regulation with potential for antimalarial drug development. J. Biol. Chem. 282, 2069\u20132080 (2007).", "journal-title": "J. Biol. Chem."}, {"key": "BFnrd3053_CR116", "doi-asserted-by": "crossref", "first-page": "3221", "DOI": "10.1128/AAC.01327-07", "volume": "52", "author": "E Cunningham", "year": "2008", "unstructured": "Cunningham, E., Drag, M., Kafarski, P. & Bell, A. Chemical target validation studies of aminopeptidase in malaria parasites using \u03b1-aminoalkylphosphonate and phosphonopeptide inhibitors. Antimicrob. Agents Chemother. 52, 3221\u20133228 (2008).", "journal-title": "Antimicrob. Agents Chemother."}, {"key": "BFnrd3053_CR117", "doi-asserted-by": "crossref", "first-page": "5435", "DOI": "10.1021/bi9003638", "volume": "48", "author": "S Maric", "year": "2009", "unstructured": "Maric, S. et al. The M17 leucine aminopeptidase of the malaria parasite Plasmodium falciparum: the importance of active site metal ions in the binding of substrates and inhibitors. Biochemistry 48, 5435\u20135439 (2009).", "journal-title": "Biochemistry"}, {"key": "BFnrd3053_CR118", "doi-asserted-by": "crossref", "first-page": "6024", "DOI": "10.1021/jm070733v", "volume": "50", "author": "TS Skinner-Adams", "year": "2007", "unstructured": "Skinner-Adams, T. S. et al. Identification of phosphinate dipeptide analog inhibitors directed against the Plasmodium falciparum M17 leucine aminopeptidase as lead antimalarial compounds. J. Med. Chem. 50, 6024\u20136031 (2007).", "journal-title": "J. Med. Chem."}, {"key": "BFnrd3053_CR119", "unstructured": "Kuebler, P. S. Method of treating stroke with thrombolytic agent. US patent 20080107641 (2007)."}, {"key": "BFnrd3053_CR120", "unstructured": "Rojkjaer, R. G. ). Pharmaceutical composition comprising factor VII polypeptides and TAFI polypeptides. US patent 20030118574 (2002)."}, {"key": "BFnrd3053_CR121", "doi-asserted-by": "crossref", "first-page": "7861", "DOI": "10.1002/anie.200800736", "volume": "47", "author": "N Varadarajan", "year": "2008", "unstructured": "Varadarajan, N., Georgiou, G. & Iverson, B. L. An engineered protease that cleaves specifically after sulfated tyrosine. Angew. Chem. Int. Ed Engl. 47, 7861\u20137863 (2008).", "journal-title": "Angew. Chem. Int. Ed Engl."}, {"key": "BFnrd3053_CR122", "doi-asserted-by": "crossref", "first-page": "290", "DOI": "10.1038/nchembio.80", "volume": "4", "author": "N Varadarajan", "year": "2008", "unstructured": "Varadarajan, N., Rodriguez, S., Hwang, B. Y., Georgiou, G. & Iverson, B. L. Highly active and selective endopeptidases with programmed substrate specificities. Nature Chem. Biol. 4, 290\u2013294 (2008).", "journal-title": "Nature Chem. Biol."}, {"key": "BFnrd3053_CR123", "unstructured": "Madison, E. L., Thanos, C., Ruggles, S. W. & Coughlin, S. Modified factor VII polypeptides and uses thereof. US patent 20090098103 (2008)."}, {"key": "BFnrd3053_CR124", "doi-asserted-by": "crossref", "first-page": "4885", "DOI": "10.1021/cr010180a", "volume": "102", "author": "F Tanaka", "year": "2002", "unstructured": "Tanaka, F. Catalytic antibodies as designer proteases and esterases. Chem. Rev. 102, 4885\u20134906 (2002).", "journal-title": "Chem. Rev."}, {"key": "BFnrd3053_CR125", "doi-asserted-by": "crossref", "first-page": "1519", "DOI": "10.1016/j.str.2004.05.023", "volume": "12", "author": "D Reverter", "year": "2004", "unstructured": "Reverter, D. & Lima, C. D. A basis for SUMO protease specificity provided by analysis of human Senp2 and a Senp2\u2013SUMO complex. Structure 12, 1519\u20131531 (2004).", "journal-title": "Structure"}, {"key": "BFnrd3053_CR126", "doi-asserted-by": "crossref", "first-page": "869", "DOI": "10.1006/jmbi.2001.5394", "volume": "316", "author": "R Friedrich", "year": "2002", "unstructured": "Friedrich, R., Steinmetzer, T., Huber, R., Sturzebecher, J. & Bode, W. The methyl group of N\u03b1(Me)Arg-containing peptides disturbs the active-site geometry of thrombin, impairing efficient cleavage. J. Mol. Biol. 316, 869\u2013874 (2002).", "journal-title": "J. Mol. Biol."}, {"key": "BFnrd3053_CR127", "doi-asserted-by": "crossref", "first-page": "265", "DOI": "10.1126/science.1162403", "volume": "322", "author": "PJ Lupardus", "year": "2008", "unstructured": "Lupardus, P. J., Shen, A., Bogyo, M. & Garcia, K. C. Small molecule-induced allosteric activation of the Vibrio cholerae RTX cysteine protease domain. Science 322, 265\u2013268 (2008).", "journal-title": "Science"}, {"key": "BFnrd3053_CR128", "doi-asserted-by": "crossref", "first-page": "157", "DOI": "10.1016/S0006-291X(67)80055-X", "volume": "27", "author": "I Schecter", "year": "1967", "unstructured": "Schecter, I. & Berger, M. On the size of the active site in proteases. Biochem. Biophys. Res. Commun. 27, 157\u2013162 (1967).", "journal-title": "Biochem. Biophys. Res. Commun."}, {"key": "BFnrd3053_CR129", "doi-asserted-by": "crossref", "first-page": "679", "DOI": "10.2165/00003495-200060030-00012", "volume": "60", "author": "AJ Matheson", "year": "2000", "unstructured": "Matheson, A.J. & Goa, K.L. Desirudin: a review of its use in the management of thrombotic disorders. Drugs 60, 679\u2013700 (2000).", "journal-title": "Drugs"}, {"key": "BFnrd3053_CR130", "first-page": "256", "volume": "8", "author": "P Kakar", "year": "2007", "unstructured": "Kakar, P., Watson, T. & Lip, G.Y. Drug evaluation: rivaroxaban, an oral, direct inhibitor of activated factor X. Curr. Opin. Investig. Drugs 8, 256\u2013265 (2007).", "journal-title": "Curr. Opin. Investig. Drugs"}, {"key": "BFnrd3053_CR131", "doi-asserted-by": "crossref", "first-page": "557", "DOI": "10.1038/nrd2622", "volume": "7", "author": "BI Eriksson", "year": "2008", "unstructured": "Eriksson, B.I., Smith, H., Yasothan, U. & Kirkpatrick, P. Dabigatran etexilate. Nature Rev. Drug Discov. 7, 557\u2013558 (2008).", "journal-title": "Nature Rev. Drug Discov."}, {"key": "BFnrd3053_CR132", "doi-asserted-by": "crossref", "first-page": "517", "DOI": "10.1055/s-2007-996129", "volume": "23", "author": "T Matsuo", "year": "1997", "unstructured": "Matsuo, T., Koide, M. & Kario, K. Development of argatroban, a direct thrombin inhibitor, and its clinical application. Semin. Thromb. Hemost. 23, 517\u2013522 (1997).", "journal-title": "Semin. Thromb. Hemost."}], "container-title": ["Nature Reviews Drug Discovery"], "language": "en", "link": [{"URL": "http://www.nature.com/articles/nrd3053.pdf", "content-type": "application/pdf", "content-version": "vor", "intended-application": "text-mining"}, {"URL": "http://www.nature.com/articles/nrd3053", "content-type": "text/html", "content-version": "vor", "intended-application": "text-mining"}, {"URL": "http://www.nature.com/articles/nrd3053.pdf", "content-type": "application/pdf", "content-version": "vor", "intended-application": "similarity-checking"}], "deposited": {"date-parts": [[2019, 4, 20]], "date-time": "2019-04-20T05:27:23Z", "timestamp": 1555738043000}, "score": 23.851755, "issued": {"date-parts": [[2010, 9]]}, "references-count": 132, "journal-issue": {"published-print": {"date-parts": [[2010, 9]]}, "issue": "9"}, "alternative-id": ["BFnrd3053"], "URL": "http://dx.doi.org/10.1038/nrd3053", "relation": {"cites": []}, "ISSN": ["1474-1776", "1474-1784"], "issn-type": [{"value": "1474-1776", "type": "print"}, {"value": "1474-1784", "type": "electronic"}]}, {"indexed": {"date-parts": [[2019, 11, 27]], "date-time": "2019-11-27T10:44:13Z", "timestamp": 1574851453587}, "publisher-location": "Cambridge", "reference-count": 0, "publisher": "Royal Society of Chemistry", "isbn-type": [{"value": "9781782628897", "type": "print"}], "content-domain": {"domain": [], "crossmark-restriction": false}, "DOI": "10.1039/9781788010177-00371", "type": "book-chapter", "created": {"date-parts": [[2017, 10, 26]], "date-time": "2017-10-26T11:00:25Z", "timestamp": 1509015625000}, "page": "371-386", "source": "Crossref", "is-referenced-by-count": 0, "title": ["Chapter 18. Molecular Basis of Drug Resistance in Leishmania"], "prefix": "10.1039", "author": [{"given": "Annelies", "family": "Mondelaers", "sequence": "first", "affiliation": []}, {"given": "Sarah", "family": "Hendrickx", "sequence": "additional", "affiliation": []}, {"given": "Guy", "family": "Caljon", "sequence": "additional", "affiliation": []}, {"given": "Louis", "family": "Maes", "sequence": "additional", "affiliation": []}], "member": "292", "container-title": ["Drug Discovery", "Drug Discovery for Leishmaniasis"], "deposited": {"date-parts": [[2018, 10, 26]], "date-time": "2018-10-26T10:00:44Z", "timestamp": 1540548044000}, "score": 23.650345, "issued": {"date-parts": [[null]]}, "ISBN": ["9781782628897"], "references-count": 0, "URL": "http://dx.doi.org/10.1039/9781788010177-00371", "ISSN": ["2041-3211"], "issn-type": [{"value": "2041-3211", "type": "print"}]}, {"indexed": {"date-parts": [[2019, 12, 1]], "date-time": "2019-12-01T14:58:44Z", "timestamp": 1575212324028}, "reference-count": 67, "publisher": "Elsevier BV", "issue": "2", "license": [{"URL": "https://www.elsevier.com/tdm/userlicense/1.0/", "start": {"date-parts": [[2013, 6, 1]], "date-time": "2013-06-01T00:00:00Z", "timestamp": 1370044800000}, "delay-in-days": 0, "content-version": "tdm"}], "content-domain": {"domain": [], "crossmark-restriction": false}, "short-container-title": ["Drug Discovery Today: Disease Models"], "published-print": {"date-parts": [[2013, 6]]}, "DOI": "10.1016/j.ddmod.2013.02.002", "type": "journal-article", "created": {"date-parts": [[2013, 4, 18]], "date-time": "2013-04-18T11:00:59Z", "timestamp": 1366282859000}, "page": "e59-e64", "source": "Crossref", "is-referenced-by-count": 0, "title": ["Cellular and animal models of type 2 diabetes GWAS gene polymorphisms: what can we learn?"], "prefix": "10.1016", "volume": "10", "author": [{"given": "Guy A.", "family": "Rutter", "sequence": "first", "affiliation": []}], "member": "78", "container-title": ["Drug Discovery Today: Disease Models"], "language": "en", "link": [{"URL": "https://api.elsevier.com/content/article/PII:S1740675713000091?httpAccept=text/xml", "content-type": "text/xml", "content-version": "vor", "intended-application": "text-mining"}, {"URL": "https://api.elsevier.com/content/article/PII:S1740675713000091?httpAccept=text/plain", "content-type": "text/plain", "content-version": "vor", "intended-application": "text-mining"}], "deposited": {"date-parts": [[2018, 10, 16]], "date-time": "2018-10-16T21:51:36Z", "timestamp": 1539726696000}, "score": 23.373016, "issued": {"date-parts": [[2013, 6]]}, "references-count": 67, "journal-issue": {"published-print": {"date-parts": [[2013, 6]]}, "issue": "2"}, "alternative-id": ["S1740675713000091"], "URL": "http://dx.doi.org/10.1016/j.ddmod.2013.02.002", "ISSN": ["1740-6757"], "issn-type": [{"value": "1740-6757", "type": "print"}], "subject": ["Molecular Medicine", "Drug Discovery"]}, {"indexed": {"date-parts": [[2019, 12, 18]], "date-time": "2019-12-18T15:03:24Z", "timestamp": 1576681404919}, "reference-count": 41, "publisher": "Elsevier BV", "issue": "2", "license": [{"URL": "https://www.elsevier.com/tdm/userlicense/1.0/", "start": {"date-parts": [[2012, 6, 1]], "date-time": "2012-06-01T00:00:00Z", "timestamp": 1338508800000}, "delay-in-days": 0, "content-version": "tdm"}], "content-domain": {"domain": [], "crossmark-restriction": false}, "short-container-title": ["Drug Discovery Today: Technologies"], "published-print": {"date-parts": [[2012, 6]]}, "DOI": "10.1016/j.ddtec.2011.10.002", "type": "journal-article", "created": {"date-parts": [[2011, 11, 23]], "date-time": "2011-11-23T22:14:51Z", "timestamp": 1322086491000}, "page": "e79-e85", "source": "Crossref", "is-referenced-by-count": 207, "title": ["The use of amorphous solid dispersions: A formulation strategy to overcome poor solubility and dissolution rate"], "prefix": "10.1016", "volume": "9", "author": [{"given": "Guy", "family": "Van den Mooter", "sequence": "first", "affiliation": []}], "member": "78", "container-title": ["Drug Discovery Today: Technologies"], "language": "en", "link": [{"URL": "https://api.elsevier.com/content/article/PII:S1740674911000205?httpAccept=text/xml", "content-type": "text/xml", "content-version": "vor", "intended-application": "text-mining"}, {"URL": "https://api.elsevier.com/content/article/PII:S1740674911000205?httpAccept=text/plain", "content-type": "text/plain", "content-version": "vor", "intended-application": "text-mining"}], "deposited": {"date-parts": [[2019, 3, 7]], "date-time": "2019-03-07T01:00:14Z", "timestamp": 1551920414000}, "score": 23.373016, "issued": {"date-parts": [[2012, 6]]}, "references-count": 41, "journal-issue": {"published-print": {"date-parts": [[2012, 6]]}, "issue": "2"}, "alternative-id": ["S1740674911000205"], "URL": "http://dx.doi.org/10.1016/j.ddtec.2011.10.002", "ISSN": ["1740-6749"], "issn-type": [{"value": "1740-6749", "type": "print"}]}, {"indexed": {"date-parts": [[2019, 12, 18]], "date-time": "2019-12-18T00:23:43Z", "timestamp": 1576628623062}, "reference-count": 111, "publisher": "Springer Science and Business Media LLC", "issue": "3", "license": [{"URL": "http://www.springer.com/tdm", "start": {"date-parts": [[2005, 2, 24]], "date-time": "2005-02-24T00:00:00Z", "timestamp": 1109203200000}, "delay-in-days": 0, "content-version": "tdm"}], "content-domain": {"domain": [], "crossmark-restriction": false}, "short-container-title": ["Nat Rev Drug Discov"], "published-print": {"date-parts": [[2005, 3]]}, "DOI": "10.1038/nrd1657", "type": "journal-article", "created": {"date-parts": [[2005, 2, 24]], "date-time": "2005-02-24T09:55:42Z", "timestamp": 1109238942000}, "page": "206-220", "source": "Crossref", "is-referenced-by-count": 1252, "title": ["The evolving role of natural products in drug discovery"], "prefix": "10.1038", "volume": "4", "author": [{"given": "Frank E.", "family": "Koehn", "sequence": "first", "affiliation": []}, {"given": "Guy T.", "family": "Carter", "sequence": "additional", "affiliation": []}], "member": "297", "published-online": {"date-parts": [[2005, 2, 24]]}, "reference": [{"key": "BFnrd1657_CR1", "doi-asserted-by": "crossref", "first-page": "1002", "DOI": "10.1021/np030096l", "volume": "66", "author": "DJ Newman", "year": "2003", "unstructured": "Newman, D. J., Cragg, G. M. & Snader, K. M. Natural products as a source of new drugs over the period 1981\u20132002. J. Nat. Prod. 66, 1002\u20131037 (2003). A detailed analysis and description of current natural-product-derived therapeutic agents.", "journal-title": "J. Nat. Prod."}, {"key": "BFnrd1657_CR2", "doi-asserted-by": "crossref", "first-page": "457", "DOI": "10.1016/j.coph.2003.07.001", "volume": "3", "author": "SJ Projan", "year": "2003", "unstructured": "Projan, S. J. Infectious diseases in the 21st century: increasing threats, fewer new treatments and a premium on prevention. Cur. Opin. Pharmacol. 3, 457\u2013458 (2003).", "journal-title": "Cur. Opin. Pharmacol."}, {"key": "BFnrd1657_CR3", "doi-asserted-by": "crossref", "first-page": "505", "DOI": "10.1007/BF01574782", "volume": "17", "author": "BE Kirsop", "year": "1996", "unstructured": "Kirsop, B. E. The convention on biological diversity: some implications for microbiology and microbial collections. J. Indust. Microbiol. Biotech. 17, 505\u2013511 (1996).", "journal-title": "J. Indust. Microbiol. Biotech."}, {"key": "BFnrd1657_CR4", "doi-asserted-by": "crossref", "first-page": "427", "DOI": "10.1016/j.mib.2003.08.003", "volume": "6", "author": "SJ Projan", "year": "2003", "unstructured": "Projan S. J. Why is big pharma getting out of antibacterial drug discovery? Curr. Opin. Microbiol. 6, 427\u2013430 (2003).", "journal-title": "Curr. Opin. Microbiol."}, {"key": "BFnrd1657_CR5", "doi-asserted-by": "crossref", "first-page": "3314", "DOI": "10.1021/jm970666c", "volume": "41", "author": "WPW Ajay", "year": "1998", "unstructured": "Ajay, W. P. W. & Murcko, M. Can we learn to distinguish between 'Drug-Like' and 'Nondrug-like' molecules? J. Med. Chem. 41, 3314\u20133324 (1998).", "journal-title": "J. Med. Chem."}, {"key": "BFnrd1657_CR6", "doi-asserted-by": "crossref", "first-page": "3325", "DOI": "10.1021/jm9706776", "volume": "41", "author": "J Sadowski", "year": "1998", "unstructured": "Sadowski, J. & Kubinyi, H. Scoring scheme for discriminating between drugs and nondrugs. J. Med. Chem. 41, 3325\u20133329 (1998).", "journal-title": "J. Med. Chem."}, {"key": "BFnrd1657_CR7", "author": "D Newman", "first-page": "91", "year": "2003", "unstructured": "Newman, D., Cragg, G., Kingston, D. in The Practice of Medicinal Chemistry (ed. Wermuth, C. G.) 91\u2013109 (Academic, London, 2003).", "volume-title": "The Practice of Medicinal Chemistry", "DOI": "10.1016/B978-012744481-9/50010-6", "doi-asserted-by": "crossref"}, {"key": "BFnrd1657_CR8", "doi-asserted-by": "crossref", "first-page": "218", "DOI": "10.1021/ci0200467", "volume": "43", "author": "M Feher", "year": "2003", "unstructured": "Feher, M. & Schmidt, J. M. Property distributions: Differences between drugs, natural products, and molecules from combinatorial chemistry. J. Chem. Inf. Comput. Sci. 43, 218\u2013227 (2003).", "journal-title": "J. Chem. Inf. Comput. Sci."}, {"key": "BFnrd1657_CR9", "doi-asserted-by": "crossref", "first-page": "3", "DOI": "10.1016/S0169-409X(96)00423-1", "volume": "23", "author": "CA Lipinski", "year": "1997", "unstructured": "Lipinski, C. A., Lombardo, F., Dominy, B. W. & Feeney, P. J. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv. Drug Del. Rev. 23, 3\u201325 (1997). Fundamental work describing important physico-chemical properties of drug molecules.", "journal-title": "Adv. Drug Del. Rev."}, {"key": "BFnrd1657_CR10", "doi-asserted-by": "crossref", "first-page": "284", "DOI": "10.1021/cc000097l", "volume": "3", "author": "ML Lee", "year": "2001", "unstructured": "Lee, M. L. & Schneider, G. Scaffold architecture and pharmacophoric properties of natural products and trade drugs: Application in the design of natural product-based combinatorial libraries J. Comb. Chem. 3, 284\u2013289 (2001).", "journal-title": "J. Comb. Chem."}, {"key": "BFnrd1657_CR11", "doi-asserted-by": "crossref", "first-page": "1245", "DOI": "10.1021/ci0003303", "volume": "40", "author": "F Stahura", "year": "2000", "unstructured": "Stahura, F., Godden, J. W., Ling, X. & Bajorath, J. Distinguishing between natural products and synthetic molecules by descriptor Shannon entropy analysis and binary QSAR calculations. J. Chem. Inf. Comput. Sci. 40, 1245\u20131252 (2000).", "journal-title": "J. Chem. Inf. Comput. Sci."}, {"key": "BFnrd1657_CR12", "doi-asserted-by": "crossref", "first-page": "643", "DOI": "10.1002/(SICI)1521-3773(19990301)38:5<643::AID-ANIE643>3.0.CO;2-G", "volume": "38", "author": "T Henkel", "year": "1999", "unstructured": "Henkel, T., Brunne, R., Muller, H. & Reichel, F. Statistical investigation of structural complementarity of natural products and synthetic compounds. Angew. Chem. Int. Ed. Engl. 38, 643\u2013647 (1999).", "journal-title": "Angew. Chem. Int. Ed. Engl."}, {"key": "BFnrd1657_CR13", "doi-asserted-by": "crossref", "first-page": "231", "DOI": "10.1021/cc000073e", "volume": "3", "author": "YC Martin", "year": "2001", "unstructured": "Martin, Y. C. Diverse viewpoints on computational aspects of molecular diversity. J. Comb. Chem. 3, 231\u2013250 (2001).", "journal-title": "J. Comb. Chem."}, {"key": "BFnrd1657_CR14", "doi-asserted-by": "crossref", "first-page": "32", "DOI": "10.1021/cc9800024", "volume": "1", "author": "YC Martin", "year": "1999", "unstructured": "Martin, Y. C. & Critchlow, R. E. Beyond mere diversity: tailoring combinatorial libraries for drug discovery. J. Comb. Chem. 1, 32\u201345 (1999).", "journal-title": "J. Comb. Chem."}, {"key": "BFnrd1657_CR15", "doi-asserted-by": "crossref", "first-page": "2235", "DOI": "10.1021/jm00120a002", "volume": "31", "author": "BE Evans", "year": "1988", "unstructured": "Evans, B. E. et al. Methods for drug discovery: development of potent, selective, orally effective cholecystokinin antagonists. J. Med. Chem. 31, 2235\u20132246 (1988). Fundamental work describing the principle of 'privileged' chemical structures.", "journal-title": "J. Med. Chem."}, {"key": "BFnrd1657_CR16", "doi-asserted-by": "crossref", "first-page": "543", "DOI": "10.1038/357543a0", "volume": "357", "author": "C Chothia", "year": "1992", "unstructured": "Chothia, C. One thousand families for the molecular biologist. Nature 357, 543\u2013544 (1992).", "journal-title": "Nature"}, {"key": "BFnrd1657_CR17", "doi-asserted-by": "crossref", "first-page": "1301", "DOI": "10.1006/jmbi.1998.2282", "volume": "284", "author": "C Zhang", "year": "1998", "unstructured": "Zhang, C. & DeLisi, C. Estimating the number of protein folds. J. Mol. Biol. 284, 1301\u20131305 (1998).", "journal-title": "J. Mol. Biol."}, {"key": "BFnrd1657_CR18", "doi-asserted-by": "crossref", "first-page": "969", "DOI": "10.1006/jmbi.1999.2642", "volume": "287", "author": "GM Salem", "year": "1999", "unstructured": "Salem, G. M., Hutchinson, E. G., Orengo, C. A. & Thornton, J. M. Correlation of observed fold frequency with the occurrence of local structural motifs. J. Mol. Biol. 287, 969\u2013981 (1999).", "journal-title": "J. Mol. Biol."}, {"key": "BFnrd1657_CR19", "doi-asserted-by": "crossref", "first-page": "595", "DOI": "10.1126/science.273.5275.595", "volume": "273", "author": "L Holm", "year": "1996", "unstructured": "Holm, L. & Sander, C. Mapping the protein universe. Science 273, 595\u2013603 (1996).", "journal-title": "Science"}, {"key": "BFnrd1657_CR20", "doi-asserted-by": "crossref", "first-page": "2386", "DOI": "10.1073/pnas.2628030100", "volume": "100", "author": "J Hou", "year": "2003", "unstructured": "Hou, J., Sims, G., Zhang, C. & Kim, S -H. A global representation of the protein fold space. Proc. Natl Acad. Sci. USA 100, 2386\u20132390 (2003).", "journal-title": "Proc. Natl Acad. Sci. USA"}, {"key": "BFnrd1657_CR21", "doi-asserted-by": "crossref", "first-page": "12", "DOI": "10.1016/S1367-5931(02)00018-2", "volume": "7", "author": "V Anantharaman", "year": "2003", "unstructured": "Anantharaman, V., Aravind, L. & Koonin, E. V. Emergence of diverse biochemical activities in evolutionarily conserved structural scaffolds of proteins. Cur. Opin. Chem. Biol. 7, 12\u201320 (2003).", "journal-title": "Cur. Opin. Chem. Biol."}, {"key": "BFnrd1657_CR22", "doi-asserted-by": "crossref", "first-page": "2878", "DOI": "10.1002/1521-3773(20020816)41:16<2878::AID-ANIE2878>3.0.CO;2-B", "volume": "41", "author": "R Breinbauer", "year": "2002", "unstructured": "Breinbauer, R., Vetter, I. R. & Waldmann, H. From protein domains to drug candidates- Natural products as guiding principles in the design and synthesis of compound libraries. Angew. Chem. Int. Ed. 41, 2878\u20132890 (2002). Analysis and description of the importance of natural products as scaffolds for drug design.", "journal-title": "Angew. Chem. Int. Ed."}, {"key": "BFnrd1657_CR23", "doi-asserted-by": "crossref", "first-page": "1097", "DOI": "10.1016/0968-0896(96)00093-4", "volume": "4", "author": "A Atuegbu", "year": "1996", "unstructured": "Atuegbu, A., MacLean, D., Nguyen, C., Gordon, E. M. & Jacobs, J. W. Combinatorial modification of natural products: Preparation of un-encoded and encoded libraries of Rauwolfia alkaloids. Bioorg. Med. Chem. 4, 1097\u20131106 (1996).", "journal-title": "Bioorg. Med. Chem."}, {"key": "BFnrd1657_CR24", "doi-asserted-by": "crossref", "first-page": "6029", "DOI": "10.1021/jo9708699", "volume": "62", "author": "XY Xaio", "year": "1997", "unstructured": "Xaio, X. Y., Parandoosh, Z. & Nova, M. P. Design and synthesis of a taxoid library using radiofrequency encoded combinatorial chemistry. J. Org. Chem. 62, 6029\u20136033 (1997).", "journal-title": "J. Org. Chem."}, {"key": "BFnrd1657_CR25", "doi-asserted-by": "crossref", "first-page": "4898", "DOI": "10.1021/ja990240i", "volume": "121", "author": "R Xu", "year": "1999", "unstructured": "Xu, R., Grieveldinger, G., Marenus, L. E., Cooper, A. & Ellman, J. A. Combinatorial library approach for the identification of synthetic receptors targeting vancomycin-resistant bacteria. J. Am. Chem. Soc. 121, 4898\u20134899 (1999).", "journal-title": "J. Am. Chem. Soc."}, {"key": "BFnrd1657_CR26", "doi-asserted-by": "crossref", "first-page": "1084", "DOI": "10.1002/(SICI)1521-3773(20000317)39:6<1084::AID-ANIE1084>3.0.CO;2-O", "volume": "39", "author": "KC Nicolaou", "year": "2000", "unstructured": "Nicolaou, K. C., Winssinger, N. Hughes, R., Smethurst, C. & Cho, S. Y. New selenium-based safety-catch linkers: solid-phase semisynthesis of vancomycin. Angew. Chem. Int. Ed. 39, 1084\u20131088 (2000).", "journal-title": "Angew. Chem. Int. Ed."}, {"key": "BFnrd1657_CR27", "doi-asserted-by": "crossref", "first-page": "9939", "DOI": "10.1021/ja002033k", "volume": "122", "author": "KC Nicolaou", "year": "2000", "unstructured": "Nicolaou, K. C., Pfefferkorn, J. A., Roecker, A. J., Cao, G. -Q. & Barluenga, S. Natural product-like combinatorial libraries based on privileged structures 1. General principles and solid phase synthesis of benzopyrans. J. Am. Chem. Soc. 122, 9939\u20139953 (2000). A demonstration of the natural products-like chemical diversity achieved by modern combinatorial chemistry.", "journal-title": "J. Am. Chem. Soc."}, {"key": "BFnrd1657_CR28", "doi-asserted-by": "crossref", "first-page": "9954", "DOI": "10.1021/ja002034c", "volume": "122", "author": "KC Nicolaou", "year": "2000", "unstructured": "Nicolaou, K. C. et al. Natural product-like combinatorial libraries based on privileged structures. 2. Construction of a 10,000-membered benzopyran library by directed split-and-pool chemistry using NanoKans and optical encoding. J. Am. Chem. Soc. 122, 9954\u20139967 (2000).", "journal-title": "J. Am. Chem. Soc."}, {"key": "BFnrd1657_CR29", "doi-asserted-by": "crossref", "first-page": "2917", "DOI": "10.1021/jm0307943", "volume": "46", "author": "L Kissau", "year": "2003", "unstructured": "Kissau, L., Stahl, P., Mazitschek, R., Giannis, A. & Waldmann, H. Development of natural product-derived receptor tyrosine kinase inhibitors based on conservation of protein domain fold. J. Med. Chem. 46, 2917\u20132931 (2003).", "journal-title": "J. Med. Chem."}, {"key": "BFnrd1657_CR30", "doi-asserted-by": "crossref", "first-page": "2479", "DOI": "10.1021/cr9900026", "volume": "100", "author": "MW Peczuh", "year": "2000", "unstructured": "Peczuh, M. W. & Hamilton, A. D. Peptide and protein recognition by designed molecules. Chem. Rev. 100, 2479\u20132494 (2000).", "journal-title": "Chem. Rev."}, {"key": "BFnrd1657_CR31", "doi-asserted-by": "crossref", "first-page": "731", "DOI": "10.2174/0929867003374723", "volume": "7", "author": "FJ Dumont", "year": "2000", "unstructured": "Dumont, F. J. FK506, An immunosuppressant targeting calcineurin function. Curr. Med. Chem. 7, 731\u2013748 (2000).", "journal-title": "Curr. Med. Chem."}, {"key": "BFnrd1657_CR32", "doi-asserted-by": "crossref", "first-page": "483", "DOI": "10.1146/annurev.immunol.14.1.483", "volume": "14", "author": "RT Abraham", "year": "1996", "unstructured": "Abraham, R. T. & Wiederrecht, G. J. Immunophamacology of rapamycin. Ann. Rev. Immunol. 14, 483\u2013510 (1996).", "journal-title": "Ann. Rev. Immunol."}, {"key": "BFnrd1657_CR33", "doi-asserted-by": "crossref", "first-page": "269", "DOI": "10.1358/dof.2000.025.03.574454", "volume": "25", "author": "R Hersperger", "year": "2000", "unstructured": "Hersperger, R. & Keller, T. H. Ascomycin derivatives and their use as immunosuppressive agents. Drugs Future 25, 269\u2013277 (2000).", "journal-title": "Drugs Future"}, {"key": "BFnrd1657_CR34", "author": "N Takahashi", "first-page": "577", "year": "2002", "unstructured": "Takahashi, N. in Macrolide Antibiotics 2nd Edn (ed. Omura, S.) 577\u2013621 (Academic, London, 2002).", "volume-title": "Macrolide Antibiotics"}, {"key": "BFnrd1657_CR35", "doi-asserted-by": "crossref", "first-page": "61", "DOI": "10.2174/1568007033482652", "volume": "2", "author": "K Pong", "year": "2003", "unstructured": "Pong, K. & Zaleska, M. M. Therapeutic implications for immunophilin ligands in the treatment of neurodegenerative diseases. Curr. Drug Targets CNS Neurol. Disord. 2, 61\u201372 (2003).", "journal-title": "Curr. Drug Targets CNS Neurol. Disord."}, {"key": "BFnrd1657_CR36", "first-page": "1", "volume": "2", "author": "MA Jordan", "year": "2002", "unstructured": "Jordan, M. A. Mechanism of action of antitumor drugs that interact with microtubules and tubulin. Curr. Med. Chem. 2, 1\u201317 (2002).", "journal-title": "Curr. Med. Chem."}, {"key": "BFnrd1657_CR37", "doi-asserted-by": "crossref", "first-page": "613", "DOI": "10.1124/mol.52.4.613", "volume": "52", "author": "RJ Kowalski", "year": "1997", "unstructured": "Kowalski, R. J. et al. The microtubule-stabilizing agent discodermolide competitively inhibits the binding of paclitaxel (Taxol) to tubulin polymers, enhances tubulin nucleation reactions more potently than paclitaxel, and inhibits the growth of paclitaxel-resistant cells. Mol. Pharmacol. 52, 613\u2013622 (1997). Fundamental work describing the mechanism of action of a potent antitubulin agent.", "journal-title": "Mol. Pharmacol."}, {"key": "BFnrd1657_CR38", "first-page": "757", "volume": "44", "author": "R Bai", "year": "1993", "unstructured": "Bai, R., Cichacz, Z. A., Herald, C. L., Pettit, G. R. & Hamel, E. Spongistatin 1, a highly cytotoxic, sponge-derived, marine natural product that inhibits mitosis, microtubule assembly, and the binding of vinblastine to tubulin. Mol. Pharmacol. 44, 757\u201366 (1993).", "journal-title": "Mol. Pharmacol."}, {"key": "BFnrd1657_CR39", "first-page": "1838", "volume": "63", "author": "F Loganzo", "year": "2003", "unstructured": "Loganzo, F. et al. HTI-286, a synthetic analogue of the tripeptide hemiasterlin, is a potent antimicrotubule agent that circumvents P-glycoprotein-mediated resistance in vitro and in vivo. Cancer Res. 63, 1838\u20131845 (2003).", "journal-title": "Cancer Res."}, {"key": "BFnrd1657_CR40", "doi-asserted-by": "crossref", "first-page": "163", "DOI": "10.1016/0163-7258(93)90044-E", "volume": "59", "author": "DL Sackett", "year": "1993", "unstructured": "Sackett, D. L. Podophyllotoxin, steganacin and combretastatin: natural products that bind at the colchicine site of tubulin. Pharmacol. Therap. 59, 163\u2013228 (1993).", "journal-title": "Pharmacol. Therap."}, {"key": "BFnrd1657_CR41", "doi-asserted-by": "crossref", "first-page": "397", "DOI": "10.1016/S1367-5931(98)80015-X", "volume": "2", "author": "L Silverman", "year": "1998", "unstructured": "Silverman, L., Campbell, R. & Broach, J. R. New assay technologies for high throughput screening. Curr. Opin. Chem. Biol. 2, 397\u2013403 (1998).", "journal-title": "Curr. Opin. Chem. Biol."}, {"key": "BFnrd1657_CR42", "doi-asserted-by": "crossref", "first-page": "309", "DOI": "10.1038/nrd773", "volume": "1", "author": "P Cohen", "year": "2002", "unstructured": "Cohen, P. Protein kinases- The major drug targets of the 21st century? Nature Rev. Drug Discov. 1, 309\u2013316 (2002).", "journal-title": "Nature Rev. Drug Discov."}, {"key": "BFnrd1657_CR43", "doi-asserted-by": "crossref", "first-page": "313", "DOI": "10.2174/138620703106298563", "volume": "6", "author": "GJR Zaman", "year": "2003", "unstructured": "Zaman, G. J. R., Garritsen, A., de Boer, T. & van Boeckel, C. A. Fluorescence assays for high throughput screening of protein kinases. Comb. Chem. High Throughput Screen. 6, 313\u2013320 (2003).", "journal-title": "Comb. Chem. High Throughput Screen."}, {"key": "BFnrd1657_CR44", "doi-asserted-by": "crossref", "first-page": "223", "DOI": "10.1016/S0003-2697(02)00245-2", "volume": "308", "author": "A Fowler", "year": "2002", "unstructured": "Fowler, A. et al. An evaluation of fluorescence polarization and lifetime discriminated polarization for high throughput screening of serine/threonine kinases. Anal. Biochem. 308, 223\u2013231 (2002).", "journal-title": "Anal. Biochem."}, {"key": "BFnrd1657_CR45", "doi-asserted-by": "crossref", "first-page": "176", "DOI": "10.1177/1087057103252304", "volume": "8", "author": "TC Turek-Etienne", "year": "2003", "unstructured": "Turek-Etienne, T. C. et al. Evaluation of fluorescent compound interference in 4 fluoroescence polarization assays: 2 kinases, 1 protease, and 1 phosphatase. J. Biomol. Screen. 8, 176\u2013184 (2003).", "journal-title": "J. Biomol. Screen."}, {"key": "BFnrd1657_CR46", "doi-asserted-by": "crossref", "first-page": "3963", "DOI": "10.1021/ac025534s", "volume": "74", "author": "GR Eldridge", "year": "2002", "unstructured": "Eldridge, G. R. et al. High-throughput method for the production and analysis of large natural product libraries for drug discovery. Anal. Chem. 74, 3963\u20133971 (2002).", "journal-title": "Anal. Chem."}, {"key": "BFnrd1657_CR47", "doi-asserted-by": "crossref", "first-page": "453", "DOI": "10.1016/S1367-5931(02)00338-1", "volume": "6", "author": "U Abel", "year": "2002", "unstructured": "Abel, U., Koch, C., Speitling, M. & Hansske, F. G. Modern methods to produce natural-product libraries. Curr. Opin. Chem. Biol. 6, 453\u2013458 (2002).", "journal-title": "Curr. Opin. Chem. Biol."}, {"key": "BFnrd1657_CR48", "doi-asserted-by": "crossref", "first-page": "1186", "DOI": "10.1021/np0301137", "volume": "66", "author": "LL Cummins", "year": "2003", "unstructured": "Cummins, L. L. et al. Multitarget affinity/specificity screening of natural products:Finding and characterizing high affinity ligands from complex mixtures by using high performance mass spectrometry. J. Nat. Prod. 66, 1186\u20131190 (2003).", "journal-title": "J. Nat. Prod."}, {"key": "BFnrd1657_CR49", "doi-asserted-by": "crossref", "first-page": "382", "DOI": "10.1039/b208815k", "volume": "20", "author": "RD Firn", "year": "2003", "unstructured": "Firn, R. D. & Jones, C. D. Natural products \u2014 a simple model to explain chemical diversity. Nat. Prod. Rep. 20, 382\u2013391 (2003). An analysis of why organisms produce natural products chemical diversity.", "journal-title": "Nat. Prod. Rep."}, {"key": "BFnrd1657_CR50", "doi-asserted-by": "crossref", "first-page": "1134", "DOI": "10.1021/jm00184a014", "volume": "23", "author": "JC Chabala", "year": "1980", "unstructured": "Chabala, J. C. et al. Ivermectin, a new broad-spectrum antiparasitic agent. J. Med. Chem. 23, 1134\u20131136 (1980).", "journal-title": "J. Med. Chem."}, {"key": "BFnrd1657_CR51", "doi-asserted-by": "crossref", "first-page": "9729", "DOI": "10.1021/ja020257s", "volume": "124", "author": "H He", "year": "2002", "unstructured": "He, H. et al. Mannopeptimycins, novel antibacterial glycopeptides from Streptomyces hygroscopicus, LL-AC98. J. Am. Chem. Soc. 124, 9729\u20139736 (2002).", "journal-title": "J. Am. Chem. Soc."}, {"key": "BFnrd1657_CR52", "unstructured": "De Voe, S. E. & Kunstmann, M. P. Antibiotic AC98 and production. US Patent 3,495,004 (1970)."}, {"key": "BFnrd1657_CR53", "doi-asserted-by": "crossref", "first-page": "728", "DOI": "10.1128/AAC.48.3.728-738.2004", "volume": "48", "author": "A Ruzin", "year": "2004", "unstructured": "Ruzin, A. et al. Mechanism of action of the mannopeptimycins, a novel class of glycopeptide antibiotics active against vancomycin-resistant Gram-positive bacteria. Antimicrob. Agent. Chemother. 48, 728\u2013738 (2004).", "journal-title": "Antimicrob. Agent. Chemother."}, {"key": "BFnrd1657_CR54", "doi-asserted-by": "crossref", "first-page": "279", "DOI": "10.1016/j.bmcl.2003.09.071", "volume": "14", "author": "H He", "year": "2004", "unstructured": "He, H. et al. Mannopeptimycin esters and carbonates, potent antibiotic agents against drug resistant bacteria. Bioorg. Med. Chem. Lett. 14, 279\u2013282 (2004).", "journal-title": "Bioorg. Med. Chem. Lett."}, {"key": "BFnrd1657_CR55", "doi-asserted-by": "crossref", "first-page": "2805", "DOI": "10.1016/S0960-894X(03)00542-0", "volume": "13", "author": "PE Sum", "year": "2003", "unstructured": "Sum, P. E., et al. Synthesis and evaluation of ether and halogenated derivatives of mannopeptimycin glycopeptide antibiotic. Biorg. Med. Chem. Lett. 13, 2805\u20132808 (2003).", "journal-title": "Biorg. Med. Chem. Lett."}, {"key": "BFnrd1657_CR56", "doi-asserted-by": "crossref", "first-page": "3487", "DOI": "10.1021/jm049765y", "volume": "47", "author": "RG Dushin", "year": "2004", "unstructured": "Dushin, R. G. et al. Hydrophobic acetal and ketal derivatives of mannopeptimycin-\u03b1 and AC98-0053: semisynthetic glycopeptides with potent activity against Gram-positive bacteria. J. Med. Chem. 47, 3487\u20133490 (2004). An extensive illustration of the capabilities of NMR spectroscopy in the structure elucidation of complex natural products.", "journal-title": "J. Med. Chem."}, {"key": "BFnrd1657_CR57", "doi-asserted-by": "crossref", "first-page": "67", "DOI": "10.1016/S0378-4347(98)00553-2", "volume": "725", "author": "MA Strege", "year": "1999", "unstructured": "Strege, M. A. High-performance liquid chromatographic-electrospray ionization mass spectrometric analyses for the integration of natural products with modern high-throughput screening. J. Chrom. B 725, 67\u201368 (1999).", "journal-title": "J. Chrom. B"}, {"key": "BFnrd1657_CR58", "doi-asserted-by": "crossref", "first-page": "111", "DOI": "10.1016/S0021-9673(03)00490-4", "volume": "1002", "author": "KF Nielsen", "year": "2003", "unstructured": "Nielsen, K. F. & Smedsgaard, J. Fungal metabolite screening: database of 474 mycotoxins and fungal metabolites for dereplication by standardised liquid chromatography-UV-mass spectrometry methodology. J. Chrom. A 1002, 111\u2013136 (2003).", "journal-title": "J. Chrom. A"}, {"key": "BFnrd1657_CR59", "first-page": "1", "volume": "1", "author": "R Freeman", "year": "1979", "unstructured": "Freeman, R. & Morris, G. A. Two-dimensional Fourier transformation in NMR. Bull. Magn. Res. 1, 1\u201326 (1979).", "journal-title": "Bull. Magn. Res."}, {"key": "BFnrd1657_CR60", "doi-asserted-by": "crossref", "first-page": "8056", "DOI": "10.1021/ja00285a029", "volume": "108", "author": "A Bax", "year": "1986", "unstructured": "Bax, A., Aszalos, A., Dinya, Z. & Sudo, K. Structure elucidation of the antibiotic desertomycin through the use of new two-dimensional NMR techniques. J. Am. Chem. Soc. 108, 8056\u20138063 (1986).", "journal-title": "J. Am. Chem. Soc."}, {"key": "BFnrd1657_CR61", "doi-asserted-by": "crossref", "first-page": "412", "DOI": "10.1002/nadc.20030510406", "volume": "51", "author": "H Schwalbe", "year": "2003", "unstructured": "Schwalbe, H. & Kessler, H. 900 MHz NMR spectrometer in Munich and Frankfurt. Nachrichten aus der Chemie 51, 412\u2013417 (2003).", "journal-title": "Nachrichten aus der Chemie"}, {"key": "BFnrd1657_CR62", "doi-asserted-by": "crossref", "first-page": "949", "DOI": "10.1002/mrc.1277", "volume": "41", "author": "M Sandvoss", "year": "2003", "unstructured": "Sandvoss, M., Preiss, A., Levsen, K., Weisemann, R. & Spraul, M. Two new asterosaponins from the starfish Asterias rubens: application of a cryogenic NMR probe head. Magn. Res. Chem. 41, 949\u2013954 (2003).", "journal-title": "Magn. Res. Chem."}, {"key": "BFnrd1657_CR63", "doi-asserted-by": "crossref", "first-page": "2966", "DOI": "10.1021/ac035426l", "volume": "76", "author": "DL Olson", "year": "2004", "unstructured": "Olson, D. L. et al. Microflow NMR: concepts and capabilities. Anal. Chem. 76, 2966\u20132974 (2004).", "journal-title": "Anal. Chem."}, {"key": "BFnrd1657_CR64", "doi-asserted-by": "crossref", "first-page": "3554", "DOI": "10.1021/ja991371m", "volume": "122", "author": "Z Serber", "year": "2000", "unstructured": "Serber, Z. et al. New carbon-detected protein NMR experiments using cryoProbes. J. Am. Chem. Soc. 122, 3554\u20133555 (2000).", "journal-title": "J. Am. Chem. Soc."}, {"key": "BFnrd1657_CR65", "doi-asserted-by": "crossref", "first-page": "7019", "DOI": "10.1021/ja00131a032", "volume": "117", "author": "M Satake", "year": "1995", "unstructured": "Satake, M. et al. Structural confirmation of maitotoxin based on complete 13C NMR assignments and the three-dimensional PFG NOESY-HMQC spectrum. J. Am. Chem. Soc. 117, 7019\u20137020 (1995).", "journal-title": "J. Am. Chem. Soc."}, {"key": "BFnrd1657_CR66", "doi-asserted-by": "crossref", "first-page": "5352", "DOI": "10.1021/ja004191h", "volume": "123", "author": "H He", "year": "2001", "unstructured": "He, H. et al. Lomaiviticins A and B, potent antitumor antibiotics from Micromonospora Lomaivitiensis. J. Am. Chem. Soc. 123, 5352\u20135363 (2001).", "journal-title": "J. Am. Chem. Soc."}, {"key": "BFnrd1657_CR67", "doi-asserted-by": "crossref", "first-page": "2730", "DOI": "10.1021/ac0264731", "volume": "75", "author": "LA McDonald", "year": "2003", "unstructured": "McDonald, L. A. et al. FTMS Structure elucidation of natural products: application to muraymycin antibiotics using ESI Multi-CHEF SORI-CIT FTMSn, the Top-Down/Bottom-Up approach, and HPLC ESI capillary-skimmer CID FTMS. Anal. Chem. 75, 2730\u20132739 (2003). Capabilities of modern mass spectrometry in the structure elucidation of complex natural products.", "journal-title": "Anal. Chem."}, {"key": "BFnrd1657_CR68", "doi-asserted-by": "crossref", "first-page": "4912", "DOI": "10.1021/jo00303a029", "volume": "55", "author": "AP Gunasekera", "year": "1990", "unstructured": "Gunasekera, A. P., Gunaskera, M., Longley, R. E. & Schulte, G. K. Discodermolide: a new bioactive polyhydroxylated lactone from the marine sponge Discodermia dissoluta. J. Org. Chem. 55, 4912\u20134915 (1990).", "journal-title": "J. Org. Chem."}, {"key": "BFnrd1657_CR69", "first-page": "1013", "volume": "61", "author": "MJ Towle", "year": "2001", "unstructured": "Towle, M. J. et al. In vitro and in vivo anticancer activities of synthetic macrocyclic ketone analogues of halichondrin B. Cancer Res. 61, 1013\u20131021 (2001).", "journal-title": "Cancer Res."}, {"key": "BFnrd1657_CR70", "doi-asserted-by": "crossref", "first-page": "5760", "DOI": "10.1158/0008-5472.CAN-04-1169", "volume": "64", "author": "G Kuznetsov", "year": "2004", "unstructured": "Kuznetsov, G. et al. Induction of morphological and biochemical apoptosis following prolonged mitotic blockage by halichondrin B macrocyclic ketone analog E7389. Cancer Res. 64, 5760\u20135766 (2004).", "journal-title": "Cancer Res."}, {"key": "BFnrd1657_CR71", "doi-asserted-by": "crossref", "first-page": "118", "DOI": "10.1016/S0003-2697(03)00038-1", "volume": "316", "author": "T Schenk", "year": "2003", "unstructured": "Schenk, T. et al. A Generic assay for phosphate-consuming or -releasing enzymes coupled on-line to liquid chromatography for lead finding in natural products. Anal. Biochem. 316, 118\u2013126 (2003).", "journal-title": "Anal. Biochem."}, {"key": "BFnrd1657_CR72", "doi-asserted-by": "crossref", "first-page": "1186", "DOI": "10.1021/np0301137", "volume": "66", "author": "LL Cummins", "year": "2003", "unstructured": "Cummins, L. L. et al. Multitarget affinity/specificity screening of natural products finding and characterizing high-affinity ligands from complex mixtures by using high-performance mass spectrometry. J. Nat. Prod. 66, 1186\u20131190 (2003).", "journal-title": "J. Nat. Prod."}, {"key": "BFnrd1657_CR73", "doi-asserted-by": "crossref", "first-page": "3383", "DOI": "10.1002/(SICI)1521-3773(19981231)37:24<3383::AID-ANIE3383>3.0.CO;2-C", "volume": "37", "author": "DC Schriemer", "year": "1998", "unstructured": "Schriemer, D. C., Bundle, D. R., Li, L. & Hindsgaul, O. Micro-scale frontal affinity chromatography with mass spectrometric detection: a new method for the screening of compound libraries. Angew. Chem. Int. Ed. 37, 3383\u20133387 (1998).", "journal-title": "Angew. Chem. Int. Ed."}, {"key": "BFnrd1657_CR74", "doi-asserted-by": "crossref", "first-page": "1", "DOI": "10.1016/S0003-2697(03)00193-3", "volume": "319", "author": "NWC Chan", "year": "2003", "unstructured": "Chan, N. W. C., Lewis, D. F., Rosner, P. J., Kelly, M. A. & Schriemer, D. C. Frontal affinity chromatography\u2013mass spectrometry assay technology for multiple stages of drug discovery: applications of a chromatographic biosensor. Anal. Biochem. 319, 1\u201312 (2003).", "journal-title": "Anal. Biochem."}, {"key": "BFnrd1657_CR75", "doi-asserted-by": "crossref", "first-page": "6388", "DOI": "10.1021/ac0341867", "volume": "75", "author": "L Zhu", "year": "2003", "unstructured": "Zhu, L., Chen, L., Luo, H. & Xu, X. Frontal affinity chromatography combined on-line with mass spectrometry: a tool for the binding study of different epidermal growth factor receptor inhibitors. Anal. Chem. 75, 6388\u20136393 (2003).", "journal-title": "Anal. Chem."}, {"key": "BFnrd1657_CR76", "doi-asserted-by": "crossref", "first-page": "437", "DOI": "10.1016/S0021-9673(03)00303-0", "volume": "1000", "author": "J-L Wolfender", "year": "2003", "unstructured": "Wolfender, J -L., Ndjoko, K. & Hostettmann, K. Liquid chromatography with ultraviolet absorbance\u2013mass spectrometric detection and with nuclear magnetic resonance spectroscopy: a powerful combination for the on-line structural investigation of plant metabolites. J. Chrom. A 1000, 437\u2013455 (2003).", "journal-title": "J. Chrom. A"}, {"key": "BFnrd1657_CR77", "doi-asserted-by": "crossref", "first-page": "6288", "DOI": "10.1021/ac0347819", "volume": "75", "author": "V Exarchou", "year": "2003", "unstructured": "Exarchou, V., Godejohann, M., van Beek, T. S., Gerothanassis, I. P. & Vervoort, J. LC-UV-solid-phase extraction-NMR-MS combined with a cryogenic flow probe and its application to the identification of compounds present in greek oregano. Anal. Chem. 75, 6288\u20136294 (2003). Capabilities of hyphenated spectroscopic techniques in the structure elucidation of complex natural product mixtures.", "journal-title": "Anal. Chem."}, {"key": "BFnrd1657_CR78", "doi-asserted-by": "crossref", "first-page": "2471", "DOI": "10.1021/ac00277a047", "volume": "56", "author": "DA Laude", "year": "1984", "unstructured": "Laude, D. A. & Wilkins, C. L. Direct-linked analytical scale high-performance liquid chromatography/nuclear magnetic resonance spectrometry. Anal. Chem. 56, 2471\u20132475 (1984).", "journal-title": "Anal. Chem."}, {"key": "BFnrd1657_CR79", "doi-asserted-by": "crossref", "first-page": "199", "DOI": "10.1016/S0021-9673(99)00831-6", "volume": "856", "author": "K Albert", "year": "1999", "unstructured": "Albert, K. Liquid chromatography-nuclear magnetic resonance spectroscopy. J. Chrom. 856, 199\u2013211 (1999).", "journal-title": "J. Chrom."}, {"key": "BFnrd1657_CR80", "doi-asserted-by": "crossref", "first-page": "2", "DOI": "10.1002/1099-1565(200101/02)12:1<2::AID-PCA552>3.0.CO;2-K", "volume": "12", "author": "J-L Wolfender", "year": "2001", "unstructured": "Wolfender, J. -L., Ndjoko, K. & Hostettmann, K. The potential of LC-NMR in phytochemical analysis. Phytochem. Anal. 12, 2\u201322 (2001).", "journal-title": "Phytochem. Anal."}, {"key": "BFnrd1657_CR81", "doi-asserted-by": "crossref", "first-page": "222", "DOI": "10.1002/1522-2675(20010131)84:1<222::AID-HLCA222>3.0.CO;2-R", "volume": "84", "author": "F Schaller", "year": "2001", "unstructured": "Schaller, F., Wolfender, J. -L., Hostettmann, K. & Mavi, S. New antifungal 'quinone methide' diterpenes from Bobgunnia madagascariensis and study of their interconversion by LC/NMR Helv. Chim. Act. 84, 222\u2013229 (2001).", "journal-title": "Helv. Chim. Act."}, {"key": "BFnrd1657_CR82", "doi-asserted-by": "crossref", "first-page": "1793", "DOI": "10.1021/ac9912303", "volume": "72", "author": "A Lommen", "year": "2000", "unstructured": "Lommen, A., Godejohann, M., Venema, D. P., Hollman, P. C. H., Spraul, M. Application of directly coupled HPLC-NMR\u2013MS to the identification and confirmation of quercetin glycosides and phloretin glycosides in apple peel. Anal. Chem. 72, 1793\u20131797 (2000).", "journal-title": "Anal. Chem."}, {"key": "BFnrd1657_CR83", "doi-asserted-by": "crossref", "first-page": "1536", "DOI": "10.1021/ac026203i", "volume": "75", "author": "M Spraul", "year": "2003", "unstructured": "Spraul, M. et al. Advancing sensitivity for LC-NMR-MS using a cryoflow probe: application to analysis of acetominophen metabolites in urine. Anal. Chem. 75, 1536\u20131541 (2003).", "journal-title": "Anal. Chem."}, {"key": "BFnrd1657_CR84", "doi-asserted-by": "crossref", "first-page": "3101", "DOI": "10.1021/ac00114a002", "volume": "67", "author": "N Wu", "year": "1995", "unstructured": "Wu, N., Webb, A., Peck, T. L., Sweedler, J. V. Online NMR detection of amino acids and peptides in microbore LC. Anal. Chem. 67, 3101\u20133107 (1995).", "journal-title": "Anal. Chem."}, {"key": "BFnrd1657_CR85", "doi-asserted-by": "crossref", "first-page": "1019", "DOI": "10.1038/nrd1256", "volume": "2", "author": "C Khosla", "year": "2003", "unstructured": "Khosla, C. & Keasling, J. D. Metabolic engineering for drug discovery and development. Nature Rev. Drug Discov. 2, 1019\u20131025 (2003).", "journal-title": "Nature Rev. Drug Discov."}, {"key": "BFnrd1657_CR86", "doi-asserted-by": "crossref", "first-page": "15433", "DOI": "10.1021/ja0304953", "volume": "125", "author": "KC Nicolaou", "year": "2003", "unstructured": "Nicolaou, K. C. et al. Total synthesis of apoptolidin: construction of enantiomerically pure fragments. J. Am. Chem. Soc. 125, 15433\u201315442 (2003).", "journal-title": "J. Am. Chem. Soc."}, {"key": "BFnrd1657_CR87", "doi-asserted-by": "crossref", "first-page": "6347", "DOI": "10.1021/ja049821k", "volume": "126", "author": "S Lin", "year": "2004", "unstructured": "Lin, S. et al. Total syntheses of TMC-95A and B via a new reaction leading to Z-enamides. Some preliminary findings as to SAR. J. Am. Chem. Soc. 126, 6347\u20136355 (2004).", "journal-title": "J. Am. Chem. Soc."}, {"key": "BFnrd1657_CR88", "doi-asserted-by": "crossref", "first-page": "7197", "DOI": "10.1073/pnas.85.19.7197", "volume": "85", "author": "PA Wender", "year": "1988", "unstructured": "Wender, P. A. et al. Modeling of the bryostatins to the phorbol ester pharmacophore on protein kinase C. Proc. Natl Acad. Sci. USA 85, 7197\u2013201 (1988).", "journal-title": "Proc. Natl Acad. Sci. USA"}, {"key": "BFnrd1657_CR89", "doi-asserted-by": "crossref", "first-page": "6624", "DOI": "10.1073/pnas.95.12.6624", "volume": "95", "author": "PA Wender", "year": "1998", "unstructured": "Wender, P. A. et al. The design, computer modeling, solution structure, and biological evaluation of synthetic analogs of bryostatin 1. Proc. Natl Acad. Sci. USA 95, 6624\u20136629 (1998).", "journal-title": "Proc. Natl Acad. Sci. USA"}, {"key": "BFnrd1657_CR90", "doi-asserted-by": "crossref", "first-page": "8625", "DOI": "10.1016/S0040-4039(98)01955-8", "volume": "39", "author": "PA Wender", "year": "1998", "unstructured": "Wender, P. A., DeBrabander, P. G, Hinkle, K. W., Lippa, B., Pettit, G. R. Synthesis and biological evaluation of fully synthetic bryostatin analogues. Tet. Lett. 39, 8625\u20138628 (1998).", "journal-title": "Tet. Lett."}, {"key": "BFnrd1657_CR91", "doi-asserted-by": "crossref", "first-page": "13648", "DOI": "10.1021/ja027509+", "volume": "124", "author": "PA Wender", "year": "2002", "unstructured": "Wender, P. A. et al. The practical synthesis of a novel and highly potent analogue of bryostatin. J. Am. Chem. Soc. 124, 13648\u201313649 (2002). Along with preceding articles, a good example of natural-products-based drug design.", "journal-title": "J. Am. Chem. Soc."}, {"key": "BFnrd1657_CR92", "doi-asserted-by": "crossref", "first-page": "69", "DOI": "10.1016/0014-5793(95)01453-5", "volume": "379", "author": "U Hommel", "year": "1996", "unstructured": "Hommel, U., Weber, H -P., Oberer, L., Naegeli, H. U., Oberhauser, B. & Foster, C. A. The 3D-structure of a natural inhibitor of cell adhesion molecule expression. FEBS Lett. 379, 69\u201373 (1996).", "journal-title": "FEBS Lett."}, {"key": "BFnrd1657_CR93", "doi-asserted-by": "crossref", "first-page": "5431", "DOI": "10.1021/ja020166v", "volume": "124", "author": "Y Chen", "year": "2002", "unstructured": "Chen, Y., Bilban, M., Foster, C. A. & Boger, D. L. Solution-phase parallel synthesis of a pharmacophore library of HUN-7293 analogues: A general chemical mutagenesis approach to defining structure-function properties of naturally occurring cyclic (depsi)peptides. J. Am. Chem. Soc. 124, 5431\u20135440 (2002).", "journal-title": "J. Am. Chem. Soc."}, {"key": "BFnrd1657_CR94", "doi-asserted-by": "crossref", "first-page": "6991", "DOI": "10.1016/S0040-4020(03)00857-3", "volume": "59", "author": "AB Smith III", "year": "2003", "unstructured": "Smith, III, A. B., Cho, Y. S., Pettit, G. R. & Hirschmann, R. Design, synthesis, and evaluation of azepine-based cryptophycin mimetics. Tetrahedron 59, 6991\u20137009 (2003).", "journal-title": "Tetrahedron"}, {"key": "BFnrd1657_CR95", "first-page": "31", "volume": "2", "author": "MD Lee", "year": "1993", "unstructured": "Lee, M. D., Durr, F. E., Hinman, L. M., Hanmann, P. R. & Ellestad, G. A. The calicheamicins. Adv. Med. Chem. 2, 31\u201366 (1993).", "journal-title": "Adv. Med. Chem."}, {"key": "BFnrd1657_CR96", "doi-asserted-by": "crossref", "first-page": "386", "DOI": "10.1016/S1471-4892(03)00083-3", "volume": "3", "author": "NK Damle", "year": "2003", "unstructured": "Damle, N. K. & Frost, P. Antibody-targeted chemotherapy with immunoconjugates of calicheamicin. Curr. Opin. Pharm. 3, 386\u2013390 (2003).", "journal-title": "Curr. Opin. Pharm."}, {"key": "BFnrd1657_CR97", "doi-asserted-by": "crossref", "first-page": "47", "DOI": "10.1021/bc010021y", "volume": "13", "author": "PR Hamann", "year": "2002", "unstructured": "Hamann, P. R. et al. Gemtuzumab ozogamicin, A potent and selective anti-CD33 antibody-calicheamicin conjugate for treatment of acute myeloid leukemia. Bioconj. Chem. 13, 47\u201358 (2002).", "journal-title": "Bioconj. Chem."}, {"key": "BFnrd1657_CR98", "doi-asserted-by": "crossref", "first-page": "46", "DOI": "10.1002/anie.200300626", "volume": "43", "author": "MD Burke", "year": "2004", "unstructured": "Burke, M. D. & Schreiber, S. L. A planning strategy for diversity oriented synthesis. Angew. Chem. Int. Ed. 43, 46\u201358 (2004).", "journal-title": "Angew. Chem. Int. Ed."}, {"key": "BFnrd1657_CR99", "doi-asserted-by": "crossref", "first-page": "8420", "DOI": "10.1021/ja0352698", "volume": "125", "author": "AN Koehler", "year": "2003", "unstructured": "Koehler, A. N., Shamji, A. F. & Schreiber, S. L. Discovery of an inhibitor of a transcription factor using small molecule microarrays and diversity-oriented synthesis. J. Am. Chem. Soc. 125, 8420\u20138421 (2003).", "journal-title": "J. Am. Chem. Soc."}, {"key": "BFnrd1657_CR100", "doi-asserted-by": "crossref", "first-page": "1246", "DOI": "10.1002/cbic.200300724", "volume": "4", "author": "AM Brik", "year": "2003", "unstructured": "Brik, A. M. et al. Rapid diversity-oriented synthesis in microtiter plates for in situ screening of HIV protease inhibitors. Chembiochem 4, 1246\u20131248 (2003).", "journal-title": "Chembiochem"}, {"key": "BFnrd1657_CR101", "doi-asserted-by": "crossref", "first-page": "2490", "DOI": "10.1039/B206953A", "volume": "1", "author": "J Niggemann", "year": "2002", "unstructured": "Niggemann, J., Michaelis, K., Frank, R., Zander, N. & H\u00f6fle, G. Natural product-derived building blocks for combinatorial synthesis. Part 1. Fragmentation of natural products from myxobacteria. J. Chem. Soc. Perkin. Trans. 1, 2490\u20132503 (2002).", "journal-title": "J. Chem. Soc. Perkin. Trans."}, {"key": "BFnrd1657_CR102", "doi-asserted-by": "crossref", "first-page": "243", "DOI": "10.1021/bi9515127", "volume": "35", "author": "E ter Haar", "year": "1996", "unstructured": "ter Haar, E. et al. Discodermolide, A cytotoxic agent that stabilizes microtubules more potently than taxol. Biochemistry 35, 243\u2013250 (1996).", "journal-title": "Biochemistry"}, {"key": "BFnrd1657_CR103", "doi-asserted-by": "crossref", "first-page": "12621", "DOI": "10.1021/ja00079a066", "volume": "115", "author": "JB Nerenberg", "year": "1993", "unstructured": "Nerenberg, J. B., Hung, D. T., Somers, P. K., Schreiber, S. L. Total synthesis of the immunosuppressive agent (-)-discodermolide. J. Am. Chem. Soc. 115, 12621\u201312622 (1993).", "journal-title": "J. Am. Chem. Soc."}, {"key": "BFnrd1657_CR104", "doi-asserted-by": "crossref", "first-page": "8654", "DOI": "10.1021/ja0015287", "volume": "122", "author": "AB Smith", "year": "2000", "unstructured": "Smith, A. B. et al. Evolution of a gram-scale synthesis of (+)-discodermolide. J. Am. Chem. Soc. 122, 8654\u20138664 (2000).", "journal-title": "J. Am. Chem. Soc."}, {"key": "BFnrd1657_CR105", "doi-asserted-by": "crossref", "first-page": "377", "DOI": "10.1002/(SICI)1521-3773(20000117)39:2<377::AID-ANIE377>3.0.CO;2-E", "volume": "39", "author": "I Paterson", "year": "2000", "unstructured": "Paterson, I., Florence, G. J., Gerlach, K. & Scott, J. P. Total synthesis of the antimicrotubule agent (+) discodermolide using boron\u2013mediated aldol reactions of chiral ketones. Angew. Chem. Int. Ed. 39, 377 (2000).", "journal-title": "Angew. Chem. Int. Ed."}, {"key": "BFnrd1657_CR106", "doi-asserted-by": "crossref", "first-page": "7885", "DOI": "10.1021/jo9811423", "volume": "63", "author": "JA Marshall", "year": "1998", "unstructured": "Marshall, J. A. & Johns, B. A. Total synthesis of (+)-discodermolide. J. Org. Chem. 63, 7885\u20137892 (1998).", "journal-title": "J. Org. Chem."}, {"key": "BFnrd1657_CR107", "doi-asserted-by": "crossref", "first-page": "92", "DOI": "10.1021/op034130e", "volume": "8", "author": "SJ Mickel", "year": "2004", "unstructured": "Mickel, S. J. et al. Large scale synthesis of the anti-cancer marine natural product (+)-discodermolide. Part 1. Org. Proc. Res. Dev. 8, 92\u2013100 (2004).", "journal-title": "Proc. Res. Dev."}, {"key": "BFnrd1657_CR108", "doi-asserted-by": "crossref", "first-page": "101", "DOI": "10.1021/op0341317", "volume": "8", "author": "SJ Mickel", "year": "2004", "unstructured": "Mickel, S. J. et al. Large scale synthesis of the anti-cancer marine natural product (+)-discodermolide. Part 2. Org. Proc. Res. Dev. 8, 101\u2013106 (2004).", "journal-title": "Proc. Res. Dev."}, {"key": "BFnrd1657_CR109", "doi-asserted-by": "crossref", "first-page": "107", "DOI": "10.1021/op034132z", "volume": "8", "author": "SJ Mickel", "year": "2004", "unstructured": "Mickel, S. J. et al. Large scale synthesis of the anti-cancer marine natural product (+)-discodermolide. Part 3. Org. Proc. Res. Dev. 8, 107\u2013112 (2004).", "journal-title": "Proc. Res. Dev."}, {"key": "BFnrd1657_CR110", "doi-asserted-by": "crossref", "first-page": "113", "DOI": "10.1021/op034133r", "volume": "8", "author": "SJ Mickel", "year": "2004", "unstructured": "Mickel, S. J. et al. Large scale synthesis of the anti-cancer marine natural product (+)-discodermolide. Part 4. Org. Proc. Res. Dev. 8, 113\u2013121 (2004).", "journal-title": "Proc. Res. Dev."}, {"key": "BFnrd1657_CR111", "doi-asserted-by": "crossref", "first-page": "122", "DOI": "10.1021/op034134j", "volume": "8", "author": "SJ Mickel", "year": "2004", "unstructured": "Mickel, S. J. et al. Large scale synthesis of the anti-cancer marine natural product (+)-discodermolide. Part 5. Org. Proc. Res. Dev. 8, 122\u2013130 (2004). References 107\u2013111 provide a strong example of successful synthetic scale-up of a natural product for clinical supply.", "journal-title": "Proc. Res. Dev."}], "container-title": ["Nature Reviews Drug Discovery"], "language": "en", "link": [{"URL": "http://www.nature.com/articles/nrd1657.pdf", "content-type": "application/pdf", "content-version": "vor", "intended-application": "text-mining"}, {"URL": "http://www.nature.com/articles/nrd1657", "content-type": "text/html", "content-version": "vor", "intended-application": "text-mining"}, {"URL": "http://www.nature.com/articles/nrd1657.pdf", "content-type": "application/pdf", "content-version": "vor", "intended-application": "similarity-checking"}], "deposited": {"date-parts": [[2019, 3, 22]], "date-time": "2019-03-22T10:25:31Z", "timestamp": 1553250331000}, "score": 23.057096, "issued": {"date-parts": [[2005, 2, 24]]}, "references-count": 111, "journal-issue": {"published-print": {"date-parts": [[2005, 3]]}, "issue": "3"}, "alternative-id": ["BFnrd1657"], "URL": "http://dx.doi.org/10.1038/nrd1657", "relation": {"cites": []}, "ISSN": ["1474-1776", "1474-1784"], "issn-type": [{"value": "1474-1776", "type": "print"}, {"value": "1474-1784", "type": "electronic"}], "subject": ["Pharmacology", "Drug Discovery", "General Medicine"]}, {"indexed": {"date-parts": [[2019, 11, 18]], "date-time": "2019-11-18T19:24:16Z", "timestamp": 1574105056594}, "reference-count": 53, "publisher": "Elsevier BV", "issue": "7", "license": [{"URL": "https://www.elsevier.com/tdm/userlicense/1.0/", "start": {"date-parts": [[1998, 7, 1]], "date-time": "1998-07-01T00:00:00Z", "timestamp": 899251200000}, "delay-in-days": 0, "content-version": "tdm"}], "content-domain": {"domain": [], "crossmark-restriction": false}, "short-container-title": ["Neuropharmacology"], "published-print": {"date-parts": [[1998, 7]]}, "DOI": "10.1016/s0028-3908(98)00077-x", "type": "journal-article", "created": {"date-parts": [[2002, 7, 25]], "date-time": "2002-07-25T22:55:58Z", "timestamp": 1027637758000}, "page": "927-935", "source": "Crossref", "is-referenced-by-count": 45, "title": ["Behavioral effects of phenelzine in an experimental model for screening anxiolytic and anti-panic drugs: correlation with changes in monoamine\u2013oxidase activity and monoamine levels"], "prefix": "10.1016", "volume": "37", "author": [{"given": "Guy", "family": "Griebel", "sequence": "first", "affiliation": []}, {"given": "Olivier", "family": "Curet", "sequence": "additional", "affiliation": []}, {"given": "Ghislaine", "family": "Perrault", "sequence": "additional", "affiliation": []}, {"given": "David J", "family": "Sanger", "sequence": "additional", "affiliation": []}], "member": "78", "container-title": ["Neuropharmacology"], "language": "en", "link": [{"URL": "https://api.elsevier.com/content/article/PII:S002839089800077X?httpAccept=text/xml", "content-type": "text/xml", "content-version": "vor", "intended-application": "text-mining"}, {"URL": "https://api.elsevier.com/content/article/PII:S002839089800077X?httpAccept=text/plain", "content-type": "text/plain", "content-version": "vor", "intended-application": "text-mining"}], "deposited": {"date-parts": [[2019, 4, 18]], "date-time": "2019-04-18T17:21:22Z", "timestamp": 1555608082000}, "score": 22.79412, "issued": {"date-parts": [[1998, 7]]}, "references-count": 53, "journal-issue": {"published-print": {"date-parts": [[1998, 7]]}, "issue": "7"}, "alternative-id": ["S002839089800077X"], "URL": "http://dx.doi.org/10.1016/s0028-3908(98)00077-x", "ISSN": ["0028-3908"], "issn-type": [{"value": "0028-3908", "type": "print"}]}, {"indexed": {"date-parts": [[2019, 11, 22]], "date-time": "2019-11-22T10:04:28Z", "timestamp": 1574417068005}, "publisher-location": "Hoboken, NJ, USA", "reference-count": 31, "publisher": "John Wiley & Sons, Inc.", "isbn-type": [{"value": "9780470571224", "type": "electronic"}], "content-domain": {"domain": [], "crossmark-restriction": false}, "DOI": "10.1002/9780470571224.pse098", "type": "reference-entry", "created": {"date-parts": [[2010, 3, 10]], "date-time": "2010-03-10T15:50:42Z", "timestamp": 1268236242000}, "source": "Crossref", "is-referenced-by-count": 0, "title": ["Drug Impurities and Degradants and Their Safety Qualification"], "prefix": "10.1002", "author": [{"given": "Robin C.", "family": "Guy", "sequence": "first", "affiliation": []}], "member": "311", "published-online": {"date-parts": [[2010, 3, 15]]}, "reference": [{"key": "10.1002/9780470571224.pse098-BIB1|cit1", "unstructured": "Janssen WF FDA Consumer 1981 http://vm.cfsan.fda.gov/\u223clrd/history1.html"}, {"key": "10.1002/9780470571224.pse098-BIB2|cit2", "unstructured": "US FDA Center for Biologics Evaluation and Research Commemorating 100 Years of Biologics Regulation, Science and the Regulation of Biological Products From a Rich History to a Challenging Future 2002 http://www.fda.gov/cber/inside/centscireg.htm"}, {"key": "10.1002/9780470571224.pse098-BIB3|cit3", "unstructured": "US FDA Office of Women's Health FDA Milestones in Women's Health: Looking Back as We Move into the New Millennium 2000 http://www.fda.gov/womens/milesbro.html"}, {"key": "10.1002/9780470571224.pse098-BIB4|cit4", "unstructured": "Roberts R Safety Assessment in Pediatrics 1999 www.fda.gov/cder/present/dia-699/sa-dia99/index.htm"}, {"key": "10.1002/9780470571224.pse098-BIB5|cit5", "unstructured": "US FDA Center for Drug Evaluation and Research Time Line: Chronology of Drug Regulation in the United States www.fda.gov/cder/about/history/time1.htm"}, {"key": "10.1002/9780470571224.pse098-BIB6|cit6", "unstructured": "US FDA Milestones in U.S. Food and Drug Law History, FDA Backgrounder: Current and Useful Information from the Food and Drug Administration 1995 www.fda.gov/opacom/backgrounders/miles.html"}, {"key": "10.1002/9780470571224.pse098-BIB7|cit7", "unstructured": "Guidance for Industry, Nonclinical Studies for the Safety Evaluation of Pharmaceutical Excipients 2005"}, {"key": "10.1002/9780470571224.pse098-BIB8|cit8", "unstructured": "United States Pharmacopoeia (USP) 2005 www.usp.org"}, {"key": "10.1002/9780470571224.pse098-BIB9|cit9", "unstructured": "ICH Guidance for Industry, Q3C Impurities: Residual Solvents 1997 http://www.fda.gov/cder/guidance/index.htm"}, {"key": "10.1002/9780470571224.pse098-BIB10|cit10", "unstructured": "ICH Guidance for Industry, Q1B Photostability Testing of New Drug Substances and Product 1996 http://www.fda.gov/cder/guidance/index.htm"}, {"key": "10.1002/9780470571224.pse098-BIB11|cit11", "unstructured": "ICH Guidance for Industry, Q3A Impurities in New Drug Substances 2003 http://www.fda.gov/cder/guidance/index.htm"}, {"key": "10.1002/9780470571224.pse098-BIB12|cit12", "unstructured": "ICH Guidance for Industry, Q3B(R) Impurities in New Drug Products 2003 http://www.fda.gov/cder/guidance/index.htm"}, {"key": "10.1002/9780470571224.pse098-BIB13|cit13", "unstructured": "ICH Guidance for Industry, Q1A Stability Testing of New Drug Substances and Products 2001 http://www.fda.gov/cder/guidance/index.htm"}, {"key": "10.1002/9780470571224.pse098-BIB14|cit14", "unstructured": "2005 http://www.fda.gov/cder/guidance/cGMPs/packaging.htm"}, {"key": "10.1002/9780470571224.pse098-BIB15|cit15", "unstructured": "ICH Guidance for Industry, Q6B Specifications: Test Procedures and Acceptance Criteria for Bio-technological/Biological Products 1999 http://www.fda.gov/cder/guidance/index.htm"}, {"issue": "1", "key": "10.1002/9780470571224.pse098-BIB16|cit16", "first-page": "1020", "article-title": "Extractables and leachables in drug products", "volume": "25", "author": "Osterberg", "year": "2005", "journal-title": "Am Coll Toxicol Newslett"}, {"issue": "2", "key": "10.1002/9780470571224.pse098-BIB17|cit17", "first-page": "1020", "article-title": "Potential toxicity of extractables and leachables in drug products", "volume": "8", "author": "Osterberg", "year": "2005", "journal-title": "Am Pharm Rev"}, {"key": "10.1002/9780470571224.pse098-BIB18|cit18", "unstructured": "Guidance for Industry, Metered Dose Inhaler (MDI) and Dry Powder Inhaler (DPI), Drug Products Chemistry, Manufacturing, and Controls Documentation 1998 http://www.fda.gov/cder/guidance/index.htm"}, {"key": "10.1002/9780470571224.pse098-BIB19|cit19", "unstructured": "ICH Guideline for Industry, Q2A Text on Validation of Analytical Procedures 1995 http://www.fda.gov/cder/guidance/index.htm"}, {"key": "10.1002/9780470571224.pse098-BIB20|cit20", "unstructured": "ICH Guidance for Industry, Q2B Validation of Analytical Procedures: Methodology 1996 http://www.fda.gov/cder/guidance/index.htm"}, {"key": "10.1002/9780470571224.pse098-BIB21|cit21", "unstructured": "ICH Guidance for Industry, Q6A Specifications: Test Procedures and Acceptance Criteria for New Drug Substances and New Drug Products: Chemical Substances 2000 http://www.fda.gov/cder/guidance/index.htm"}, {"key": "10.1002/9780470571224.pse098-BIB22|cit22", "unstructured": "Application for FDA Approval to Market a New Drug General Provisions Definitions www.fda.gov"}, {"key": "10.1002/9780470571224.pse098-BIB23|cit23", "unstructured": "ICH Guidance for Industry, Q3C-Tables and List 2003 http://www.fda.gov/cder/guidance/index.htm"}, {"key": "10.1002/9780470571224.pse098-BIB24|cit24", "unstructured": "Guidance for Industry, NDAs: Impurities in Drug Substances 2000 http://www.fda.gov/cder/guidance/3622fnl.htm"}, {"key": "10.1002/9780470571224.pse098-BIB25|cit25", "unstructured": "Guidance for Industry, ANDAs: Impurities in Drug Substances 2005 http://www.fda.gov/cder/guidance/index.htm"}, {"key": "10.1002/9780470571224.pse098-BIB26|cit26", "unstructured": "Current Good Manufacturing Practice for Finished Pharmaceuticals 2005 www.fda.gov"}, {"key": "10.1002/9780470571224.pse098-BIB27|cit27", "unstructured": "Draft Guidance for Industry, Analytical Procedures and Methods Validation Chemistry, Manufacturing, and Controls Documentation 2000 http://www.fda.gov/cder/guidance/2396dft.htm"}, {"key": "10.1002/9780470571224.pse098-BIB28|cit28", "unstructured": "Good Laboratory Practice for Nonclinical Laboratory Studies 2005 www.fda.gov"}, {"key": "10.1002/9780470571224.pse098-BIB29|cit29", "author": "Thornton", "year": "1994", "volume-title": "Clinical Laboratory Instrumentation and Automation-Principles, Applications and Selection"}, {"key": "10.1002/9780470571224.pse098-BIB30|cit30", "author": "Bender", "year": "1987", "volume-title": "Principles of Chemical Instrumentation"}, {"key": "10.1002/9780470571224.pse098-BIB31|cit31", "author": "Narayanan", "year": "1989", "volume-title": "Principles and Applications of Laboratory Instrumentation"}], "container-title": ["Pharmaceutical Sciences Encyclopedia"], "link": [{"URL": "https://onlinelibrary.wiley.com/doi/full/10.1002/9780470571224.pse098", "content-type": "unspecified", "content-version": "vor", "intended-application": "similarity-checking"}], "deposited": {"date-parts": [[2018, 8, 5]], "date-time": "2018-08-05T10:19:14Z", "timestamp": 1533464354000}, "score": 22.67443, "issued": {"date-parts": [[2010, 3, 15]]}, "ISBN": ["9780470571224"], "references-count": 31, "URL": "http://dx.doi.org/10.1002/9780470571224.pse098", "relation": {"cites": []}}, {"indexed": {"date-parts": [[2019, 12, 1]], "date-time": "2019-12-01T00:56:33Z", "timestamp": 1575161793712}, "reference-count": 0, "publisher": "Clarivate Analytics (US)", "issue": "8", "content-domain": {"domain": [], "crossmark-restriction": false}, "short-container-title": ["Drug News Perspect"], "published-print": {"date-parts": [[1999]]}, "DOI": "10.1358/dnp.1999.12.8.655779", "type": "journal-article", "created": {"date-parts": [[2005, 7, 15]], "date-time": "2005-07-15T16:08:54Z", "timestamp": 1121443734000}, "page": "484", "source": "Crossref", "is-referenced-by-count": 25, "title": ["5-HT1A receptor blockers as potential drug candidates for the treatment of anxiety disorders"], "prefix": "10.1358", "volume": "12", "author": [{"given": "G.", "family": "Griebel", "sequence": "first", "affiliation": []}], "member": "71", "container-title": ["Drug News & Perspectives"], "language": "en", "deposited": {"date-parts": [[2011, 8, 8]], "date-time": "2011-08-08T17:21:16Z", "timestamp": 1312824076000}, "score": 22.53655, "issued": {"date-parts": [[1999]]}, "references-count": 0, "journal-issue": {"published-print": {"date-parts": [[1999]]}, "issue": "8"}, "URL": "http://dx.doi.org/10.1358/dnp.1999.12.8.655779", "ISSN": ["0214-0934"], "issn-type": [{"value": "0214-0934", "type": "print"}], "subject": ["Pharmacology", "Drug Discovery", "General Medicine"]}, {"indexed": {"date-parts": [[2019, 11, 20]], "date-time": "2019-11-20T10:05:25Z", "timestamp": 1574244325289}, "reference-count": 28, "publisher": "Elsevier BV", "issue": "1-2", "license": [{"URL": "https://www.elsevier.com/tdm/userlicense/1.0/", "start": {"date-parts": [[2007, 1, 1]], "date-time": "2007-01-01T00:00:00Z", "timestamp": 1167609600000}, "delay-in-days": 0, "content-version": "tdm"}], "content-domain": {"domain": [], "crossmark-restriction": false}, "short-container-title": ["Drug Discovery Today"], "published-print": {"date-parts": [[2007, 1]]}, "DOI": "10.1016/j.drudis.2006.10.014", "type": "journal-article", "created": {"date-parts": [[2006, 11, 14]], "date-time": "2006-11-14T12:19:35Z", "timestamp": 1163506775000}, "page": "45-53", "source": "Crossref", "is-referenced-by-count": 17, "title": ["Data reduction and representation in drug discovery"], "prefix": "10.1016", "volume": "12", "author": [{"given": "Trevor J.", "family": "Howe", "sequence": "first", "affiliation": []}, {"given": "Guy", "family": "Mahieu", "sequence": "additional", "affiliation": []}, {"given": "Patrick", "family": "Marichal", "sequence": "additional", "affiliation": []}, {"given": "Tom", "family": "Tabruyn", "sequence": "additional", "affiliation": []}, {"given": "Pieter", "family": "Vugts", "sequence": "additional", "affiliation": []}], "member": "78", "container-title": ["Drug Discovery Today"], "language": "en", "link": [{"URL": "https://api.elsevier.com/content/article/PII:S1359644606004351?httpAccept=text/xml", "content-type": "text/xml", "content-version": "vor", "intended-application": "text-mining"}, {"URL": "https://api.elsevier.com/content/article/PII:S1359644606004351?httpAccept=text/plain", "content-type": "text/plain", "content-version": "vor", "intended-application": "text-mining"}], "deposited": {"date-parts": [[2019, 1, 11]], "date-time": "2019-01-11T14:56:14Z", "timestamp": 1547218574000}, "score": 22.1256, "issued": {"date-parts": [[2007, 1]]}, "references-count": 28, "journal-issue": {"published-print": {"date-parts": [[2007, 1]]}, "issue": "1-2"}, "alternative-id": ["S1359644606004351"], "URL": "http://dx.doi.org/10.1016/j.drudis.2006.10.014", "ISSN": ["1359-6446"], "issn-type": [{"value": "1359-6446", "type": "print"}]}], "items-per-page": 20, "query": {"start-index": 0, "search-terms": null}}}